

Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis

Jonathan AC Sterne, Pritesh N Bodalia, Peter A Bryden, Philippa A Davies, Jose A López-López, George N Okoli, Howard HZ Thom, Deborah M Caldwell, Sofia Dias, Diane Eaton, Julian PT Higgins, Will Hollingworth, Chris Salisbury, Jelena Savović, Reece Sofat, Annya Stephens-Boal, Nicky J Welton and Aroon D Hingorani



**National Institute for
Health Research**

Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis

Jonathan AC Sterne,^{1*} Pritesh N Bodalia,^{2,3}
Peter A Bryden,¹ Philippa A Davies,¹
Jose A López-López,¹ George N Okoli,¹
Howard HZ Thom,¹ Deborah M Caldwell,¹ Sofia Dias,¹
Diane Eaton,⁴ Julian PT Higgins,¹ Will Hollingworth,¹
Chris Salisbury,¹ Jelena Savović,¹ Reecha Sofat,^{5,6}
Annya Stephens-Boal,⁷ Nicky J Welton¹
and Aroon D Hingorani^{5,6}

¹School of Social and Community Medicine, University of Bristol, Bristol, UK

²University College London Hospitals, NHS, London, UK

³Royal National Orthopaedic Hospital, NHS, London, UK

⁴AntiCoagulation Europe, Bromley, UK

⁵University College London, London, UK

⁶London School of Hygiene and Tropical Medicine, London, UK

⁷Thrombosis UK, Llanwrda, UK

*Corresponding author

Declared competing interests of authors: Jonathan AC Sterne was a National Institute for Health Research (NIHR) Health Technology Assessment Clinical Trial Board member from 2010 to 2014 and is a NIHR Senior Investigator (award NF-SI-0611-10168). Chris Salisbury is a NIHR Health Services and Delivery Research Board member, and also reports receipt of a research grant from NIHR. Howard HZ Thom reports personal fees for consultancy work from Novartis Pharma, Eli Lilly and company, and ICON Plc, all outside this work. Sofia Dias reports grants from NIHR, Novartis and Pfizer, all outside this work. Diane Eaton reports other from Boehringer Ingelheim, Pfizer, Bayer, Leo Pharmaceuticals and Bristol-Myers Squib, outside the submitted work, and AntiCoagulation Europe (ACE), a registered charity, the aims of which include raising awareness of the risk and prevention of thrombosis, and providing information, education and support to people who are on anticoagulation therapy for any duration, including long term for those with chronic conditions. Diane Eaton works with ACE in an associate consultant capacity in the role of Project Development Manager. She has over 40 years of personal experience of anticoagulation therapy and represents ACE as a patient expert at the National Institute for Health and Care Excellence (NICE). On behalf of the charity, she has provided the patient perspective for the submissions for the technology appraisals for the novel oral anticoagulants (NOACs) and Diagnostic Guidance for Coagulometers over a 4-year period. Please note that the financial information has been prepared by Eve Knight, Chief Executive of AntiCoagulation Europe, for the purpose of inclusion in this document.

Published March 2017

DOI: 10.3310/hta21090

This report should be referenced as follows:

Sterne JAC, Botalia PN, Bryden PA, Davies PA, López-López JA, Okoli GN, *et al.* Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. *Health Technol Assess* 2017;**21**(9).

Health Technology Assessment is indexed and abstracted in *Index Medicus/MEDLINE*, *Excerpta Medica/EMBASE*, *Science Citation Index Expanded (SciSearch®)* and *Current Contents®/Clinical Medicine*.

ISSN 1366-5278 (Print)

ISSN 2046-4924 (Online)

Impact factor: 4.058

Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the ISI Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: journals.library@nhr.ac.uk

The full HTA archive is freely available to view online at www.journalslibrary.nhr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nhr.ac.uk

Criteria for inclusion in the *Health Technology Assessment* journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: <http://www.nets.nhr.ac.uk/programmes/hta>

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 11/92/17. The contractual start date was in October 2013. The draft report began editorial review in May 2015 and was accepted for publication in December 2015. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen's Printer and Controller of HMSO 2017. This work was produced by Sterne *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nhr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).

Health Technology Assessment Editor-in-Chief

Professor Hywel Williams Director, HTA Programme, UK and Foundation Professor and Co-Director of the Centre of Evidence-Based Dermatology, University of Nottingham, UK

NIHR Journals Library Editor-in-Chief

Professor Tom Walley Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

NIHR Journals Library Editors

Professor Ken Stein Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin Senior Scientific Advisor, Wessex Institute, UK

Ms Tara Lamont Scientific Advisor, NETSCC, UK

Dr Catriona McDaid Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads Professor of Health Sciences Research, Health and Wellbeing Research Group, University of Winchester, UK

Professor John Norrie Chair in Medical Statistics, University of Edinburgh, UK

Professor John Powell Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Jonathan Ross Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of members of the NIHR Journals Library Board:
www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk

Abstract

Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis

Jonathan AC Sterne,^{1*} Pritesh N Bodalia,^{2,3} Peter A Bryden,¹ Philippa A Davies,¹ Jose A López-López,¹ George N Okoli,¹ Howard HZ Thom,¹ Deborah M Caldwell,¹ Sofia Dias,¹ Diane Eaton,⁴ Julian PT Higgins,¹ Will Hollingworth,¹ Chris Salisbury,¹ Jelena Savović,¹ Reecha Sofat,^{5,6} Annya Stephens-Boal,⁷ Nicky J Welton¹ and Aroon D Hingorani^{5,6}

¹School of Social and Community Medicine, University of Bristol, Bristol, UK

²University College London Hospitals, NHS, London, UK

³Royal National Orthopaedic Hospital, NHS, London, UK

⁴AntiCoagulation Europe, Bromley, UK

⁵University College London, London, UK

⁶London School of Hygiene and Tropical Medicine, London, UK

⁷Thrombosis UK, Llanwrda, UK

*Corresponding author Jonathan.Sterne@bristol.ac.uk

Background: Warfarin is effective for stroke prevention in atrial fibrillation (AF), but anticoagulation is underused in clinical care. The risk of venous thromboembolic disease during hospitalisation can be reduced by low-molecular-weight heparin (LMWH): warfarin is the most frequently prescribed anticoagulant for treatment and secondary prevention of venous thromboembolism (VTE). Warfarin-related bleeding is a major reason for hospitalisation for adverse drug effects. Warfarin is cheap but therapeutic monitoring increases treatment costs. Novel oral anticoagulants (NOACs) have more rapid onset and offset of action than warfarin, and more predictable dosing requirements.

Objective: To determine the best oral anticoagulant/s for prevention of stroke in AF and for primary prevention, treatment and secondary prevention of VTE.

Design: Four systematic reviews, network meta-analyses (NMAs) and cost-effectiveness analyses (CEAs) of randomised controlled trials.

Setting: Hospital (VTE primary prevention and acute treatment) and primary care/anticoagulation clinics (AF and VTE secondary prevention).

Participants: Patients eligible for anticoagulation with warfarin (stroke prevention in AF, acute treatment or secondary prevention of VTE) or LMWH (primary prevention of VTE).

Interventions: NOACs, warfarin and LMWH, together with other interventions (antiplatelet therapy, placebo) evaluated in the evidence network.

Main outcome measures: *Efficacy* Stroke, symptomatic VTE, symptomatic deep-vein thrombosis and symptomatic pulmonary embolism. *Safety* Major bleeding, clinically relevant bleeding and intracranial haemorrhage. We also considered myocardial infarction and all-cause mortality and evaluated cost-effectiveness.

Data sources: MEDLINE and PREMEDLINE In-Process & Other Non-Indexed Citations, EMBASE and The Cochrane Library, reference lists of published NMAs and trial registries. We searched MEDLINE and PREMEDLINE In-Process & Other Non-Indexed Citations, EMBASE and The Cochrane Library. The stroke prevention in AF review search was run on the 12 March 2014 and updated on 15 September 2014, and covered the period 2010 to September 2014. The search for the three reviews in VTE was run on the 19 March 2014, updated on 15 September 2014, and covered the period 2008 to September 2014.

Review methods: Two reviewers screened search results, extracted and checked data, and assessed risk of bias. For each outcome we conducted standard meta-analysis and NMA. We evaluated cost-effectiveness using discrete-time Markov models.

Results: Apixaban (Eliquis®, Bristol-Myers Squibb, USA; Pfizer, USA) [5 mg bd (twice daily)] was ranked as among the best interventions for stroke prevention in AF, and had the highest expected net benefit. Edoxaban (Lixiana®, Daiichi Sankyo, Japan) [60 mg od (once daily)] was ranked second for major bleeding and all-cause mortality. Neither the clinical effectiveness analysis nor the CEA provided strong evidence that NOACs should replace postoperative LMWH in primary prevention of VTE. For acute treatment and secondary prevention of VTE, we found little evidence that NOACs offer an efficacy advantage over warfarin, but the risk of bleeding complications was lower for some NOACs than for warfarin. For a willingness-to-pay threshold of > £5000, apixaban (5 mg bd) had the highest expected net benefit for acute treatment of VTE. Aspirin or no pharmacotherapy were likely to be the most cost-effective interventions for secondary prevention of VTE: our results suggest that it is not cost-effective to prescribe NOACs or warfarin for this indication.

Conclusions: NOACs have advantages over warfarin in patients with AF, but we found no strong evidence that they should replace warfarin or LMWH in primary prevention, treatment or secondary prevention of VTE.

Limitations: These relate mainly to shortfalls in the primary data: in particular, there were no head-to-head comparisons between different NOAC drugs.

Future work: Calculating the expected value of sample information to clarify whether or not it would be justifiable to fund one or more head-to-head trials.

Study registration: This study is registered as PROSPERO CRD42013005324, CRD42013005331 and CRD42013005330.

Funding: The National Institute for Health Research Health Technology Assessment programme.

Contents

List of tables	xv
List of figures	xxvii
List of boxes	xxxvii
Glossary	xxxix
List of abbreviations	xli
Plain English summary	xlili
Scientific summary	xliv
Chapter 1 Background	1
Description of health problem	1
<i>Atrial fibrillation, stroke and myocardial infarction</i>	1
<i>Venous thromboembolic disease</i>	1
Current usage and cost of warfarin in the NHS	1
Description of interventions under assessment: new oral anticoagulants	2
Rationale for undertaking this evidence review	2
Chapter 2 Research questions	5
Aim	5
Objectives of evidence review	5
Chapter 3 Review methods (1): assessment of clinical effectiveness and safety	7
Introduction	7
Eligibility criteria	7
<i>Study designs</i>	7
<i>Participants</i>	7
<i>Interventions and comparators</i>	8
Outcomes of interest	8
<i>Prevention of stroke in atrial fibrillation</i>	8
<i>Venous thromboembolism</i>	9
Identification of evidence	10
<i>Search strategy</i>	10
<i>Assessing relevance and inclusion</i>	10
Data extraction	10
Assessment of risk of bias in included trials	11
Selection of data for analysis	11
<i>Choice of interventions</i>	11
<i>Choice of time points</i>	11
<i>Choice of outcomes</i>	11
Quantitative synthesis (including network meta-analysis)	11
<i>Investigation of heterogeneity</i>	13
<i>Investigation of inconsistency</i>	13

Chapter 4 Review methods (2): cost-effectiveness analysis	15
Introduction	15
Decision questions	15
Previous economic models	15
Atrial fibrillation: patients and interventions	16
<i>Atrial fibrillation: patient population</i>	16
<i>Atrial fibrillation: interventions</i>	16
Venous thromboembolism: patients and interventions	16
<i>Venous thromboembolism: patient populations</i>	16
<i>Venous thromboembolism: interventions</i>	22
<i>Outcomes of atrial fibrillation and venous thromboembolism models</i>	24
Atrial fibrillation model structure	24
Venous thromboembolism model structures: overview	26
<i>Venous thromboembolism model structure: secondary prevention</i>	26
<i>Venous thromboembolism model structure: acute treatment</i>	28
<i>Venous thromboembolism model structure: primary prevention</i>	29
Inputs partially shared between atrial fibrillation and venous thromboembolism models	30
<i>Cost of pharmacotherapy</i>	30
<i>Cost of acute venous thromboembolism, atrial fibrillation and anticoagulant-related events</i>	31
<i>Cost of chronic care for venous thromboembolism, atrial fibrillation and anticoagulant-related events</i>	31
<i>Utilities</i>	32
<i>Utilities of venous thromboembolism, atrial fibrillation and anticoagulant-related acute health events</i>	32
<i>Utilities of venous thromboembolism, atrial fibrillation and anticoagulant-related chronic health states</i>	34
Summary	35
Chapter 5 Clinical results (1): stroke prevention in atrial fibrillation	37
Included studies	37
Time in therapeutic range for warfarin interventions	48
Risk of bias in included studies	50
Results on clinical effectiveness and safety	50
<i>Stroke or systemic embolism</i>	60
<i>Ischaemic stroke</i>	64
<i>Myocardial infarction</i>	67
<i>Major bleeding</i>	70
<i>Clinically relevant bleeding</i>	73
<i>Intracranial bleeding</i>	77
<i>All-cause mortality</i>	79
<i>Summary of results and ranking of interventions</i>	81
Chapter 6 Cost-effectiveness results (1) stroke prevention in atrial fibrillation	85
Introduction	85
Model inputs	85
<i>Relative treatment efficacy</i>	85
<i>Effect of past health events and states on future event rates</i>	87
<i>Transition probabilities with usual care (warfarin)</i>	88
<i>Mortality</i>	88
<i>Treatment switching probabilities</i>	88
Sensitivity analyses	89

Results of the cost-effectiveness model: atrial fibrillation	90
<i>Results of base-case analyses</i>	90
<i>Results of sensitivity analyses</i>	94
<i>Summary of cost-effectiveness findings</i>	95
Chapter 7 Clinical results (2): primary prevention of venous thromboembolism	101
Included studies	101
Time in therapeutic range for warfarin interventions	119
Risk of bias in included studies	119
Results of clinical effectiveness and safety	119
<i>Symptomatic venous thromboembolism</i>	147
<i>Symptomatic deep-vein thrombosis</i>	151
<i>Symptomatic pulmonary embolism</i>	153
<i>Myocardial infarction</i>	156
<i>Major bleeding</i>	157
<i>Clinically relevant bleeding</i>	163
<i>All-cause mortality</i>	166
<i>Summary of results and ranking of interventions</i>	166
Chapter 8 Clinical results (3): acute treatment of venous thromboembolism	171
Included studies	171
Time in therapeutic range for warfarin interventions	171
Risk of bias in included studies	176
Results of clinical effectiveness and safety	176
<i>Symptomatic venous thromboembolism</i>	180
<i>Symptomatic deep-vein thrombosis</i>	180
<i>Symptomatic pulmonary embolism</i>	184
<i>Myocardial infarction</i>	185
<i>Major bleeding</i>	185
<i>Clinically relevant bleeding</i>	187
<i>All-cause mortality</i>	191
<i>Summary of results and ranking of interventions</i>	193
Chapter 9 Clinical results (4): secondary prevention of venous thromboembolism	197
Included studies	197
Time in therapeutic range for warfarin interventions	202
Risk of bias in included studies	202
Results of clinical effectiveness and safety	202
<i>Symptomatic venous thromboembolism</i>	208
<i>Symptomatic deep-vein thrombosis</i>	208
<i>Symptomatic pulmonary embolism</i>	214
<i>Myocardial infarction</i>	216
<i>Major bleeding</i>	216
<i>Clinically relevant bleeding</i>	220
<i>Bleeding (sensitivity analysis)</i>	221
<i>All-cause mortality</i>	223
<i>Summary of results</i>	225
Chapter 10 Clinical results (5): combined safety analyses	227
Myocardial infarction	227
Major bleeding	229
Clinically relevant bleeding	230
All-cause mortality	230

Chapter 11 Cost-effectiveness results (2): venous thromboembolism	233
Introduction	233
Model inputs: venous thromboembolism secondary prevention	233
Overview	233
Relative treatment efficacy	233
Relative treatment safety	234
Transition probabilities with usual care (no pharmacotherapy)	234
Future venous thromboembolism-related events	235
Mortality	236
Model inputs: venous thromboembolism acute treatment	236
Overview	236
Relative treatment efficacy	236
Relative treatment safety	237
Mortality	237
Transition probabilities with usual care (warfarin)	237
Model inputs: venous thromboembolism primary prevention	238
Overview	238
Relative treatment efficacy	238
Relative treatment safety	238
Mortality	238
Transition probabilities with usual care (low-molecular-weight heparin)	239
Sensitivity analyses	239
Proportion of venous thromboembolism events that are fatal and non-fatal pulmonary embolism (secondary prevention)	239
Risk of clinically relevant bleed on warfarin (secondary prevention)	239
Rate of non-fatal intracranial haemorrhage (acute treatment)	240
Cost of edoxaban (acute treatment)	240
Changing the time on treatment (acute treatment)	240
Pooling post total hip replacement and post total knee replacement populations for relative treatment effect of venous thromboembolism (primary prevention)	240
Dabigatran dose for elderly patients (primary prevention)	240
Cost of treatment-related adverse events (all models)	240
Cost of venous thromboembolism events (all models)	240
Utility decrements of treatment-related adverse events (all models)	240
Utility decrements of venous thromboembolism events (all models)	240
Cost of warfarin (all models)	240
Results of the cost-effectiveness model: venous thromboembolism secondary prevention	241
Results of the cost-effectiveness model: low-molecular-weight heparin acute treatment	241
Results of the cost-effectiveness model: low-molecular-weight heparin primary prevention	248
Total hip replacement	248
Total knee replacement	250
Results of sensitivity analyses for secondary prevention model	254
Results of sensitivity analyses for acute treatment model	254
Results of sensitivity analyses for primary prevention model	256
Total knee replacement	256
Total hip replacement	258
Summary of cost-effectiveness findings	258
Comparisons with the literature	260
Chapter 12 Discussion and conclusions	261
Main findings	261
Atrial fibrillation: results of clinical effectiveness analyses	261
Atrial fibrillation: results of cost-effectiveness analyses	262

<i>Primary prevention of venous thromboembolism: results of clinical effectiveness analyses</i>	262
<i>Primary prevention of venous thromboembolism following hip and knee surgery: results of cost-effectiveness analyses</i>	263
<i>Acute treatment of venous thromboembolic disease: results of clinical effectiveness analyses</i>	264
<i>Acute treatment of venous thromboembolic disease: results of cost-effectiveness analyses</i>	264
<i>Secondary prevention of venous thromboembolism: results of clinical effectiveness analyses</i>	265
<i>Secondary prevention of venous thromboembolism: results of cost-effectiveness analyses</i>	266
<i>Analyses of the value of information from future research</i>	266
Strengths and limitations	267
<i>Strengths</i>	267
<i>Limitations</i>	267
Research needs	269
Implications for practice	270
Chapter 13 Patient perspective	271
Acknowledgements	273
References	275
Appendix 1 MEDLINE search strategy	293
Appendix 2 Forest plots: stroke prevention in atrial fibrillation	297
Appendix 3 Forest plots: primary prevention of venous thromboembolism	313
Appendix 4 Forest plots: acute treatment of venous thromboembolism	337
Appendix 5 Forest plots: secondary prevention of venous thromboembolism	345
Appendix 6 Discussion of previous economic models	353
Appendix 7 Competing risks network meta-analysis for hazard ratios of events	355
Appendix 8 Competing risks model for hazard in warfarin arms of trials	359
Appendix 9 All-cause mortality minus venous thromboembolism-related mortality data (acute treatment of venous thromboembolism)	361
Appendix 10 Office for National Statistics life tables stratified by age and gender	363
Appendix 11 Log-odds ratios relative to low-molecular-weight heparin	365
Appendix 12 Venous thromboembolism sensitivity analyses	367

List of tables

TABLE 1 Summary of sample of 18 previous economic models of anticoagulation for AF	17
TABLE 2 Summary of previous economic models for acute treatment of VTE	19
TABLE 3 Summary of previous economic models for primary prevention of VTE	20
TABLE 4 First-line anticoagulants and dose compared in the CEA	22
TABLE 5 Secondary prevention comparators	23
TABLE 6 Acute treatment comparators	23
TABLE 7 Total hip replacement and TKR primary prevention comparators	23
TABLE 8 Health states in the secondary prevention model	27
TABLE 9 Drug dose, duration and costs for the AF and VTE secondary prevention interventions	30
TABLE 10 Drug dose, duration and costs for VTE acute treatment interventions	30
TABLE 11 Drug dose per day for VTE primary prevention comparators	31
TABLE 12 Acute event costs and their distributions	31
TABLE 13 Annual post-ischaemic stroke and post-ICH management costs	32
TABLE 14 Utilities	33
TABLE 15 Transient event utility values for primary prevention, acute treatment and secondary prevention models	33
TABLE 16 General population utility values (mean and SD) by age and gender	34
TABLE 17 Health-state utility values for primary prevention, acute treatment and secondary prevention models	34
TABLE 18 Characteristics of 23 included randomised trials in stroke prevention in AF	38
TABLE 19 Mean TTR for warfarin in stroke prevention in AF	49
TABLE 20 Risk-of-bias assessment for 23 included randomised trials in stroke prevention in AF	51
TABLE 21 List of distinct interventions examined by included randomised trials in stroke prevention in AF	57

TABLE 22 Efficacy outcomes reported by 23 included randomised trials in stroke prevention in AF: number of events for each outcome in each trial	58
TABLE 23 Safety outcomes reported by 23 included randomised trials in stroke prevention in AF: number of events for each outcome in each trial	59
TABLE 24 Included trials and risk-of-bias assessment for stroke or SE (stroke prevention in AF)	61
TABLE 25 Results for stroke or SE (stroke prevention in AF): comparisons with warfarin (INR 2–3)	62
TABLE 26 Results for stroke or SE (stroke prevention in AF): NOACs (licensed doses only)	62
TABLE 27 Results for stroke or SE (stroke prevention in AF): comparisons with warfarin (INR 2–3) – sensitivity analysis using HRs instead of ORs	63
TABLE 28 Results for stroke or SE (stroke prevention in AF): NOACs (licensed doses only): sensitivity analysis using HRs instead of ORs	64
TABLE 29 Included trials and risk-of-bias assessment for ischaemic stroke (stroke prevention in AF)	65
TABLE 30 Results for ischaemic stroke (stroke prevention in AF): comparisons with warfarin (INR 2–3)	65
TABLE 31 Results for ischaemic stroke (stroke prevention in AF): NOACs (licensed doses only)	66
TABLE 32 Results for ischaemic stroke (stroke prevention in AF): comparisons with warfarin (INR 2–3) – sensitivity analysis using HRs instead of ORs	66
TABLE 33 Results for ischaemic stroke (stroke prevention in AF): NOACs (licensed doses only) – sensitivity analysis using HRs instead of ORs	67
TABLE 34 Included trials and risk-of-bias assessment for MI (stroke prevention in AF)	68
TABLE 35 Results for MI (stroke prevention in AF): comparisons with warfarin (INR 2–3)	68
TABLE 36 Results for MI (stroke prevention in AF): NOACs (licensed doses only)	69
TABLE 37 Results for MI (stroke prevention in AF): comparisons with warfarin (INR 2–3): sensitivity analysis using HRs instead of ORs	69
TABLE 38 Results for MI (stroke prevention in AF): NOACs (licensed doses only): sensitivity analysis using HRs instead of ORs	69
TABLE 39 Included trials and risk-of-bias assessment for major bleeding (stroke prevention in AF)	70

TABLE 40 Results for major bleeding (stroke prevention in AF): comparisons with warfarin (INR 2–3)	71
TABLE 41 Results for major bleeding (stroke prevention in AF): NOACs (licensed doses only)	72
TABLE 42 Results for major bleeding (stroke prevention in AF): comparisons with warfarin (INR 2–3): sensitivity analysis using HRs instead of ORs	72
TABLE 43 Results for major bleeding (stroke prevention in AF): NOACs (licensed doses only) – sensitivity analysis using HRs instead of ORs	73
TABLE 44 Included trials and risk-of-bias assessment for CRB (stroke prevention in AF)	74
TABLE 45 Results for CRB (stroke prevention in AF): comparisons with warfarin (INR 2–3)	75
TABLE 46 Results for CRB (stroke prevention in AF): NOACs (licensed doses only)	75
TABLE 47 Results for CRB (stroke prevention in AF): comparisons with warfarin (INR 2–3): sensitivity analysis using HRs instead of ORs	76
TABLE 48 Results for CRB (stroke prevention in AF): NOACs (licensed doses only): sensitivity analysis using HRs instead of ORs	77
TABLE 49 Included trials and risk-of-bias assessment for intracranial bleeding (stroke prevention in AF)	78
TABLE 50 Results for intracranial bleeding (stroke prevention in AF): comparisons with warfarin (INR 2–3)	78
TABLE 51 Results for intracranial bleeding (stroke prevention in AF): NOACs (licensed doses only)	78
TABLE 52 Results for intracranial bleeding (stroke prevention in AF): comparisons with warfarin (INR 2–3) – sensitivity analysis using HRs instead of ORs	79
TABLE 53 Results for intracranial bleeding (stroke prevention in AF): NOACs (licensed doses only) – sensitivity analysis using HRs instead of ORs	79
TABLE 54 Included trials and risk-of-bias assessment for all-cause mortality (stroke prevention in AF)	80
TABLE 55 Results for all-cause mortality (stroke prevention in AF): comparisons with warfarin (INR 2–3)	80
TABLE 56 Results for all-cause mortality (stroke prevention in AF): NOACs (licensed doses only)	81
TABLE 57 Results for all-cause mortality (stroke prevention in AF): comparisons with warfarin (INR 2–3): sensitivity analysis using HRs instead of ORs	81

TABLE 58 Results for all-cause mortality (stroke prevention in AF): NOACs (licensed doses only): sensitivity analysis using HRs instead of ORs	82
TABLE 59 Mean and 95% CI for HRs relative to warfarin from the competing risks NMA for each event and treatment included in the economic model	86
TABLE 60 Data and HR from meta-analysis of no treatment/placebo vs. warfarin	86
TABLE 61 Hazard ratios of effect of history of previous events on future events (Friberg <i>et al.</i>)	87
TABLE 62 Reported HRs for effect of no previous events on mortality in patients with AF (Andersen and Olsen)	87
TABLE 63 Estimated log-HR (standard error) for the effect of previous events on future events	87
TABLE 64 Mean and 95% CI for hazard of events, estimated from warfarin arms of RCTs identified in our systematic review	88
TABLE 65 Treatment switching rules and assumed probabilities	89
TABLE 66 Hazard ratio from meta-analysis of no treatment/placebo vs. warfarin, including and excluding BAATAF study	90
TABLE 67 Cost-effectiveness of first-line treatment strategies for patients with AF	91
TABLE 68 Main assumptions in the AF model	99
TABLE 69 Characteristics of 43 included randomised trials in primary prevention of VTE	102
TABLE 70 Risk-of-bias assessments for 43 included randomised trials in primary prevention of VTE	120
TABLE 71 List of distinct interventions examined by included randomised trials of primary prevention of VTE	142
TABLE 72 Efficacy outcomes reported by 38 included randomised trials in primary prevention of VTE: number of events for each outcome in each trial	143
TABLE 73 Safety outcomes reported by 38 included randomised trials in primary prevention of VTE: number of events for each outcome in each trial	145
TABLE 74 Included trials and risk-of-bias assessment for symptomatic VTE (primary prevention of VTE)	148
TABLE 75 Results for symptomatic VTE in hip surgery patients (primary prevention of VTE): comparisons with LMWH	149
TABLE 76 Results for symptomatic VTE in hip surgery patients (primary prevention of VTE): NOACs (licensed doses only)	149

TABLE 77 Results for symptomatic VTE in knee surgery patients (primary prevention of VTE): comparisons with LMWH	150
TABLE 78 Results for symptomatic VTE in knee surgery patients (primary prevention of VTE): NOACs (licensed doses only)	150
TABLE 79 Results for symptomatic VTE in medical patients (primary prevention of VTE): comparisons with LMWH	151
TABLE 80 Results for symptomatic VTE in medical patients (primary prevention of VTE): NOACs (licensed doses only)	151
TABLE 81 Included trials and risk-of-bias assessment for symptomatic DVT (primary prevention of VTE)	152
TABLE 82 Results for symptomatic DVT in hip surgery patients (primary prevention of VTE): comparisons with LMWH	153
TABLE 83 Results for symptomatic DVT in hip surgery patients (primary prevention of VTE): NOACs (licensed doses only)	153
TABLE 84 Results for symptomatic DVT in knee surgery patients (primary prevention of VTE): comparisons with LMWH	154
TABLE 85 Results for symptomatic DVT in knee surgery patients (primary prevention of VTE): NOACs (licensed doses only)	154
TABLE 86 Results for symptomatic DVT in medical patients (primary prevention of VTE): comparisons with LMWH	155
TABLE 87 Results for symptomatic DVT in medical patients (primary prevention of VTE): NOACs (licensed doses only)	155
TABLE 88 Included trials and risk-of-bias assessment for symptomatic PE (primary prevention of VTE)	155
TABLE 89 Results for symptomatic PE in hip surgery patients (primary prevention of VTE): comparisons with LMWH	157
TABLE 90 Results for symptomatic PE in hip surgery patients (primary prevention of VTE): NOACs (licensed doses only)	157
TABLE 91 Results for symptomatic PE in knee surgery patients (primary prevention of VTE): comparisons with LMWH	158
TABLE 92 Results for symptomatic PE in knee surgery patients (primary prevention of VTE): NOACs (licensed doses only)	159
TABLE 93 Results for symptomatic PE in medical patients (primary prevention of VTE): comparisons with LMWH	159
TABLE 94 Results for symptomatic PE in medical patients (primary prevention of VTE): NOACs (licensed doses only)	159

TABLE 95 Included trials and risk-of-bias assessment for MI (primary prevention of VTE)	160
TABLE 96 Results for MI (primary prevention of VTE): comparisons with LMWH	160
TABLE 97 Results for MI (primary prevention of VTE): NOACs (licensed doses only)	161
TABLE 98 Included trials and risk-of-bias assessment for major bleeding (primary prevention of VTE)	161
TABLE 99 Results for major bleeding (primary prevention of VTE): comparisons with LMWH	162
TABLE 100 Results for major bleeding (primary prevention of VTE): NOACs (licensed doses only)	163
TABLE 101 Included trials and risk-of-bias assessment for CRB (primary prevention of VTE)	164
TABLE 102 Results for CRB (primary prevention of VTE): comparisons with LMWH	165
TABLE 103 Results for CRB (primary prevention of VTE): NOACs (licensed doses only)	166
TABLE 104 Included trials and risk-of-bias assessment for all-cause mortality (primary prevention of VTE)	167
TABLE 105 Results for all-cause mortality (primary prevention of VTE): comparisons with LMWH	167
TABLE 106 Results for all-cause mortality (primary prevention of VTE): NOACs (licensed doses only)	168
TABLE 107 Characteristics of nine included randomised trials in acute treatment of VTE	172
TABLE 108 Mean TTR for warfarin in acute treatment of VTE	176
TABLE 109 Risk-of-bias assessments for nine included randomised trials in acute treatment of VTE	177
TABLE 110 List of distinct interventions examined by included randomised trials in acute treatment of VTE	180
TABLE 111 Efficacy outcomes reported by nine included randomised trials in acute treatment of VTE: number of events for each outcome in each trial	181
TABLE 112 Safety outcomes reported for nine included randomised trials in acute treatment of VTE: number of events for each outcome in each trial	181

TABLE 113 Included trials and risk-of-bias assessment for symptomatic VTE (acute treatment of VTE)	182
TABLE 114 Results for symptomatic VTE (acute treatment of VTE): comparisons with warfarin (INR 2–3)	182
TABLE 115 Results for symptomatic VTE (acute treatment of VTE): NOACs (licensed doses only)	183
TABLE 116 Included trials and risk-of-bias assessment for symptomatic DVT (acute treatment of VTE)	183
TABLE 117 Results for symptomatic DVT (acute treatment of VTE): comparisons with warfarin (INR 2–3)	184
TABLE 118 Results for symptomatic DVT (acute treatment of VTE): NOACs (licensed doses only)	184
TABLE 119 Included trials and risk-of-bias assessment for symptomatic PE (acute treatment of VTE)	185
TABLE 120 Results for symptomatic PE (acute treatment of VTE): comparisons with warfarin (INR 2–3)	186
TABLE 121 Results for symptomatic PE (acute treatment of VTE): NOACs (licensed doses only)	186
TABLE 122 Included trials and risk-of-bias assessment for MI (acute treatment of VTE)	187
TABLE 123 Results for MI (acute treatment of VTE): comparisons with warfarin (INR 2–3)	187
TABLE 124 Results for MI (acute treatment of VTE): NOACs (licensed doses only)	188
TABLE 125 Included trials and risk-of-bias assessment for major bleeding (acute treatment of VTE)	188
TABLE 126 Results for major bleeding (acute treatment of VTE): comparisons with warfarin (INR 2–3)	189
TABLE 127 Results for major bleeding (acute treatment of VTE): NOACs (licensed doses only)	189
TABLE 128 Included trials and risk-of-bias assessment for CRB (acute treatment of VTE)	190
TABLE 129 Results for CRB (acute treatment of VTE): comparisons with warfarin (INR 2–3)	190
TABLE 130 Results for CRB (acute treatment of VTE): NOACs (licensed doses only)	191

TABLE 131 Included trials and risk-of-bias assessment for all-cause mortality (acute treatment of VTE)	192
TABLE 132 Results for all-cause mortality (acute treatment of VTE): comparisons with warfarin (INR 2–3)	192
TABLE 133 Results for all-cause mortality (acute treatment of VTE): NOACs (licensed doses only)	192
TABLE 134 Characteristics of 10 included randomised trials in secondary prevention of VTE	198
TABLE 135 Mean TTR for warfarin in secondary prevention of VTE	202
TABLE 136 Risk-of-bias assessments for 10 included randomised trials in secondary prevention of VTE	203
TABLE 137 List of distinct interventions examined by included randomised trials in secondary prevention of VTE	208
TABLE 138 Efficacy outcomes reported by 10 included randomised trials in secondary prevention of VTE: number of events for each outcome in each trial	209
TABLE 139 Safety outcomes reported by 10 included randomised trials in secondary prevention of VTE: number of events for each outcome in each trial	209
TABLE 140 Included trials and risk-of-bias assessment for symptomatic VTE (secondary prevention of VTE)	210
TABLE 141 Results for symptomatic VTE (secondary prevention of VTE): comparisons with placebo	210
TABLE 142 Results for symptomatic VTE (secondary prevention of VTE): comparisons with aspirin	211
TABLE 143 Results for symptomatic VTE (secondary prevention of VTE): comparisons with warfarin (INR 2–3)	211
TABLE 144 Results for symptomatic VTE (secondary prevention of VTE): NOACs (licensed doses only)	211
TABLE 145 Results for recurrent VTE (secondary prevention of VTE): comparisons with placebo	211
TABLE 146 Results for recurrent VTE (secondary prevention of VTE): comparisons with aspirin	212
TABLE 147 Results for recurrent VTE (secondary prevention of VTE): comparisons with warfarin (INR 2–3)	212
TABLE 148 Results for recurrent VTE (secondary prevention of VTE): NOACs (licensed doses only)	212

TABLE 149 Included trials and risk-of-bias assessment for symptomatic DVT (secondary prevention of VTE)	213
TABLE 150 Results for symptomatic DVT (secondary prevention of VTE): comparisons with placebo	213
TABLE 151 Results for symptomatic DVT (secondary prevention of VTE): comparisons with aspirin	213
TABLE 152 Results for symptomatic DVT (secondary prevention of VTE): comparisons with warfarin (INR 2–3)	214
TABLE 153 Results for symptomatic DVT (secondary prevention of VTE): NOACs (licensed doses only)	214
TABLE 154 Included trials and risk-of-bias assessment for symptomatic PE (secondary prevention of VTE)	215
TABLE 155 Results for symptomatic PE (secondary prevention of VTE): comparisons with placebo	215
TABLE 156 Results for symptomatic PE (secondary prevention of VTE): comparisons with aspirin	215
TABLE 157 Results for symptomatic PE (secondary prevention of VTE): comparisons with warfarin (INR 2–3)	216
TABLE 158 Results for symptomatic PE (secondary prevention of VTE): NOACs (licensed doses only)	216
TABLE 159 Included trials and risk-of-bias assessment for MI (secondary prevention of VTE)	217
TABLE 160 Results for MI (secondary prevention of VTE): comparisons with placebo	217
TABLE 161 Results for MI (secondary prevention of VTE): comparisons with aspirin	217
TABLE 162 Results for MI (secondary prevention of VTE): comparisons with warfarin (INR 2–3)	217
TABLE 163 Results for MI (secondary prevention of VTE): NOACs (licensed doses only)	218
TABLE 164 Included trials and risk-of-bias assessment for major bleeding (secondary prevention of VTE)	218
TABLE 165 Results for major bleeding (secondary prevention of VTE): comparisons with placebo	219
TABLE 166 Results for major bleeding (secondary prevention of VTE): comparisons with aspirin	219

TABLE 167 Results for major bleeding (secondary prevention of VTE): comparisons with warfarin (INR 2–3)	219
TABLE 168 Results for major bleeding (secondary prevention of VTE): NOACs (licensed doses only)	219
TABLE 169 Included trials and risk-of-bias assessment for CRB (secondary prevention of VTE)	220
TABLE 170 Results for CRB (secondary prevention of VTE): comparisons with placebo	220
TABLE 171 Results for CRB (secondary prevention of VTE): comparisons with aspirin	221
TABLE 172 Results for CRB (secondary prevention of VTE): comparisons with warfarin (INR 2–3)	221
TABLE 173 Results for CRB (secondary prevention of VTE): NOACs (licensed doses only)	221
TABLE 174 Results for bleeding (secondary prevention of VTE): comparisons with placebo	222
TABLE 175 Results for bleeding (secondary prevention of VTE): comparisons with aspirin	222
TABLE 176 Results for bleeding (secondary prevention of VTE): comparisons with warfarin (INR 2–3)	223
TABLE 177 Results for bleeding (secondary prevention of VTE): NOACs (licensed doses only)	223
TABLE 178 Included trials and risk-of-bias assessment for all-cause mortality (secondary prevention of VTE)	224
TABLE 179 Results for all-cause mortality (secondary prevention of VTE): comparisons with placebo	224
TABLE 180 Results for all-cause mortality (secondary prevention of VTE): comparisons with aspirin	224
TABLE 181 Results for all-cause mortality (secondary prevention of VTE): comparisons with warfarin (INR 2–3)	225
TABLE 182 Results for all-cause mortality (secondary prevention of VTE): NOACs (licensed doses only)	225
TABLE 183 List of distinct interventions examined in the combined safety analyses	228
TABLE 184 Results for MI (combined analysis): comparisons with warfarin (INR 2–3)	229

TABLE 185 Results for major bleeding (combined analysis): comparisons with warfarin (INR 2–3)	230
TABLE 186 Results for CRB (combined analysis): comparisons with warfarin (INR 2–3)	231
TABLE 187 Results for all-cause mortality (combined analysis): comparisons with warfarin (INR 2–3)	232
TABLE 188 Estimated risk for DVT given VTE recurrence and non-fatal PE given PE	234
TABLE 189 Parameters and AIC for recurrent VTE baseline risk based on Prandoni <i>et al.</i>	235
TABLE 190 Cumulative PTS rates, given DVT	236
TABLE 191 Incidence of CTPH, given PE	236
TABLE 192 Odds ratios of VTE recurrence on acute treatment: all ORs are compared with warfarin	236
TABLE 193 Estimated risk of DVT given VTE recurrence and non-fatal PE given PE	237
TABLE 194 Odds ratios of non-fatal ICH in the acute treatment: NOACs combined, compared with warfarin	237
TABLE 195 Odds ratios of clinically relevant bleeds in acute treatment: all ORs are compared with warfarin	237
TABLE 196 Odds ratios of non-VTE/ICH-related mortality in acute treatment: all ORs are compared with warfarin	238
TABLE 197 Estimated risk on warfarin for recurrent VTE, non-fatal ICH, CRB and non-VTE-related mortality	238
TABLE 198 Estimated risk on LMWH for VTE, CRB and mortality minus VTE-related mortality	239
TABLE 199 Results of the secondary prevention CEA	242
TABLE 200 Results of the acute treatment CEA: costs, QALYs, incremental costs, incremental QALYs and incremental NMB at willingness-to-pay thresholds of £20,000 and £30,000	245
TABLE 201 Results of the THR primary prevention CEA: costs, QALYs, incremental costs, incremental QALYs and incremental NMB	248
TABLE 202 Results of the TKR primary prevention CEA: costs, QALYs, incremental costs, incremental QALYs and incremental NMB at willingness-to-pay thresholds of £20,000 and £30,000	251
TABLE 203 All-cause mortality minus VTE-related mortality data (acute treatment of VTE)	361

TABLE 204 Office for National Statistics life tables stratified by age and gender	363
TABLE 205 Estimated (posterior mean) log-ORs relative to LMWH post-op (standard dose): pooled surgical primary population	365

List of figures

FIGURE 1 Treatment strategies and switching/discontinuation rules	22
FIGURE 2 Markov model for AF	25
FIGURE 3 Population pathway	27
FIGURE 4 Venous thromboembolism secondary prevention Markov model	27
FIGURE 5 Venous thromboembolism acute treatment decision tree	28
FIGURE 6 Primary prevention decision tree	29
FIGURE 7 Primary prevention Markov model	29
FIGURE 8 The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow chart for review of stroke prevention in AF	37
FIGURE 9 Network plot for stroke or SE (stroke prevention in AF)	60
FIGURE 10 Network plot for ischaemic stroke (stroke prevention in AF)	64
FIGURE 11 Network plot for MI (stroke prevention in AF)	67
FIGURE 12 Network plot for major bleeding (stroke prevention in AF)	70
FIGURE 13 Network plot for CRB (stroke prevention in AF)	74
FIGURE 14 Network plot for intracranial bleeding (stroke prevention in AF)	77
FIGURE 15 Network plot for all-cause mortality (stroke prevention in AF)	79
FIGURE 16 Rankogram for licensed interventions examined in stroke prevention in AF	83
FIGURE 17 Incremental cost-effectiveness plane, warfarin (INR 2–3) is reference	92
FIGURE 18 Cost-effectiveness acceptability curves	93
FIGURE 19 Cost-effectiveness acceptability frontier	93
FIGURE 20 Per-person EVPI over range of willingness-to-pay thresholds	93
FIGURE 21 Expected value of partial perfect information for subsets of parameters	94
FIGURE 22 Cost-effectiveness acceptability curves for sensitivity analysis assuming that the cost of warfarin treatment is zero	95
FIGURE 23 Cost-effectiveness acceptability curves for sensitivity analysis assuming no effect of bleed or ICH on mortality risk	95

FIGURE 24 Cost-effectiveness acceptability curves for sensitivity analysis assuming that no patients switch treatment following stroke, bleed, SE or TIA	96
FIGURE 25 Cost-effectiveness acceptability curves for sensitivity analysis assuming that all patients switch treatment following stroke, bleed, SE or TIA	96
FIGURE 26 Cost-effectiveness acceptability curves for sensitivity analysis assuming that all patients switch treatment following stroke or bleed, and none switches following SE or TIA	96
FIGURE 27 Cost-effectiveness acceptability curves for sensitivity analysis excluding the BAATAF study from meta-analysis of the treatment effect of warfarin compared with no treatment	97
FIGURE 28 Cost-effectiveness acceptability curves for sensitivity analysis assuming that the cohort starts at age 60 years, rather than 70 years	97
FIGURE 29 Cost-effectiveness acceptability curves for sensitivity analysis assuming that the cohort starts at age 80 years, rather than 70 years	97
FIGURE 30 Cost-effectiveness acceptability curves for sensitivity analysis comparing lower doses of apixaban and dabigatran, as would be administered in older patients with AF	98
FIGURE 31 Cost-effectiveness acceptability curves for sensitivity analysis assuming that the hazard of ICH is the same on warfarin and no treatment	98
FIGURE 32 The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow chart for reviews of primary prevention, acute treatment and secondary prevention of VTE	101
FIGURE 33 Network plot for symptomatic VTE in hip surgery patients (primary prevention of VTE)	148
FIGURE 34 Network plot for symptomatic VTE in knee surgery patients (primary prevention of VTE)	149
FIGURE 35 Network plot for symptomatic VTE in medical patients (primary prevention of VTE)	151
FIGURE 36 Network plot for symptomatic DVT in hip surgery patients (primary prevention of VTE)	152
FIGURE 37 Network plot for symptomatic DVT in knee surgery patients (primary prevention of VTE)	153
FIGURE 38 Network plot for symptomatic DVT in medical patients (primary prevention of VTE)	155
FIGURE 39 Network plot for symptomatic PE in hip surgery patients (primary prevention of VTE)	157

FIGURE 40 Network plot for symptomatic PE in knee surgery patients (primary prevention of VTEs)	158
FIGURE 41 Network plot for symptomatic PE in medical patients (primary prevention of VTE)	159
FIGURE 42 Network plot for MI (primary prevention of VTE)	160
FIGURE 43 Network plot for major bleeding (primary prevention of VTE)	161
FIGURE 44 Network plot for CRB (primary prevention of VTE)	164
FIGURE 45 Network plot for all-cause mortality (primary prevention of VTE)	166
FIGURE 46 Rankogram for licensed interventions examined in primary prevention of VTE	169
FIGURE 47 Network plot for symptomatic VTE (acute treatment of VTE)	182
FIGURE 48 Network plot for symptomatic DVT (acute treatment of VTE)	183
FIGURE 49 Network plot for symptomatic PE (acute treatment of VTE)	185
FIGURE 50 Network plot for MI (acute treatment of VTE)	187
FIGURE 51 Network plot for major bleeding (acute treatment of VTE)	188
FIGURE 52 Network plot for CRB (acute treatment of VTE)	190
FIGURE 53 Network plot for all-cause mortality (acute treatment of VTE)	191
FIGURE 54 Rankogram for licensed interventions examined in acute treatment of VTE	193
FIGURE 55 Network plot for symptomatic VTE (secondary prevention of VTE)	210
FIGURE 56 Network plot for symptomatic DVT (secondary prevention of VTE)	212
FIGURE 57 Network plot for symptomatic PE (secondary prevention of VTE)	214
FIGURE 58 Network plot for MI (secondary prevention of VTE)	216
FIGURE 59 Network plot for major bleeding (secondary prevention of VTE)	218
FIGURE 60 Network plot for CRB (secondary prevention of VTE)	220
FIGURE 61 Network plot for bleeding (secondary prevention of VTE)	222
FIGURE 62 Network plot for all-cause mortality (secondary prevention of VTE)	223
FIGURE 63 Network plot for MI (combined analysis)	228
FIGURE 64 Network plot for major bleeding (combined analysis)	229

FIGURE 65 Network plot for CRB (combined analysis)	231
FIGURE 66 Network plot for all-cause mortality (combined analysis)	232
FIGURE 67 Parametric distributions for recurrent VTE baseline risk fitted to results reported in Prandoni <i>et al.</i>	235
FIGURE 68 Incremental cost-effectiveness plane for secondary prevention (no pharmacotherapy: reference)	243
FIGURE 69 Cost-effectiveness acceptability frontier for secondary prevention	243
FIGURE 70 Cost-effectiveness acceptability curve for secondary prevention	244
FIGURE 71 Expected value of partial perfect information for subsets of model input parameters in the VTE secondary prevention model, presented as a proportion of the total EVPI	244
FIGURE 72 Incremental cost-effectiveness plane for acute treatment (warfarin: reference)	246
FIGURE 73 Cost-effectiveness acceptability curve for acute treatment	247
FIGURE 74 Cost-effectiveness acceptability frontier for acute treatment	247
FIGURE 75 Expected value of partial perfect information subsets of parameters in the VTE acute treatment model, as a proportion of the total EVPI	248
FIGURE 76 Incremental cost-effectiveness plane for THR primary prevention (LMWH reference)	249
FIGURE 77 Cost-effectiveness acceptability curve for THR primary prevention	249
FIGURE 78 Cost-effectiveness acceptability frontier for THR primary prevention	250
FIGURE 79 Expected value of partial perfect information for subsets of model input parameters in the VTE primary prevention THR model, presented as a proportion of the total EVPI	251
FIGURE 80 Incremental cost-effectiveness plane for TKR primary prevention (LMWH: reference)	252
FIGURE 81 Cost-effectiveness acceptability curve for TKR primary prevention	252
FIGURE 82 Cost-effectiveness acceptability frontier for TKR primary prevention	253
FIGURE 83 Expected value of partial perfect information for subsets of parameters in the VTE primary prevention TKR model, as a proportion of the total EVPI	253
FIGURE 84 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analysis: vary proportion of DVT, non-fatal PE and fatal PE of recurrent VTE	254

FIGURE 85 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analyses: reduction in VTE costs by 50%	255
FIGURE 86 Cost-effectiveness acceptability frontier secondary prevention: risk of ICH for no pharmacotherapy is set to zero	255
FIGURE 87 Cost-effectiveness acceptability frontier acute treatment model: assuming a zero cost for edoxaban	256
FIGURE 88 Cost-effectiveness acceptability frontier for TKR primary prevention sensitivity analysis: increasing AE costs by 50%	256
FIGURE 89 Cost-effectiveness acceptability frontier for TKR primary prevention sensitivity analysis: increasing AE utilities by 50%	257
FIGURE 90 Cost-effectiveness acceptability frontier for TKR primary prevention sensitivity analysis: decreasing VTE costs by 50%	257
FIGURE 91 Cost-effectiveness acceptability frontier for TKR primary prevention sensitivity analysis: decreasing VTE utilities by 50%	258
FIGURE 92 Stroke or SE [1/4] (stroke prevention in AF)	297
FIGURE 93 Stroke or SE [2/4] (stroke prevention in AF)	298
FIGURE 94 Stroke or SE [3/4] (stroke prevention in AF)	299
FIGURE 95 Stroke or SE [4/4] (stroke prevention in AF)	300
FIGURE 96 Ischaemic stroke (stroke prevention in AF)	301
FIGURE 97 Myocardial infarction (stroke prevention in AF)	302
FIGURE 98 Major bleeding [1/4] (stroke prevention in AF)	303
FIGURE 99 Major bleeding [2/4] (stroke prevention in AF)	304
FIGURE 100 Major bleeding [3/4] (stroke prevention in AF)	305
FIGURE 101 Major bleeding [4/4] (stroke prevention in AF)	306
FIGURE 102 Clinically relevant bleeding [1/3] (stroke prevention in AF)	307
FIGURE 103 Clinically relevant bleeding [2/3] (stroke prevention in AF)	308
FIGURE 104 Clinically relevant bleeding [3/3] (stroke prevention in AF)	309
FIGURE 105 Intracranial bleeding (stroke prevention in AF)	310
FIGURE 106 All-cause mortality (stroke prevention in AF)	311
FIGURE 107 Symptomatic DVT [1/3] (primary prevention of VTE)	313

FIGURE 108 Symptomatic DVT [2/3] (primary prevention of VTE)	314
FIGURE 109 Symptomatic DVT [3/3] (primary prevention of VTE)	315
FIGURE 110 Symptomatic PE [1/4] (primary prevention of VTE)	316
FIGURE 111 Symptomatic PE [2/4] (primary prevention of VTE)	317
FIGURE 112 Symptomatic PE [3/4] (primary prevention of VTE)	319
FIGURE 113 Symptomatic PE [4/4] (primary prevention of VTE)	321
FIGURE 114 Symptomatic VTE [1/3] (primary prevention of VTE)	323
FIGURE 115 Symptomatic VTE [2/3] (primary prevention of VTE)	324
FIGURE 116 Symptomatic VTE [3/3] (primary prevention of VTE)	325
FIGURE 117 Myocardial infarction (primary prevention of VTE)	326
FIGURE 118 Major bleeding [1/4] (primary prevention of VTE)	327
FIGURE 119 Major bleeding [2/4] (primary prevention of VTE)	328
FIGURE 120 Major bleeding [3/4] (primary prevention of VTE)	329
FIGURE 121 Major bleeding [4/4] (primary prevention of VTE)	330
FIGURE 122 Clinically relevant bleeding [1/2] (primary prevention of VTE)	331
FIGURE 123 Clinically relevant bleeding [2/2] (primary prevention of VTE)	332
FIGURE 124 All-cause mortality [1/3] (primary prevention of VTE)	333
FIGURE 125 All-cause mortality [2/3] (primary prevention of VTE)	334
FIGURE 126 All-cause mortality [3/3] (primary prevention of VTE)	335
FIGURE 127 Symptomatic DVT (acute treatment of VTE)	337
FIGURE 128 Symptomatic PE (acute treatment of VTE)	338
FIGURE 129 Symptomatic VTE (acute treatment of VTE)	339
FIGURE 130 Myocardial infarction (acute treatment of VTE)	340
FIGURE 131 Major bleeding (acute treatment of VTE)	341
FIGURE 132 Clinically relevant bleeding (acute treatment of VTE)	342
FIGURE 133 All-cause mortality (acute treatment of VTE)	343
FIGURE 134 Symptomatic DVT (secondary prevention of VTE)	345

FIGURE 135 Symptomatic PE (secondary prevention of VTE)	346
FIGURE 136 Symptomatic VTE (secondary prevention of VTE)	347
FIGURE 137 Myocardial infarction (secondary prevention of VTE)	348
FIGURE 138 Major bleeding (secondary prevention of VTE)	349
FIGURE 139 Clinically relevant bleeding (secondary prevention of VTE)	350
FIGURE 140 For all-cause mortality (secondary prevention of VTE)	351
FIGURE 141 Cost-effectiveness acceptability frontier for TKR primary prevention sensitivity analysis: pooling post THR and post TKR populations for relative treatment effect of VTE	367
FIGURE 142 Cost-effectiveness acceptability frontier for TKR primary prevention sensitivity analysis: setting the cost of dabigatran to 150 mg od	367
FIGURE 143 Cost-effectiveness acceptability frontier for TKR primary prevention sensitivity analysis: pooling over surgical population for VTE relative treatment effects	368
FIGURE 144 Cost-effectiveness acceptability frontier for TKR primary prevention sensitivity analysis: decreasing AE costs by 50%	368
FIGURE 145 Cost-effectiveness acceptability frontier for TKR primary prevention sensitivity analysis: decreasing AE utilities by 50%	369
FIGURE 146 Cost-effectiveness acceptability frontier for TKR primary prevention sensitivity analysis: increasing VTE costs by 50%	369
FIGURE 147 Cost-effectiveness acceptability frontier for TKR primary prevention sensitivity analysis: increasing VTE utilities by 50%	370
FIGURE 148 Cost-effectiveness acceptability frontier for THR primary prevention sensitivity analysis: pooling post THR and post TKR populations for relative treatment effect of VTE	370
FIGURE 149 Cost-effectiveness acceptability frontier for THR primary prevention sensitivity analysis: setting the cost of dabigatran to 150 mg od	371
FIGURE 150 Cost-effectiveness acceptability frontier for THR primary prevention sensitivity analysis: decreasing AE costs by 50%	371
FIGURE 151 Cost-effectiveness acceptability frontier for THR primary prevention sensitivity analysis: increasing AE costs by 50%	372
FIGURE 152 Cost-effectiveness acceptability frontier for THR primary prevention sensitivity analysis: decreasing AE utilities by 50%	372
FIGURE 153 Cost-effectiveness acceptability frontier for THR primary prevention sensitivity analysis: increasing AE utilities by 50%	373

FIGURE 154 Cost-effectiveness acceptability frontier for THR primary prevention sensitivity analysis: decreasing VTE costs by 50%	373
FIGURE 155 Cost-effectiveness acceptability frontier for THR primary prevention sensitivity analysis: increasing VTE costs by 50%	374
FIGURE 156 Cost-effectiveness acceptability frontier for THR primary prevention sensitivity analysis: decreasing VTE utilities by 50%	374
FIGURE 157 Cost-effectiveness acceptability frontier for THR primary prevention sensitivity analysis: increasing VTE utilities by 50%	375
FIGURE 158 Cost-effectiveness acceptability frontier for acute treatment sensitivity analysis: decreasing AE cost by 50%	375
FIGURE 159 Cost-effectiveness acceptability frontier acute treatment model: increasing AE costs by 50%	376
FIGURE 160 Cost-effectiveness acceptability frontier for acute treatment sensitivity analysis: decreasing AE utility by 50%	376
FIGURE 161 Cost-effectiveness acceptability frontier for acute treatment sensitivity analysis: increasing AE utility by 50%	377
FIGURE 162 Cost-effectiveness acceptability frontier for acute treatment sensitivity analysis: decreasing VTE cost by 50%	377
FIGURE 163 Cost-effectiveness acceptability frontier for acute treatment sensitivity analysis: increasing VTE cost by 50%	378
FIGURE 164 Cost-effectiveness acceptability frontier for acute treatment sensitivity analysis: decreasing VTE utility by 50%	378
FIGURE 165 Cost-effectiveness acceptability frontier for acute treatment sensitivity analysis: increasing VTE utility by 50%	379
FIGURE 166 Cost-effectiveness acceptability frontier for acute treatment sensitivity analysis: NOACs rate of non-fatal ICH rate equal to warfarin	379
FIGURE 167 Cost-effectiveness acceptability frontier for acute treatment sensitivity analysis: changing time on treatment from 6 months to 3 months	380
FIGURE 168 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analysis: patients on no pharmacotherapy and aspirin receive warfarin after a second VTE event	380
FIGURE 169 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analysis: change bleed base rate	381
FIGURE 170 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analysis: setting the cost of warfarin to £0	381

FIGURE 171 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analysis: decreasing the AE cost by 50%	382
FIGURE 172 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analysis: increasing the AE cost by 50%	382
FIGURE 173 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analysis: decreasing the AE utility by 50%	383
FIGURE 174 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analysis: increasing the AE utility by 50%	383
FIGURE 175 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analysis: increasing the cost of VTE events by 50%	384
FIGURE 176 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analysis: decreasing VTE utility by 50%	384
FIGURE 177 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analysis: increasing VTE utility by 50%	385

List of boxes

BOX 1 Main assumptions of the VTE models

259

Glossary

CHADS₂ A clinical prediction rule for estimating the risk of stroke in patients with non-rheumatic atrial fibrillation.

CHADS₂ VASC A modified clinical prediction rule for estimating the risk of stroke in patients with non-rheumatic atrial fibrillation.

HAS-BLED Hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalised ratio, elderly (aged > 65 years), drugs/alcohol concomitantly: this estimates risk of major bleeding for patients on anticoagulation for atrial fibrillation.

List of abbreviations

AE	adverse event	ICH	intracranial haemorrhage
AF	atrial fibrillation	INB	incremental net benefit
AIC	Akaike information criterion	INR	international normalised ratio
BAATAF	Boston Area Anticoagulation Trial for Atrial Fibrillation	LMWH	low-molecular-weight heparin
bd	twice daily	log-OR	log-odds ratio
BMI	body mass index	MCMC	Markov chain Monte Carlo
BNF	<i>British National Formulary</i>	MI	myocardial infarction
CADTH	Canadian Agency for Drugs and Technologies in Health	NICE	National Institute for Health and Care Excellence
CAFA	Canadian Atrial Fibrillation Anticoagulation	NIHR	National Institute for Health Research
CEA	cost-effectiveness analysis	NMA	network meta-analysis
CEAC	cost-effectiveness acceptability curve	NMB	net monetary benefit
CEAF	cost-effectiveness acceptability frontier	NOAC	novel oral anticoagulant
CI	confidence interval	od	once daily
CRB	clinically relevant bleeding	ONS	Office for National Statistics
CRD	Centre for Reviews and Dissemination	OR	odds ratio
CRNM	clinically relevant non-major	PE	pulmonary embolism
CTPH	chronic thromboembolic pulmonary hypertension	post-op	postoperative
DIC	deviance information criterion	pre-op	preoperative
DVT	deep-vein thrombosis	PROSPERO	international prospective register of systematic reviews
EQ-5D	European Quality of life-5 Dimensions	PTS	post-thrombotic syndrome
EVPI	expected value of perfect information	QALY	quality-adjusted life-year
EVPII	expected value of perfect partial information	RCT	randomised controlled trial
HR	hazard ratio	RIND	reversible ischaemic neurological deficit
		SAVI	Sheffield Accelerated Value of Information
		SD	standard deviation
		SE	systemic embolism

LIST OF ABBREVIATIONS

SMC	Scottish Medicines Consortium	TTR	time in therapeutic range
THR	total hip replacement	VKA	vitamin K antagonist
TIA	transient ischaemic attack	VOI	value of information
TKR	total knee replacement	VTE	venous thromboembolism

Plain English summary

Blood clots, which can occur in both arteries and veins, sometimes break loose and move to other organs where they cause serious health problems. Venous thromboembolism (VTE) includes clots in deep veins of the legs or pelvis, and their displacement to the artery from the heart to the lungs. Atrial fibrillation (AF) is a form of irregular heartbeat that is associated with an increased risk of stroke. The UK NHS tries to reduce these problems in high-risk patients through anticoagulant drugs, which lower the risk of blood clots but increase the risk of bleeding. New oral anticoagulant drugs (NOACs) offer potential advantages compared with warfarin and low-molecular-weight heparin (LMWH), the current standard treatments. They cost more, but this might be offset by reduced need for anticoagulation services, better effectiveness or improved safety. We compared the clinical effectiveness and cost-effectiveness of these treatments in people with AF, and people with, or at risk of, VTE. We searched for relevant randomised trials, and compared all of the treatments that had been evaluated. One of the NOACs, apixaban, was among the best treatments for stroke prevention in AF, and was the most cost-effective. We found little evidence, in terms of clinical effectiveness or cost-effectiveness, that NOACs should replace LMWH for prevention of VTE after hip or knee surgery. For treatment of VTE, and for preventing repeat venous thromboembolisms, risk of complications due to bleeding was lower for some NOACs than for warfarin. Apixaban was the most cost-effective treatment for VTE, but it is not cost-effective to prescribe NOACs or warfarin for preventing recurrence of VTE.

Scientific summary

Background

Warfarin is an effective oral anticoagulant for stroke prevention in atrial fibrillation (AF), but anticoagulation is underused in clinical care. The risk of venous thromboembolic disease during hospitalisation can be reduced by low-molecular-weight heparin (LMWH): warfarin is the most frequently prescribed anticoagulant for treatment and secondary prevention of venous thromboembolism (VTE). Warfarin-related bleeding is a major reason for hospitalisation for adverse drug effects. The cost of warfarin is low, but therapeutic monitoring increases treatment costs. Novel oral anticoagulants (NOACs) have a more rapid onset and offset of action than warfarin, and more predictable dosing requirements.

Objectives

To identify the most effective, safe and cost-effective anticoagulant for stroke prevention in AF, and for primary prevention, treatment and secondary prevention of VTE.

Methods

We conducted four systematic reviews, with network meta-analyses (NMAs), of randomised controlled trials addressing (1) stroke prevention in AF (for which the search was run on 12 March 2014 and updated on 15 September 2014, and covered the period 2010 to September 2014), (2) primary prevention of VTE, (3) acute treatment of VTE and (4) secondary prevention of VTE (for all three of which the search was run on 19 March 2014, updated on 15 September 2014, and covered the period 2008 to September 2014). We extracted data on clinically relevant efficacy outcomes [stroke, symptomatic VTE, symptomatic deep-vein thrombosis (DVT) and symptomatic pulmonary embolism] and safety outcomes [major bleeding, clinically relevant bleeding (CRB) and intracranial haemorrhage], as well as myocardial infarction (MI) and all-cause mortality. We searched MEDLINE and PubMed In-Process & Other Non-Indexed Citations, EMBASE and The Cochrane Library, reference lists of published NMAs and trial registries. Two reviewers screened search results, extracted and checked data, and assessed risk of bias. For each outcome we analysed each direct pairwise comparison and performed NMAs to compare all interventions simultaneously.

We constructed discrete-time Markov models to evaluate cost-effectiveness of the different interventions included in the four networks. These synthesised evidence on a number of parameters (e.g. incidence of VTE and ischaemic stroke, relative treatment efficacy, adverse events, costs) to estimate the relative cost-effectiveness of treatment options. Model inputs were based on a variety of evidence sources, including routine data on drug costs and observational studies of long-term costs of, and quality of life with, AF and VTE. Model inputs on relative treatment efficacy and safety of anticoagulants were derived from the results of the NMAs.

Results

For stroke prevention in AF, apixaban (Eliquis[®], Bristol-Myers Squibb, USA; Pfizer, USA) [5 mg twice daily (bd)] was ranked as being among the best interventions for a wide range of the outcomes evaluated, including stroke or systemic embolism (SE), MI, major bleeding, and all-cause mortality. Edoxaban (Lixiana[®], Daiichi Sankyo, Japan) [60 mg od (once daily)] was ranked second for major bleeding and all-cause mortality. Except for all-cause mortality, outcomes for rivaroxaban (Xarelto[®], Bayer HealthCare, Germany) (20 mg od) were ranked less highly than several other NOACs. The non-NOAC interventions {warfarin [international normalised

ratio (INR 2–3] and antiplatelet therapy [aspirin/clopidogrel (Plavix®, Sanofi, USA) \geq 150 mg od]) were ranked worst for stroke or SE, and were not among the best three interventions for any of the outcomes.

At a willingness-to-pay threshold of £20,000 per quality-adjusted life-year (QALY), all NOACs had positive expected incremental net benefit (INB) compared with warfarin (INR 2–3), suggesting that their use in AF may be a cost-effective use of UK NHS resources. Apixaban (5 mg bd) had the highest expected INB (£7533), followed by rivaroxaban (20 mg od) (£6365), edoxaban (£5279) and dabigatran (Pradaxa®, Prazaxa®, Pradax®, Boehringer Ingelheim GmbH, Germany) (£5279). Apixaban (5 mg bd) was the only NOAC for which the 95% confidence interval around INB was positive, suggesting that it is cost-effective compared with warfarin.

For primary prevention of VTE, we found little evidence that risk of symptomatic VTE, symptomatic DVT or symptomatic PE were lower for NOACs than for LMWH. We also found little evidence that risk of major bleeding or CRB is lower for NOACs than for LMWH. Warfarin was ranked with high probability as the best intervention for major bleeding events and LMWH [postoperative (post-op), standard dose] was ranked with high probability as best, or second-best, intervention for CRB. Neither the clinical effectiveness analysis nor the cost-effectiveness analysis (CEA) provided strong evidence that NOACs should replace post-op LMWH in primary prevention of VTE in patients undergoing hip or knee surgery.

For acute treatment of VTE, we found little evidence that NOACs reduced risk of symptomatic VTE, symptomatic DVT or symptomatic PE compared with warfarin or that the risk of any of these outcomes differed between licensed doses of NOACs. However, there was evidence that risk of major bleeding and CRB was lower with apixaban (5 mg bd) and rivaroxaban (15 mg bd then 20 mg od) than with warfarin (INR 2–3). There was a high probability that warfarin (INR 2–3) was ranked worst for major bleeding and CRB. There was a high probability that apixaban 5 mg bd was ranked best for major bleeding and CRB, and this intervention also had a high probability of being ranked best, or second best, for symptomatic DVT, symptomatic VTE and all-cause mortality. For a willingness-to-pay threshold of $>$ £5000, apixaban 5 mg bd was the most cost-effective alternative to warfarin.

For secondary prevention of VTE, risk of symptomatic VTE and risk of symptomatic DVT were lower for all NOACs (at the doses included in the network) than placebo and aspirin. However, there was no clear evidence that risk of these outcomes differed between the NOAC interventions and warfarin. Risk of major bleeding and CRB was higher with warfarin and some NOAC interventions than placebo, but there was evidence that risk of these outcomes is lower with apixaban (2.5 mg or 5 mg bd) and dabigatran (150 mg bd) than warfarin. Aspirin had the highest expected net benefit for secondary prevention of VTE at willingness-to-pay thresholds of £20,000 and £30,000 per QALY. By contrast, all NOAC interventions had negative expected INBs at the £20,000 and £30,000 thresholds, indicating that they are not cost-effective compared with no pharmacotherapy.

Conclusions

Novel oral anticoagulants have advantages over warfarin in patients with AF. Of the available NOACs, apixaban 5 mg bd offers the best balance between efficacy and safety, and has the highest probability of being most cost-effective. NOACs offer no efficacy advantage over warfarin in the acute treatment of VTE, but have a lower rate of bleeding complications albeit at a higher cost. For a willingness-to-pay threshold of $>$ £5000, apixaban 5 mg bd emerges as the most cost-effective alternative to warfarin. Neither the clinical effectiveness analysis nor the CEA provided strong evidence that NOACs should replace post-op LMWH in primary prevention of VTE in patients who are undergoing hip or knee surgery. If secondary prevention after 3–6 months of anticoagulation for a first episode of VTE is to be considered (this is not currently established practice), NOACs provide no advantage over aspirin 100 mg od.

The research needs identified by this review are for (1) calculations of the expected value of sample information, in order to clarify whether or not it would be justifiable to fund one more trial making direct comparisons between the most promising NOACs and NOAC doses, in situations typical of NHS clinical practice; (2) information on long-term rates of the main efficacy and safety outcomes among patients receiving anticoagulants for AF, for example from registries or health record data; (3) information on the role (if any) of therapeutic monitoring to enhance the safety and efficacy of NOACs; and (4) information on long-term adherence rates in patients receiving NOACs for AF.

Study registration

This study is registered as PROSPERO CRD42013005324, CRD42013005331 and CRD42013005330.

Funding

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.

Chapter 1 Background

Description of health problem

Atrial fibrillation, stroke and myocardial infarction

Atrial fibrillation (AF) is the most common cardiac arrhythmia.¹ The prevalence of AF roughly doubles with each decade of age, rising to almost 9% at age 80–90 years.² AF substantially increases (by up to five times) the risk of thromboembolic stroke (annual incidence 114 per 100,000) because of blood pooling in the left atrium and systemic embolisation to the brain. More than 20% of the 130,000 annual strokes in England and Wales are attributed to AF. Approximately one-third of stroke patients die in the first 10 days, one-third recover in 1 month and one-third have disabilities necessitating rehabilitation, making stroke the leading cause of adult disability. Patients with thromboembolic stroke from AF have higher mortality and morbidity and longer hospital stay than patients with other stroke subtypes. Warfarin is an effective oral anticoagulant for the prevention of stroke in patients with AF.³ Although the incidence and mortality of stroke continue to fall in the UK, the underutilisation of anticoagulation in patients with AF at high risk of stroke is a major gap in clinical care.⁴ In patients with AF, antiplatelet and anticoagulant therapies are generally considered from the perspective of mitigation of stroke risk. However, the presence of AF is also associated with an approximately twofold higher risk of future acute myocardial infarction (MI),⁵ whose annual incidence in England (130 and 55.9 per 100,000 for men and women, respectively)⁶ is higher than that of stroke.

Venous thromboembolic disease

The annual incidence of venous thromboembolic disease from a study⁷ conducted in Europe is 183 per 100,000. It encompasses clot formation in deep veins of the legs or pelvis [deep-vein thrombosis (DVT); annual incidence 124 per 100,000] and the displacement of clots to the pulmonary arteries [pulmonary embolism (PE); annual incidence 60 per 100,000]. Important risk factors for venous thromboembolism (VTE) include major surgery, particularly lower limb orthopaedic surgery and surgery for cancer, as well as hospitalisation in acutely ill general medical patients (approximate incidence 15%). VTE costs the UK NHS £640M and is responsible for approximately 30,000 deaths each year in hospitals in England. DVT is an important cause of long-term morbidity, being a risk factor for chronic leg ulceration. PE may also lead to long-term morbidity due to pulmonary hypertension. There is an approximately 30% risk of recurrence of VTE within 8 years.

The risk of VTE during hospitalisation for surgical or medical treatment can be reduced by low-molecular-weight heparin (LMWH), fondaparinux (Arixtra®, GlaxoSmithKline, London, UK) or unfractionated heparin.⁸ Warfarin is the most frequently prescribed anticoagulant for the initial treatment and for the long-term secondary prevention of VTE in those who are deemed to be at high risk of recurrence.

Current usage and cost of warfarin in the NHS

A 2007 Health Technology Assessment report⁹ stated that approximately 950,000 people (2% of the general practice population) in the UK are prescribed warfarin, increasing by about 10% per year. Warfarin-related bleeding is one of the top five reasons for hospitalisation for adverse drug effects in England¹⁰ because of the narrow therapeutic index and numerous drug/dietary interactions. Although the approximate acquisition cost of warfarin is only £10 per patient per year, the requirement for therapeutic monitoring to ensure optimal efficacy and to reduce the risk of bleeding, through hospital-, primary care- or pharmacist-based anticoagulation clinics, or by home monitoring with anticoagulant clinic support, increases the cost of warfarin treatment. The estimated annual cost of managing patients on warfarin in the NHS in England and Wales is approximately £90M.¹¹ A 2006 National Institute for Health and Care

Excellence (NICE) report¹¹ estimated that 46% of patients who should be on warfarin are not receiving it, and that many receiving anticoagulation are not in the optimal therapeutic range, perhaps because of concern about the risk and inconvenience of warfarin treatment.

Description of interventions under assessment: new oral anticoagulants

The class of novel oral anticoagulants (NOACs) [or non-vitamin K antagonist (VKA)], sometimes called direct-acting oral anticoagulants, includes dabigatran (Pradaxa[®], Praxaxa[®], Pradax[®], Boehringer Ingelheim GmbH, Germany) (a direct inhibitor of clotting factor II) and rivaroxaban (Xarelto[®], Bayer HealthCare, Germany), apixaban (Eliquis[®], Bristol-Myers Squibb, USA; Pfizer, USA), edoxaban (Lixiana[®], Daiichi Sankyo, Japan), otamixaban (Sanofi, Paris, France) and betrixaban (Portola Pharmaceuticals, San Francisco, CA, USA) (which are factor X inhibitors). These agents have a more rapid onset and offset of action than warfarin, and are considered to have more predictable dosing requirements than warfarin, possibly reducing the need for therapeutic drug monitoring, increasing convenience and reducing overall cost.¹² However, the safety and efficacy of at least one of the NOACs (dabigatran) may vary according to achieved plasma concentration, which may differ between individuals receiving the same dose,¹³ suggesting a potential benefit from therapeutic drug monitoring. If this proved to be the case, the corollary would be an increase in the overall cost of treatment.

These drugs have been evaluated in clinical trials as an alternative to warfarin for the prevention of stroke in patients with AF (in whom warfarin is given lifelong); as an alternative to LMWH for prevention of VTE in high-risk patients who are undergoing major orthopaedic surgery, as well as those hospitalised with acute medical conditions (in whom LMWH is given to cover the high-risk period); as an alternative to a period of LMWH and then warfarin for acute treatment of a first VTE (usually for 6 months); and for secondary prevention after a first episode of VTE, for which there is currently no widely used treatment.

The estimated annual acquisition cost per patient of new anticoagulants is substantially higher than that of warfarin and will remain so until patent expiry (e.g. 2020 for rivaroxaban). However, the higher acquisition cost could be offset by the reduced need for therapeutic monitoring through anticoagulation services, by increased effectiveness, or by improved safety. Potential limitations of NOACs include class- and drug-specific cautions/contraindications, potential for subtherapeutic dosing, reduced adherence owing to lack of regular monitoring, and absence of, or limited experience with, antidotes, as well as the added cost of maintaining stocks of numerous different anticoagulants and the potential for prescribing errors as a result of unfamiliarity.

Rationale for undertaking this evidence review

Limitations of the previous evidence base (and shortfalls in previous attempts at evidence synthesis) make rational selection from the now wide range of available oral anticoagulants difficult for NHS commissioners, doctors and patients. Much of the existing NICE guidance in this area is limited to technology appraisals of the individual agents.

Clinical trials in this area have the following limitations:

- Few, if any, trials have made direct comparisons of NOAC drugs with one another. This limitation can be addressed through the use of network meta-analysis (NMA) to estimate the comparative efficacy and safety of agents that have been tested against a common comparator, for example warfarin.
- Different rates of subtherapeutic anticoagulation with warfarin within trials (as measured by the time spent in the therapeutic range) may have artificially inflated the apparent efficacy of newer agents. This limitation can be addressed to some extent by investigating the relation of average time in therapeutic range (TTR) with efficacy, within the NMA framework.

Prior synthesis research in this area has the following limitations:

- Some meta-analyses preceded recently published, potentially influential trials.
- Failure to fully incorporate evidence on the adverse effects of oral anticoagulants by including data from all trials, regardless of indication, to maximise power and provide the most robust evidence on the balance between benefit and harm.
- The lack of cost-effective analyses (CEAs) relevant to England and Wales.

Thus, there is a need for an up-to-date comprehensive evidence synthesis of all competing treatments to inform the rational choice of a minimum set of oral anticoagulants needed by NHS hospitals for the main therapeutic indications to avoid unnecessary overstocking and to reduce the risk of prescription error due to unfamiliarity.

Chapter 2 Research questions

Aim

We set out to determine what is/are the best oral anticoagulant(s) for prevention of stroke in AF, and for primary prevention, treatment and secondary prevention of venous thromboembolic disease.

Objectives of evidence review

Our specific objectives were to:

- identify the most effective, safe and cost-effective anticoagulant for stroke prevention in AF, and consider whether or not the evidence is consistent across important patient subgroups (e.g. presence of comorbidities, age)
- identify the most effective, safe and cost-effective oral anticoagulant for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and consider whether or not the evidence is consistent for both prevention and treatment, and across important patient subgroups (e.g. patients undergoing cancer surgery or hip and knee replacement and hospital admission for acute medical illness)
- identify optimal anticoagulation strategies for use by Trust Drugs and Therapeutics Committees, based on the best drug(s) for each of the main therapeutic indications
- estimate the value of conducting further research on the cost-effectiveness of these drugs, for example by conducting a head-to-head trial of two or more new anticoagulants.

Chapter 3 Review methods (1): assessment of clinical effectiveness and safety

Introduction

We conducted four systematic reviews, with NMAs, of randomised controlled trials (RCTs) addressing questions relevant to the study objectives.

Effectiveness and safety of oral anticoagulants for:

1. prevention of stroke in non-valvular AF
2. primary prevention of venous thromboembolic disease
3. acute treatment of venous thromboembolic disease
4. secondary prevention of venous thromboembolic disease.

We undertook these reviews in accordance with the Centre for Reviews and Dissemination (CRD) guidelines for undertaking systematic reviews¹⁴ and the *Cochrane Handbook for Systematic Reviews of Interventions*¹⁵ (as updated online during 2011: see www.cochrane-handbook.org). We prospectively registered the reviews in the PROSPERO (international prospective register of systematic reviews) database (www.crd.york.ac.uk/prospero), with registration numbers CRD42013005324, CRD42013005331 and CRD42013005330.

Eligibility criteria

Study designs

In all reviews we included Phase II or Phase III RCTs using either a superiority or a non-inferiority design.

Participants

In all reviews we included adults (≥ 18 years) who were eligible for oral anticoagulation or (antithrombotic) treatment. Trials in participants who were eligible for only parenteral (injected) anticoagulation were excluded. Unless otherwise specified, anticoagulation services may have been delivered in hospital-, primary care- and pharmacy-based clinics or through home monitoring and telephone support. The review was not limited to NHS anticoagulation services.

Specific criteria for inclusion in the four reviews were as follows.

1. *Stroke prevention in AF* Adults with non-valvular AF.
2. *Primary prevention of VTE* Adults admitted to hospital who were considered to be at high risk of VTE, including those with a medical condition (e.g. cancer, major trauma, stroke) or undergoing a surgical procedure (e.g. total knee or hip arthroplasty, hip fracture surgery) that carries a high risk of VTE.
3. *Acute treatment of VTE* Adults who have received a new or recurrent objectively confirmed diagnosis of acute symptomatic VTE.
4. *Secondary prevention of VTE* Adults who have completed a minimum of 3 months of anticoagulant treatment for objectively confirmed first VTE without recurrence (secondary prevention).

Interventions and comparators

Five NOACs were the focus of all reviews: dabigatran, apixaban, edoxaban, betrixaban, rivaroxaban. NOACs not considered were eribaxaban (the current stage of development was unclear), ximelagatran (withdrawn because of liver toxicity), darexaban (YM150) and AZD0837 (both discontinued), LY517717 and letaxaban (TAK442) (no available information on any further clinical development for both); and otamixaban (parenteral administration).

As the reviews were conducted to inform NMAs, we determined the comparator interventions to ensure that they would provide information on the relative effectiveness of the interventions of interest. We constructed preliminary networks of available treatment comparisons from trials included in previously published NMAs (irrespective of the outcome data available from them). Comparators were chosen based on the possibility of informing indirect evidence on the relative effectiveness of oral anticoagulants, and on the 'distance' of these comparators from our interventions of interest in the network, which relates to the likely increase in precision in the estimates of relative effectiveness of the oral anticoagulants.

Specific comparators in the four reviews were as follows:

1. *Stroke prevention in AF* Therapeutic doses of warfarin or other VKA [with optimal international normalised ratio (INR) range 2–4]; aspirin; clopidogrel (Plavix®, Sanofi, USA).
2. *Primary prevention of VTE* Standard dose LMWH; therapeutic doses of warfarin or other VKA (with optimal INR range 2–4); placebo.
3. *Acute treatment of VTE* Therapeutic doses of warfarin or other VKA (with optimal INR range 2–4).
4. *Secondary prevention of VTE* Therapeutic doses of warfarin or other VKA (with optimal INR range 2–4); placebo; no treatment.

Studies evaluating fixed-dose administration of warfarin were excluded. Studies evaluating warfarin with suboptimal target INR compared with UK guidelines were excluded from the main analyses but combined with studies evaluating warfarin with standard target INR in sensitivity analyses. Unfractionated heparin and fondaparinux were excluded from the primary prevention of VTE review, as they would be distant from the NOACs in the network and hence contribute very little information. Non-standard doses of LMWH that were excluded from this review included enoxaparin (Lovenox®, Clexane®, Sanofi-Aventis, France) at 20 mg twice daily (bd), ardeparin (Normiflo, Wyeth-Ayerst, USA) at 25 anti-Xa units/kg bd or 35 anti-Xa units/kg bd and nadroparin (Fraxiparine®, Sanofi-Synthelabo, France) 3800 IU anti-Xa once daily (od).

Outcomes of interest

Prevention of stroke in atrial fibrillation

We sought data on the following outcomes:

- stroke or systemic embolism (SE)*
- all stroke
- ischaemic stroke (major ischaemic stroke or minor ischaemic stroke)*
- fatal stroke
- non-fatal stroke
- haemorrhagic stroke (major haemorrhagic stroke or minor haemorrhagic stroke)
- any bleeding
- minor bleeding
- major bleeding*
- clinically relevant non-major (CRNM) bleeding
- clinically relevant bleeding (CRB)* (defined as CRNM bleeding or major bleeding)
- intracranial bleeding*
- extracranial major bleeding

- extracranial minor bleeding
- fatal bleeding
- bleeding from surgical site
- thrombocytopenia
- MI*
- transient ischaemic attack (TIA)
- arterial event
- quality-of-life outcomes
- hospital admission
- death (cardiovascular)
- all-cause mortality.*

The outcomes addressed in NMAs are marked with an asterisk in the list above. These were chosen based on three considerations: (1) their clinical importance; (2) the consistency of reporting across studies included in the network; and (3) the number of data that were available for inclusion in NMAs.

Venous thromboembolism

For all VTE reviews we sought data on the following outcomes.

Efficacy

- Symptomatic VTE.*
- Non-symptomatic VTE.
- Major VTE (defined as symptomatic or asymptomatic proximal DVT, non-fatal PE and VTE-related death).
- Fatal VTE.
- Symptomatic DVT.*
- Non-symptomatic DVT.
- Distal DVT.
- Symptomatic distal DVT.
- Proximal DVT.
- Symptomatic proximal DVT.
- PE.
- Symptomatic PE.*
- Non-symptomatic PE.
- Fatal PE.
- Non-fatal PE.
- Symptomatic non-fatal PE.

Safety

- Any bleeding.
- Minor bleeding.
- Major bleeding.*
- CRNM bleeding.
- CRB* (defined as CRNM bleeding or major bleeding).
- Intracranial bleeding.
- Extracranial major bleeding.
- Extracranial minor bleeding.
- Fatal bleeding.
- Bleeding from surgical site.
- Thrombocytopenia.

Other

- MI.*
- TIA.
- Arterial event.
- Quality-of-life outcomes.
- Hospital admission.
- Cardiovascular mortality.
- All-cause mortality.*

The outcomes addressed in NMAs are marked with an asterisk in the list above. These were chosen based on three considerations: (1) their clinical importance; (2) the consistency of reporting across studies included in the network; and (3) the number of data that were available for inclusion in NMAs.

Identification of evidence

Search strategy

Scoping searches that were conducted during protocol development identified some previously published NMAs of oral anticoagulants. We rescreened the studies included in these NMAs against our eligibility criteria, and developed searches to identify any additional studies published beyond the search dates of the most recent NMAs in each population.^{8,16–18}

We used two separate search strategies, one for the review of stroke prevention in AF (for which the search was run on 12 March 2014 and updated on 15 September 2014, and covered the period 2010 to September 2014) and one for the three reviews in VTE (for all three of which the search was run on 19 March 2014, updated on 15 September 2014, and covered the period 2008 to September 2014). In each search strategy we combined terms for either AF or VTE with terms for the interventions and comparators of interest and added a filter to focus the search on RCTs. We searched MEDLINE and PREMEDLINE In-Process & Other Non-Indexed Citations, EMBASE and The Cochrane Library. The stroke prevention in AF review search was run on the 12 March 2014 and updated on 15 September 2014, and covered the period 2010 to September 2014. The search for the three reviews in VTE was run on the 19 March 2014, updated on the 15 September 2014 and covered the period 2008 to September 2014. We applied no restrictions on language. The principal search strategy is included in *Appendix 1*. We removed duplicate records, identified by title, authors, journal citation and date published.

We sought information on studies in progress, unpublished research or research reported in the grey literature from www.clinicaltrials.gov (to September 2012). We screened reference lists of retrieved studies and relevant review articles. We also searched the NHS Economic Evaluation Database (NHS EED) and NICE Technology Appraisals.

Assessing relevance and inclusion

Two reviewers independently screened the results of the searches by title and abstract. We resolved disagreements through consensus or referral to a third reviewer where necessary. We obtained full texts of all potentially relevant reports and two reviewers assessed these independently against the eligibility criteria, with disagreements resolved by a third reviewer. We collated multiple reports of the same study and mapped them to unique studies.

Data extraction

We developed data extraction forms and piloted them on a small selection of studies. Data were extracted from the trial reports by one reviewer and checked by a second. Disagreements were resolved through consensus or by referral to a third reviewer where necessary. We extracted data on the following: study

details (identifier, study design, location, year, length of follow-up, industry sponsorship); participant details (number of participants, age, gender); intervention details (drug name, dose, timing); comparator details; details relevant to risk-of-bias assessment (including adherence to and withdrawal from randomised allocation); and effect modifiers. Multiple reports from a study informed a single data extraction form. We extracted and managed data using Microsoft Access® 2013 software (Microsoft Corporation, Redmond, WA, USA).

We extracted dichotomous data based on the full randomised samples, as number of events in intervention and control groups and numbers of participants, and we sought details of follow-up time (e.g. participant-years in each treatment group). We also extracted estimates of hazard ratios (HRs) and their confidence intervals (CIs) when available.

Assessment of risk of bias in included trials

We assessed studies using the Cochrane Risk of Bias Tool.¹⁹ This assigns a judgement of high, low or unclear risk of bias for each of the following domains: selection bias (randomisation sequence and allocation concealment), performance bias (blinding of participants and carers), detection bias (blinding of outcome assessment), attrition bias (due to dropouts and exclusions), and reporting bias (selective outcome reporting). Assessments were carried out by one reviewer and checked by a second. We resolved disagreements through consensus or by referral to a third reviewer where necessary.

Selection of data for analysis

Choice of interventions

To perform NMAs we had to allocate each intervention group in each trial to a category, with each intervention category forming a 'node' in the network. We kept different doses or frequencies of administration (i.e. od or bd) of oral anticoagulants in separate nodes. We assigned different VKAs to one node (named 'Warfarin'), but separated intended INR range 2–3 from intended INR range 3–4 and from other ranges. For LMWH interventions in the review of primary prevention of VTE, we separated preoperative (pre-op) LMWH from postoperative (post-op) LMWH. The intervention categories (or network nodes) are labelled throughout the report using drug, frequency and dose, or INR range, as appropriate.

Choice of time points

When outcome data were presented for multiple time points, we took the longest period of follow-up, except for bleeding events in the review of primary prevention of VTE, which we assessed at the end of the treatment period.

Choice of outcomes

When outcome data were not presented directly, we computed or substituted them, using data for other outcomes, making assumptions that we considered to be reasonable. When we could not extract data for the outcome 'stroke or SE' in the review of stroke prevention in AF, we used 'all stroke'. When CRB was not reported but both major bleeding and CRNM bleeding events were, we used the total number of events across these two categories. If symptomatic PE was not reported in any of the three VTE reviews, we used symptomatic non-fatal PE if available, or the sum of fatal PE and non-fatal PE. Additionally, in the review of primary prevention of VTE, when symptomatic VTE was not reported, we added across symptomatic DVT and symptomatic PE, if available.

Quantitative synthesis (including network meta-analysis)

For each analysed outcome in each review (see *Choice of outcomes*), we undertook both standard meta-analyses of 'direct evidence' (evidence based on head-to-head comparisons between interventions

made within studies) and a NMA. Results of the individual studies are available in forest plots, arranged within each possible pairwise analysis. The comparisons displayed in the forest plots were computed from the raw data reported in the studies, and we calculated effect estimates using standard frequentist techniques.

Network meta-analysis is a method of synthesising information from a collection of studies by combining evidence from all intervention comparisons that have been made among the studies. The results it produces for each pairwise comparison combine all of the 'direct evidence' (evidence based on head-to-head comparisons between interventions made within individual studies) with all of the 'indirect evidence' (comparisons between interventions inferred from the network via common comparator interventions).^{20,21} For example, indirect evidence comparing the effect of interventions A and B can be inferred from the direct evidence provided by a trial comparing A with C and a trial comparing B with C. NMA thus enables estimation of relative intervention effect estimates for every pair of interventions, regardless of whether or not they have been compared directly in a RCT. It also enables the ranking of treatments according to the probability that each is the best, or worst, for a given outcome.

We plotted the networks to illustrate the data structure for each review and outcome. In these plots, the size of the node for each intervention is proportional to the number of patients randomised to that intervention. When direct evidence comparing two interventions was available, these two interventions are connected by an edge (line) that thickness is proportional to the number of patients who contributed to the comparison. The intervention labels are formatted as follows:

- Licensed doses of NOACs are written in bold typeface; these are interventions of primary interest.
- Interventions that were excluded from the primary analysis labels are presented in square brackets. Such exclusions are because (1) they were not considered to be of interest to inform health decisions in the UK (e.g. warfarin interventions using subtherapeutic INR ranges); or (2) the total number of events was zero, so they are uninformative; or (3) they do not connect with the other trials in the network.
- Excluded interventions that were included in sensitivity analyses are marked with an asterisk.

We had planned to take a random-effects approach to the meta-analyses, assuming a common heterogeneity variance across all comparisons.²⁰ In most networks there was insufficient replication of intervention comparisons to allow estimation of the heterogeneity variance. All of our analyses are therefore based on fixed-effects models.

The primary NMAs treat the data as binomial, modelling the number of events out of the total number of participants using a logistic model. When there were no events in either arm of a trial, it was omitted from the analysis. When there were events in at least one arm of a trial, but no events in at least one other arm, we added 0.5 events to all intervention arms in the trial. In supplementary analyses for some outcomes we modelled HRs rather than odds ratios (ORs). For this we used a complementary log–log link to account for differential follow-up times (thereby assuming a constant hazard of the outcome over time), modelled possibly repeated events as rate data or included HRs extracted directly from trial reports. Some of these analyses were used in the economic models (see *Chapter 4*).

All meta-analyses were performed within a Bayesian framework, using freely available WinBUGS software version 1.4.3 (MRC Biostatistics Unit, Cambridge, UK) and code.²² We assessed convergence of the Markov chains using the potential scale reduction factor, as well as visual examination of history and autocorrelation plots for each estimated parameter. We assessed goodness of fit by calculating the posterior mean residual deviance. This is defined as the difference between the deviance for the fitted model and the saturated model, whereby the deviance measures the fit of the model using the likelihood function. Comparisons of models were made using the deviance information criterion (DIC), which is equal to the sum of the posterior mean of the residual deviance and the effective number of parameters.²³ The DIC penalises the posterior mean residual deviance (a measure of model fit) by the effective number of parameters in the model (as measure of complexity) and can therefore be viewed as a trade-off between the fit and complexity of the model.

Investigation of heterogeneity

We had planned to use subgroup and meta-regression²⁴ analyses to examine the extent to which patient- and study-level characteristics explain between-study heterogeneity. We prespecified the important characteristics to be age, gender, ethnicity/race, body mass index (BMI) or weight, renal status or creatinine clearance, blood pressure, diabetes mellitus, hypertension, previous thrombotic event, liver disease, chronic heart failure, cancer, pregnancy, intervention dose, average TTR in the warfarin group, and summary assessment of risk of bias for each outcome. Additional factors for AF trials were CHADS₂, CHADS₂ VASC, HAS-BLED, history of previous stroke or TIA and previous MI. Additional factors for primary prevention of VTE were general surgery compared with orthopaedic surgery, elective emergency surgery compared with non-elective emergency surgery, and medical trials compared with surgical trials. An additional factor for acute treatment or secondary prevention of VTE was the nature of the index event (whether PE or DVT). When available, inferences about subgroup effects would be based on within-trial subgroup analyses (e.g. comparing relative intervention effects in older and younger participants). Investigation of between-study variation using these characteristics could not be studied in most cases because of the lack of multiple trials of the same pairwise comparison, although we conducted some sensitivity analyses for the review of stroke prevention in patients with AF. Specifically, we performed several meta-regressions using the average TTR in the warfarin group as a covariate.

Investigation of inconsistency

The validity of a NMA depends on the assumption that there is no effect modification of the pairwise intervention effects or, that the prevalence of effect modifiers is similar in the different studies. This key assumption has been referred to variously as exchangeability,²² transitivity,²⁵ similarity²⁶ and consistency.^{27,28} For a clinical and epidemiological judgement of the plausibility of this assumption we examined whether or not the trials were similar in ways that might modify treatment effect, based on the prespecified list of potential effect modifiers (see *Investigation of heterogeneity*).

'Evidence inconsistency' can be considered an additional layer of heterogeneity that occurs in networks of evidence when there is a discrepancy between the direct and indirect estimates of relative intervention effects. Therefore, inconsistency is a property of 'closed loops' of evidence, in which both direct and indirect evidence are available for each comparison. We visually inspected the network diagrams to identify potential for inconsistency (closed loops), and used model fit and selection statistics to informally assess whether or not it was evident. Where there was potential for inconsistency, we compared the residual deviance from the consistency model (providing NMA evidence) with the residual deviance from an 'inconsistency model', without consistency constraints (in which only direct evidence is analysed for each comparison). When both direct and indirect evidence were available, and the direct evidence had a standard error that differed (beyond the second decimal place) from the NMA estimate, we used results from these two analyses to back-compute the indirect estimates, on the basis that the NMA estimates (from the consistency model) would be equivalent to a weighted average of the direct estimate (from the inconsistency model) and the indirect estimate. In the results tables we present all three of these estimates. The extent of the disagreement between the direct and indirect estimates can be used as a local measure of inconsistency for that comparison. Note that for the vast majority of comparisons there was either only direct evidence or only indirect evidence, so that the NMA estimates correspond to one of these.

Chapter 4 Review methods (2): cost-effectiveness analysis

Introduction

This chapter describes the structure of the decision analysis models that we developed to assess the cost-effectiveness of NOACs in the primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of ischaemic stroke in AF. We also provide a brief overview of previous cost-effectiveness models that we identified and used to inform the development of our models.

Our models synthesise evidence on a number of parameters [e.g. incidence of VTE or ischaemic stroke, relative treatment efficacy, adverse events (AEs), costs, etc.] in order to estimate the relative cost-effectiveness of treatment options. The 'model inputs' are based on a variety of evidence sources. These include routine data on drug costs and observational studies of the long-term costs and quality of life (i.e. utilities) in AF and VTE. Many of these model inputs are shared between the AF and VTE cost-effectiveness models, and we summarise them in this chapter. However, other model inputs (e.g. on relative treatment efficacy and safety of anticoagulants) are derived from the results of meta-analyses of RCTs that are identified in our systematic review. We summarise these efficacy and safety model inputs in *Chapters 6 and 11*, which present the results of the cost-effectiveness models for AF and VTE, respectively.

The VTE secondary prevention, acute treatment and primary prevention models were constructed in Microsoft Excel® (Microsoft Corporation, Redmond, WA, USA) and the AF model was constructed in R version 3.02 (The R Foundation for Statistical Computing, Vienna, Austria).²⁹ All (network) meta-analyses were conducted in WinBUGS.³⁰

Decision questions

The questions we addressed were:

1. What is the most cost-effective first-line anticoagulant in the prevention of ischaemic stroke for patients with AF?
2. What is the most cost-effective first-line strategy for the secondary prevention of VTE after an initial PE or DVT?
3. What is the most cost-effective first-line anticoagulant for the acute treatment of symptomatic VTE?
4. What is the most cost-effective first-line anticoagulant for primary prevention of VTE following two types of elective surgery [a, total hip replacement (THR) or b, total knee replacement (TKR)]?

In each case, we evaluated cost-effectiveness from a NHS perspective. We modelled costs and outcomes over the expected lifetime of patients. In the next section, we give a brief overview of previous cost-effectiveness models addressing these decision questions. We then describe the patients, interventions, outcomes, model structure and shared model inputs for each of the four decision questions.

Previous economic models

We performed an informal search of the literature, including NICE technology appraisals, for previous model-based CEAs addressing one of the four decision questions. Our literature search was not intended to be exhaustive, but we aimed to identify a representative sample of existing modelling methods and

structures to inform our models. We developed the structure of our models from a critical appraisal of these previous models together with discussions with clinical experts and patient group representatives on the project team.

For prevention of ischaemic stroke in AF, we identified 18 previous models, summarised in *Table 1* and discussed in detail in *Appendix 6*. A recently published systematic review⁴⁹ identified 30 models on prevention of stroke in AF; however, the main model structures identified in that review were covered by the 12 studies we found. For the prevention and treatment of VTE, we identified 16 previous models, two acute treatment models (*Table 2*) and 14 primary prevention models post orthopaedic surgery (*Table 3*).

Atrial fibrillation: patients and interventions

Atrial fibrillation: patient population

We considered patients with non-valvular AF who were eligible for anticoagulation. We made no distinction between paroxysmal, persistent and permanent AF. The RCTs identified in the systematic review did not distinguish between AF type, but patients with paroxysmal AF are less likely to be included in RCTs than those with other AF types; therefore, our results are most applicable to patients with persistent and permanent AF. We consider a cohort of patients receiving first-line anticoagulation at the age of 70 years, based on the mean age observed in the RCTs identified in the systematic review [mean age 70 years, standard deviation (SD) 8 years], and consider costs and benefits over a lifetime. We assume a 60 : 40 split in favour of males, similar to that observed in the RCTs.

Atrial fibrillation: interventions

The first-line treatments for AF included in the CEA, alongside their standard or licensed doses, are listed in *Table 4*. We consider only licensed treatments and doses in our analysis. Although a few small RCTs have compared betrixaban with warfarin in AF, there was not enough evidence to include it in the economic model. Standard care for patients with AF, before the introduction of NOACs, was warfarin.⁶⁸

Treatment switching may occur as a result of treatment failure, indicated by ischaemic stroke or serious AEs, such as intracranial haemorrhage (ICH). For patients on warfarin first-line treatment, the only second-line intervention available was assumed to be no treatment. For patients on a NOAC first-line treatment, second-line treatment may be either warfarin or no treatment. No treatment is the only third-line treatment. These rules are illustrated in *Figure 1*, where the events that may lead to treatment switching are indicated.

Venous thromboembolism: patients and interventions

Venous thromboembolism: patient populations

For primary prevention, we estimated cost-effectiveness in two distinct subpopulations: patients undergoing elective THR or TKR. We considered including other populations (e.g. patients who were hospitalised for medical treatment) but there was not enough evidence identified in the literature review to inform a model.

After a confirmed VTE event, patients receive acute treatment. The population of patients in the acute treatment model includes those for whom a non-fatal symptomatic VTE event (DVT or PE) followed a THR or TKR, as well as patients with a symptomatic VTE from other causes. Patients who completed at least 3 months of anticoagulant treatment for symptomatic VTE without recurrence are included in the secondary prevention model.

We assumed an average age of subjects entering the primary prevention model of 68.7 years (SD 11.4 years) and the split between males and females of 40 : 60, based on estimates from the National Joint Registry.⁶⁹ The assumed age is in line with the median of the mean age of patients enrolled in the primary prevention

TABLE 1 Summary of sample of 18 previous economic models of anticoagulation for AF

Author, year	Setting	Model type	Interventions	Events	Health states	Time horizon
Gage 1995 ³¹	USA	Markov	Warfarin, aspirin	TIA, stroke, haemorrhage, death	Well, RIND, mild stroke, moderate-severe stroke, second stroke, mild ICH, moderate-severe ICH, RIND and ICH, stroke and ICH, dead	10 years
Lightowlers 1998 ³²	UK	Decision tree	Warfarin (several monitoring strategies), no treatment	Bleed, stroke	NA	10 years
Bayer plc 2011 ³³	UK	Markov	Rivaroxaban, dabigatran, warfarin, aspirin, no treatment	Minor stroke, major stroke, minor bleed, major bleed, MI, ICH, SE, death	On and off treatment for AF stable and post event states for minor stroke, major stroke, minor bleed, major bleed, MI and ICH, dead	Lifetime
Shah 2011 ³⁴	USA	Markov	Dabigatran, warfarin, aspirin	MI, TIA, stroke (four severities), minor bleed, major bleed, dyspepsia, death	Well, TIA, mild stroke, major stroke, second stroke, ICH, stroke and ICH, dead	Lifetime
Freeman 2011 ³⁵	USA	Markov	Dabigatran, warfarin	TIA, stroke, ICH, ECH, MI, death	Well, RIND, mild stroke, moderate-severe stroke, mild ICH, moderate-severe ICH, MI, dead	Lifetime
Lee 2012 ³⁶	USA	Markov	Apixaban, warfarin	Stroke, bleed, MI, ICH, death	Well, RIND, minor ischaemic stroke, major ischaemic stroke, MI, minor ICH, major ICH, ischaemic stroke and ICH, death	Lifetime
Lee 2012 ³⁷	USA	Markov	Rivaroxaban, warfarin	RIND, minor stroke, major stroke, minor ICH, major ICH, stroke and ICH, ECH, MI, death	Well, minor stroke, major stroke, minor ICH, major ICH, MI, dead	Lifetime
Harrington 2013 ³⁸	USA	Markov	Apixaban, dabigatran, rivaroxaban, warfarin	Minor ischaemic stroke, major ischaemic stroke, ICH, MI, death	Well, post minor ischaemic stroke, post major ischaemic stroke, post ICH minor disability, post ICH major disability, post MI, dead	30 years
Kamel 2012 ³⁹	USA	Markov	Apixaban, warfarin	TIA, ECH, MI, mild ischaemic stroke, moderate-severe ischaemic stroke, mild ICH, moderate-severe ICH, death	AF and history of stroke/TIA, mild ischaemic stroke, moderate-severe ischaemic stroke, mild ICH, moderate-severe ICH, recurrent ischaemic stroke or combined stroke and ICH, dead	20 years

continued

TABLE 1 Summary of sample of 18 previous economic models of anticoagulation for AF (continued)

Author, year	Setting	Model type	Interventions	Events	Health states	Time horizon
CADTH – Wells 2012 ⁴⁰	Canada	Markov	Apixaban, dabigatran, rivaroxaban, warfarin	Minor stroke, major stroke, fatal stroke, non-fatal MI, fatal MI, TIA, non-fatal PE, fatal PE, ICH, major bleed, minor bleed, fatal bleed, no-event death	Well, previous TIA, previous minor stroke, previous major stroke, previous MI	40 years
Wisloff 2013 ⁴¹	Norway	Markov	Apixaban, dabigatran, rivaroxaban, warfarin	Gastrointestinal bleed, ischaemic stroke, ICH, acute MI, heart failure, death	Well, previous bleed, previous stroke, moderate stroke sequelae, severe stroke sequelae, previous MI, death	Lifetime
Kansal 2012 ⁴²	UK	Markov	Dabigatran, warfarin	Ischaemic stroke, haemorrhagic stroke, TIA, SE, MI, minor bleed, ICH, ECH, death	Eight states combining stroke history/no stroke history with no disability and mild, moderate and severe disability, death	Lifetime
Canestaro 2013 ⁴³	USA	Markov	Dabigatran, apixaban, rivaroxaban, warfarin	Ischaemic stroke, MI, SE, ICH, ECH, other cause death	Well, post-MI and death states, as well as three severities of each of post-ischaemic stroke, post-ischaemic stroke and MI, post-ICH, post-ICH and MI, post-ICH and ischaemic stroke, post-ICH ischaemic stroke and MI. 21 states in total	Lifetime
Nshimyumukiza 2013 ⁴⁴	Canada	Markov	Dabigatran, warfarin	ICH, ECH, stroke, MI, DVT, PE, death	Daily cycles over four states: no event, major bleeding event, major thromboembolism event, mild/severe deficit	5 years
Krejczyk 2014 ⁴⁵	Germany	Markov	Dabigatran, apixaban, rivaroxaban, warfarin	TIA, ischaemic stroke (fatal, moderate to severe, mild), haemorrhage (fatal, moderate to severe intracranial, mild intracranial, major non-cerebral, minor non-cerebral), MI and death	Healthy with non-valvular AF, TIA, ischaemic stroke (fatal, moderate to severe, mild), haemorrhage (fatal, moderate to severe intracranial, mild intracranial, major non-cerebral, minor non-cerebral), MI and death	20 years
Pink 2011 ⁴⁶	UK	Discrete event simulation	Dabigatran, warfarin	Stroke, PE, TIA, congestive heart failure, fatal stroke, fatal PE, other vascular death, ICH, other major bleed, minor bleed, non-bleed AEs, MI, treatment discontinuation	Combinations of these events were included Recorded patient characteristics were hypertension, diabetes mellitus, congestive heart failure, previous stroke, previous TIA, previous MI, previous ICH	Lifetime

Author, year	Setting	Model type	Interventions	Events	Health states	Time horizon	
Lip 2014 ⁴⁷	UK	Markov	Dabigatran, apixaban, Rivaroxaban	Ischaemic stroke, ICH, gastrointestinal major bleed, other major bleed, CRNM bleed, MI, SE, other cardiovascular hospitalisation, death	Healthy with non-valvular AF, ischaemic stroke, ICH, gastrointestinal major bleed, other major bleed, CRNM bleed, MI, SE, other cardiovascular hospitalisation, death, non-valvular AF on aspirin	Lifetime	
Rognoni 2014 ⁴⁸	Italy	Markov	Dabigatran, apixaban, rivaroxaban, warfarin	Temporary/mild/moderate-severe ischaemic stroke, temporary/mild/moderate-severe ICH, MI, minor extracranial bleeding, major extracranial bleeding, death	Non-valvular AF only, temporary/mild/moderate-severe ischaemic stroke, temporary/mild/moderate-severe ICH, MI, minor extracranial bleeding, major extracranial bleeding, death	Lifetime	
CADTH, Canadian Agency for Drugs and Technologies in Health; NA, not applicable; RIND, reversible ischaemic neurological deficit.							
TABLE 2 Summary of previous economic models for acute treatment of VTE							
Author, year	Setting	Population	Model type	Interventions	Events	Health states	Time horizon
Bayer TA261 2012 ⁵⁰	UK	Adults receiving acute treatment for DVT	Markov model	Rivaroxaban and dual therapy (LMWH and VKA)	Mortality, VTE recurrence, CTPH, PTS, CRB	On treatment: major bleed – ICH, major bleed – ECH, CRNM bleed, recurrent DVT, recurrent PE, CTPH, post intracranial bleed, long-term chronic thromboembolic pulmonary disease, PTS mild/moderate and severe, off treatment and dead	40 years
Bayer TA287 2013 ⁵¹	UK	Adults who are receiving acute treatment for PE	Markov model	Rivaroxaban, LMWH or fondaparinux with continued therapy as follows VKA or LMWH for people for whom a VKA is not considered an appropriate treatment	Mortality, VTE recurrence, CTPH, PTS, CRB	On treatment, major bleed – ICH, major bleed – ECH, CRNM bleed, recurrent DVT, recurrent PE ± DVT, PE post DVT, CTPH, post intracranial bleed, long-term CTPH, severe PTS, off treatment post PE, off treatment post DVT and dead	40 years
CTPH, chronic thromboembolic pulmonary hypertension; PTS, post-thrombotic syndrome.							

TABLE 3 Summary of previous economic models for primary prevention of VTE

Author, year	Setting	Population	Model type	Interventions	Events	Health states	Time horizon
Boehringer Ingelheim TA157 2008 ⁵²	UK	Adults undergoing elective THR or TKR (model parameters and time on treatment differs between populations)	Decision tree and Markov model	Dabigatran, LMWH and fondaparinux	Mortality, incidence of DVT, incidence of PE, post DVT complications including PTS, health-related quality of life, adverse effects of treatment including bleeding events (minor and major) and joint outcomes (medium and long-term) including joint infection	Based on the structure by Botteman <i>et al.</i> ⁵³	60 years
Bayer TA170 2012 ⁵⁴	UK	Adults undergoing elective THR or TKR (model parameters and time on treatment differs between populations)	Decision tree and Markov model	Rivaroxaban, and LMWH	VTE, symptomatic VTE, non-fatal PE, fatal PE and prophylaxis-related bleeding	Text and model schematic has been blanked out	Lifetime
Bristol-Myers Squibb TA245 2012 ⁵⁵	UK	Adults undergoing elective THR or TKR (model parameters and time on treatment differs between populations)	Decision tree and Markov model	Apixaban, LMWH, fondaparinux, rivaroxaban and dabigatran	Mortality, VTE, PTS syndrome and treatment-related bleeding events	Well, untreated VTE, treated VTE, disabled, mild to moderate PTS year 1, mild to moderate PTS year 2+, severe PTS year 1, severe PTS year 2+, DVT, PE, dead	35 years
Botteman 2002 ⁵³	USA	Adults undergoing elective THR	Decision tree and Markov model	LMWH and warfarin	DVT, PE, PTS and mortality	Surgery, DVT, DVT death, DVT survivor, post DVT, mild/moderate PTS year 1, mild/moderate PTS year 2+, severe PTS year 1, severe PTS year 2+, death	Lifetime
Dranitsaris 2009 ⁵⁶	Canada	Adults undergoing elective THR, TKR or hip fracture surgery	Decision tree	Dalteparin (Fragmin®, Pfizer, USA) 10 days, dalteparin 35 days and warfarin	Major bleed, symptomatic DVT at discharge, symptomatic DVT by day 35	NA	3 months
Duran 2012, ⁵⁷ Monreal 2013 ⁵⁸	USA, France, Italy and Spain	Adults undergoing elective THR or TKR	Decision tree and Markov model	Rivaroxaban, enoxaparin and dabigatran	Symptomatic VTE, non-fatal PE, fatal PE, prophylaxis-related bleeding	No PTS, PTS, death	5 years

Author, year	Setting	Population	Model type	Interventions	Events	Health states	Time horizon
Mahmoudi 2013 ⁵⁹	USA	Adults undergoing elective THR or TKR	Decision tree	Xa inhibitors and LMWH	Distal DVT, proximal DVT, fatal PE, non-fatal PE major bleed, stroke	NA	6 months
McCullagh 2009 ⁶⁰	Ireland	Adults undergoing elective hip or knee replacement surgery	Decision tree	Rivaroxaban and dabigatran	Distal DVT, proximal DVT, symptomatic PE, fatal PE, major bleed and fatal bleed	NA	180 days
McCullagh 2012 ⁶¹	Ireland	Adults undergoing elective hip replacement	Decision tree and Markov model	Rivaroxaban, dabigatran and enoxaparin sodium	Distal DVT, proximal DVT, symptomatic PE, fatal PE, major bleed and fatal bleed	No VTE, treated VTE, untreated VTE, PTS year 1, PTS maintenance, stroke and dead	Lifetime
Lundkvist 2007 ⁶²	Sweden	Patients following hip fracture surgery	Decision tree	Fondaparinux and enoxaparin	Symptomatic VTE events, fatal and non-fatal recurrent VTE events and PTS	NA (model closely follows the structure of Gordois <i>et al.</i> ⁶³ and Sullivan <i>et al.</i> ⁶⁵)	5 years
Gordois 2003 ⁶³	England and Wales	Adults following major orthopaedic surgery	Decision tree	Fondaparinux and enoxaparin	Clinical VTE and VTE-related deaths	NA	5 years
Pishko 2012 ⁶⁴	USA	Ambulatory patients with cancer	Decision tree and Markov model	LMWH and no intervention	Major bleed, minor bleed, post bleed, VTE	Malignancy, major bleed, minor bleed, post bleed, VTE, post VTE	2 years
Sullivan 2004 ⁶⁵	USA	Adults following major orthopaedic surgery	Decision tree	Fondaparinux and enoxaparin	Rates of symptomatic thromboembolic events	NA	5 years
Zindel 2012 ⁶⁶	Germany	Adults undergoing elective THR or TKR	Decision tree	Rivaroxaban and enoxaparin sodium	DVT, fatal PE, non-fatal PE major bleed	NA	3 months

NA, not applicable; PTS, post-thrombotic syndrome.

TABLE 4 First-line anticoagulants and dose compared in the CEA

Intervention	Dose/target INR	Time on treatment
Apixaban	2.5 mg bd (elderly) 5 mg bd	Lifetime
Dabigatran	110 mg bd (elderly) 150 mg bd	
Rivaroxaban	20 mg od	
Warfarin	INR 2–3	

Source: *British National Formulary*⁶⁷ or trial based.




FIGURE 1 Treatment strategies and switching/discontinuation rules. The events that may lead to treatment switching are indicated next to the arrows between treatments.

RCTs (median 64.6 years). The starting age in the acute and secondary prevention populations was 57.35 years, the median (across RCTs) of the mean age of patients enrolled in the acute treatment and secondary prevention RCTs. We assumed that the index VTE event on entry to the acute treatment and secondary prevention models was split between DVT and based on the proportion of non-fatal PE and DVT in the acute treatment population.

Venous thromboembolism: interventions

For each indication we compared first-line treatments for which we have sufficient evidence to estimate model parameters. There are seven comparators evaluated in the secondary prevention model (Table 5), four in the acute treatment model (Table 6) and four in each of the two primary prevention subpopulations (Table 7). Before the introduction of NOACs, standard practice⁷⁰ for primary prevention was LMWH, and for acute treatment was LMWH and warfarin for at least 5 days, then continue with warfarin only. In secondary prevention, NICE guidance⁷¹ recommends that clinicians, after discussion with patients, consider extending warfarin therapy beyond 3 months if the risk of VTE recurrence is high and there is no additional risk of major bleeding. However, NICE also acknowledged the need for further research to establish the cost-effectiveness of long-term anticoagulation after unprovoked VTE. In clinical practice, patients may be offered long-term anticoagulation after a second VTE event. Owing to this uncertainty about best practice, we compared all anticoagulants to a 'no pharmacotherapy' secondary

TABLE 5 Secondary prevention comparators

Intervention	Dose/target INR	Time on treatment
Apixaban	2.5 mg bd	Lifetime
	5 mg bd	Lifetime
Aspirin	75 mg od	Lifetime
Dabigatran	150 mg bd	Lifetime
Rivaroxaban	20 mg od	Lifetime
Warfarin	INR 2–3	Lifetime
No long-term pharmacotherapy	–	–

Source: *British National Formulary*.⁶⁷

TABLE 6 Acute treatment comparators

Intervention	Dose	Time on treatment
Apixaban	10 mg bd for 7 days then 5 mg bd	6 months
Dabigatran	150 mg bd	
Rivaroxaban	15 mg bd for 21 days then 20 mg od	
Warfarin	INR range 2–3 plus LMWH ^a for initial 5 days	

a LMWHs [enoxaparin 1 mg/kg bd, enoxaparin 1.5 mg/kg od and tinzaparin (Innohep®, LEO Pharmaceutical Products, Germany) 175 IU/kg].
Source: *British National Formulary*.⁶⁷

TABLE 7 Total hip replacement and TKR primary prevention comparators

Intervention	Dose	Time on treatment	
		THR	TKR
Apixaban	2.5 mg bd	28–35 days	10–14 days
Dabigatran	220 mg od		
LMWH	^a		
Rivaroxaban	10 mg od		

a LMWHs [enoxaparin 40 mg od, enoxaparin 30 mg bd, enoxaparin 20 mg bd, ardeparin 25 anti-Xa units/kg bd, ardeparin 35 anti-Xa units/kg bd, ardeparin 50 anti-Xa units/kg bd, nadroparin 3800IU anti-Xa od, certoparin (Mono-Embolex®, Novartis, Switzerland) 3000 IU od, dalteparin 2.5 mg od, dalteparin 5000 IU od].
Source: *British National Formulary*.⁶⁷

prevention strategy in the base-case model. In a sensitivity analysis, we assumed that patients in this reference group would receive warfarin after a second VTE event. We assumed that all treatment will be stopped for subjects who have an ICH and that no other treatment switching occurs. This assumption differs from the AF population for whom treatment can be stopped or switched for other reasons (see *Atrial fibrillation: interventions*, above).

Outcomes of atrial fibrillation and venous thromboembolism models

We present results on total costs and quality-adjusted life-years (QALYs), both discounted at 3.5%. We present a probabilistic analysis, for which model parameters are given probability distributions to reflect uncertainty in their values.⁷² We summarised the results with the expected costs, expected QALYs and expected net monetary benefit (NMB) for a range of willingness to pay per additional QALY gained (where expected values are an average over the joint distribution of the model parameters). NICE has a stated willingness-to-pay threshold of £20,000–30,000 per QALY.⁷³

Uncertainty in the model input parameters is captured using simulation [Monte Carlo simulation for parameters with assumed distributions, and Markov chain Monte Carlo (MCMC) simulation for parameters estimated from the NMA]. We represent decision uncertainty using the cost-effectiveness plane, cost-effectiveness acceptability curves (CEACs), and cost-effectiveness acceptability frontiers (CEAFs). The cost-effectiveness plane plots incremental effects (QALYs) against incremental costs for each simulation sample. The CEAC plots the proportion of the simulation samples where each strategy had the highest net benefit (i.e. was most cost-effective) against willingness-to-pay-per-QALY threshold. These proportions are estimates of the probability that the treatment is the most cost-effective. If this probability is close to one for a particular treatment, this suggests very little uncertainty as to the most cost-effective treatment, whereas if it is low the choice of most cost-effective treatment is uncertain. This allows decision-makers to identify interventions that are unlikely to be cost-effective at any plausible threshold and to judge how sensitive treatment choice is to the amount that the NHS is willing to pay for a QALY. The CEAC is not robust when there is a treatment with a high degree of uncertainty in net benefit, giving high probabilities of being both most cost-effective and least cost-effective. For this reason the CEAF has been proposed.⁷⁴ This plots, for each willingness-to-pay threshold, the probability of being most cost-effective only for the treatment with the highest expected net benefit at that willingness-to-pay threshold.

We use value of information (VOI) methods to explore how sensitive the optimal treatment is to uncertainty in the model inputs, and guide research recommendations. We estimate the expected value of perfect information (EVPI) and the expected value of partial perfect information (EVPPPI). EVPI and EVPPPI measure the expected improvement to our decision-making (in monetary units) if we were to eliminate uncertainty in all (EVPI) or some (EVPPPI) of the model input parameters. We present EVPI per person per year and also per population over 10 years discounted at 3.5%, for given annual incidence for each of our populations. EVPPPI for subsets of parameters are computed using the Sheffield Accelerated Value of Information (SAVI) version 2.0.9 (University of Sheffield, Sheffield, UK) web application.^{75,76} This method gives only approximate results, which can be interpreted as indicative of the relative sensitivity of the decision to different groups of parameters.

Atrial fibrillation model structure

The discrete-time Markov multistate model structure (*Figure 2*) used a cycle length of 3 months, as in other recent models.^{33,40,42} We ran the model for a cohort starting at age 70 years and used a lifetime time horizon with a cut-off at 100 years, thus giving 120 cycles. Patients were initially assigned to first-line treatment, which may be warfarin or a NOAC. There is a probability of switching to another therapy or discontinuing treatment entirely (see *Figure 1*).

Each of the treatment strategies has the same model structure but with different costs, utilities and event probabilities. From any state, a patient can have a clinically relevant (extracranial) bleed, an ICH, an ischaemic stroke, a MI, a TIA, a SE, can discontinue or switch treatment because of these events or die. These events are similar to those used in earlier models.^{34,42} The primary difference is that we do not distinguish between minor and major ischaemic stroke, as there was limited evidence from the RCTs to estimate the relative rates of these events. We also do not include non-clinically relevant minor bleed events, as it is assumed that they will not have a significant impact on costs, quality of life or future risks. As in most previous models, memory states are used to record a history of the most important previous events.




FIGURE 2 Markov model for AF. Patients can experience transient events (TIA or SE) but stay in same health state, with possibly changed treatment, thereafter. B, other clinically relevant bleed; S, ischaemic stroke.

The model assumes that SE and TIA have only short-term effects on future risks, costs and utilities, whereas ischaemic stroke, ICH, other CRB and MI have long-term consequences that must be modelled. Up to four major events are therefore recorded and assumed to affect future risks, costs and utilities. For example, patients with MI + ICH will have different risks, costs and utilities to patients with MI or ICH alone. Unlike the Wisloff 2013 model,⁴¹ our model does not distinguish between bleed locations, such as gastrointestinal and other types of bleed. Based on advice from clinical project team members, we assumed that the greatest impact on risks, costs and effects is captured by the broad definition of 'clinically relevant bleeds', as reported in the RCTs. In total, our model has 17 states, including a well state ('AF Well') and death.

At any cycle, patients can switch treatments to second-line or no treatment. All adverse health events increase the probability of treatment switching. An ICH is assumed to always lead to treatment switching. Patients are assumed to always switch treatment from dabigatran to warfarin if they experience a MI as a result of recent findings suggesting a link between dabigatran and MI risk.⁷⁷ Whether or not patients switch treatment after an ischaemic stroke depends on whether it was due to treatment failure or non-compliance. We assume it is due to treatment failure but that only a proportion of patients will switch treatment following an ischaemic stroke.

In the Markov model, future state transitions depend only on the current state in which the patient is (and not past history). We assume homogeneous transition probabilities that do not change with time. However, the age of the cohort will increase with each cycle and mortality risk increases accordingly, based on general population life tables. There is no available evidence to suggest treatment effects change with age or that they depend on event history. The model therefore makes the assumption that treatment effects are independent of age and event history.

Venous thromboembolism model structures: overview

There were three model structures for the primary prevention, acute treatment and secondary prevention decision problems. The structure of the primary prevention model was identical in the two subpopulations (THR and TKR); however, the parameter values differ. Decision trees were used to model the initial costs and outcomes of primary prevention and acute treatment, where anticoagulation is used over short periods of time, and a Markov model evaluated secondary prevention, where anticoagulation may be prescribed over prolonged periods. The models are linked because most patients who have acute treatment for VTE will be considered for extended secondary prevention of recurrence and it is possible that a patient receiving anticoagulation for primary prevention will have a VTE requiring acute treatment and eventually secondary prevention (*Figure 3*). Therefore, we modelled the decision problems sequentially. We first estimated the most cost-effective method of secondary prevention. We then estimated the most cost-effective method of acute treatment, assuming that all patients who subsequently require secondary prevention are managed using the most cost-effective method from the secondary prevention model. Finally, we estimated the most cost-effective method of primary prevention, with the therapy used for acute treatment and secondary prevention determined based on the results of the first two models. For this reason, we begin our detailed discussion of the three models with the secondary prevention model.

Venous thromboembolism model structure: secondary prevention

A Markov model with half-cycle correction⁷⁸ was used to evaluate the cost-effectiveness of prophylaxis in patients who have experienced a previous non-fatal VTE event (*Figure 4*). The model has a cycle length of 1 year and includes eight health states (*Table 8*). Subjects enter the model in post PE or post DVT. Subjects in the 'post DVT' (or 'post PE') state can have an additional non-fatal DVT (or PE) event with a transient utility decrement and cost, but remain in the same health state. Subjects in the 'post DVT' state who experience a non-fatal PE and subjects in 'post PE' who experience a non-fatal DVT transition to 'post PE DVT'. Subjects in the 'post DVT' and 'post PE DVT' states can develop post-thrombotic syndrome (PTS) and transition to either 'mild/moderate PTS' or 'severe PTS'. Subjects who have had a PE may experience chronic thromboembolic pulmonary hypertension (CTPH). Subjects can transition to CTPH from 'post PE' and 'post PE DVT'.




FIGURE 3 Population pathway. THR primary prevention, TKR primary prevention, VTE with acute treatment and secondary prevention.




FIGURE 4 Venous thromboembolism secondary prevention Markov model. Nodes represent the health states; lines between nodes represent possible transitions; all health states can transition to death. ICH, other clinically relevant bleeds, DVT and PE are acute events, which may lead to a change in chronic health state (e.g. post ICH).

TABLE 8 Health states in the secondary prevention model

Health state	Description
Post DVT	Experienced at least one DVT event and no PE events
Post PE	Experienced at least one PE event and no DVT events
Post PE DVT	Experienced at least one DVT event and at least one PE event
PTS mild/moderate	Mild/moderate PTS after one or more DVT events
PTS severe	Severe PTS after one or more DVT events
CTPH	CTPH after PE event
Post ICH	Post ICH
Death	Dead (any cause)

All subjects who are receiving treatment can transition to the ICH health state. After entering this state, we assumed that anticoagulation therapy will be stopped and subjects will remain there until death, as this is considered to be the state with the lowest quality of life.

Venous thromboembolism model structure: acute treatment

The acute treatment of symptomatic VTE was modelled using a decision tree covering the first 6 months of therapy, in line with current guidelines for the duration of acute treatment (Figure 5). There is a probability that patients will experience recurrent symptomatic VTE during the acute treatment period and, regardless of VTE recurrence, all patients are at risk of other CRB or ICH. Longer-term costs and outcomes following acute treatment were estimated using the secondary prevention Markov model for patients who are alive at the end of acute treatment.




FIGURE 5 Venous thromboembolism acute treatment decision tree. At the end of each branch in the decision tree, patients progress to the secondary prevention model. ICH branches enter in 'post ICH' state; treated symptomatic DVT (with bleed or no AE) will enter the post DVT state; treated symptomatic PE (with bleed or no AE) will enter the post PE state; recurrent symptomatic VTE post DVT will enter the post DVT or post DVT PE state, depending on the previous event; and recurrent symptomatic VTE post PE will enter the post PE or post DVT PE state, depending on the previous event.

Venous thromboembolism model structure: primary prevention

The primary prevention model consists of a decision tree covering the first 180 days of prophylactic anticoagulation (Figure 6). After this initial period, the long-term cost and outcomes of patients who do not have a symptomatic VTE are tracked using a two-state Markov model (Figure 7). This Markov model has two health states: no VTE/asymptomatic VTE and dead. The Markov model has a lifetime time horizon and yearly cycles. The longer-term costs and outcomes of patients who have a symptomatic VTE are tracked in the acute treatment model (see Figure 5) and the secondary prevention model (see Figure 4).

Patients enter the primary prevention model after having elective surgery (TKR or THR). They then experience either a symptomatic VTE event or no VTE/asymptomatic VTE. Patients who experience a symptomatic event have a fatal PE, non-fatal PE or DVT, and are treated. Regardless of VTE incidence, all patients are at risk of another CRB during the initial 90-day period of anticoagulation. Because treatment duration is short for primary prevention, the risk of ICH is very low, and there is no evidence of a relative effect of NOACs compared with LMWH in this patient population. Therefore, we have not incorporated ICH in the primary prevention model.




FIGURE 6 Primary prevention decision tree. At the end of the decision tree, subjects will have experienced a symptomatic VTE or not; if they have then they will enter the acute treatment model. Those who did not experience a symptomatic VTE will enter the two-stage Markov model.




FIGURE 7 Primary prevention Markov model.

Inputs partially shared between atrial fibrillation and venous thromboembolism models

Cost of pharmacotherapy

Average drug costs were based on the *British National Formulary* (BNF) March 2015 update,⁶⁷ using the most economical pack size (Tables 9–11). Edoxaban does not currently have a list price in the UK. For the base case we assume that the 6-monthly cost is equivalent to dabigatran. We tested this assumption in a sensitivity analysis. As all of the NOACs are taken orally, it was assumed that there are no administration or monitoring costs, following the costing report in AF of Ali *et al.*⁷⁹ Average drug and monitoring cost of warfarin comes from a costing report by NICE⁶⁸ and is cited in the study by Kansal *et al.*⁴² The cost of LMWH was an average over all of the LMWHs included in the meta-analyses and listed in the BNF.

The unit costs of drugs are assumed to be fixed and known, so that point estimates – rather than distributions – are entered into the models. However, the administration and monitoring cost of warfarin is uncertain, and in the absence of other information we assumed a uniform distribution ranging from 50% to 150% of the estimated cost from the NICE costing report.⁶⁸ We performed a sensitivity analysis for the assumed cost of warfarin monitoring.

TABLE 9 Drug dose, duration and costs for the AF and VTE secondary prevention interventions

Intervention	Dose per day (mg)	mg per tablet	No. in pack	Cost (£) per pack	Cost (£) per day	Administration cost (£)	Cost (£) per 3-month cycle AF model	Cost (£) per annual cycle VTE secondary prevention model
Apixaban	10	5	56	61.50	2.20	0.00	200.42	802.25
	5	2.5	60	65.90	2.20	0.00	200.44	802.33
Dabigatran	300	150	60	65.90	2.20	0.00	200.44	802.33
	220	110	60	65.90	2.20	0.00	200.44	NA
Rivaroxaban	20	20	100	210.00	2.10	0.00	191.63	767.03
Warfarin							^a 105.13 ⁶⁸	420.52 ^a

NA, not applicable.

a We inflated to 2013–14 values using the Office for National Statistics (ONS) Consumer Price Inflation Index for Medical Services (DKC3)⁸⁰ and placed a uniform distribution $\sim(52.57, 157.70)$ and $(210.26, 630.79)$ (on the cost per 3-month and yearly cycles, respectively).

TABLE 10 Drug dose, duration and costs for VTE acute treatment interventions

Intervention	Dose per day (mg)	mg per tablet	No. in pack	Cost (£) per pack	Time (days)	Cost (£) per treatment
Warfarin					182.5	210.26 ^a
Dabigatran	300	150	60	65.90	182.5	400.89
Edoxaban	60	–	–	–	–	400.89 ^b
Rivaroxaban	30	15	14	29.40	21	427.35
	20	20	100	210	161.5	
Apixaban	10	5	56	61.50	182.5	400.85

a Total cost of warfarin includes 5 days of LMWH at £9.38 per day.

b The 6-monthly cost of edoxaban is assumed to be equal to that of dabigatran.

TABLE 11 Drug dose per day for VTE primary prevention comparators

Intervention	Dose per day (mg)	mg per tablet	No. in pack	Cost (£) per pack	Cost (£) per day
Apixaban (2.5 mg bd)	5	2.5	60	65.90	2.20
Dabigatran (220 mg od)	220	110	60	65.90	2.20
Rivaroxaban (10 mg od)	10	10	100	210.00	2.10
LMWH (post-op, standard dose)	–	–	–	–	4.17 ^a

a Average daily cost of enoxaparin 20 mg bd, enoxaparin 40 mg od, dalteparin 5000 IU, fondaparinux 2.5 mg od.

Cost of acute venous thromboembolism, atrial fibrillation and anticoagulant-related events

All costs of acute and chronic care were inflated to 2013–14 values using the Office for National Statistics (ONS) Consumer Price Inflation Index for Medical Services (DKC3).⁸⁰ Acute management costs for SE, MI, TIA, DVT, PE and CRB come from the 2012–13 NHS reference costs.⁸¹ The reference costs for MI account for only direct hospitalisation; we assumed that total costs would be double this amount to account for follow-up costs.⁸² The cost of a sudden fatal PE is assumed to be zero and the patients who have a non-fatal PE are assumed to accrue the full cost of a PE. Acute management costs for ischaemic stroke and ICH come from a study of patients with AF on a UK stroke registry.⁸³ Normal distributions are assumed for the mean acute costs, with SDs defined by the standard errors of the source data (Table 12).

Cost of chronic care for venous thromboembolism, atrial fibrillation and anticoagulant-related events

Long-term management costs of stroke (ischaemic stroke or ICH) also come from the UK stroke registry⁸³ (Table 13). This registry⁸³ stratified the severity of ischaemic strokes by disability (non-disabling, moderately disabling, totally disabling) and we averaged their annual costs and SDs, weighted by the number of events. As in the study by Kansal *et al.*,⁴² we assumed the same cost for ICH as for ischaemic stroke. Normal distributions are assumed, with SDs defined by the standard errors of the source data.

TABLE 12 Acute event costs and their distributions

Event	Mean event cost (£)	Distribution(mean, standard error)	Source
Ischaemic stroke	11,626 (SD = 16,868)	Normal(11,626, 1325)	^a Ischaemic stroke, all strokes ⁸³
ICH	11,453 (SD = 13,815)	Normal(11,453, 3350)	ICH or haemorrhagic stroke, all haemorrhagic strokes ⁸³
SE (non-fatal)	2373	Uniform(1186.5, 3559.5)	NHS reference costs ⁸¹
TIA	1064	Uniform(532, 1596)	NHS reference costs ⁸¹
PE ^b	1596	Normal(1596, 159.6) ^c	NHS reference costs ⁸¹
DVT ^d	712	Normal(712, 71.2) ^c	NHS reference costs ⁸¹
CRB ^e	1751.50	Uniform(875.75, 2627.25)	NHS reference costs ⁸¹
MI	4830	Uniform(2415.24, 7245.72)	Acute MI, NHS reference costs for hospitalisation, ⁸¹ doubled to include follow-up costs

HRG, Healthcare Resource Group.

a We inflated to 2013–14 values using the ONS Consumer Price Inflation index for medical services (DKC3).⁸⁰

b Weighted average of HRG codes DZ09D, DZ09E, DZ09F, DZ09G, DZ09H.

c We assumed a standard error of 10% of the mean event cost.

d Weighted average of HRG codes YQ51A, YQ51B, YQ51C, YQ51D, YQ51E.

e Average of gastrointestinal and non-gastrointestinal bleed.

TABLE 13 Annual post-ischaemic stroke and post-ICH management costs^a

Event	Mean cost (£)	Distribution	Source
Non-disabling	2135 (SD = 3676, <i>n</i> = 66)		Luengo <i>et al.</i> ⁸³
Moderately disabling	4165 (SD = 7668, <i>n</i> = 58)		
Totally disabling	6324 (SD = 14,898, <i>n</i> = 6324)		
All (ischaemic stroke and ICH)	3613 (SD = 4235, <i>n</i> = 136)	Normal (3613, 363)	Weighted average of the mean and SD, inflated to 2013–14 prices

a These are divided by four to obtain 3-monthly cycle costs.

For states with a history of multiple events, we assumed that the additional post-event management costs were the maximum of the management costs for the constituent events. We divided sampled costs by four to obtain 3-monthly cycle costs.

Costs for mild to moderate and severe PTS have previously been estimated in a NICE technology appraisal,⁸⁴ which looked at the clinical effectiveness and cost-effectiveness of dabigatran for the prevention of VTE after a TKR or THR in adults. This study⁸⁴ converted and inflated costs from a US economic burden study⁸⁵ of long-term complications of primary prevention of DVT after a THR. This study⁸⁴ estimated the cost of mild to moderate PTS to be £541 for the first year and £220 for subsequent years, and severe PTS to be £2461 for the first year and £602 for subsequent years. Inflating to 2013–14 values resulted in a cost of £689 for the first year and £280 for subsequent years for mild/moderate PTS, and £3136 for the first year and £767 for subsequent years of severe PTS. NICE guidance for the management of VTE⁷¹ estimated a 4-weekly cost of CTPH to be £2173, equivalent to an annual cost of £33,028 in 2013–14 prices.

Utilities

The AF and VTE models used utility weights combined with survival to estimate QALYs. Utility weights are anchored at 1 (best health) and 0 (as bad as death), such that a year spent in an intermediate health state with a utility weight of 0.5 would be considered equivalent to 6 months in the best health state with a utility value of 1. The models have a number of acute health events that affect patients for a short period, followed by a partial or full recovery and a number of chronic health states from which patients do not recover. Several of these health events and health states are shared between the AF and VTE models.

Utilities were identified from a previous NICE technology appraisal submission on rivaroxaban³³ and from a rapid literature review to identify quality-of-life studies in VTE. The rivaroxaban technology appraisal submission³³ conducted a systematic literature search for evidence on EQ-5D (European Quality of Life-5 Dimensions) utility index in health states related to AF. For VTE events (DVT and PE), Locadia *et al.*⁸⁶ estimated health utilities, using time trade-off methods, from a cohort of 53 patients who had experienced a VTE event.

Utilities of venous thromboembolism, atrial fibrillation and anticoagulant-related acute health events

The acute health event disutilities for AF for other CRB, SE and TIA are reported in *Table 14*. The remaining acute health event disutilities for AF (acute ICH and acute MI; see *Table 14*) are obtained by subtracting 'Stable AF' from the utility of the event. For example, the disutility for MI would be $0.683 - 0.779 = -0.096$.

These disutilities are capped above at 0. Further acute event utility values extracted from the literature for VTE primary prevention, acute treatment and secondary prevention models are reported in *Table 15*. When uncertainty estimates were reported, we assumed that mean utilities would be normally distributed, as indicated by the central limit theorem. When uncertainty estimates and sample sizes were not available (acute ischaemic stroke, TIA, SE), we assumed mean utilities to follow a uniform distribution ranging from 50% to 150% of the reported mean. The duration of the decrements for DVT and PE was assumed to be

TABLE 14 Utilities

Health state	Utility score	Distribution ^a	Source
Reference group health state			
Stable AF quality of life (for AF model)	0.779 (SD = 0.253, n = 3045, standard error = 0.0045)	Normal(0.779, 0.0045)	Berg 2010 ⁸⁷
No VTE quality of life (for VTE model)	0.96 (SD = 0.046)	Beta(16.52, 0.69)	Locadia 2004 ⁸⁶
Acute health events^b			
TIA and SE disutility	-0.131	Uniform(-0.197, -0.066)	Robinson 2001 ⁸⁸
Acute ischaemic stroke disutility	-0.59	Uniform(-0.885, -0.295)	Robinson 2001 ⁸⁸
DVT (first and subsequent)	0.84 (SD = 0.087)	Beta(14.17, 2.70)	Locadia 2004 ⁸⁶
PE (first and subsequent)	0.63 (SD = 0.128)	Beta(8.40, 4.93)	Locadia 2004 ⁸⁶
Acute ICH disutility	Median 0.60 (95% CI 0.02 to 1.00) (n = 60)	Normal(0.60, 0.064) – AF well	Lenert 1997 ⁸⁹
Other CRB disutility	-0.03 (standard error = 0.001531)	Normal(-0.03, 0.001531)	Robinson 2001 ⁸⁸
Acute MI disutility	0.683 (SD = 0.233, n = 222, standard error = 0.0156)	Normal(0.683, 0.0156) – AF well	^c Lacey 2003 ⁹⁰
Chronic health states			
Post ischaemic stroke quality of life	0.69 (SD = 0.18, n = 77, standard error = 0.0205)	Normal(0.69, 0.0205)	^d Haacke 2006 ⁹¹
Mild/moderate PTS	-0.02 ^e	Beta(97.98, 4801.02)	Lenert 1997 ⁸⁹
Severe PTS	-0.07 ^e	Beta(92.93, 1234.64)	Lenert 1997 ⁸⁹
CTPH	0.57 (SD 0.31)	Beta(1.20, 0.94)	Meads 2008 ⁹³
Post ICH quality of life	0.74 (SD = 0.39, n = 5, standard error = 0.1744)	Beta(3.941, 1.385)	^f Haacke 2006 ⁹¹
Post MI quality of life	0.718 (SD = 0.243, n = 222, standard error = 0.0163)	Normal(0.718, 0.0163)	^c Lacey 2003 ⁹⁰

a Capped above at 1 for quality of life and 0 for disutility.

b Disutilities assumed to last for 3 months.

c Table 3, year mean EQ-5D score utility decrement.

d Table 2 in source article, weighted average EQ-5D score for ischaemic stroke

e Utility decrement with an assumed standard error of 10% of the mean.

f Table 3 in source article, EQ-5D for haemorrhagic stroke.

TABLE 15 Transient event utility values for primary prevention, acute treatment and secondary prevention models

Transient event	Utility/decrement	Duration of decrement	Source
DVT (first and subsequent)	0.84 (0.64 to 0.98)	6 months	Locadia 2004 ⁸⁶
PE (first and subsequent)	0.63 (0.36 to 0.86)	6 months	Locadia 2004 ⁸⁶
ICH	0.60 (0.02 to > 0.99)	3 months	Lenert 1997 ⁸⁹
Other clinically relevant bleed	0.03 (standard error 0.001531) ^a	Absolute decrement	Robinson 2001 ⁸⁸

a Decrement.

6 months⁷¹ and 3 months for ICH, before moving to the post-ICH health state.⁵¹ Duration of decrements was generally not reported for the AF disutilities, so they were assumed to last one cycle.

In both the AF and VTE model, to account for quality of life decreasing with age, all utility decrements were multiplied by the ratio of the utility for a given age range relative to a reference age (65–75 years), based on general population utilities estimated in Kind *et al.*⁹² (Table 16). Utilities were also adjusted by gender in this way for the VTE models, whereas for the AF models all utilities were weighted averages across gender.

Utilities of venous thromboembolism, atrial fibrillation and anticoagulant-related chronic health states

In the AF model, for which patients can have more than one chronic health condition, utilities for chronic health states are assumed to be multiplicative. For example, the utility of a patient who has experienced both an ischaemic stroke and a MI will be the product of the two utility scores (see Table 14): $0.690 \times 0.718 = 0.495$.

Utilities are multiplied by 0.25 to get a QALY for 3-month cycle.

For the VTE-related chronic health states, we used estimates from the study by Lenert and Soetikno,⁸⁹ who elicited preferences in 30 volunteers and 30 medicine physicians with mild/moderate PTS and severe PTS, and the study of Meads *et al.*,⁹³ who used the Cambridge Pulmonary Hypertension Outcome Review utility index⁹⁴ to estimate a utility value for CTPH from 308 patients (see Table 14). Further chronic VTE-related chronic health-state utilities extracted from the literature are reported in Table 17.

TABLE 16 General population utility values (mean and SD) by age and gender^a

Age (years)	Male		Female		Source
	Mean (SD)	Alpha, beta	Mean (SD)	Alpha, beta	
< 25	0.94 (0.12)		0.94 (0.12)		Kind 1999 ⁹²
25–34	0.93 (0.16)		0.93 (0.15)		
35–44	0.91 (0.17)	656.7, 65.0	0.91 (0.15)	1006.6, 99.5	
45–54	0.84 (0.27)	341.4, 65.0	0.85 (0.23)	544.1, 96.0	
55–64	0.78 (0.28)	330.4, 93.2	0.81 (0.26)	526.6, 123.5	
65–74	0.78 (0.28)	388.5, 109.6	0.78 (0.25)	551.7, 155.6	
≥ 75	0.75 (0.28)	191.2, 63.7	0.71 (0.27)	406.4, 166.0	

a Assumed beta distribution parameters; alpha and beta are given by age and gender.

TABLE 17 Health-state utility values for primary prevention, acute treatment and secondary prevention models

Health state	Utility/decrement	Source
Reference – no VTE	0.96 (0.82 to 1.00)	Locadia 2004 ⁸⁶
Mild/moderate PTS	0.02 (SD 0.04) ^a	Lenert 1997 ⁸⁹
Severe PTS	0.07 (SD 0.07) ^a	Lenert 1997 ⁸⁹
CTPH	0.57 (SD 0.31)	Meads 2008 ⁹³
Post ICH	0.74 (standard error 0.1744)	Haacke 2006 ⁹¹
Death	0.00 (0 to 0)	Definition

a Decrement.

Summary

This chapter summarises the decision problems addressed by the cost-effectiveness models; the structure, perspective, and target population of the models; and the interventions and outcomes represented by the models. We developed the structure of the model based on existing cost-effectiveness models that were identified in the literature, and the structure evolved based on feedback from clinical experts in order to reflect current disease knowledge and clinical practice. We used decision trees to reflect the short-term nature of the VTE primary prevention and acute treatment decision problems, and Markov models to address the AF-related ischaemic stroke and VTE secondary prevention decision problems for which longer periods of prophylaxis are required.

This chapter also summarises the cost and utility model inputs shared by the AF and VTE models. Model inputs on the relative treatment efficacy and safety of anticoagulants were derived from the results of meta-analyses of RCTs identified in our systematic review. We summarise these efficacy and safety model inputs in *Chapters 6 and 11*, which also present the results of the cost-effectiveness models for AF and VTE.

Chapter 5 Clinical results (1): stroke prevention in atrial fibrillation

Included studies

A total of 1852 unique records were identified from various data sources for the review of stroke prevention in AF (Figure 8).

Twenty-three completed eligible RCTs were identified for inclusion in the review, with a total of 41 associated references for these trials.⁹⁵⁻¹³⁵ No ongoing trials were identified. A summary of the characteristics of the 23 trials is presented in Table 18. Twenty of the trials were multicentre;




FIGURE 8 The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow chart for review of stroke prevention in AF.

TABLE 18 Characteristics of 23 included randomised trials in stroke prevention in AF

Study (centre type) [countries]	Study type, sponsor (sponsor's role)	Age eligibility (mean age, years) [% male]	AF type	No. randomised	Interventions compared	Treatment duration (months)	Mean TTR (INR), %	Outcomes	Time of outcome assessment (months)
ACTIVE W¹⁰⁰ (Multicentre) [North and South America, Europe, Russia, Israel, Australia, Asia and South Africa]	Phase III Sanofi-Aventis and Bristol-Myers Squibb (The sponsor contributed to the study design 'but had no role in data collection, data analysis, data interpretation, or writing of the report')	≥ 18 (70.2) [66.1]	Non-valvular ECG diagnosed	6706	<i>Antiplatelet:</i> 1. Clopidogrel 75 mg + (aspirin 75–100 mg) od <i>Warfarin:</i> 2. INR 2–3 (some patients may have received other VKAs in use in their country)	Not given	63.8	<i>Efficacy:</i> All stroke, ischaemic stroke, haemorrhagic stroke, MI <i>Safety:</i> All bleeding, major bleeding, minor bleeding, fatal bleeding, death (all causes)	15.4
AFASAK⁹⁵ (Two centres) [Denmark]	Phase III NycMed AS, Oslo, Norway; Henrik Henriksen's Foundation; Kathrine and Vigo Skovgaard's Foundation; and Danish Medical Research Foundation (Not stated)	≥ 18 (74.2) [53.6]	Chronic non-valvular ECG diagnosed	1007	<i>Warfarin:</i> 1. INR 2–3 <i>Antiplatelet (aspirin):</i> 2. 75 mg od 3. Placebo od	24	73	<i>Efficacy:</i> All stroke, fatal stroke, minor ischaemic stroke, TIA <i>Safety:</i> Bleeding, death (all causes)	24
AFASAK II⁹⁷ (Single centre) [Denmark]	Phase III The Danish Heart Foundation, Copenhagen; Nycomed DAK A/S Roskilde, Denmark; DuPont Pharma, Wilmington, DE, USA; The Danish Foundation for Medical Research for the Region of Copenhagen; and many other non-industry funders (Not stated)	≥ 18 (74.2) [60]	Chronic non-valvular ECG diagnosed	677	<i>Warfarin:</i> 1. 1.25 mg/day fixed dose 2. 1.25 mg/day fixed dose plus aspirin 300 mg/day od 3. INR 2–3 <i>Aspirin:</i> 4. 300 mg od	42	73	<i>Efficacy:</i> All stroke, ischaemic stroke, haemorrhagic stroke, fatal stroke, stroke or SE, TIA, MI <i>Safety:</i> Major bleeding, minor bleeding, intracranial bleeding, death (all causes)	42

Study (centre type) [countries]	Study type, sponsor (sponsor's role)	Age eligibility (mean age, years) [% male]	AF type	No. randomised	Interventions compared	Treatment duration (months)	Mean TTR (INR), %	Outcomes	Time of outcome assessment (months)
AF-ASA-VKA-CHINA ¹³⁵ (Two centres) [China]	Phase III Grant from talent pool subject of Shanghai Shi Dong Hospital (Not applicable)	≥ 80 (NR) [NR]	Persistent and non-valvular Confirmed by the case history and ECG	110	Warfarin: 1. INR 1.6–2.5 <i>Antiplatelet (aspirin):</i> 2. 100 mg od	24	NR	Efficacy: Stroke or SE, ischaemic stroke, MI Safety: All bleeding, major bleeding, minor bleeding, fatal bleeding, death (all causes)	1, 6, 12, 18, 24
AF-DABIG-VKA-JAPAN ¹¹⁰ (Multicentre) [Japan]	Phase II Boehringer Ingelheim (The sponsor was involved in the trial)	≥ 20 (NR) [NR]	Paroxysmal, persistent or permanent non-valvular ECG diagnosed	174	<i>Dabigatran:</i> 1. 110 mg bd 2. 150 mg bd Warfarin:	3	NR	Efficacy: Stroke or SE Safety: All bleeding, major bleeding, composite CRB	3
AF-EDOX-VKA-ASIA ¹¹⁵ (Multicentre) [Taiwan, South Korea, Hong Kong and Singapore]	Phase II Daiichi Sankyo Co., Ltd, Tokyo, Japan (The sponsor had influence on the study design, data management and analysis, and key decisions)	18–80 (65.1) [65.4]	Non-valvular ECG diagnosed CHADS ₂ ≥ 1	235	<i>Edoxaban:</i> 1. 30 mg od 2. 60 mg od Warfarin: 3. INR 2–3	3 (edoxaban) 6 (warfarin)	45.1	Efficacy: Stroke or SE Safety: All bleeding, major bleeding, minor bleeding, CRNM bleeding	3

continued

TABLE 18 Characteristics of 23 included randomised trials in stroke prevention in AF (continued)

Study (centre type) [countries]	Study type, sponsor (sponsor's role)	Age eligibility (mean age, years) [% male]	AF type	No. randomised	Interventions compared	Treatment duration (months)	Mean TTR (INR), %	Outcomes	Time of outcome assessment (months)
AF-EDOX-VKA-JAPAN ¹² (Multicentre) [Japan]	Phase II Daiichi Sankyo Co., Ltd, Tokyo, Japan (The funder 'had input on the study design and data analysis and interpretation of results and wrote the clinical study report')	≥ 20 (NR) [NR]	Non-valvular ECG diagnosed CHADS ₂ ≥ 1	536	Edoxaban: 1. 30 mg od 2. 45 mg od 3. 60 mg od Warfarin: 4. INR 2–3	3	83 (≥ 70) 73 (< 70 years)	Efficacy: Stroke or SE Safety: All bleeding, major bleeding, CRNM bleeding, composite CRB	3
AF-EDOX-VKA-MULTI ¹⁰⁸ (Multicentre) [North America, Chile, Europe and Russia]	Phase II Daiichi Sankyo Co., Ltd, Tokyo, Japan (Not clear)	18–85 (65.1) [62.1]	Persistent non-valvular ECG diagnosed CHADS ₂ ≤ 2	1146	(INR 1.6–2.6 in ≥ 70 years) Edoxaban: 1. 30 mg od 2. 60 mg od 3. 30 mg bd 4. 60 mg bd Warfarin: 5. INR 2–3	3	49.7	Efficacy: Stroke or SE, MI, hospital admission Safety: All bleeding, major bleeding, minor bleeding, CRNM bleed, composite CRB, death (cardiovascular)	3
AF-VKA-ASA-CHINA ¹²² (Multicentre) [China]	Phase III 10th National Five-year Project of China (Not applicable)	50–80 (NR) [NR]	Non-valvular Diagnosis based on medical history, ECG and/or Holter recordings	690	Warfarin: 1. INR 2.1–2.5 2. INR 1.6–2 Antiplatelet (aspirin): 3. 200 mg od	24 (mean 15)	NR	Efficacy: All stroke, ischaemic stroke, haemorrhagic stroke, TIA Safety: Major bleeding, minor bleeding, death (all causes)	24

Study (centre type) [countries]	Study type, sponsor (sponsor's role)	Age eligibility (mean age, years) [% male]	AF type	No. randomised	Interventions compared	Treatment duration (months)	Mean TTR (INR), %	Outcomes	Time of outcome assessment (months)
ARISTOTLE ^{107,114, 119,124-127,130,132-134} (Multicentre)	Phase III Bristol-Myers Squibb and Pfizer	≥ 18 (median 70) [64.7]	Non-valvular or flutter ECG diagnosed	18,201	Apixaban: 1. 5 mg bd (2.5 mg bd in participants with more than one of: ≥ 80 years, ≤ 60 kg body weight, serum creatinine level of 1.5 mg per decilitre or more Warfarin:	21.6 (median)	62.2	Efficacy: All stroke, ischaemic stroke, haemorrhagic stroke, stroke or SE, MI Safety: All bleeding, major bleeding, composite CRB, intracranial bleeding, death (all causes)	21.6 (median for intracranial bleeding)
[North and South America, Europe, Russia, Israel, Australia, Asia and South Africa]	(The trial was designed in conjunction with the sponsors and The primary analyses were performed both at Bristol-Myers Squibb and at the Duke Clinical Research Institute)								
ARISTOTLE-J ¹¹³ (Multicentre) [Japan]	Phase II Pfizer Inc. and Bristol-Myers Squibb (Not clear)	≥ 20 (70.3) [82.9]	Non-valvular Diagnosis based on ECG, Holter recording or intracardiac electrogram	222	2. INR 2-3 Apixaban: 1. 2.5 mg bd 2. 5 mg bd Warfarin: 3. INR 2-3 (INR 2-2.6 in ≥ 70 years)	3	60	Efficacy: Stroke or SE, ischaemic stroke, TIA Safety: All bleeding, major bleeding, minor bleeding, CRNM bleeding, composite CRB, death (all causes)	3

continued

TABLE 18 Characteristics of 23 included randomised trials in stroke prevention in AF (continued)

Study (centre type) [countries]	Study type, sponsor (sponsor's role)	Age eligibility (mean age, years) [% male]	AF type	No. randomised	Interventions compared	Treatment duration (months)	Mean TTR (INR), %	Outcomes	Time of outcome assessment (months)
AVERROES ¹⁰⁵ , 116,117,121 (Multicentre)	Phase III Bristol-Myers Squibb and Pfizer	≥ 50 (70) [58.5]	Non-valvular ECG diagnosed	5599	Apixaban: 1. 5 mg bd (2.5 mg if > 80 years/ ≤ 60 kg/renal status) Antiplatelet (aspirin): 2. 81–324 mg od	13.1 (mean)		Efficacy: All stroke, stroke or SE, ischaemic stroke, haemorrhagic stroke, MI Safety: Major bleeding, minor bleeding, CRNM bleeding, intracranial bleeding, fatal bleeding, death (cardiovascular), death (all causes)	13.1 (mean)
[North and South America, Europe, Russia, Israel, Australia, Asia and South Africa]	(The sponsor was involved in the design, data collection and analysis)								
BAFTA ¹⁰³ (Multicentre) [UK]	Phase III The Medical Research Council UK and supported by MidReC and the Primary Care Research Trust (The sponsor had no direct role in study design, data collection, analysis or interpretation, writing the report the decision to submit for publication)	≥ 75 (81.5) [54.6]	Non-valvular or atrial flutter ECG diagnosed	973	Antiplatelet (aspirin): 1. 75 mg od Warfarin: 2. INR 2–3	32.4 (mean)	67	Efficacy: All stroke, MI Safety: Major bleeding, death (all causes)	32.4 (mean)
Chinese ATAFs ⁹⁹ (Multicentre) [China]	Phase III (Not disclosed)	40–80 (63.3) [59.7]	Non-valvular	704	Antiplatelet (aspirin): 1. 150–160 mg od Warfarin: 2. INR 2–3 (INR 1.6–2.5 in > 75 years)	NR	NR	Efficacy: All stroke Safety: Death (all causes)	2–24 (median = 19)

Study (centre type) [countries]	Study type, sponsor (sponsor's role)	Age eligibility (mean age, years) [% male]	AF type	No. randomised	Interventions compared	Treatment duration (months)	Mean TTR (INR), %	Outcomes	Time of outcome assessment (months)
ENGAGE AF-TIMI 48 ^{111,131} (Multicentre) [North and South America, Europe, Russia, Israel, Australia, Asia and South Africa]	Phase III Daiichi Sankyo Pharma Development (Not clear)	≥ 21 (NR) [61.9]	Non-valvular ECG diagnosed CHADS ₂ ≥ 2	21,105	Edoxaban: 1. 30 mg od 2. 60 mg od (half dose if creatinine clearance is 30–50 ml/minute, ≤ 60 kg body weight, or concomitant use of verapamil or quinidine or dronedarone) <i>Warfarin:</i>	29.8 (median)	64.9	<i>Efficacy:</i> All stroke, ischaemic stroke, haemorrhagic stroke, fatal stroke, stroke or SE, MI <i>Safety:</i> Major bleeding, minor bleeding, fatal bleeding, intracranial bleeding, CRNM bleeding, composite CRB, death (cardiovascular), death (all causes)	29.8 (median)
EXPLORE-Xa ¹²⁸ (Multicentre) [USA, Canada and Germany]	Phase II Portola Pharmaceuticals, South San Francisco, CA, USA (Not stated)	≥ 18 (73) [66.5]	New or existing non-valvular or atrial flutter Diagnosed by Holter, ECG, rhythm strip, pacemaker or other intracardiac recording	508	3. INR 2–3 <i>Betrixaban:</i> 1. 40 mg od 2. 60 mg od 3. 80 mg od <i>Warfarin:</i> 4. INR 2–3	4.9 (mean)	63.4	<i>Efficacy:</i> All stroke <i>Safety:</i> All bleeding, major bleeding, minor bleeding, CRNM bleeding, composite CRB, death (all causes)	4.9 (mean)

continued

TABLE 18 Characteristics of 23 included randomised trials in stroke prevention in AF (continued)

Study (centre type) [countries]	Study type, sponsor (sponsor's role)	Age eligibility (mean age, years) [% male]	AF type	No. randomised	Interventions compared	Treatment duration (months)	Mean TTR (INR), %	Outcomes	Time of outcome assessment (months)
J-ROCKET AF ¹²⁰	Phase III	≥ 20 (71.1)	Non-valvular	1280	Rivaroxaban:	30	65%	Efficacy: All stroke, ischaemic stroke, haemorrhagic stroke, stroke or SE, MI	30
(Multicentre)	Bayer Yakuin Ltd	[80.6]	ECG diagnosed		1. 15 mg od (10 mg od if creatinine clearance 30–49 ml/minute)			Safety: Composite CRB, death (cardiovascular), death (all causes)	
[Japan]	(The funder was 'responsible for trial design and study data collection')				Warfarin:				
					2. INR 2–3 (INR 1.6–2.6 in ≥ 70 years)				
PATAF ⁹⁸	Phase III	≥ 60 (74.8)	Chronic or intermittent	729	Warfarin:	32.4 (mean)	NR	Efficacy: All stroke, ischaemic stroke, arterial event	32.4 (mean)
(Multicentre)	Prevention fund (grant 002817010), Zorgonderzoek Nederland; Roche Nicholas BV, Bladel, Holland, donated aspirin	[44.9]	ECG diagnosed		1. INR < 2			Safety: Death (cardiovascular), death (all causes)	
[Netherlands]	(Not stated)				2. INR 2.5–3.5 (some patients received other coumarins – phenprocoumon or acenocoumarol)				
					Antiplatelet (aspirin):				
					3. 150 mg od				

Study (centre type) [countries]	Study type, sponsor (sponsor's role)	Age eligibility (mean age, years) [% male]	AF type	No. randomised	Interventions compared	Treatment duration (months)	Mean TTR (INR), %	Outcomes	Time of outcome assessment (months)
PETRO ¹⁰² (Multicentre) [USA, Denmark, the Netherlands and Sweden]	Phase II Boehringer Ingelheim Pharmaceuticals, Biberach, Germany (The funder was responsible for the statistical analysis conducted according to a prospectively designed plan approved by the steering committee)	≥ 18 (69.5) [81.9]	Permanent, persistent and paroxysmal non-valvular with coronary artery disease Diagnosis not explained	502 ^a	<i>Dabigatran</i> : 1. 50 mg bd 2. 50 mg + (aspirin 81 mg) bd 3. 50 mg + (aspirin 325 mg) bd 4. 150 mg bd 5. 150 mg + (aspirin 81 mg) bd 6. 150 mg + (aspirin 325 mg) bd 7. 300 mg bd 8. 300 mg + (aspirin 81 mg) bd 9. 300 mg + (aspirin 325 mg) bd <i>Warfarin</i> : 10. INR 2–3	3	57.2	<i>Efficacy</i> : Stroke or SE <i>Safety</i> : All bleeding, major bleeding, composite CRB	3

continued

TABLE 18 Characteristics of 23 included randomised trials in stroke prevention in AF (continued)

Study (centre type) [countries]	Study type, sponsor (sponsor's role)	Age eligibility (mean age, years) [% male]	AF type	No. randomised	Interventions compared	Treatment duration (months)	Mean TTR (INR), %	Outcomes	Time of outcome assessment (months)
RE-LY ^{104,109} (Multicentre)	Phase III Boehringer Ingelheim	≥ 18 (71) [63.6]	Non-valvular ECG diagnosed	18,113	<i>Dabigatran</i> : 1. 110 mg bd 2. 150 mg bd <i>Warfarin</i> : 3. INR 2–3	24 (mean)	64	<i>Efficacy</i> : Stroke or SE, ischaemic stroke, haemorrhagic stroke, MI, PE, hospital admission <i>Safety</i> : Major bleeding, minor bleeding, intracranial bleeding, extracranial minor bleeding, death (cardiovascular), death (all causes)	24 (mean)
[North and South America, Europe, Russia, Israel, Australia, Asia and South Africa]	(The sponsor contributed to the design, conduct, and reporting of the study)		Mean CHADS ₂ = 2.1						
ROCKET AF ^{106,112,123,129} (Multicentre)	Phase III Johnson & Johnson, Bayer (The sponsor was not involved in the coordination of the trial, data management and analyses)	≥ 18 (median 73) [60.3]	Non-valvular ECG diagnosed CHADS ₂ ≥ 2	14,264	<i>Aivaroxaban</i> : 1. 20 mg od (15 mg in patients with a creatinine clearance of 30–49 ml/minute) <i>Warfarin</i> : 2. INR 2–3	19.4 (median)	55	<i>Efficacy</i> : All stroke, stroke or SE, MI <i>Safety</i> : Major bleeding, CRNM bleeding, composite CRB, fatal bleeding, intracranial bleeding, death (all causes)	19.4 (median)
[North and South America, Europe, Russia, Israel, Australia, New Zealand, Asia and South Africa]									

Study (centre type) [countries]	Study type, sponsor (sponsor's role)	Age eligibility (mean age, years) [% male] AF type	No. randomised	Interventions compared	Treatment duration (months)	Mean TTR (INR), %	Outcomes	Time of outcome assessment (months)
SPAF II ⁹⁶ (Multicentre) [USA]	Phase III The Division of Stroke and Trauma, National Institute of Neurological Disorders and Stroke (Not clear)	Not clear (NR) [NR] Non-valvular	1100	<i>Warfarin</i> : 1. INR 2–4.5 in < 75 years 2. INR 2.0–4.5 in > 75 years <i>Antiplatelet (aspirin)</i> : 3. 325 mg (in < 75 years) od 4. 325 mg (in > 75 years) od	37.2 (mean for age < 75 years); 24 (mean for age > 75 years)	NR	<i>Efficacy</i> : Stroke or SE, ischaemic stroke, MI, TIA <i>Safety</i> : Intracranial bleeding, death (all causes)	27.6 (mean)
WASPO ¹⁰¹ (Multicentre) [UK]	Phase III Not declared	> 80 and < 90 (median 83) [47] Permanent non-valvular ECG diagnosed	75	<i>Warfarin</i> : 1. INR 2–3 <i>Antiplatelet (aspirin)</i> : 2. 300 mg od	12	69.2%	<i>Efficacy</i> : All stroke, TIA <i>Safety</i> : Death (all causes)	12

ECG, electrocardiogram; NR, not reported; NVAF, non-valvular atrial fibrillation.

a Our results are based on 515 patients as reported in the results tables; the trial report is inconsistent in this regard.

two trials were each conducted in two centres; and one trial was conducted in one centre. The majority of the multicentre trials were conducted across several countries in North and South America, Europe, Asia, Russia and Israel, Australia and South Africa. The two-centre trials were conducted in one country: one in China and the other in Denmark. The single-centre trial was conducted in Denmark. Sixteen of the trials were Phase III studies and seven were Phase II studies. The number of patients randomised across the 23 trials ranged from 75 to 21,105, with a total of 94,656 patients, of whom 97% (91,333) were from the Phase III studies. Thirteen studies: six Phase III and seven Phase II studies examined a NOAC. Four studies examined edoxaban, three each examined apixaban and dabigatran, two examined rivaroxaban and one examined betrixaban.

Eligibility criteria for patient participation were similar across studies: all patients having non-valvular AF, whether new or existing, and including paroxysmal, persistent or permanent types. Diagnosis of AF was predominantly by electrocardiography. In a few cases, Holter recording, pacemaker or other intracardiac recording was used. The mean age of included patients was reported in only 61% of the studies and this ranged from 63.3 to 81.5 years. The percentage of male patients was reported in 78% of the studies, and this varied significantly across the studies, ranging from 44.9% to 82.9%. Mean BMI was not often reported and ranged from 24.4 to 30.5 kg/m². Percentage of patients with previous stroke, hypertension and chronic heart failure varied significantly across the studies, ranging from 5% to 63.8%, from 38% to 93.7%, and from 0% to 100%, respectively. Bleeding risk among patients was assessed predominantly with the CHADS₂ scoring system.

Warfarin was examined in all but two of the 23 of the included studies, against a NOAC in 12 studies, and against aspirin in nine studies. Standard intensity warfarin (INR 2–3) was examined by all of the studies, although in a few studies the warfarin arm was a mixture of low intensity (INR < 2) and standard intensity, in unknown proportions. Across all of the studies, mean TTR for warfarin ranged from 45.1% to 83% of the treatment duration. One study⁹⁸ compared both low intensity warfarin (INR < 2) and standard intensity (INR 2.5–3.5) dicoumarol with aspirin, but the mean TTR was not reported for the standard intensity dicoumarol arm. The doses of NOACs we examined were edoxaban 30 mg, 45 mg, and 60 mg od and 30 mg and 60 mg bd; apixaban 2.5 mg and 5 mg bd; dabigatran 50 mg, 110 mg, 150 mg and 300 mg bd; rivaroxaban 15 mg and 20 mg od; and betrixaban 40 mg, 60 mg and 80 mg od. Examined aspirin dosages ranged from 75 mg to 325 mg od.

Treatment duration in the edoxaban and dabigatran studies was predominantly 3 months, although one study reported mean treatment durations of 24 months and another reported a median treatment duration of 29.8 months. Mean treatment duration for apixaban studies ranged from 13.1 to 21.6 months and one study reported 3 months' treatment duration. The two studies on rivaroxaban reported 30 months' treatment duration and a mean treatment duration of 19.4 months, respectively. Mean treatment duration 4.9 months was reported in the betrixaban study. Treatment duration was similar for each comparator in almost all the NOAC studies. Reported efficacy and safety outcome types were similar across studies and these were reported at the end of the treatment periods. All 23 studies reported data on stroke, 15 studies reported data on MI, 18 studies reported data on major bleeding, 12 studies reported data on CRB, and 18 studies reported data on all-cause mortality. Fifteen of the 23 studies, including all the NOAC studies, were sponsored by pharmaceutical companies. Six studies were funded by grants from medical research bodies although two of these grants contained contributions from a pharmaceutical company. Sponsor detail was not reported in two studies. In most of the pharmaceutical company sponsored studies, the sponsor(s) had influence on the study design, data management and analysis.

Time in therapeutic range for warfarin interventions

Table 19 shows the comparator interventions, target INR and (where reported) mean TTR for the 22 studies that included a warfarin intervention arm. Sixteen (73%) of these studies reported mean TTR, which varied substantially (from 45.1% to 83%) between studies.

TABLE 19 Mean TTR for warfarin in stroke prevention in AF

Study	Interventions that were compared with warfarin	Warfarin INR	Mean TTR (INR), %
ACTIVE W ¹⁰⁰	Antiplatelet (clopidogrel 75 mg + (aspirin 75–100 mg) od	2–3 (some patients may have received other VKAs)	63.8
AFASAK ⁹⁵	Aspirin 75 mg od	2–3	73
	Placebo od		
AFASAK II ⁹⁷	Aspirin 300 mg od	2–3	73
AF-ASA-VKA-CHINA ¹³⁵	Aspirin 100 mg od	1.6–2.5	NR
AF-DABIG-VKA-JAPAN ¹¹⁰	Dabigatran 110 mg, 150 mg bd	2–3 (≥ 1.6 to ≤ 2.6 in ≥ 70 years)	NR
AF-EDOX-VKA-ASIA ¹¹⁵	Edoxaban 30 mg, 60 mg od	2–3	45.1
AF-EDOX-VKA-JAPAN ¹¹⁸	Edoxaban 30 mg, 45 mg, 60 mg od	2–3 (1.6–2.6 in ≥ 70 years)	83 (≥ 70) 73 (< 70 years)
AF-EDOX-VKA-MULTI ¹⁰⁸	Edoxaban 30 mg, 60 mg od, 30 mg, 60 mg bd	2–3	49.7
AF-VKA-ASA-CHINA ¹²²	Aspirin 200 mg od	2.1–2.5	NR
ARISTOTLE ^{107,114,119,124–127,130,132–134}	Apixaban 5 mg bd	2–3	62.2
ARISTOTLE-J ¹¹³	Apixaban 2.5 mg, 5 mg bd	2–3 (2–2.6 in ≥ 70 years)	60
BAFTA ¹⁰³	Aspirin 75 mg od	2–3	67
Chinese ATAFS ⁹⁹	Aspirin 150–160 mg od	2–3 (1.6–2.5 in > 75 years)	NR
ENGAGE AF-TIMI 48 ^{111,131}	Edoxaban 30 mg, 60 mg od	2–3	64.9
EXPLORE-Xa ¹²⁸	Betrixaban 40 mg, 60 mg, 80 mg od	2–3	63.4
J-ROCKET AF ¹²⁰	Rivaroxaban 15 mg od	2–3 (1.6–2.6 in ≥ 70 years)	65
PATAF ⁹⁸	Aspirin 150 mg od	2.5–3.5 (some patients received other coumarins – phenprocoumon or acenocoumarol)	NR
PETRO ¹⁰²	Dabigatran 50 mg, 50 mg + (aspirin 81 mg), 50 mg + (aspirin 325 mg), 150 mg, 150 mg + (aspirin 81 mg), 150 mg + (aspirin 325 mg), 300 mg, 300 mg + (aspirin 81 mg), 300 mg + (aspirin 325 mg) bd	2–3	57.2
RE-LY ^{104,109}	Dabigatran 110 mg, 150 mg bd	2–3	64
ROCKET AF ^{106,112,123,129}	Rivaroxaban 20 mg od	2–3	55
SPAF II ⁹⁶	Aspirin 325 mg (in < 75 years), 325 mg (in > 75 years) od	2–4.5 in < 75 years 2–4.5 in > 75 years	NR
WASPO ¹⁰¹	Aspirin 300 mg od	2–3	69.2

NR, not reported.

Risk of bias in included studies

Detailed risk-of-bias assessments for each included study for each domain of the Cochrane assessment tool are provided in *Table 20*. The assessments ranged from low to high risk of bias, but it was difficult to judge some studies as a result of inaccessibility of study protocols. For most of the outcomes assessed in the studies, all randomised patients were either accounted for in the analysis, or in some cases a small number of patients were unaccounted for with reasons judged likely to be unrelated to the outcome. The majority of the studies were judged to be at low risk of bias for allocation concealment and incomplete outcome data. The majority of the studies were judged to be at a low or unclear risk of bias for sequence generation. Randomisation sequence across the low-risk studies was predominantly computerised. Most studies were also judged to be of low risk of bias for blinding of outcome assessment, with three studies judged to be at high risk of bias in this domain. Fourteen studies were judged to be at high risk of bias for blinding of participants and personnel, mainly because they were open label. Where studies were blinded for different dose groups of a novel anticoagulant, but not in the comparison of these to warfarin, we assigned a high risk of bias because the principal contribution of the study to our analyses would be the comparison of warfarin with the licensed dose of the anticoagulant. Risk-of-bias judgements for studies contributing to analyses of each outcome are presented graphically in the sections that follow.

Results on clinical effectiveness and safety

The 27 different interventions considered in the 23 trials are listed in *Tables 21–23*, which show the number of patients analysed and the number of outcome events for each outcome reported in each trial. We performed NMAs for seven outcomes: stroke or SE, ischaemic stroke, MI, major bleeding, CRB, intracranial bleeding and all-cause mortality. Arms that were considered not to provide any evidence of interest to inform health decisions in the UK were excluded from the analyses. Specifically, we excluded the warfarin arm with INR range 1.6–2 from the AF-VKA-ASA-CHINA trial,¹²² the warfarin arm with INR range of < 2 from PATAF,⁹⁸ the placebo arm from AFASAK,⁹⁵ and the two warfarin arms with a fixed daily dose from AFASAK II.⁹⁷

We defined two independent nodes for warfarin interventions, labelled as ‘warfarin (INR 2–3)’ and ‘warfarin (INR 3–4)’, respectively. The first of these formed the reference treatment across all networks in the AF review. We included in ‘warfarin (INR 2–3)’ the trials with a therapeutic INR range of 2–3 (e.g. ACTIVE W,¹⁰⁰ AFASAK⁹⁵), as well as some interventions with an INR range of 2.5–3.5 (AF-EDOX-VKA-ASIA¹¹⁵ and PATAF⁹⁸) or 2.0–4.5 (SPAF II⁹⁶). In some trials the INR range for some of patients in the warfarin arm was subtherapeutic (< 2.0), so that the total INR range was 1.6–3.0. These interventions were excluded from the main analysis, but merged with the INR 2–3 node in a sensitivity analysis. As a consequence, there were three two-arm trials (J-ROCKET AF,¹²⁰ Chinese ATAFS⁹⁹ and AF-ASA-VKA-CHINA¹³⁵) that were included only in sensitivity analyses.

We also defined two independent nodes for antiplatelet interventions (‘aspirin’ or ‘aspirin plus clopidogrel’), using the cut-off point of 150 mg, with the understanding that daily doses above that were appropriate for stroke prevention in AF, whereas lower doses were appropriate for secondary prevention of cardiovascular events. The dose range considered in the AVERROES trial^{105,116,117,121} (81–324 mg od) was much wider than in any other trial, and we included this intervention in the lower-dose node (< 150 mg od) because some patients from that study had received a low daily dose. As a sensitivity analysis, we excluded the AVERROES trial^{105,116,117,121} from the network. Finally, our main analysis used a binomial model, assuming equal follow-up times across arms within trials and ignoring some variations in how results were reported. We undertook a separate analysis for all outcomes taking into account the differences in duration of follow-up within and between trials, and the differences in the definition of event used across trials (e.g. total number of events vs. first events only).

TABLE 20 Risk-of-bias assessment for 23 included randomised trials in stroke prevention in AF

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcomes assessment	Incomplete outcome data	Selective reporting
ACTIVE W ¹⁰⁰	L – 'Patients were randomised by an automated central interactive voice-response system, in a 1 : 1 ratio, to receive clopidogrel plus aspirin or oral anticoagulation therapy'	L – By means of a central, interactive, voice response system	H – Treatment was open, with blinded adjudication of outcomes	L – 'All major outcomes were adjudicated by a blinded committee and all strokes were adjudicated by neurologists'	L – All patients were included in the analyses	U – Study protocol not found
AFASAK ⁹⁵	L – 'The patients were randomised to receive warfarin, aspirin 75 mg od, or placebo. They received consecutive numbers, which corresponded to numbered packages containing the study medication, the order of which was determined by computer-generated randomisation'	L – 'They received consecutive numbers, which corresponded to numbered packages containing the study medication, the order of which was determined by computer-generated randomisation'	H – 'Warfarin was given openly, but the aspirin and placebo arms were double blind. The warfarin tablets looked different from the aspirin and placebo tablets, which were indistinguishable'	U – No information on blinding of outcome assessors	L – All patients were included in the analyses	U – Study protocol not found
AFASAK II ⁹⁷	L – 'According to a computer-generated sequence, eligible participants were assigned to daily treatment'	U – No information on whether or not and how treatment allocation was concealed	H – This was an open-label study	L – 'All end-points were evaluated by an end-point committee unaware of treatment status. The committee consisted of two neurologists and two cardiologists'	L – All patients were included in the analyses	U – Study protocol not found
AF-ASA-VKA-CHINA ³⁵	U – 'A total of 110 patients met the inclusion criteria and were randomly divided into warfarin study and aspirin control groups'	H – No information and no indication of treatment allocation concealment	H – No details, but monitoring of INR implies the study was open label	H – No information, and no indication of blinding of outcomes assessors	L – Small numbers of missing data in the two randomised arms and the number missing in each arm seem to be balanced; also with comparable reasons for the missing data. It is unlikely that missing data are related to the outcome	U – Study protocol not found

continued

TABLE 20 Risk-of-bias assessment for 23 included randomised trials in stroke prevention in AF (continued)

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcomes assessment	Incomplete outcome data	Selective reporting
AF-DABIG-VKA-JAPAN ¹⁰	U – Available information is from a preliminary report and not a published article. Therefore, no information to enable judgement	U – Available information is from a preliminary report and not a published article. Therefore, no information to enable judgement	U – Available information is from a preliminary report and not a published article. Therefore, no information to enable judgement	U – Available information is from a preliminary report and not a published article. Therefore, no information to enable judgement	U – Available information is from a preliminary report and not a published article. Therefore, no information to enable judgement	U – Available information is from a preliminary report and not a published article. Therefore, no information to enable judgement
AF-EDOX-VKA-ASIA ¹¹⁵	L – ‘Via Fisher Automated Clinical Trials System (FACTS)’	L – ‘Block randomisation was done by FACTS; Conduit produced the randomisation schedule, which was kept confidential until the end of the study’	H – ‘The investigator, patients and sponsor were blinded to the dose of edoxaban, but not to the identity of edoxaban and warfarin’	L – ‘The independent CEC, which was blinded to study treatments, adjudicated all bleeding events and thromboembolic events (stroke, systemic embolic event, MI) during the study’	L – Only one person with missing outcome data	L – All outcomes are reported as per study protocol
AF-EDOX-VKA-JAPAN ¹¹⁸	L – ‘Treatment was assigned using the biased coin method’	U – ‘Patients were randomised using the specifications of dynamic allocation procedures’	H – ‘This was a multicentre, randomised, dose-ranging study of edoxaban (double-blind to dose) and open-label warfarin’	U – ‘Secondary endpoints consisted of thromboembolic events including stroke assessed by an independent Event Assessment Committee’	L – Some missing data with reasons although the number of missing data are quite minimal and unlikely related to the outcome	L – All outcomes are reported as per study protocol
AF-EDOX-VKA-MULTI ¹⁰⁸	L – ‘The randomisation schedule was generated by an independent biostatistician who was not part of the study team. Using a central, interactive, automated telephone system’	L – ‘Using a central, interactive, automated telephone system, eligible patients who provided written informed consent were randomly allocated’	H – ‘The study was double blind with respect to edoxaban dose, but open-label for randomisation between edoxaban and warfarin’	U – ‘For efficacy outcomes: Stroke confirmed by CT or autopsy; TIA confirmed by a neurologist’ L – ‘For safety outcomes: Suspected bleeding events were assessed by an independent blinded adjudication committee’	L – Very minimal missing data in three arms (1 patient); otherwise, all patients are accounted for in the analysis	L – All outcomes are reported as per protocol

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcomes assessment	Incomplete outcome data	Selective reporting
AF-VKA-ASA-CHINA ¹²²	L – 'Stratified block randomisation'	U – Not enough information: 'After giving a signed informed consent, patients who met the inclusion criteria were enrolled and randomly allocated to one of three study groups according to a stratified block randomisation'	U – 'In the warfarin groups, an initial dose of 1–3 mg/day of warfarin was prescribed after the baseline INR values were measured'. 'In the aspirin group, a fixed dose of 200 mg/day of aspirin was used'	U – Not clearly described 'Medical records from all potential events were further reviewed by a five-physician clinical outcomes committee'	U – A total of 96 patients withdrew from the study after randomisation but the remaining 690 patients were all included in the analysis	U – Study protocol not found
ARISTOTLE ^{107,114,119,124–127,130,132–134}	L – 'Randomisation was stratified according to whether patients had received warfarin previously and according to clinical site'	U – 'An algorithm was provided to manage temporary discontinuations of the study drug around the time of interventional procedures while maintaining concealment of the group assignments'	L – 'An algorithm was provided to manage temporary discontinuations of the study drug around the time of interventional procedures while maintaining concealment of the group assignments'	L – 'The primary and secondary efficacy and safety outcomes were adjudicated on the basis of prespecified criteria by a clinical events committee whose members were not aware of study-group assignments'	L – For efficacy outcomes: No missing outcome data U – For bleeding outcomes: Some missing outcome data with reason which appear to be similar in the groups. However, it is not clear whether or not the reasons for the missing outcome data are related to the outcome	L – All outcome are reported as per protocol
ARISTOTLE-J ¹¹³	U – 'Patients were randomised in a 1 : 1 : 1. The randomisation assignment method (Pocock <i>et al.</i>) incorporated trial site and warfarin status (experienced or naive) as factors'	U – Not enough information: 'On the first day of study drug dosing (week 0), patients were randomised in a 1 : 1 : 1 fashion'	H – 'This was a randomised, partially blinded study comparing high double-blinded doses of apixaban with open-label warfarin'	L – 'An independent blinded end-point committee adjudicated all reported bleeding and efficacy events'	L – Few outcome missing data with reasons. Reasons almost balance out across groups and it is unlikely that the reasons are related to the outcome	L – All outcomes are reported as per protocol
AVERROES ^{105,116,117,121}	L – 'Randomisation was performed with the use of a 24-hour central, computerised, automated voice-response system'	L – 'Randomisation was performed with the use of a 24-hour central, computerised, automated voice-response system'	L – 'In keeping with the double-dummy design, patients who were assigned to receive apixaban also received an aspirin placebo, and those assigned to receive aspirin also received an apixaban placebo'	L – 'All outcomes were adjudicated by a committee whose members were unaware of the treatment assignments. Cases of stroke and ICH were adjudicated by neurologists'	L – All participants included in the analyses	L – All outcomes are reported as per protocol

continued

TABLE 20 Risk-of-bias assessment for 23 included randomised trials in stroke prevention in AF (continued)

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcomes assessment	Incomplete outcome data	Selective reporting
BAFTA ¹⁰³	L – ‘Within each stratum, randomly permuted blocks of eight were generated to produce allocation tables’	L – ‘Primary care physicians telephoned for the treatment allocation when they had an eligible patient’	H – ‘BAFTA was a prospective randomised open-label trial’	L – ‘Clinical details on possible primary events were sent to two independent neurologists who were blind to treatment allocation’	L – All patients were included in the analyses	L – All outcomes are reported as per protocol
Chinese ATAFS ⁹⁹	U – ‘The randomised study of efficacy and safety of antithrombotic therapy in non-valvular AF: warfarin compared with aspirin’	U – No information on whether or not and how treatment allocation was concealed	U – No information on whether or not participants and personnel were blinded to treatment	U – No information on blinding of outcome assessors	L – All patients were included in the analyses	U – Study protocol not found
ENGAGE AF-TIMI 48 ^{111,131}	L – ‘Randomisation was performed with the use of a central, 24-hour, interactive, computerised response system’	L – ‘Randomisation was performed with the use of a central, 24-hour, interactive, computerised response system’	L – ‘Each patient received two sets of study drugs: either active edoxaban and a placebo matching warfarin, or a placebo matching edoxaban and active warfarin’	L – ‘An independent clinical end-point committee, whose members were unaware of the study assignment, adjudicated all deaths and suspected cerebrovascular events, systemic embolic events, MIs, bleeding events, and hepatic events’	L – All patients were included in the analyses	L – All outcomes are reported as per study protocol
EXPLORE-Xa ¹²⁸	U – ‘Patients were randomly assigned (1 : 1 : 1 allocation) A dynamic randomisation was used to assign and balance patients by country, concurrent aspirin use, and antecedent warfarin’	U – Not enough information. ‘Patients were randomly assigned (1 : 1 : 1 allocation)’	H – ‘Assignment to betrixaban or warfarin was not blinded, but the betrixaban dose was double-blinded’	L – ‘An independent adjudicator, blinded to treatment groups, adjudicated all major bleeds, CRNM bleeds, strokes, MI, other SE and deaths’	L – All participants were included in analyses	L – All outcomes are reported as per study protocol

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcomes assessment	Incomplete outcome data	Selective reporting
J-ROCKET AF ²⁰	L – No details provided but assumed to follow robust design of the ROCKET AF study	L – No details provided but assumed to follow robust design of the ROCKET AF study	L – ‘As part of the double-dummy design, patients in each group also received a tablet of either titrated warfarin placebo or rivaroxaban placebo, respectively, to preserve the treatment blind’	U – ‘An independent clinical end-point committee adjudicated all suspected strokes, SEs, MIs, deaths, and bleeding events contributing to the prespecified end-points’	L – Very few missing data. Unlikely to influence the true outcome	L – All outcomes are reported as per study protocol
PATAF ⁸⁸	L – Randomisation was computer generated	L – ‘Patients eligible for standard anticoagulation were randomly assigned (centrally, by telephone)’	U – ‘Patients were single blinded for the two intensities of anticoagulant’	L – ‘End-point ascertainment were blinded for treatment. Events were independently reviewed by two members of the (neurological, cardiological, vascular, ophthalmological and internal medicine) event committees (or three, in case of disagreement’	U – Some missing data and although with similar reasons across groups, the missing numbers in the groups are not balanced	L – Study protocol not found
PETRO ¹⁰²	U – ‘The PETRO study was a randomised trial of patients with AF at high risk for thromboembolic events’	U – Not enough information ‘Randomisation was stratified in the ratio 6 : 9 : 9 : 4 (50-, 150- and 300-mg dabigatran, and warfarin, respectively)’	H – ‘The trial was double-blind with respect to dabigatran dose but open-label for concomitant aspirin treatment’	U – <i>For efficacy outcomes:</i> No information but the outcomes may have been blinded L – For bleeding outcomes: ‘An independent adjudication committee blinded to treatment evaluated all bleeding events’	L – All patients were included in the analyses	L – All outcomes are reported as per protocol

continued

TABLE 20 Risk-of-bias assessment for 23 included randomised trials in stroke prevention in AF (continued)

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcomes assessment	Incomplete outcome data	Selective reporting
RE-LY ^{104,109}	L – ‘After providing written informed consent, all trial participants were randomly assigned to receive one of two doses of dabigatran, or to receive warfarin, by means of a central, interactive, automated telephone system’	L – By means of a central, interactive, automated telephone system	H – ‘RE-LY was a randomised trial designed to compare two fixed doses of dabigatran, each administered in a blinded manner, with open-label use of warfarin’	L – ‘Each primary and secondary outcome event was adjudicated by two independent investigators who were unaware of the treatment assignments’	L – All patients were included in the analyses	L – All outcomes are reported as per protocol
ROCKET AF ^{106,112,123,129}	L – ‘Randomisation was performed with the use of a central 24-hour, computerised, automated voice-response system’	L – ‘Randomisation was performed with the use of a central 24-hour, computerised, automated voice-response system’	L – ‘Patients were randomly assigned to receive fixed-dose rivaroxaban or adjusted-dose warfarin. Patients in each group also received a placebo tablet in order to maintain blinding’	U – ‘An independent clinical end-point committee applied protocol definitions to adjudicate all suspected cases of stroke, SE, MI, death and bleeding events that contributed to the prespecified end-points’	L – Very few missing outcome data but with reasons which appear to balance across groups. Unlikely that the missing data are related to the true outcome	L – All outcomes are reported as per protocol
SPAF II ⁹⁶	L – Randomisation was done separately at each clinical site by computer	U – Not enough information: ‘The randomisation sequence could not be pre-reviewed’	H – Both patient and investigator were aware of therapy assignment	L – For neurological efficacy outcomes: ‘All suspected neurological events were evaluated by an on-site study neurologist and verified by an events committee; evaluation was based on review of original medical records, from which information about therapy assignment had been removed’	L – All patients were included in the analyses	U – Study protocol not found
WASPO ¹⁰¹	L – ‘Randomisation was prepared from a computer-generated random numbers programme’	L – ‘Randomisation was performed by opening sealed envelopes in numbered sequence’	H – This was an open-label study	H – No information and no indication of blinding outcome assessment	L – All patients were included in the analyses	U – Study protocol not found

H, high risk; L, low risk; U, unclear risk. Quotations are denoted by inverted commas.

TABLE 21 List of distinct interventions examined by included randomised trials in stroke prevention in AF

No.	Intervention
1	Warfarin (INR 2–3)
2	Warfarin (INR 1.6–3)
3	Warfarin (INR 3–4 od)
4	Antiplatelet (< 150 mg od)
5	Antiplatelet (\geq 150 mg od)
6	Dabigatran (50 mg bd) + aspirin (81 mg bd)
7	Dabigatran (50 mg bd) + aspirin (325 mg bd)
8	Dabigatran (150 mg bd) + aspirin (81 mg bd)
9	Dabigatran (150 mg bd) + aspirin (325 mg bd)
10	Dabigatran (300 mg bd) + aspirin (81 mg bd)
11	Dabigatran (300 mg bd) + aspirin (325 mg bd)
12	Apixaban (2.5 mg bd)
13	Apixaban (5 mg bd)
14	Dabigatran (50 mg bd)
15	Dabigatran (110 mg bd)
16	Dabigatran (150 mg bd)
17	Dabigatran (300 mg bd)
18	Betrixaban (40 mg od)
19	Betrixaban (60 mg od)
20	Betrixaban (80 mg od)
21	Edoxaban (30 mg od)
22	Edoxaban (45 mg od)
23	Edoxaban (60 mg od)
24	Edoxaban (30 mg bd)
25	Edoxaban (60 mg bd)
26	Rivaroxaban (15 mg od)
27	Rivaroxaban (20 mg od)

Results are presented as follows for each of the six outcomes. First, we provide network plots to illustrate the comparisons of interventions made in the different trials. Second, we illustrate the risk-of-bias assessments specific to the outcome for each trial included in the network. Third, we present results tables for each intervention compared with the reference treatment (warfarin with a target INR range of 2–3). Fourth, we present results tables for pairwise comparisons among licensed doses of the NOACs. For both sets of results tables, posterior median ORs and 95% credible intervals from Bayesian fixed-effects analyses are shown, although we refer to the latter as CIs for convenience. In these tables we present results separately for any available direct evidence, for any indirect comparisons that can be made (excluding the direct evidence) and for the NMA (which combines the direct and the indirect evidence). Comparisons

TABLE 22 Efficacy outcomes reported by 23 included randomised trials in stroke prevention in AF: number of events for each outcome in each trial

Study	Study size	TIA	All stroke	Stroke or SE	Ischaemic stroke	Minor ischaemic stroke	Major ischaemic stroke	Haemorrhagic stroke	Fatal stroke	PE	MI	Hospital admission
ACTIVE W ¹⁰⁰	6706		159		132			20			59	
AF-ASA-VKA-CHINA ¹³⁵	101		18	18	14						5	
AF-DABIG-VKA-JAPAN ¹¹⁰	166		1	1								
AF-EDOX-VKA-ASIA ¹¹⁵	234		0	0								
AF-EDOX-VKA-JAPAN ¹¹⁸	519		1	1								
AF-EDOX-VKA-MULTI ¹⁰⁸	1143		11	11							5	12
AF-VKA-ASA-CHINA ¹²²	440	13	10		9		1					
AFASAK ⁹⁵	671	2	20			1			4			
AFASAK II ⁹⁷	339	3	19	22	8		2		2		8	
ARISTOTLE ^{107,114,119,124-127,130,132-134}	18,140		449	477	337		118				192	
ARISTOTLE-J ¹¹³	218	1		3	1						0	
AVERROES ^{105,116,117,121}	5599		154	164	128		15				52	
BAFTA ¹⁰³	973		94								30	
Chinese ATAFS ⁹⁹	704		23									
ENGAGE AF-TIMI 48 ^{111,131}	21,026		958	1016	804		169		239		443	
EXPLORE-Xa ¹²⁸	508		2		2						0	
J-ROCKET AF ¹²⁰	1278		31	33	24		7				4	
PATAF ⁹⁸	272		7		7	2	5				5	
PETRO ¹⁰²	515			2								
RE-LY ^{104,109}	18,113			519	389		71			43	270	7199
ROCKET AF ^{106,112,123,129}	14,236		405	575	310						227	
SPAF II ⁹⁶	1100	25	67	67	63						34	
WASPO ¹⁰¹	75	1	0									

TABLE 23 Safety outcomes reported by 23 included randomised trials in stroke prevention in AF: number of events for each outcome in each trial

Study	Study size	All bleeding	Minor bleeding	Major bleeding	Fatal bleeding	Extracranial minor bleeding	Intracranial bleeding	Arterial event	CRNM bleeding	CRB	Cardiovascular deaths	All-cause mortality
ACTIVE W ¹⁰⁰	6706	1199	1049	194	18							317
AF-ASA-VKA-CHINA ¹³⁵	101	14	9	3	2							4
AF-DABIG-VKA-JAPAN ¹¹⁰	166	45		3						14		
AF-EDOX-VKA-ASIA ¹¹⁵	234	57	48	2				9	11			
AF-EDOX-VKA-JAPAN ¹¹⁸	519	115		5				15	20			
AF-EDOX-VKA-MULTI ¹⁰⁸	1143	114	52	13				49	62	8		
AF-VKA-ASA-CHINA ¹²²	440		25	8								11
AFASAK ⁹⁵	671	23										15
AFASAK II ⁹⁷	339		68	9			3					31
ARISTOTLE ^{107,114,119,124-127,130,132-134}	18,140	5416		789			174			1490		1272
ARISTOTLE-J ¹¹³	218	41	36	1				5	6			0
AVERROES ^{105,116,117,121}	5599		341	83	10		24	180	263	180		251
BAFTA ¹⁰³	973			50								215
Chinese ATAFS ⁹⁹	704											12
ENGAGE AF-TIMI 48 ^{111,131}	21,026		1851	1196	112		234	3579	4450	1668		2349
EXPLORE-Xa ¹²⁸	508	118	109	8				12	18			2
J-ROCKET AF ¹²⁰	1278						15		262	8		12
PATAF ⁹⁸	272							8		18		29
PETRO ¹⁰²	515	88		4					36			
RE-LY ^{104,109}	18,113		5284	1162		956	150			880		1371
ROCKET AF ^{106,112,123,129}	14,236			781	82		139	2336	2924			458
SPAF II ⁹⁶	1100						18					127
WASPO ¹⁰¹	75		10	3								3

from the NMA with a ratio between interval limits of > 9 were considered 'imprecisely estimated' and are presented at the bottom of each table (note that calculation of indirect evidence was not undertaken for imprecisely estimated comparisons). A summary of results across outcomes is provided at the end, in the form of a 'rankogram', which illustrates the probability that each treatment is best, second best, and so on, for each outcome. Last, forest plots of all contributing data, with ORs calculated using standard frequentist methods, are included in *Appendix 2*.

Stroke or systemic embolism

Sixteen studies reported the number of stroke or SE events, and the other seven trials reported the number of stroke events, so that the resulting network was based on data from all 23 trials, comparing a total of 26 interventions (*Figure 9*). There were 3217 stroke or SE events. Twenty studies were included in the main analysis, with the remaining three included only in sensitivity analyses. The thicker lines joining interventions, which mainly correspond with comparisons between licensed doses of NOACs and warfarin (INR 2–3) represent the larger (mainly Phase III) trials. Similarly, the larger green circles represent the interventions to which the largest number of patients were randomised. Importantly, there were no direct comparisons between different NOACs, although there were numerous comparisons between different doses of the same NOAC in mainly Phase II trials, and some such comparisons in larger trials. Therefore, comparisons between the effects of different NOACs need to be inferred from the network (indirect evidence).

Table 24 shows risk-of-bias judgements for studies reporting stroke or SE. The studies were at mixed risks of bias: there were concerns about lack of blinding of participants for most trials, and about lack of allocation concealment and blinding of outcome assessment in some.

Table 25, which shows comparisons of licensed doses with warfarin (INR 2–3), suggests that both low- and high-dose antiplatelet drugs increase the risk of stroke or SE compared with warfarin (INR 2–3). Among NOACs, there was some evidence that apixaban [5 mg bd], dabigatran (150 mg bd), edoxaban (60 mg od) and rivaroxaban (20 mg od) reduce the risk of stroke or SE compared with warfarin (INR 2–3). Most other comparisons were imprecisely estimated. Comparisons among licensed doses of




FIGURE 9 Network plot for stroke or SE (stroke prevention in AF). a, Excluded interventions that were included in sensitivity analyses.

TABLE 24 Included trials and risk-of-bias assessment for stroke or SE (stroke prevention in AF)

Study	Interventions compared	SG	AC	BPP	BOA	IOD	SR
ACTIVE W ⁹⁸	1, 4	+	+	-	+	+	?
AFASAK ⁹⁵	1, 4	+	+	-	?	+	?
AFASAK II ⁹⁷	1, 5	+	?	-	+	+	?
AF-ASA-VKA-CHINA ¹³⁵	2, 4	?	-	-	-	+	?
AF-DABIG-VKA-JAPAN ¹¹⁰	2, 15, 16	?	?	?	?	?	?
AF-EDOX-VKA-ASIA ¹¹⁵	1, 21, 23	+	+	-	+	+	+
AF-EDOX-VKA-JAPAN ¹¹⁸	2, 21, 22, 23	+	?	-	?	+	+
AF-EDOX-VKA-MULTI ¹⁰⁸	1, 21, 23, 24, 25	+	+	-	?	+	+
AF-VKA-ASA-CHINA ¹²²	1, 5	+	?	?	?	?	?
ARISTOTLE ^{107,114,119,124-127,130,132-134}	1, 13	+	?	+	+	+	+
ARISTOTLE-J ¹¹³	1, 12, 13	?	?	-	+	+	+
AVERROES ^{103,114,115,119}	4, 13	+	+	+	+	+	+
BAFTA ¹⁰³	1, 4	+	+	-	+	+	+
Chinese ATAFS ⁹⁹	2, 5	?	?	?	?	+	?
ENGAGE AF-TIMI 48 ^{111,131}	1, 21, 23	+	+	+	+	+	+
EXPLORE-Xa ¹²⁶	1, 18, 19, 20	?	?	-	+	+	+
J-ROCKET AF ¹²⁰	2, 26	+	+	+	?	+	+
PATAF ⁹⁸	1, 5	+	+	?	+	?	+
PETRO ¹⁰²	1, 6, 7, 8, 9, 10, 11, 14, 16, 17	?	?	-	?	+	+
RE-LY ^{104,109}	1, 15, 16	+	+	-	+	+	+
ROCKET AF ^{106,112,123,129}	1, 27	+	+	+	?	+	+
SPAF II ⁹⁶	1, 5	+	?	-	+	+	?
WASPO ¹⁰¹	1, 5	+	+	-	-	+	?

–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation; SR, selective reporting.

NOACs were almost all based on indirect evidence (Table 26). Among the comparisons that were not classified as imprecisely estimated, there was some evidence that edoxaban (60 mg od) and rivaroxaban (20 mg od) increase the risk of stroke or SE compared with dabigatran (150 mg bd).

Results from a supplementary analysis taking into account the differences in duration of follow-up within and between trials, and the differences in the definition of event used across trials (e.g. total number of events vs. first events only), are presented in Tables 27 and 28. They are very similar to those for ORs.

As a post hoc sensitivity analysis, we fitted a fixed-effects meta-regression model using the mean TTR for warfarin patients (see Table 19) as a covariate and the mean log-odds ratio (log-OR) from each pairwise comparison (with warfarin as the reference category) as the response variable. There was little evidence of effect modification due to mean TTR (estimated coefficient 0.0021 with 95% CI –0.07 to 0.08 per 1% increase). The model fit indices were very similar with and without the covariate.

TABLE 25 Results for stroke or SE (stroke prevention in AF): comparisons with warfarin (INR 2–3)

Comparisons with warfarin (INR 2–3)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Antiplatelet (< 150 mg od)	1.99 (1.28 to 3.15)	1.80 (1.22 to 2.65)	1.88 (1.40 to 2.51)
Antiplatelet (≥ 150 mg od)	1.61 (1.25 to 2.07)	–	1.61 (1.25 to 2.07)
Apixaban (5 mg bd)	0.79 (0.66 to 0.94)	–	0.79 (0.66 to 0.94)
Dabigatran (110 mg bd)	0.90 (0.74 to 1.10)	–	0.90 (0.74 to 1.10)
Dabigatran (150 mg bd)	0.65 (0.52 to 0.81)	–	0.65 (0.52 to 0.81)
Edoxaban (30 mg od)	1.13 (0.97 to 1.32)	–	1.13 (0.97 to 1.32)
Edoxaban (60 mg od)	0.86 (0.74 to 1.01)	–	0.86 (0.74 to 1.01)
Rivaroxaban (20 mg od)	0.88 (0.74 to 1.03)	–	0.88 (0.74 to 1.03)
Imprecisely estimated comparisons			
Warfarin (INR 3–4)	–	0.58 (0.17 to 1.62)	0.58 (0.17 to 1.62)
Dabigatran (50 mg bd) + aspirin (81 mg bd)	11.4 (0.63 to 402)	–	11.4 (0.63 to 402)
Dabigatran (50 mg bd) + aspirin (325 mg bd)	1.62 (0 to 94.3)	–	1.62 (0 to 94.3)
Dabigatran (150 mg bd) + aspirin (81 mg bd)	1.23 (0 to 75.3)	–	1.23 (0 to 75.3)
Dabigatran (150 mg bd) + aspirin (325 mg bd)	1.35 (0 to 81.1)	–	1.35 (0 to 81.1)
Dabigatran (300 mg bd) + aspirin (81 mg bd)	1.32 (0 to 77.1)	–	1.32 (0 to 77.1)
Dabigatran (300 mg bd) + aspirin (325 mg bd)	1.50 (0 to 89.1)	–	1.50 (0 to 89.1)
Apixaban (2.5 mg bd)	0.11 (0 to 1.69)	–	0.11 (0 to 1.69)
Dabigatran (50 mg bd)	3.90 (0.21 to 137)	–	3.90 (0.21 to 137)
Dabigatran (300 mg bd)	0.42 (0 to 24)	–	0.42 (0 to 24)
Betrixaban (40 mg od)	1.01 (0 to 977)	–	1.01 (0 to 977)
Betrixaban (60 mg od)	5.14 (0.17 to 3780)	–	5.14 (0.17 to 3780)
Betrixaban (80 mg od)	5.18 (0.17 to 3920)	–	5.18 (0.17 to 3920)
Edoxaban (45 mg od)	3.36 (0.18 to 121)	–	3.36 (0.18 to 121)
Edoxaban (30 mg bd)	1.39 (0.27 to 5.61)	–	1.39 (0.27 to 5.61)
Edoxaban (60 mg bd)	1.19 (0.15 to 5.56)	–	1.19 (0.15 to 5.56)

TABLE 26 Results for stroke or SE (stroke prevention in AF): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd)	–	0.82 (0.62 to 1.08)	0.82 (0.62 to 1.08)
Edoxaban (60 mg od) vs. apixaban (5 mg bd)	–	1.09 (0.87 to 1.39)	1.09 (0.87 to 1.39)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd)	–	1.11 (0.87 to 1.41)	1.11 (0.87 to 1.41)
Edoxaban (60 mg od) vs. dabigatran (150 mg bd)	–	1.33 (1.02 to 1.75)	1.33 (1.02 to 1.75)
Rivaroxaban (20 mg od) vs. dabigatran (150 mg bd)	–	1.35 (1.03 to 1.78)	1.35 (1.03 to 1.78)
Rivaroxaban (20 mg od) vs. edoxaban (60 mg od)	–	1.01 (0.80 to 1.27)	1.01 (0.80 to 1.27)

TABLE 26 Results for stroke or SE (stroke prevention in AF): NOACs (licensed doses only) (*continued*)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
<i>Imprecisely estimated comparisons</i>			
<i>Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)</i>	7.01 (0.50 to 3450)	–	7.01 (0.47 to 3450)
<i>Dabigatran (150 mg bd) vs. apixaban (2.5 mg bd)</i>	–	5.77 (0.38 to 2850)	5.77 (0.38 to 2850)
<i>Betrixaban (40 mg od) vs. apixaban (2.5 mg bd)</i>	–	12.1 (0.01 to 70300)	12.1 (0.01 to 70300)
<i>Edoxaban (60 mg od) vs. apixaban (2.5 mg bd)</i>	–	7.67 (0.51 to 3730)	7.67 (0.51 to 3730)
<i>Rivaroxaban (20 mg od) vs. apixaban (2.5 mg bd)</i>	–	7.78 (0.52 to 3820)	7.78 (0.52 to 3820)
<i>Betrixaban (40 mg od) vs. apixaban (5 mg bd)</i>	–	1.28 (0 to 1210)	1.28 (0 to 1210)
<i>Betrixaban (40 mg od) vs. dabigatran (150 mg bd)</i>	–	1.56 (0 to 1490)	1.56 (0 to 1490)
<i>Edoxaban (60 mg od) vs. betrixaban (40 mg od)</i>	–	0.85 (0 to 566)	0.85 (0 to 566)
<i>Rivaroxaban (20 mg od) vs. betrixaban (40 mg od)</i>	–	0.86 (0 to 575)	0.86 (0 to 575)

TABLE 27 Results for stroke or SE (stroke prevention in AF): comparisons with warfarin (INR 2–3) – sensitivity analysis using HRs instead of ORs

Comparisons with warfarin (INR 2–3)	HR (95% CI)
Warfarin (INR 3–4)	0.58 (0.18 to 1.58)
Antiplatelet (< 150 mg od)	1.82 (1.39 to 2.41)
Antiplatelet (≥ 150 mg od)	1.58 (1.23 to 2.02)
Apixaban (5 mg bd)	0.79 (0.67 to 0.94)
Dabigatran (110 mg bd)	0.91 (0.75 to 1.11)
Dabigatran (150 mg bd)	0.66 (0.53 to 0.82)
Edoxaban (30 mg od)	1.13 (0.98 to 1.31)
Edoxaban (60 mg od)	0.87 (0.74 to 1.01)
Rivaroxaban (20 mg od)	0.88 (0.75 to 1.03)
<i>Imprecisely estimated comparisons</i>	
<i>Dabigatran (50 mg bd) + aspirin (81 mg bd)</i>	11.0 (0.66 to 366)
<i>Dabigatran (50 mg bd) + aspirin (325 mg bd)</i>	1.73 (0 to 94.9)
<i>Dabigatran (150 mg bd) + aspirin (81 mg bd)</i>	1.33 (0 to 63.4)
<i>Dabigatran (150 mg bd) + aspirin (325 mg bd)</i>	1.41 (0 to 72.6)
<i>Dabigatran (300 mg bd) + aspirin (81 mg bd)</i>	1.33 (0 to 75.9)
<i>Dabigatran (300 mg bd) + aspirin (325 mg bd)</i>	1.48 (0 to 86.3)
<i>Apixaban (2.5 mg bd)</i>	0.11 (0 to 1.66)
<i>Dabigatran (50 mg bd)</i>	3.96 (0.18 to 121)
<i>Dabigatran (300 mg bd)</i>	0.44 (0 to 23.9)
<i>Betrixaban (40 mg od)</i>	0.82 (0 to 313)
<i>Betrixaban (60 mg od)</i>	4.98 (0.17 to 1420)
<i>Betrixaban (80 mg od)</i>	4.87 (0.16 to 1340)
<i>Edoxaban (45 mg od)</i>	3.54 (0.19 to 159)
<i>Edoxaban (30 mg bd)</i>	1.40 (0.28 to 5.57)
<i>Edoxaban (60 mg bd)</i>	1.20 (0.15 to 5.39)

TABLE 28 Results for stroke or SE (stroke prevention in AF): NOACs (licensed doses only): sensitivity analysis using HRs instead of ORs

Licensed NOACs only	HR (95% CI)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd)	0.83 (0.63 to 1.10)
Edoxaban (60 mg od) vs. apixaban (5 mg bd)	1.10 (0.87 to 1.38)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd)	1.11 (0.88 to 1.40)
Edoxaban (60 mg od) vs. dabigatran (150 mg bd)	1.32 (1.01 to 1.73)
Rivaroxaban (20 mg od) vs. dabigatran (150 mg bd)	1.34 (1.02 to 1.76)
Rivaroxaban (20 mg od) vs. edoxaban (60 mg od)	1.01 (0.81 to 1.27)
Imprecisely estimated comparisons	
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)	7.39 (0.48 to 1990)
Dabigatran (150 mg bd) vs. apixaban (2.5 mg bd)	6.16 (0.38 to 1650)
Betrixaban (40 mg od) vs. apixaban (2.5 mg bd)	10.1 (0 to 22900)
Edoxaban (60 mg od) vs. apixaban (2.5 mg bd)	8.11 (0.51 to 2190)
Rivaroxaban (20 mg od) vs. apixaban (2.5 mg bd)	8.29 (0.53 to 2230)
Betrixaban (40 mg od) vs. apixaban (5 mg bd)	1.05 (0 to 401)
Betrixaban (40 mg od) vs. dabigatran (150 mg bd)	1.26 (0 to 466)
Edoxaban (60 mg od) vs. betrixaban (40 mg od)	1.05 (0 to 2320)
Rivaroxaban (20 mg od) vs. betrixaban (40 mg od)	1.07 (0 to 2270)

Ischaemic stroke

Fourteen studies reported on 2228 ischaemic stroke events, leading to a connected network comparing a total of 15 interventions (Figure 10). Twelve studies were included in the main analysis, with the remaining two included only in sensitivity analyses. The studies were at mixed risks of bias (Table 29). There were concerns about lack of blinding of participants for most trials, and about lack of allocation concealment and blinding of outcome assessment in one trial (AF-ASA-VKA-CHINA,¹³⁵ only included in sensitivity analyses due to implementation of warfarin within non-standard INR range).




FIGURE 10 Network plot for ischaemic stroke (stroke prevention in AF). a, Excluded interventions that were included in sensitivity analyses.

TABLE 29 Included trials and risk-of-bias assessment for ischaemic stroke (stroke prevention in AF)

Study	Interventions compared	SG	AC	BPP	BOA	IOD	SR
ACTIVE W ⁹⁸	1, 4	+	+	-	+	+	?
AFASAK II ⁹⁷	1, 5	+	?	-	+	+	?
AF-ASA-VKA-CHINA ¹³⁵	2, 4	?	-	-	-	+	?
AF-VKA-ASA-CHINA ¹²²	1, 5	+	?	?	?	?	?
ARISTOTLE ^{107,114,119,124-127,130,132-134}	1, 13	+	?	+	+	+	+
ARISTOTLE-J ¹¹³	1, 12, 13	?	?	-	+	+	+
AVERROES ^{103,114,115,119}	4, 13	+	+	+	+	+	+
ENGAGE AF-TIMI 48 ^{111,131}	1, 21, 23	+	+	+	+	+	+
EXPLORE-Xa ¹²⁶	1, 18, 19, 20	?	?	-	+	+	+
J-ROCKET AF ¹²⁰	2, 26	+	+	+	?	+	+
PATAF ⁹⁸	1, 5	+	+	?	+	?	+
RE-LY ^{104,109}	1, 15, 16	+	+	-	+	+	+
ROCKET AF ^{106,112,123,129}	1, 27	+	+	+	?	+	+
SPAF II ⁹⁶	1, 5	+	?	-	+	+	?

–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation; SR, selective reporting.

Table 30, which shows comparisons of all interventions with warfarin (INR 2–3), suggests that both low- and high-dose antiplatelets increase the risk of ischaemic stroke compared with warfarin (INR 2–3). Among NOACs, there was some evidence that dabigatran (150 mg bd) reduces the risk of ischaemic stroke compared with warfarin, whereas edoxaban (30 mg od) increases that risk. There was little evidence that the risk of ischaemic stroke differed between licensed doses of NOACs (Table 31).

In a sensitivity analysis to take into account the differences in duration of follow-up, NMA results were as presented in Tables 32 and 33, and show very similar results.

TABLE 30 Results for ischaemic stroke (stroke prevention in AF): comparisons with warfarin (INR 2–3)

Comparisons with warfarin (INR 2–3)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Antiplatelet (< 150 mg od)	–	2.52 (1.62 to 3.99)	2.52 (1.62 to 3.99)
Antiplatelet (≥ 150 mg od)	2.00 (1.51 to 2.67)	–	2.00 (1.51 to 2.67)
Apixaban (5 mg bd)	0.92 (0.74 to 1.14)	–	0.92 (0.74 to 1.14)
Dabigatran (110 mg bd)	1.14 (0.90 to 1.44)	–	1.14 (0.90 to 1.44)
Dabigatran (150 mg bd)	0.76 (0.58 to 0.98)	–	0.76 (0.58 to 0.98)
Edoxaban (30 mg od)	1.44 (1.21 to 1.71)	–	1.44 (1.21 to 1.71)
Edoxaban (60 mg od)	1.01 (0.84 to 1.21)	–	1.01 (0.84 to 1.21)
Rivaroxaban (20 mg od)	0.93 (0.74 to 1.16)	–	0.93 (0.74 to 1.16)
<i>Imprecisely estimated comparisons</i>			
Apixaban (2.5 mg bd)	0.26 (0 to 5.89)	–	0.26 (0 to 5.89)
Betrixaban (40 mg od)	1.05 (0 to 751)	–	1.05 (0 to 751)
Betrixaban (60 mg od)	5.41 (0.18 to 3290)	–	5.41 (0.18 to 3290)
Betrixaban (80 mg od)	5.43 (0.17 to 3230)	–	5.43 (0.17 to 3230)

TABLE 31 Results for ischaemic stroke (stroke prevention in AF): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd)	–	0.83 (0.59 to 1.16)	0.83 (0.59 to 1.16)
Edoxaban (60 mg od) vs. apixaban (5 mg bd)	–	1.10 (0.83 to 1.46)	1.10 (0.83 to 1.46)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd)	–	1.01 (0.74 to 1.38)	1.01 (0.74 to 1.38)
Edoxaban (60 mg od) vs. dabigatran (150 mg bd)	–	1.33 (0.97 to 1.83)	1.33 (0.97 to 1.83)
Rivaroxaban (20 mg od) vs. dabigatran (150 mg bd)	–	1.22 (0.87 to 1.73)	1.22 (0.87 to 1.73)
Rivaroxaban (20 mg od) vs. edoxaban (60 mg od)	–	0.92 (0.69 to 1.23)	0.92 (0.69 to 1.23)
<i>Imprecisely estimated comparisons</i>			
<i>Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)</i>	<i>3.47 (0.16 to 1730)</i>	–	<i>3.47 (0.16 to 1730)</i>
<i>Dabigatran (150 mg bd) vs. apixaban (2.5 mg bd)</i>	–	<i>2.88 (0.13 to 1430)</i>	<i>2.88 (0.13 to 1430)</i>
<i>Betrixaban (40 mg od) vs. apixaban (2.5 mg bd)</i>	–	<i>5.02 (0 to 25,800)</i>	<i>5.02 (0 to 25,800)</i>
<i>Edoxaban (60 mg od) vs. apixaban (2.5 mg bd)</i>	–	<i>3.82 (0.17 to 1920)</i>	<i>3.82 (0.17 to 1920)</i>
<i>Rivaroxaban (20 mg od) vs. apixaban (2.5 mg bd)</i>	–	<i>3.52 (0.16 to 1740)</i>	<i>3.52 (0.16 to 1740)</i>
<i>Betrixaban (40 mg od) vs. apixaban (5 mg bd)</i>	–	<i>1.15 (0 to 847)</i>	<i>1.15 (0 to 847)</i>
<i>Betrixaban (40 mg od) vs. dabigatran (150 mg bd)</i>	–	<i>1.39 (0 to 1010)</i>	<i>1.39 (0 to 1010)</i>
<i>Edoxaban (60 mg od) vs. betrixaban (40 mg od)</i>	–	<i>0.96 (0 to 633)</i>	<i>0.96 (0 to 633)</i>
<i>Rivaroxaban (20 mg od) vs. betrixaban (40 mg od)</i>	–	<i>0.88 (0 to 578)</i>	<i>0.88 (0 to 578)</i>

TABLE 32 Results for ischaemic stroke (stroke prevention in AF): comparisons with warfarin (INR 2–3) – sensitivity analysis using HRs instead of ORs

Comparisons with warfarin (INR 2–3)	HR (95% CI)
Antiplatelet (< 150 mg od)	2.46 (1.59 to 3.92)
Antiplatelet (≥ 150 mg od)	1.94 (1.47 to 2.59)
Apixaban (5 mg bd)	0.92 (0.75 to 1.15)
Dabigatran (110 mg bd)	1.12 (0.89 to 1.42)
Dabigatran (150 mg bd)	0.76 (0.59 to 0.99)
Edoxaban (30 mg od)	1.43 (1.22 to 1.69)
Edoxaban (60 mg od)	1.01 (0.84 to 1.20)
Rivaroxaban (20 mg od)	0.92 (0.74 to 1.15)
<i>Imprecisely estimated comparisons</i>	
<i>Apixaban (2.5 mg bd)</i>	<i>0.26 (0 to 5.77)</i>
<i>Betrixaban (40 mg od)</i>	<i>0.90 (0 to 233)</i>
<i>Betrixaban (60 mg od)</i>	<i>4.72 (0.18 to 787)</i>
<i>Betrixaban (80 mg od)</i>	<i>4.67 (0.18 to 838)</i>

TABLE 33 Results for ischaemic stroke (stroke prevention in AF): NOACs (licensed doses only) – sensitivity analysis using HRs instead of ORs

Licensed NOACs only	HR (95% CI)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd)	0.83 (0.59 to 1.15)
Edoxaban (60 mg od) vs. apixaban (5 mg bd)	1.09 (0.83 to 1.44)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd)	1.00 (0.73 to 1.35)
Edoxaban (60 mg od) vs. dabigatran (150 mg bd)	1.32 (0.96 to 1.80)
Rivaroxaban (20 mg od) vs. dabigatran (150 mg bd)	1.21 (0.86 to 1.70)
Rivaroxaban (20 mg od) vs. edoxaban (60 mg od)	0.92 (0.69 to 1.22)
Imprecisely estimated comparisons	
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)	3.54 (0.16 to 1750)
Dabigatran (150 mg bd) vs. apixaban (2.5 mg bd)	2.90 (0.13 to 1480)
Betrixaban (40 mg od) vs. apixaban (2.5 mg bd)	4.05 (0 to 9940)
Edoxaban (60 mg od) vs. apixaban (2.5 mg bd)	3.81 (0.18 to 1960)
Rivaroxaban (20 mg od) vs. apixaban (2.5 mg bd)	3.50 (0.16 to 1780)
Betrixaban (40 mg od) vs. apixaban (5 mg bd)	0.96 (0 to 241)
Betrixaban (40 mg od) vs. dabigatran (150 mg bd)	1.18 (0 to 307)
Edoxaban (60 mg od) vs. betrixaban (40 mg od)	1.11 (0 to 723)
Rivaroxaban (20 mg od) vs. betrixaban (40 mg od)	1.03 (0 to 660)

Myocardial infarction

A total of 15 studies reported 1334 MI events, leading to a network of 16 interventions (*Figure 11*). Thirteen studies were included in the main analysis, with the other two included only in sensitivity analyses. The studies were at mixed risks of bias (*Table 34*). There were concerns about lack of blinding of participants for most trials, and about lack of allocation concealment and blinding of outcome assessment in some.


**FIGURE 11** Network plot for MI (stroke prevention in AF). a, Excluded interventions that were included in sensitivity analyses.

TABLE 34 Included trials and risk-of-bias assessment for MI (stroke prevention in AF)

Study	Interventions compared	SG	AC	BPP	BOA	IOD	SR
ACTIVE W ⁹⁸	1, 4	+	+	-	+	+	?
AFASAK II ⁹⁷	1, 5	+	?	-	+	+	?
AF-ASA-VKA-CHINA ¹³⁵	2, 4	?	-	-	-	+	?
AF-EDOX-VKA-MULTI ¹⁰⁸	1, 21, 23, 24, 25	+	+	-	?	+	+
ARISTOTLE ^{107,114,119,124-127,130,132-134}	1, 13	+	?	+	+	+	+
ARISTOTLE-J ¹¹³	1, 12, 13	?	?	-	+	+	+
AVERROES ^{103,114,115,119}	4, 13	+	+	+	+	+	+
BAFTA ¹⁰³	1, 4	+	+	-	+	+	+
ENGAGE AF-TIMI 48 ^{111,131}	1, 21, 23	+	+	+	+	+	+
EXPLORE-Xa ¹²⁶	1, 18, 19, 20	?	?	-	+	+	+
J-ROCKET AF ¹²⁰	2, 26	+	+	+	?	+	+
PATAF ⁹⁸	1, 5	+	+	?	+	?	+
RE-LY ^{104,109}	1, 15, 16	+	+	-	+	+	+
ROCKET AF ^{106,112,123,129}	1, 27	+	+	+	?	+	+
SPAF II ⁹⁶	1, 5	+	?	-	-	+	?

–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation; SR, selective reporting.

Table 35 shows weak evidence that dabigatran (110 mg bd), dabigatran (150 mg bd) and edoxaban (30 mg od) increase the risk of MI compared with warfarin (INR 2–3), and weak evidence that rivaroxaban (20 mg od) decreases risk of MI compared with warfarin (INR 2–3). None of the interventions was superior or inferior to warfarin (INR 2–3). The pairwise comparisons of licensed NOACs, presented in Table 36, show weak evidence that dabigatran (150 mg bd) increases the risk of MI compared with apixaban (5 mg bd), and evidence that rivaroxaban (20 mg od) reduces the risk of MI compared with dabigatran (150 mg bd). Results were similar in a sensitivity analysis, taking into account the differences in duration of follow-up within and between trials, and the differences in the definition of event used across trials (e.g. total number of events vs. first events only) (Tables 37 and 38).

TABLE 35 Results for MI (stroke prevention in AF): comparisons with warfarin (INR 2–3)

Comparisons with warfarin (INR 2–3)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Antiplatelet (< 150 mg od)	1.00 (0.47 to 2.10)	1.02 (0.55 to 1.87)	1.01 (0.64 to 1.61)
Antiplatelet (≥ 150 mg od)	1.38 (0.94 to 2.03)	–	1.38 (0.94 to 2.03)
Apixaban (5 mg bd)	0.87 (0.66 to 1.15)	–	0.87 (0.66 to 1.15)
Dabigatran (110 mg bd)	1.32 (0.97 to 1.79)	–	1.32 (0.97 to 1.79)
Dabigatran (150 mg bd)	1.29 (0.96 to 1.75)	–	1.29 (0.96 to 1.75)
Edoxaban (30 mg od)	1.22 (0.97 to 1.53)	–	1.22 (0.97 to 1.53)
Edoxaban (60 mg od)	0.96 (0.75 to 1.22)	–	0.96 (0.75 to 1.22)
Rivaroxaban (20 mg od)	0.80 (0.61 to 1.04)	–	0.80 (0.61 to 1.04)
Imprecisely estimated comparisons			
Edoxaban (30 mg bd)	0.71 (0.06 to 3.97)	–	0.71 (0.06 to 3.97)
Edoxaban (60 mg bd)	0.19 (0 to 2.60)	–	0.19 (0 to 2.60)

TABLE 36 Results for MI (stroke prevention in AF): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd)	–	1.48 (0.98 to 2.22)	1.48 (0.98 to 2.22)
Edoxaban (60 mg od) vs. apixaban (5 mg bd)	–	1.10 (0.76 to 1.58)	1.10 (0.76 to 1.58)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd)	–	0.92 (0.63 to 1.34)	0.92 (0.63 to 1.34)
Edoxaban (60 mg od) vs. dabigatran (150 mg bd)	–	0.74 (0.50 to 1.09)	0.74 (0.50 to 1.09)
Rivaroxaban (20 mg od) vs. dabigatran (150 mg bd)	–	0.62 (0.41 to 0.93)	0.62 (0.41 to 0.93)
Rivaroxaban (20 mg od) vs. edoxaban (60 mg od)	–	0.84 (0.59 to 1.20)	0.84 (0.59 to 1.20)

TABLE 37 Results for MI (stroke prevention in AF): comparisons with warfarin (INR 2–3): sensitivity analysis using HRs instead of ORs

Comparisons with warfarin (INR 2–3)	HR (95% CI)
Antiplatelet (< 150 mg od)	1.01 (0.64 to 1.61)
Antiplatelet (≥ 150 mg od)	1.36 (0.93 to 2.01)
Apixaban (5 mg bd)	0.88 (0.67 to 1.16)
Dabigatran (110 mg bd)	1.31 (0.96 to 1.77)
Dabigatran (150 mg bd)	1.30 (0.96 to 1.77)
Edoxaban (30 mg od)	1.22 (0.97 to 1.52)
Edoxaban (60 mg od)	0.96 (0.76 to 1.22)
Rivaroxaban (20 mg od)	0.80 (0.62 to 1.04)
<i>Imprecisely estimated comparisons</i>	
<i>Edoxaban (30 mg bd)</i>	<i>0.97 (0.09 to 5.40)</i>
<i>Edoxaban (60 mg bd)</i>	<i>0.13 (0 to 1.81)</i>

TABLE 38 Results for MI (stroke prevention in AF): NOACs (licensed doses only): sensitivity analysis using HRs instead of ORs

Licensed NOACs only	HR (95% CI)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd)	1.48 (0.98 to 2.23)
Edoxaban (60 mg od) vs. apixaban (5 mg bd)	1.09 (0.76 to 1.57)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd)	0.91 (0.62 to 1.33)
Edoxaban (60 mg od) vs. dabigatran (150 mg bd)	0.74 (0.49 to 1.08)
Rivaroxaban (20 mg od) vs. dabigatran (150 mg bd)	0.62 (0.41 to 0.92)
Rivaroxaban (20 mg od) vs. edoxaban (60 mg od)	0.84 (0.59 to 1.19)

Major bleeding

Eighteen studies reported 4314 major bleeding events, leading to a network of 24 interventions (Figure 12). Seventeen studies were included in the main analysis, with the remaining study included only in sensitivity analyses. These studies were at mixed risks of bias (Table 39). There were concerns about lack of blinding of participants for most trials, and about lack of allocation concealment and blinding of outcome assessment in some.




FIGURE 12 Network plot for major bleeding (stroke prevention in AF). a, Excluded interventions that were included in sensitivity analyses.

TABLE 39 Included trials and risk-of-bias assessment for major bleeding (stroke prevention in AF)

Study	Interventions compared	SC	AC	BPP	BOA	IOD	SR
ACTIVE W ⁹⁸	1, 4	+	+	-	+	+	?
AFASAK II ⁹⁷	1, 5	+	?	-	+	+	?
AF-ASA-VKA-CHINA ¹³⁵	2, 4	?	-	-	-	+	?
AF-DABIG-VKA-JAPAN ¹¹⁰	2, 15, 16	?	?	?	?	?	?
AF-EDOX-VKA-ASIA ¹¹⁵	1, 21, 23	+	+	-	+	+	+
AF-EDOX-VKA-JAPAN ¹¹⁸	2, 21, 22, 23	+	?	-	?	+	+
AF-EDOX-VKA-MULTI ¹⁰⁸	1, 21, 23, 24, 25	+	+	-	+	+	+
AF-VKA-ASA-CHINA ¹²²	1, 5	+	?	-	?	?	?
ARISTOTLE ^{107,114,119,124-127,130,132-134}	1, 13	+	?	+	+	?	+
ARISTOTLE-J ¹¹³	1, 12, 13	?	?	-	+	+	+
AVERROES ^{103,114,115,119}	4, 13	+	+	+	+	+	+
BAFTA ¹⁰³	1, 4	+	+	-	+	+	+
ENGAGE AF-TIMI 48 ^{111,131}	1, 21, 23	+	+	+	+	+	+
EXPLORE-Xa ¹²⁶	1, 18, 19, 20	?	?	-	+	+	+
PETRO ¹⁰²	1, 6, 7, 8, 9, 10, 11, 14, 16, 17	?	?	-	+	+	+
RE-LY ^{104,109}	1, 15, 16	+	+	-	+	+	+
ROCKET AF ^{106,112,123,129}	1, 27	+	+	+	?	+	+
WASPO ¹⁰¹	1, 5	+	+	-	-	+	?

-, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation; SR, selective reporting.

There was weak evidence that antiplatelet therapy (< 150 mg od) reduced major bleeding compared with warfarin (INR 2–3). There was evidence that apixaban (5 mg bd), dabigatran (110 mg bd), edoxaban (30 mg od) and edoxaban (60 mg od) reduced major bleeding risk compared with warfarin (INR 2–3) (Table 40). Comparisons among licensed doses of NOACs, presented in Table 41, suggest that dabigatran (150 mg bd) increases risk of major bleeding compared with apixaban (5 mg bd), whereas rivaroxaban (20 mg od) increases risk of major bleeding compared with apixaban (5 mg bd) and edoxaban (60 mg od).

In a sensitivity analysis to take into account the differences in duration of follow-up, NMA results were as presented in Tables 42 and 43, and show very similar results. Another sensitivity analysis involved fitting a fixed-effects meta-regression model using the mean TTR for warfarin patients (see Table 19) as a covariate and the mean log-OR from each pairwise comparison (with warfarin as the reference category) as the response variable. We found no evidence of an effect modification according to mean TTR (estimated coefficient 0.04 with 95% CI –0.03 to 0.12 per 1% increase). The model fit indices yielded almost identical values for the models with and without the covariate.

TABLE 40 Results for major bleeding (stroke prevention in AF): comparisons with warfarin (INR 2–3)

Comparisons with warfarin (INR 2–3)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Antiplatelet (< 150 mg od)	1.00 (0.56 to 1.77)	0.63 (0.40 to 0.98)	0.75 (0.52 to 1.06)
Antiplatelet (≥ 150 mg od)	1.07 (0.82 to 1.42)	–	1.07 (0.82 to 1.42)
Apixaban (5 mg bd)	0.71 (0.61 to 0.81)	–	0.71 (0.61 to 0.81)
Dabigatran (110 mg bd)	0.80 (0.69 to 0.93)	–	0.80 (0.69 to 0.93)
Dabigatran (150 mg bd)	0.94 (0.81 to 1.08)	–	0.94 (0.81 to 1.08)
Edoxaban (30 mg od)	0.46 (0.40 to 0.54)	–	0.46 (0.40 to 0.54)
Edoxaban (60 mg od)	0.78 (0.69 to 0.90)	–	0.78 (0.69 to 0.90)
Rivaroxaban (20 mg od)	1.03 (0.89 to 1.18)	–	1.03 (0.89 to 1.18)
Imprecisely estimated comparisons			
<i>Dabigatran (50 mg bd) + aspirin (81 mg bd)</i>	<i>2.54 (0 to 146)</i>	–	<i>2.54 (0 to 146)</i>
<i>Dabigatran (50 mg bd) + aspirin (325 mg bd)</i>	<i>1.99 (0 to 112)</i>	–	<i>1.99 (0 to 112)</i>
<i>Dabigatran (150 mg bd) + aspirin (81 mg bd)</i>	<i>1.52 (0 to 82.0)</i>	–	<i>1.52 (0 to 82.0)</i>
<i>Dabigatran (150 mg bd) + aspirin (325 mg bd)</i>	<i>1.63 (0 to 90.4)</i>	–	<i>1.63 (0 to 90.4)</i>
<i>Dabigatran (300 mg bd) + aspirin (81 mg bd)</i>	<i>8.38 (0.45 to 266)</i>	–	<i>8.38 (0.45 to 266)</i>
<i>Dabigatran (300 mg bd) + aspirin (325 mg bd)</i>	<i>27.6 (3.05 to 749)</i>	–	<i>27.6 (3.05 to 749)</i>
<i>Apixaban (2.5 mg bd)</i>	<i>0.24 (0 to 5.48)</i>	–	<i>0.24 (0 to 5.48)</i>
<i>Dabigatran (50 mg bd)</i>	<i>0.89 (0 to 52.4)</i>	–	<i>0.89 (0 to 52.4)</i>
<i>Dabigatran (300 mg bd)</i>	<i>0.50 (0 to 28.6)</i>	–	<i>0.50 (0 to 28.6)</i>
<i>Betrixaban (40 mg od)</i>	<i>0.04 (0 to 0.58)</i>	–	<i>0.04 (0 to 0.58)</i>
<i>Betrixaban (60 mg od)</i>	<i>0.04 (0 to 0.59)</i>	–	<i>0.04 (0 to 0.59)</i>
<i>Betrixaban (80 mg od)</i>	<i>0.60 (0.13 to 2.40)</i>	–	<i>0.60 (0.13 to 2.40)</i>
<i>Edoxaban (45 mg od)</i>	<i>1.45 (0.27 to 8.29)</i>	–	<i>1.45 (0.27 to 8.29)</i>
<i>Edoxaban (30 mg bd)</i>	<i>3.68 (0.94 to 16.9)</i>	–	<i>3.68 (0.94 to 16.9)</i>
<i>Edoxaban (60 mg bd)</i>	<i>6.01 (1.64 to 27.0)</i>	–	<i>6.01 (1.64 to 27.0)</i>

TABLE 41 Results for major bleeding (stroke prevention in AF): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd)	–	1.33 (1.09 to 1.62)	1.33 (1.09 to 1.62)
Edoxaban (60 mg od) vs. apixaban (5 mg bd)	–	1.11 (0.92 to 1.35)	1.11 (0.92 to 1.35)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd)	–	1.45 (1.19 to 1.78)	1.45 (1.19 to 1.78)
Edoxaban (60 mg od) vs. dabigatran (150 mg bd)	–	0.84 (0.69 to 1.02)	0.84 (0.69 to 1.02)
Rivaroxaban (20 mg od) vs. dabigatran (150 mg bd)	–	1.10 (0.90 to 1.34)	1.10 (0.90 to 1.34)
Rivaroxaban (20 mg od) vs. edoxaban (60 mg od)	–	1.31 (1.07 to 1.59)	1.31 (1.07 to 1.59)
Imprecisely estimated comparisons			
<i>Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)</i>	2.93 (0.13 to 1320)	–	2.93 (0.13 to 1320)
<i>Dabigatran (150 mg bd) vs. apixaban (2.5 mg bd)</i>	–	3.88 (0.17 to 1740)	3.88 (0.17 to 1740)
<i>Betrixaban (40 mg od) vs. apixaban (2.5 mg bd)</i>	–	0.17 (0 to 124)	0.17 (0 to 124)
<i>Edoxaban (60 mg od) vs. apixaban (2.5 mg bd)</i>	–	3.25 (0.14 to 1460)	3.25 (0.14 to 1460)
<i>Rivaroxaban (20 mg od) vs. apixaban (2.5 mg bd)</i>	–	4.27 (0.19 to 1910)	4.27 (0.19 to 1910)
<i>Betrixaban (40 mg od) vs. apixaban (5 mg bd)</i>	–	0.06 (0 to 0.84)	0.06 (0 to 0.84)
<i>Betrixaban (40 mg od) vs. dabigatran (150 mg bd)</i>	–	0.04 (0 to 0.63)	0.04 (0 to 0.63)
<i>Edoxaban (60 mg od) vs. betrixaban (40 mg od)</i>	–	18.7 (1.34 to 9160)	18.7 (1.34 to 9160)
<i>Rivaroxaban (20 mg od) vs. betrixaban (40 mg od)</i>	–	24.5 (1.76 to 12,000)	24.5 (1.76 to 12,000)

TABLE 42 Results for major bleeding (stroke prevention in AF): comparisons with warfarin (INR 2–3): sensitivity analysis using HRs instead of ORs

Comparisons with warfarin (INR 2–3)	HR (95% CI)
Antiplatelet (< 150 mg od)	0.76 (0.53 to 1.08)
Antiplatelet (≥ 150 mg od)	1.07 (0.82 to 1.41)
Apixaban (5 mg bd)	0.72 (0.62 to 0.82)
Dabigatran (110 mg bd)	0.81 (0.70 to 0.93)
Dabigatran (150 mg bd)	0.94 (0.82 to 1.07)
Edoxaban (30 mg od)	0.47 (0.41 to 0.55)
Edoxaban (60 mg od)	0.79 (0.70 to 0.90)
Rivaroxaban (20 mg od)	1.02 (0.89 to 1.18)
Imprecisely estimated comparisons	
<i>Dabigatran (50 mg bd) + aspirin (81 mg bd)</i>	2.58 (0 to 151)
<i>Dabigatran (50 mg bd) + aspirin (325 mg bd)</i>	2.07 (0 to 114)
<i>Dabigatran (150 mg bd) + aspirin (81 mg bd)</i>	1.51 (0 to 78.3)
<i>Dabigatran (150 mg bd) + aspirin (325 mg bd)</i>	1.62 (0 to 94.8)
<i>Dabigatran (300 mg bd) + aspirin (81 mg bd)</i>	8.36 (0.50 to 281)
<i>Dabigatran (300 mg bd) + aspirin (325 mg bd)</i>	26.3 (3.08 to 697)

TABLE 42 Results for major bleeding (stroke prevention in AF): comparisons with warfarin (INR 2–3): sensitivity analysis using HRs instead of ORs (*continued*)

Comparisons with warfarin (INR 2–3)	HR (95% CI)
Apixaban (2.5 mg bd)	0.25 (0 to 5.49)
Dabigatran (50 mg bd)	0.93 (0 to 53.2)
Dabigatran (300 mg bd)	0.52 (0 to 29.7)
Betrixaban (40 mg od)	0.05 (0 to 0.55)
Betrixaban (60 mg od)	0.04 (0 to 0.60)
Betrixaban (80 mg od)	0.60 (0.13 to 2.38)
Edoxaban (45 mg od)	1.49 (0.28 to 8.31)
Edoxaban (30 mg bd)	3.64 (0.95 to 17.1)
Edoxaban (60 mg bd)	6.00 (1.66 to 27.5)

TABLE 43 Results for major bleeding (stroke prevention in AF): NOACs (licensed doses only) – sensitivity analysis using HRs instead of ORs

Licensed NOACs only	HR (95% CI)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd)	1.31 (1.08 to 1.59)
Edoxaban (60 mg od) vs. apixaban (5 mg bd)	1.10 (0.91 to 1.33)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd)	1.43 (1.17 to 1.75)
Edoxaban (60 mg od) vs. dabigatran (150 mg bd)	0.84 (0.70 to 1.02)
Rivaroxaban (20 mg od) vs. dabigatran (150 mg bd)	1.09 (0.90 to 1.33)
Rivaroxaban (20 mg od) vs. edoxaban (60 mg od)	1.30 (1.07 to 1.57)
<i>Imprecisely estimated comparisons</i>	
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)	2.89 (0.13 to 519)
Dabigatran (150 mg bd) vs. apixaban (2.5 mg bd)	3.80 (0.17 to 683)
Betrixaban (40 mg od) vs. apixaban (2.5 mg bd)	0.18 (0 to 61.9)
Edoxaban (60 mg od) vs. apixaban (2.5 mg bd)	3.19 (0.14 to 579)
Rivaroxaban (20 mg od) vs. apixaban (2.5 mg bd)	4.13 (0.19 to 751)
Betrixaban (40 mg od) vs. apixaban (5 mg bd)	0.06 (0 to 0.77)
Betrixaban (40 mg od) vs. dabigatran (150 mg bd)	0.05 (0 to 0.58)
Edoxaban (60 mg od) vs. betrixaban (40 mg od)	17.1 (1.44 to 2160)
Rivaroxaban (20 mg od) vs. betrixaban (40 mg od)	22.1 (1.89 to 2770)

Clinically relevant bleeding

Twelve studies reported 9556 CRB events, leading to a network of 23 interventions (*Figure 13*). Eleven studies were included in the main analysis, with the remaining study included only in sensitivity analyses. These studies were at mixed risks of bias (*Table 44*), the concerns being due to lack of blinding of participants for most trials.




FIGURE 13 Network plot for CRB (stroke prevention in AF). a, Excluded interventions that were included in sensitivity analyses.

TABLE 44 Included trials and risk-of-bias assessment for CRB (stroke prevention in AF)

Study	Interventions compared	SG	AC	BPP	BOA	IOD	SR
AF-DABIG-VKA-JAPAN ¹¹⁰	2, 15, 16	?	?	?	?	?	?
AF-EDOX-VKA-ASIA ¹¹⁵	1, 21, 23	+	+	-	+	+	+
AF-EDOX-VKA-JAPAN ¹¹⁸	2, 21, 22, 23	+	?	-	?	+	+
AF-EDOX-VKA-MULTI ¹⁰⁸	1, 21, 23, 24, 25	+	+	-	+	+	+
ARISTOTLE ^{107,114,119,124-127,130,132-134}	1, 13	+	?	+	+	?	+
ARISTOTLE-J ¹¹³	1, 12, 13	?	?	-	+	+	+
AVERROES ^{103,114,115,119}	4, 13	+	+	+	+	+	+
ENGAGE AF-TIMI 48 ^{111,131}	1, 21, 23	+	+	+	+	+	+
EXPLORE-Xa ¹²⁶	1, 18, 19, 20	?	?	-	+	+	+
J-ROCKET AF ¹²⁰	2, 26	+	+	+	?	+	+
PETRO ¹⁰²	1, 6, 7, 8, 9, 10, 11, 14, 16, 17	?	?	-	+	+	+
ROCKET AF ^{106,112,123,129}	1, 27	+	+	+	?	+	+

-, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation; SR, selective reporting.

Results presented in Table 45 suggest that antiplatelet therapy (< 150 mg od) reduces CRB compared with warfarin (INR 2–3). Note that the licensed dose for of antiplatelet therapy for AF is ≥ 150 mg od: no studies provided data for that dose for CRB. Among NOACs, there was evidence that apixaban (5 mg bd), edoxaban (30 mg od) and edoxaban (60 mg od) reduce CRB compared with warfarin (INR 2–3). However, edoxaban (30 mg bd) and edoxaban (60 mg bd) increased CRB compared with warfarin (INR 2–3). Among licensed NOACs (Table 46), there was evidence that edoxaban (60 mg od) and rivaroxaban (20 mg od) increase CRB compared with apixaban (5 mg bd) and that rivaroxaban (20 mg od) increased CRB compared with edoxaban (60 mg od).

Supplementary NMAs of HRs rather than ORs show very similar results (Tables 47 and 48).

TABLE 45 Results for CRB (stroke prevention in AF): comparisons with warfarin (INR 2–3)

Comparisons with warfarin (INR 2–3)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Antiplatelet (< 150 mg od)	–	0.59 (0.45 to 0.77)	0.59 (0.45 to 0.77)
Apixaban (5 mg bd)	0.67 (0.60 to 0.75)	–	0.67 (0.60 to 0.75)
Edoxaban (30 mg od)	0.59 (0.54 to 0.64)	–	0.59 (0.54 to 0.64)
Edoxaban (45 mg od)	1.09 (0.37 to 3.04)	–	1.09 (0.37 to 3.04)
Edoxaban (60 mg od)	0.84 (0.77 to 0.90)	–	0.84 (0.77 to 0.90)
Edoxaban (30 mg bd)	1.97 (1.04 to 3.67)	–	1.97 (1.04 to 3.67)
Edoxaban (60 mg bd)	2.76 (1.46 to 5.17)	–	2.76 (1.46 to 5.17)
Rivaroxaban (20 mg od)	1.03 (0.95 to 1.11)	–	1.03 (0.95 to 1.11)
Imprecisely estimated comparisons			
<i>Dabigatran (50 mg bd) + aspirin (81 mg bd)</i>	<i>0.91 (0.07 to 5.87)</i>	–	<i>0.91 (0.07 to 5.87)</i>
<i>Dabigatran (50 mg bd) + aspirin (325 mg bd)</i>	<i>0.70 (0.06 to 4.50)</i>	–	<i>0.70 (0.06 to 4.50)</i>
<i>Dabigatran (150 mg bd) + aspirin (81 mg bd)</i>	<i>0.99 (0.15 to 4.99)</i>	–	<i>0.99 (0.15 to 4.99)</i>
<i>Dabigatran (150 mg bd) + aspirin (325 mg bd)</i>	<i>1.08 (0.17 to 5.58)</i>	–	<i>1.08 (0.17 to 5.58)</i>
<i>Dabigatran (300 mg bd) + aspirin (81 mg bd)</i>	<i>2.76 (0.71 to 11.7)</i>	–	<i>2.76 (0.71 to 11.7)</i>
<i>Dabigatran (300 mg bd) + aspirin (325 mg bd)</i>	<i>3.98 (1.10 to 16.3)</i>	–	<i>3.98 (1.10 to 16.3)</i>
<i>Apixaban (2.5 mg bd)</i>	<i>0.25 (0.01 to 1.88)</i>	–	<i>0.25 (0.01 to 1.88)</i>
<i>Dabigatran (50 mg bd)</i>	<i>0.06 (0 to 0.91)</i>	–	<i>0.06 (0 to 0.91)</i>
<i>Dabigatran (110 mg bd)</i>	<i>0.67 (0.06 to 5.47)</i>	–	<i>0.67 (0.06 to 5.47)</i>
<i>Dabigatran (150 mg bd)</i>	<i>1.56 (0.50 to 5.74)</i>	–	<i>1.56 (0.50 to 5.74)</i>
<i>Dabigatran (300 mg bd)</i>	<i>0.96 (0.27 to 3.78)</i>	–	<i>0.96 (0.27 to 3.78)</i>
<i>Betrixaban (40 mg od)</i>	<i>0.10 (0 to 0.67)</i>	–	<i>0.10 (0 to 0.67)</i>
<i>Betrixaban (60 mg od)</i>	<i>0.69 (0.19 to 2.27)</i>	–	<i>0.69 (0.19 to 2.27)</i>
<i>Betrixaban (80 mg od)</i>	<i>0.69 (0.19 to 2.22)</i>	–	<i>0.69 (0.19 to 2.22)</i>

TABLE 46 Results for CRB (stroke prevention in AF): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Edoxaban (60 mg od) vs. apixaban (5 mg bd)	–	1.24 (1.09 to 1.42)	1.24 (1.09 to 1.42)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd)	–	1.53 (1.33 to 1.75)	1.53 (1.33 to 1.75)
Rivaroxaban (20 mg od) vs. edoxaban (60 mg od)	–	1.23 (1.10 to 1.37)	1.23 (1.10 to 1.37)
Imprecisely estimated comparisons			
<i>Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)</i>	<i>2.69 (0.35 to 79.9)</i>	–	<i>2.69 (0.35 to 79.9)</i>
<i>Dabigatran (150 mg bd) vs. apixaban (2.5 mg bd)</i>	–	<i>6.59 (0.60 to 220)</i>	<i>6.59 (0.60 to 220)</i>
<i>Betrixaban (40 mg od) vs. apixaban (2.5 mg bd)</i>	–	<i>0.39 (0.01 to 18.7)</i>	<i>0.39 (0.01 to 18.7)</i>
<i>Edoxaban (60 mg od) vs. apixaban (2.5 mg bd)</i>	–	<i>3.35 (0.44 to 99.4)</i>	<i>3.35 (0.44 to 99.4)</i>

continued

TABLE 46 Results for CRB (stroke prevention in AF): NOACs (licensed doses only) (*continued*)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
<i>Rivaroxaban (20 mg od) vs. apixaban (2.5 mg bd)</i>	–	4.12 (0.54 to 123)	4.12 (0.54 to 123)
<i>Dabigatran (150 mg bd) vs. apixaban (5 mg bd)</i>	–	2.32 (0.74 to 8.63)	2.32 (0.74 to 8.63)
<i>Betrixaban (40 mg od) vs. apixaban (5 mg bd)</i>	–	0.15 (0 to 1.00)	0.15 (0 to 1.00)
<i>Betrixaban (40 mg od) vs. dabigatran (150 mg bd)</i>	–	0.06 (0 to 0.60)	0.06 (0 to 0.60)
<i>Edoxaban (60 mg od) vs. dabigatran (150 mg bd)</i>	–	0.54 (0.14 to 1.68)	0.54 (0.14 to 1.68)
<i>Rivaroxaban (20 mg od) vs. dabigatran (150 mg bd)</i>	–	0.66 (0.18 to 2.07)	0.66 (0.18 to 2.07)
<i>Edoxaban (60 mg od) vs. betrixaban (40 mg od)</i>	–	8.50 (1.25 to 251)	8.50 (1.25 to 251)

TABLE 47 Results for CRB (stroke prevention in AF): comparisons with warfarin (INR 2–3): sensitivity analysis using HRs instead of ORs

Comparisons with warfarin (INR 2–3)	HR (95% CI)
Antiplatelet (< 150 mg od)	0.59 (0.46 to 0.76)
Apixaban (5 mg bd)	0.67 (0.60 to 0.75)
Edoxaban (30 mg od)	0.59 (0.55 to 0.64)
Edoxaban (45 mg od)	1.09 (0.37 to 3.01)
Edoxaban (60 mg od)	0.83 (0.77 to 0.90)
Edoxaban (30 mg bd)	1.98 (1.05 to 3.71)
Edoxaban (60 mg bd)	2.78 (1.46 to 5.20)
Rivaroxaban (20 mg od)	1.03 (0.95 to 1.11)
<i>Imprecisely estimated comparisons</i>	
<i>Dabigatran (50 mg bd) + aspirin (81 mg bd)</i>	0.93 (0.07 to 5.79)
<i>Dabigatran (50 mg bd) + aspirin (325 mg bd)</i>	0.72 (0.06 to 4.54)
<i>Dabigatran (150 mg bd) + aspirin (81 mg bd)</i>	1.01 (0.15 to 4.99)
<i>Dabigatran (150 mg bd) + aspirin (325 mg bd)</i>	1.10 (0.17 to 5.53)
<i>Dabigatran (300 mg bd) + aspirin (81 mg bd)</i>	2.84 (0.72 to 11.4)
<i>Dabigatran (300 mg bd) + aspirin (325 mg bd)</i>	4.06 (1.10 to 16.1)
<i>Apixaban (2.5 mg bd)</i>	0.25 (0.01 to 1.87)
<i>Dabigatran (50 mg bd)</i>	0.06 (0 to 0.89)
<i>Dabigatran (110 mg bd)</i>	0.68 (0.06 to 5.65)
<i>Dabigatran (150 mg bd)</i>	1.60 (0.51 to 5.72)
<i>Dabigatran (300 mg bd)</i>	0.99 (0.28 to 3.71)
<i>Betrixaban (40 mg od)</i>	0.10 (0 to 0.66)
<i>Betrixaban (60 mg od)</i>	0.69 (0.19 to 2.26)
<i>Betrixaban (80 mg od)</i>	0.69 (0.19 to 2.30)

TABLE 48 Results for CRB (stroke prevention in AF): NOACs (licensed doses only): sensitivity analysis using HRs instead of ORs

Licensed NOACs only	HR (95% CI)
Edoxaban (60 mg od) vs. apixaban (5 mg bd)	1.24 (1.09 to 1.42)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd)	1.53 (1.33 to 1.74)
Rivaroxaban (20 mg od) vs. edoxaban (60 mg od)	1.23 (1.10 to 1.37)
Imprecisely estimated comparisons	
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)	2.67 (0.36 to 81.0)
Dabigatran (150 mg bd) vs. apixaban (2.5 mg bd)	6.69 (0.61 to 235)
Betrixaban (40 mg od) vs. apixaban (2.5 mg bd)	0.39 (0.01 to 19.0)
Edoxaban (60 mg od) vs. apixaban (2.5 mg bd)	3.32 (0.44 to 100)
Rivaroxaban (20 mg od) vs. apixaban (2.5 mg bd)	4.08 (0.55 to 124)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd)	2.38 (0.75 to 8.56)
Betrixaban (40 mg od) vs. apixaban (5 mg bd)	0.15 (0.01 to 0.99)
Betrixaban (40 mg od) vs. dabigatran (150 mg bd)	0.06 (0 to 0.58)
Edoxaban (60 mg od) vs. dabigatran (150 mg bd)	0.52 (0.15 to 1.64)
Rivaroxaban (20 mg od) vs. dabigatran (150 mg bd)	0.64 (0.18 to 2.03)
Edoxaban (60 mg od) vs. betrixaban (40 mg od)	8.45 (1.25 to 247)
Rivaroxaban (20 mg od) vs. betrixaban (40 mg od)	10.4 (1.55 to 305)

Intracranial bleeding

Eight studies reported a total of 757 intracranial bleeds, leading to a network of 10 interventions (*Figure 14*). Seven trials were included in the primary analysis, with the remaining study included only in sensitivity analyses. These studies were at mixed risks of bias (*Table 49*), the concerns being due to lack of blinding of participants and, in one study, lack of blinding of outcome assessment.

There was strong evidence that apixaban (5 mg bd), dabigatran (110 mg bd), dabigatran (150 mg bd), edoxaban (30 mg od), edoxaban (60 mg od) and rivaroxaban (20 mg od) reduced risk of intracranial bleeding compared with warfarin (INR 2–3) (*Table 50*). For each of these NOAC doses except rivaroxaban


**FIGURE 14** Network plot for intracranial bleeding (stroke prevention in AF). a, Excluded interventions that were included in sensitivity analyses.

TABLE 49 Included trials and risk-of-bias assessment for intracranial bleeding (stroke prevention in AF)

Study	Interventions compared	SG	AC	BPP	BOA	IOD	SR
AFASAK II ⁹⁷	1, 5	+	?	-	+	+	?
ARISTOTLE ^{107,114,119,124-127,130,132-134}	1, 13	+	?	+	+	?	+
AVERROES ^{103,114,115,119}	4, 13	+	+	+	+	+	+
ENGAGE AF-TIMI 48 ^{111,131}	1, 21, 23	+	+	+	+	+	+
RE-LY ^{104,109}	1, 15, 16	+	+	-	+	+	+
J-ROCKET AF ¹²⁰	2, 26	+	+	+	?	+	+
ROCKET AF ^{106,112,123,129}	1, 27	+	+	+	?	+	+
SPAF II ⁹⁶	1, 5	+	?	-	-	+	?

–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation; SR, selective reporting.

TABLE 50 Results for intracranial bleeding (stroke prevention in AF): comparisons with warfarin (INR 2–3)

Comparisons with warfarin (INR 2–3)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Antiplatelet (< 150 mg od)	–	0.50 (0.21 to 1.23)	0.50 (0.21 to 1.23)
Antiplatelet (≥ 150 mg od)	0.39 (0.13 to 0.98)	–	0.39 (0.13 to 0.98)
Apixaban (5 mg bd)	0.42 (0.30 to 0.58)	–	0.42 (0.30 to 0.58)
Dabigatran (110 mg bd)	0.31 (0.19 to 0.47)	–	0.31 (0.19 to 0.47)
Dabigatran (150 mg bd)	0.40 (0.27 to 0.59)	–	0.40 (0.27 to 0.59)
Edoxaban (30 mg od)	0.31 (0.21 to 0.43)	–	0.31 (0.21 to 0.43)
Edoxaban (60 mg od)	0.46 (0.33 to 0.62)	–	0.46 (0.33 to 0.62)
Rivaroxaban (20 mg od)	0.65 (0.46 to 0.91)	–	0.65 (0.46 to 0.91)

(20 mg od), the estimated reduction in risk was > 50%. There was weak evidence that risk of intracranial bleeding was increased for rivaroxaban (20 mg od) compared with apixaban (5 mg bd), dabigatran (150 mg bd) and edoxaban (60 mg od) (Table 51). Analysing HRs rather than ORs led to similar results (Tables 52 and 53).

TABLE 51 Results for intracranial bleeding (stroke prevention in AF): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd)	–	0.96 (0.58 to 1.60)	0.96 (0.58 to 1.60)
Edoxaban (60 mg od) vs. apixaban (5 mg bd)	–	1.09 (0.69 to 1.70)	1.09 (0.69 to 1.70)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd)	–	1.55 (0.97 to 2.49)	1.55 (0.97 to 2.49)
Edoxaban (60 mg od) vs. dabigatran (150 mg bd)	–	1.13 (0.69 to 1.87)	1.13 (0.69 to 1.87)
Rivaroxaban (20 mg od) vs. dabigatran (150 mg bd)	–	1.61 (0.96 to 2.72)	1.61 (0.96 to 2.72)
Rivaroxaban (20 mg od) vs. edoxaban (60 mg od)	–	1.43 (0.90 to 2.26)	1.43 (0.90 to 2.26)

TABLE 52 Results for intracranial bleeding (stroke prevention in AF): comparisons with warfarin (INR 2–3) – sensitivity analysis using HRs instead of ORs

Comparisons with warfarin (INR 2–3)	HR (95% CI)
Antiplatelet (< 150 mg od)	0.50 (0.21 to 1.20)
Antiplatelet (\geq 150 mg od)	0.39 (0.14 to 0.97)
Apixaban (5 mg bd)	0.42 (0.30 to 0.58)
Dabigatran (110 mg bd)	0.31 (0.19 to 0.46)
Dabigatran (150 mg bd)	0.41 (0.27 to 0.59)
Edoxaban (30 mg od)	0.31 (0.21 to 0.43)
Edoxaban (60 mg od)	0.46 (0.34 to 0.62)
Rivaroxaban (20 mg od)	0.66 (0.47 to 0.91)

TABLE 53 Results for intracranial bleeding (stroke prevention in AF): NOACs (licensed doses only) – sensitivity analysis using HRs instead of ORs

Licensed NOACs only	HR (95% CI)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd)	0.97 (0.57 to 1.58)
Edoxaban (60 mg od) vs. apixaban (5 mg bd)	1.09 (0.70 to 1.71)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd)	1.55 (0.97 to 2.48)
Edoxaban (60 mg od) vs. dabigatran (150 mg bd)	1.13 (0.70 to 1.87)
Rivaroxaban (20 mg od) vs. dabigatran (150 mg bd)	1.62 (0.96 to 2.74)
Rivaroxaban (20 mg od) vs. edoxaban (60 mg od)	1.43 (0.91 to 2.25)

All-cause mortality

Eighteen studies reported 6479 all-cause mortality events, leading to a network of fifteen interventions (*Figure 15*). Fifteen studies were included in the primary analysis, with the remaining three studies included in sensitivity analyses. These studies were at mixed risks of bias (*Table 54*). There were concerns about lack of blinding of participants for most trials, and about lack of allocation concealment and blinding of outcome assessment in some studies.

Table 55 suggests that all NOAC doses with comparisons that were not imprecisely estimated [apixaban (5 mg bd), dabigatran (110 mg bd), dabigatran (150 mg bd), edoxaban (30 mg od), edoxaban (60 mg od)


**FIGURE 15** Network plot for all-cause mortality (stroke prevention in AF). a, Excluded interventions that were included in sensitivity analyses.

TABLE 54 Included trials and risk-of-bias assessment for all-cause mortality (stroke prevention in AF)

Study	Interventions compared	SG	AC	BPP	BOA	IOD	SR
ACTIVE W ⁹⁸	1, 4	+	+	-	+	+	?
AFASAK ⁹⁵	1, 4	+	+	-	?	+	?
AFASAK II ⁹⁷	1, 5	+	?	-	+	+	?
AF-ASA-VKA-CHINA ¹³⁵	2, 4	?	-	-	-	+	?
AF-VKA-ASA-CHINA ¹²²	1, 5	+	?	-	?	?	?
ARISTOTLE ^{107,114,119,124-127,130,132-134}	1, 13	+	?	+	+	+	+
ARISTOTLE-J ¹¹³	1, 12, 13	?	?	-	+	+	+
AVERROES ^{103,114,115,119}	4, 13	+	+	+	+	+	+
BAFTA ¹⁰³	1, 4	+	+	-	+	+	+
Chinese ATAFS ⁹⁹	2, 5	?	?	?	?	+	?
ENGAGE AF-TIMI 48 ^{111,131}	1, 21, 23	+	+	+	+	+	+
EXPLORE-Xa ¹²⁶	1, 18, 19, 20	?	?	-	+	+	+
J-ROCKET AF ¹²⁰	2, 26	+	+	+	?	+	+
PATAF ⁹⁸	1, 5	+	+	?	+	?	+
RE-LY ^{104,109}	1, 15, 16	+	+	-	+	+	+
ROCKET AF ^{106,112,123,129}	1, 27	+	+	+	+	+	+
SPAF II ⁹⁶	1, 5	+	?	-	-	+	?
WASPO ¹⁰¹	1, 5	+	+	-	-	+	?

-, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation; SR, selective reporting.

TABLE 55 Results for all-cause mortality (stroke prevention in AF): comparisons with warfarin (INR 2-3)

Comparisons with warfarin (INR 2-3)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Antiplatelet (< 150 mg od)	1.02 (0.75 to 1.38)	1.13 (0.87 to 1.47)	1.08 (0.88 to 1.33)
Antiplatelet (≥ 150 mg od)	1.04 (0.87 to 1.25)	-	1.04 (0.87 to 1.25)
Apixaban (5 mg bd)	0.88 (0.79 to 0.98)	-	0.88 (0.79 to 0.98)
Dabigatran (110 mg bd)	0.91 (0.80 to 1.04)	-	0.91 (0.80 to 1.04)
Dabigatran (150 mg bd)	0.88 (0.77 to 1.01)	-	0.88 (0.77 to 1.01)
Edoxaban (30 mg od)	0.86 (0.78 to 0.96)	-	0.86 (0.78 to 0.96)
Edoxaban (60 mg od)	0.91 (0.82 to 1.01)	-	0.91 (0.82 to 1.01)
Rivaroxaban (20 mg od)	0.83 (0.69 to 1.00)	-	0.83 (0.69 to 1.00)
Imprecisely estimated comparisons			
Warfarin (INR 3-4)	-	0.24 (0.05 to 0.81)	0.24 (0.05 to 0.81)
Betrixaban (40 mg od)	0.99 (0.06 to 15.5)	-	0.99 (0.06 to 15.5)
Betrixaban (60 mg od)	0.19 (0 to 5.70)	-	0.19 (0 to 5.70)
Betrixaban (80 mg od)	0.19 (0 to 5.88)	-	0.19 (0 to 5.88)

and rivaroxaban (20 mg od)] were associated with a reduced risk of all-cause mortality compared with warfarin (INR 2–3). There was little evidence that the risk of all-cause mortality differed between licensed doses of NOACs (Table 56). Analysing HRs rather than ORs produced similar results (Tables 57 and 58).

Summary of results and ranking of interventions

Results from NMAs suggest that a number of the licensed doses of NOACs reduce the risk of the outcomes stroke or SE, major bleeding, CRB, intracranial bleeding and all-cause mortality compared with the reference treatment, warfarin (INR 2–3). There was evidence that edoxaban increased CRB compared

TABLE 56 Results for all-cause mortality (stroke prevention in AF): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd)	–	1.00 (0.84 to 1.19)	1.00 (0.84 to 1.19)
Edoxaban (60 mg od) vs. apixaban (5 mg bd)	–	1.03 (0.89 to 1.20)	1.03 (0.89 to 1.20)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd)	–	0.94 (0.76 to 1.17)	0.94 (0.76 to 1.17)
Edoxaban (60 mg od) vs. dabigatran (150 mg bd)	–	1.03 (0.87 to 1.22)	1.03 (0.87 to 1.22)
Rivaroxaban (20 mg od) vs. dabigatran (150 mg bd)	–	0.94 (0.74 to 1.18)	0.94 (0.74 to 1.18)
Rivaroxaban (20 mg od) vs. edoxaban (60 mg od)	–	0.91 (0.73 to 1.13)	0.91 (0.73 to 1.13)
Imprecisely estimated comparisons			
Betrixaban (40 mg od) vs. apixaban (5 mg bd)	–	1.13 (0.07 to 17.7)	1.13 (0.07 to 17.7)
Betrixaban (40 mg od) vs. dabigatran (150 mg bd)	–	1.12 (0.07 to 17.6)	1.12 (0.07 to 17.6)
Edoxaban (60 mg od) vs. betrixaban (40 mg od)	–	0.92 (0.06 to 14.1)	0.92 (0.06 to 14.1)
Rivaroxaban (20 mg od) vs. betrixaban (40 mg od)	–	0.83 (0.05 to 13.0)	0.83 (0.05 to 13.0)

TABLE 57 Results for all-cause mortality (stroke prevention in AF): comparisons with warfarin (INR 2–3): sensitivity analysis using HRs instead of ORs

Comparisons with warfarin (INR 2–3)	HR (95% CI)
Antiplatelet (< 150 mg od)	1.07 (0.88 to 1.30)
Antiplatelet (≥ 150 mg od)	1.04 (0.87 to 1.24)
Apixaban (5 mg bd)	0.89 (0.80 to 0.99)
Dabigatran (110 mg bd)	0.91 (0.80 to 1.04)
Dabigatran (150 mg bd)	0.89 (0.78 to 1.01)
Edoxaban (30 mg od)	0.88 (0.80 to 0.97)
Edoxaban (60 mg od)	0.92 (0.83 to 1.02)
Rivaroxaban (20 mg od)	0.83 (0.69 to 1.00)
Imprecisely estimated comparisons	
Warfarin (INR 3–4)	0.24 (0.05 to 0.81)
Betrixaban (40 mg od)	1.01 (0.06 to 15.7)
Betrixaban (60 mg od)	^a
Betrixaban (80 mg od)	^a

^a Not enough information to compute this pairwise comparison.

TABLE 58 Results for all-cause mortality (stroke prevention in AF): NOACs (licensed doses only): sensitivity analysis using HRs instead of ORs

Licensed NOACs only	HR (95% CI)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd)	1.00 (0.85 to 1.18)
Edoxaban (60 mg od) vs. apixaban (5 mg bd)	1.03 (0.90 to 1.20)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd)	0.94 (0.76 to 1.15)
Edoxaban (60 mg od) vs. dabigatran (150 mg bd)	1.03 (0.88 to 1.22)
Rivaroxaban (20 mg od) vs. dabigatran (150 mg bd)	0.93 (0.75 to 1.17)
Rivaroxaban (20 mg od) vs. edoxaban (60 mg od)	0.90 (0.73 to 1.11)
<i>Imprecisely estimated comparisons</i>	
<i>Betrixaban (40 mg od) vs. apixaban (5 mg bd)</i>	<i>1.13 (0.07 to 17.6)</i>
<i>Betrixaban (40 mg od) vs. dabigatran (150 mg bd)</i>	<i>1.14 (0.07 to 17.6)</i>
<i>Edoxaban (60 mg od) vs. betrixaban (40 mg od)</i>	<i>0.91 (0.06 to 14.7)</i>
<i>Rivaroxaban (20 mg od) vs. betrixaban (40 mg od)</i>	<i>0.82 (0.05 to 13.2)</i>

with warfarin (INR 2–3). Risk of MI appeared higher for some NOACs than for warfarin (INR 2–3). Comparisons for some licensed NOAC doses, such as apixaban (2.5 mg bd) and betrixaban (40 mg od), could not be estimated precisely.

Several studies conducted in Asian countries considered a lower INR range for warfarin interventions in elderly patients. We excluded these from the main analysis but included them (merged with the reference treatment, warfarin INR 2–3) as a second sensitivity analysis for each outcome. This allowed us to incorporate a non-licensed dose of rivaroxaban (15 mg od) that was included in the J-ROCKET AF trial,^{106,112,123,129} showing a reduced risk of stroke compared with warfarin (INR 1.6–3), with a median OR of 0.49 (95% CI 0.24 to 0.99). Apart from this, results (available on request) showed the same trends as described above.

The dose range for the antiplatelet arm in the AVERROES trial^{105,116,117,121} was unusually wide (81–324 mg od). Because some of the patients had received a dose that was below standard, it was decided to merge it with the antiplatelets (< 150 mg od) node for the primary analysis. In a further sensitivity analysis for each outcome, this trial^{105,116,117,121} was excluded. Again, the results (available from the authors) were not substantially different from those presented above. With regard to model appraisal, we did not identify any instance of lack of convergence among the Markov chains, poor model fit or inconsistency. Few of the comparisons were replicated across studies; when there were multiple estimates we did not find evidence of statistical heterogeneity.

Rankograms plotting the probability that each of the licensed interventions for AF is ranked best, second best, and so on, for preventing each outcome, are displayed in *Figure 16*. The non-NOAC interventions (warfarin, INR 2–3) and antiplatelet therapy (aspirin/clopidogrel, ≥ 150 mg od) were ranked worst for stroke or SE and ischaemic stroke and were not among the best three interventions for any of the outcomes. Warfarin (INR 2–3) was also ranked as the worst intervention to reduce the risk of intracranial bleeding. Among the licensed NOACs, apixaban (5 mg bd) was ranked as among the best interventions for major bleeding, intracranial bleeding, all-cause mortality, stroke or SE, ischaemic stroke and MI. Edoxaban (60 mg od) was ranked second for major bleeding and all-cause mortality. Except for all-cause mortality and MI, outcomes for rivaroxaban (20 mg od) were ranked less highly than those for apixaban (5 mg bd), dabigatran (150 mg bd) and edoxaban (60 mg od).




FIGURE 16 Rankogram for licensed interventions examined in stroke prevention in AF. IC, intracranial. (*continued*)




FIGURE 16 Rankogram for licensed interventions examined in stroke prevention in AF. IC, intracranial.

Chapter 6 Cost-effectiveness results (1) stroke prevention in atrial fibrillation

Introduction

In this chapter we present the results of the CEA for first-line treatments for patients with AF. The decision question, population, interventions, outcomes, model structure, cost and utility inputs have been previously described in *Chapter 4*. In this chapter we begin by describing clinical effectiveness inputs to the model, including relative treatment effects based on the evidence identified in the systematic review (see *Chapter 5*), other state-transition probabilities based on evidence from longitudinal studies, transition probabilities on the reference treatment (warfarin) on which relative effects are applied, mortality, and treatment switching parameters. We then present the results from our cost-effectiveness model, together with sensitivity analyses to key assumptions made. Results are presented from Bayesian analyses with 95% credible intervals, although we refer to these as confidence intervals for convenience.

Model inputs

Relative treatment efficacy

The NMA results presented in *Chapter 5* consider each outcome separately and independently. However, for our economic model we need to consider the different outcomes jointly. We use a competing risks NMA model to jointly estimate the log-HRs for the different possible events needed in the economic model. The analysis uses data from the RCTs identified in our systematic review; however, results were reported in three different ways in the RCTs: number of first events, number of patients experiencing at least one event, and total number of events. The analysis needs to account for the way the results are reported. For example, if a patient's first event was CRB, they cannot also have ischaemic stroke as their first event. Joint estimation leads to correlated estimates that need to be reflected in the economic model. In *Appendix 7* we provide details on the competing risks NMA, and HRs relative to warfarin (INR 2–3) are given in *Table 59*. Note that it was possible to include studies with zero events in this analysis. Lower doses for apixaban and dabigatran are included, as they were evaluated in a sensitivity analysis. MI and all-cause mortality are common to both the NMA of *Chapter 5* and the competing risks analysis, and their estimated HRs are similar. The competing risks model is restricted to ischaemic stroke and excludes both haemorrhagic stroke and SE, and so it is not precisely comparable to the stroke outcome of *Chapter 5*.

Patients may discontinue NOACs and warfarin, and so we also need estimates of the relative efficacy of warfarin compared with no treatment. Warfarin has been the established standard of care for patients with AF for at least 20 years and we therefore relied on previous meta-analyses to estimate the relative effect of warfarin compared with no treatment. We chose the meta-analysis by Hart *et al.*,¹³⁶ as it is the most recent and comprehensive. Hart *et al.*¹³⁶ identified six studies^{137–142} comparing warfarin to either 'control' or placebo, from which we extracted evidence on stroke, bleeds, ICH, death, SE and TIA, summarised in *Table 60*. The Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF) study¹³⁹ used patients on no treatment but with the option of aspirin as the control; this study was omitted in a sensitivity analysis. The INR ranges for warfarin were frequently outside the 2–3 range chosen for our NMA. Under clinical advice, we did not exclude on the basis of INR range; however, we note that the results from the only study with INR 2–3 [the Canadian Atrial Fibrillation Anticoagulation (CAFA) study¹⁴⁰] were in line with the results from the other studies, providing support for the inclusion of all six studies. For each outcome, we separately conducted a random-effects meta-analysis using a Poisson likelihood, as described in *Appendix 7*, but without accounting for competing risks as a result of insufficient detail available from the trials. Random-effects models were used, as we expected some heterogeneity because of differences in INR range; however, on the basis of the

TABLE 59 Mean and 95% CI for HRs relative to warfarin from the competing risks NMA for each event and treatment included in the economic model

NOAC	Ischaemic stroke	TIA	SE ^a	ICH	Other CRB	MI	Death (all causes)
Apixaban (5 mg bd)	0.90 (0.72 to 1.11)	0.74 (0.041 to 3.26)	0.65 (0.33 to 1.18)	0.46 (0.36 to 0.58)	0.82 (0.70 to 0.94)	0.86 (0.65 to 1.1)	0.89 (0.8 to 0.99)
Dabigatran (150 mg bd)	0.75 (0.58 to 0.97)	2.68 (0.062 to 16.1)	0.65 (0.52 to 0.80)	0.36 (0.26 to 0.49)	1.07 (0.92 to 1.24)	1.27 (0.93 to 1.68)	0.88 (0.77 to 1)
Edoxaban (60 mg od)	1.00 (0.83 to 1.2)	2.76 (0.06 to 15.8)	0.58 (0.30 to 0.97)	0.49 (0.39 to 0.61)	0.88 (0.82 to 0.94)	0.95 (0.74 to 1.19)	0.92 (0.83 to 1.01)
Rivaroxaban (20 mg od)	0.92 (0.73 to 1.13)	2.68 (0.063 to 15.9)	0.95 (0.79 to 1.13)	0.65 (0.46 to 0.89)	1.05 (0.98 to 1.13)	0.79 (0.61 to 1.01)	0.83 (0.69 to 0.99)
Apixaban (2.5 mg bd)	0.74 (0.042 to 3.37)	0.76 (0.041 to 3.51)	0.48 (0.031 to 1.97)	2.78 (0.06 to 16.2)	0.63 (0.080 to 2.06)	1.01 (0.049 to 4.67)	1.03 (0.050 to 5.03)
Dabigatran (110 mg bd)	1.13 (0.89 to 1.42)	2.82 (0.062 to 16.4)	0.90 (0.73 to 1.1)	0.31 (0.22 to 0.43)	0.94 (0.81 to 1.09)	1.29 (0.94 to 1.71)	0.91 (0.80 to 1.03)

^a SE excludes stroke events.

TABLE 60 Data and HR from meta-analysis of no treatment/placebo vs. warfarin

Treatment	AFASAK ⁹⁵		SPAF I ¹³⁸		BAATAF ¹³⁹		CAFA ¹⁴⁰		SPINAF ¹³⁷		EAFIT ⁴¹		HR, mean (SD)
	Placebo	Warfarin	Placebo	Warfarin	Control ^b	Warfarin	Placebo	Warfarin	Placebo	Warfarin	Placebo	Warfarin	
Patients	336	335	211	210	208	212	191	187	290	281	214	225	-
Patient-years at risk	398	413	245	263	435	487	241	237	483	489	405	507	-
Warfarin INR	2.8-4.2		2.0-4.5		1.5-2.7		2.0-3.0		1.4-2.8		2.5-4.0		-
Strokes	19	9	19	8	13	2	9	6	23	7	50	20	0.359 (0.213)
Bleeds	NR	NR	1	5	21	38	18	35	50	72	14	60	2.3 (3.53)
Deaths	NR	NR	NR	NR	25	11	8	10	26	20	44	41	0.849 (3)
TIA	3	1	NR	NR	NR	NR	2	2	7	4	0	1	4.86 (369)
SE ^b	NR	NR	NR	NR	NR	NR	2	1	1	2	4	1	3.18 (63)
ICH	NR	NR	NR	NR	0	1	0	1	0	1	0	0	- ^c

NR, not reported.

^a BAATAF¹³⁹ control patients were not given warfarin but could choose to take aspirin.

^b SE excludes stroke events.

^c Not possible to estimate HR because all included placebo arms had zero events.

Deviance Information Criteria²³ there was not any evidence in favour of or against a fixed-effects model, and results were similar. We excluded studies with no events in any arm and added a continuity correction of 0.5 to arms with zero events if other arms in the trial had an event. The results of this analysis are presented in *Table 60*. Owing to insufficient evidence for ICH, we assumed the treatment effect was the same as that for bleeds, as these are clinically similar AEs. However, the estimated HRs for NOACs presented in *Table 59* do not support this assumption of similarity. We therefore conducted a sensitivity analysis that sets the HR of 'no treatment' against warfarin for ICH to 1.

Effect of past health events and states on future event rates

The primary source of evidence for the effect of prior events on stroke, SE, TIA and bleed risk is a study in 182,678 Swedish patients by Friberg *et al.*¹⁴³ Reported HRs (*Table 61*) are for male patients aged < 65 years. We make the assumption that these HRs can be generalised to a population of 70-year-olds with 60 : 40 split of males–females.

We also estimated the effect of previous events on mortality. Andersen and Olsen¹⁴⁴ provided estimates of the HRs for the effect of prior stroke or MI in patients with AF. These are reproduced in *Table 62*, and normal distributions representing uncertainty in the estimated log-HRs are summarised in *Table 63*. No evidence was available for the effect of prior bleeds or ICH on mortality. We made the assumption that bleeds and ICH would have the same effect as stroke on future risk of death. We conducted a sensitivity analysis in which we assumed bleeds and ICH to have no effect on future risk of death. The effects of prior events on future risks are assumed to be multiplicative, so a history of both stroke and MI will give a HR for mortality of $1/0.758 \times 1/0.972 = 1.03 \times 1.32 = 1.36$.

TABLE 61 Hazard ratios of effect of history of previous events on future events (Friberg *et al.*¹⁴³)

Risk factor	Future ischaemic stroke (95% CI)	Future TIA/SE (95% CI)	Future intracranial bleeding (ICH) (95% CI)	Future bleed (95% CI)
Ischaemic stroke	4.00 (3.78 to 4.22)	3.61 (3.44 to 3.78)	1.64 (1.39 to 1.94)	1.39 (1.27 to 1.52)
ICH	1.78 (1.56 to 2.03)	1.82 (1.62 to 2.04)	10.2 (8.59 to 12.2)	2.95 (2.57 to 3.39)
Any significant bleeding (major bleed)	1.32 (1.21 to 1.44)	1.36 (1.26 to 1.46)	3.54 (3.02 to 4.17)	3.32 (3.06 to 3.60)
MI	1.24 (1.17 to 1.33)	1.29 (1.22 to 1.36)	0.94 (0.78 to 1.12)	1.24 (1.15 to 1.35)

TABLE 62 Reported HRs for effect of no previous events on mortality in patients with AF (Andersen and Olsen¹⁴⁴)

Event history	Effect on mortality (HR with 95% CI)
No MI	0.972 (0.687 to 1.378)
No stroke	0.758 (0.565 to 1.017)

TABLE 63 Estimated log-HR (standard error) for the effect of previous events on future events

Risk factor	Future ischaemic stroke	Future TIA/SE	Future ICH	Future bleed	Future death
Stroke	1.39 (0.03)	1.28 (0.02)	0.49 (0.09)	0.33 (0.05)	0.28 (0.15)
ICH	0.58 (0.07)	0.60 (0.06)	2.32 (0.09)	1.08 (0.07)	0.28 (0.15)
Bleed	0.28 (0.04)	0.31 (0.04)	1.26 (0.08)	1.20 (0.04)	0.28 (0.15)
MI	0.22 (0.03)	0.25 (0.03)	-0.06 (0.09)	0.22 (0.04)	0.03 (0.18)

Normal distributions are used to reflect uncertainty in the estimated log-HRs.

We reflect uncertainty in the mean estimates by assuming normal distributions for the logs of these HRs (see *Table 63*).

Transition probabilities with usual care (warfarin)

We estimated transition probabilities for the usual care (first-line warfarin) treatment strategy using the trials identified in our systematic review that included a warfarin arm. The model includes the following correlated outcomes: (1) ischaemic stroke; (2) ICH; (3) other clinically relevant bleed; (4) TIA; (5) SE; (6) MI; and (7) death.

Previous economic models have used evidence from single trials, such as RE-LY^{104,109} in Kansal *et al.*,⁴² to estimate the risk of events with warfarin treatment. However, this disregards the evidence available from other published trials. QRISK2¹⁴⁵ provides long-term information on MI in patients with AF. However, this estimates only a joint risk of stroke and MI, rather than for each event individually. Another possible source of evidence for the rate of MI in AF is Soliman *et al.*,⁵ but this provides a HR for MI only in AF relative to the non-AF population, which is not what is needed for our model. Therefore, we used evidence from the warfarin arms in the trials that were identified in our systematic review because it is based on patients with AF, has similar demographics to our target population and represented the risk for patients specifically on warfarin treatment.

We estimated the hazard of events on warfarin, taking into account the competing risks nature of the outcomes and the format in which results are reported, in the same way as we did for the relative effects (see *Appendix 7*). Details of the model are given in *Appendix 8* and estimated hazards are shown in *Table 64*.

Mortality

The risk of death in a 70-year-old AF population on warfarin with a 60 : 40 male–female split is obtained from the usual care hazard described above. This is adjusted for each age group aged > 70 years using the 2011–13 life tables for England and Wales,¹⁴⁶ which provide the probability that an individual from the general population and at a specific age will die within 1 year. The hazard of death (λ) in each age group is: $\lambda = -\log(1 - (0.6 \times PD_{male} + 0.4 \times PD_{female}))$, where PD_{male} and PD_{female} are the annual probability of death for males and females, respectively. We use the ratio of this hazard for each age group to the hazard for 70-year-olds to adjust the usual care (warfarin) hazard of death for each age group in the model.

Treatment switching probabilities

Post-event treatment switching rules and probabilities were based on clinical opinion. Clinicians advised ‘definite’ switching in the event of ICH for all treatments and also in the event of MI for dabigatran; a ‘chance’ of switching in the case of CRB and ischaemic stroke; and a ‘slight chance’ of switching following

TABLE 64 Mean and 95% CI for hazard of events, estimated from warfarin arms of RCTs identified in our systematic review

Event	Mean hazard (95% CI)
MI	0.0079 (0.0064 to 0.01)
Ischaemic stroke	0.012 (0.01 to 0.013)
Death (all causes)	0.038 (0.028 to 0.052)
TIA	0.025 (0.006 to 0.089)
CRB	0.066 (0.031 to 0.13)
SE	0.017 (0.0059 to 0.041)
ICH	0.0094 (0.0057 to 0.017)

TABLE 65 Treatment switching rules and assumed probabilities

Event leading to switching	Probability of switching, mean (95% CI)	Distribution for probability of switching	Rule for switching
ICH	1.00	–	Always switch to no treatment
MI	1.00	–	If on dabigatran, switch to warfarin; no switching otherwise
CRB	0.30 (0.00 to 1.00)	Beta(0.3,0.7)	Switch to next line treatment
Ischaemic stroke	0.30 (0.00 to 1.00)	Beta(0.3,0.7)	Switch to next line treatment
TIA	0.10 (0.00 to 1.00)	Beta(0.1,0.9)	Switch to next line treatment
SE	0.10 (0.00 to 1.00)	Beta(0.1,0.9)	Switch to next line treatment

SE or TIA, due to concern about treatment failure. We assume a probability of switching of 0.3 for ‘chance’ and 0.1 for ‘slight chance’, but reflect our high degree of uncertainty in these switching probabilities with beta distributions, summarised in *Table 65*. We subject these assumed switching probabilities to sensitivity analysis.

Sensitivity analyses

We explored the robustness of our results to various assumptions through sensitivity analyses.

Warfarin monitoring costs In this sensitivity analysis, we assumed that there is no drug or monitoring cost associated with warfarin. This explores whether or not warfarin is cost-effective, even in the absence of monitoring costs. We also considered running sensitivity analyses to fixed warfarin monitoring costs at £70.75 and £106.13 per 3-month cycle (mean and upper limit of assumed distribution for warfarin monitoring costs). Note, however, it is worth doing these sensitivity analyses only if warfarin is found to be cost-effective with no monitoring costs (otherwise it clearly will not be cost-effective for positive monitoring costs).

Mortality risk following bleeds/ICH In this sensitivity analysis we assumed that there is no effect of previous bleeds and ICH on future risk of death. This was motivated by the lack of evidence on this effect and the assumption of the base case that the effect of previous bleeds and ICH on mortality risk was the same as that of stroke.

Probabilities of treatment switching We ran three sensitivity analyses to the assumptions around treatment switching: in the first, we assumed that no patients switch treatment following ischaemic stroke, bleed, SE or TIA; in the second, we assumed that all patients switch after a ischaemic stroke or bleed, but none switches after a SE or TIA; and, in the third, we assumed that all patients switch treatments following these four events. In all sensitivity analyses, it is assumed that all patients discontinue treatment following an ICH, and patients on dabigatran switch to warfarin following a MI, as in the base case.

Excluding ‘no treatment control’ study from meta-analysis of warfarin vs. placebo trials The meta-analysis estimating the effect of warfarin compared with ‘no treatment’ included five studies comparing warfarin with placebo and one study, BAATAF,¹³⁹ comparing warfarin with ‘control’. This control arm consisted of patients on no treatment who had the option of starting aspirin. When the BAATAF study¹³⁹ is removed from the meta-analysis comparing warfarin with no treatment (*Table 66*), the effect of no treatment, compared with warfarin, on bleeds and deaths is decreased, although the uncertainty is greatly increased. This sensitivity analysis uses a meta-analysis that excludes the BAATAF study.¹³⁹

Sensitivity to initial age of cohort We ran two sensitivity analyses to the initial age of the cohort, ages 60 and 80 years, respectively, rather than 70 years in the base case. These ages are roughly one SD from the mean age of patients included in the trials.

TABLE 66 Hazard ratio from meta-analysis of no treatment/placebo vs. warfarin, including and excluding BAATAF study¹³⁹

Event	Mean HR	
	Including BAATAF ¹³⁹ (SD)	Excluding BAATAF ¹³⁹ (SD)
Strokes	0.359 (0.213)	0.391 (0.246)
Bleeds	2.3 (3.53)	3.23 (18.9)
Deaths	0.849 (3)	1.37 (13.6)
TIA	4.86 (369)	4.86 (369)
SE	3.18 (63)	3.18 (63)
ICH	NA	NA

NA, not available.

Apixaban 2.5 mg bd and dabigatran 110 mg bd This sensitivity analysis uses different doses (apixaban 2.5 mg bd and dabigatran 110 mg bd) than those used in the base-case analysis (5 mg and 150 mg, respectively). This is motivated by the licensing of these drugs by the European Medicines Agency, which specifies that the lower dose should be prescribed for older patients (> 75 years).

No difference in hazard of ICH between 'no treatment' and warfarin As our meta-analysis comparing warfarin and 'no treatment' had insufficient evidence to estimate the HR for ICH, we assumed it to be the same as for bleeds. In this sensitivity analysis we assumed that the hazard of ICH is the same in warfarin patients and 'no treatment' patients.

Results of the cost-effectiveness model: atrial fibrillation

Results of base-case analyses

We ran 10,000 iterations of our model for 120 cycles (each iteration representing a simulation from the joint distribution of our model parameters). We estimated expected total costs and QALYs for each first-line anticoagulation strategy (Table 67). Expected incremental costs and QALYs for each first-line strategy compared with warfarin (INR 2–3) are also given.

Dabigatran (150 mg bd) has the lowest expected total cost (£23,064), followed by apixaban (5 mg bd), edoxaban (60 mg od), warfarin (INR 2–3) and rivaroxaban (20 mg od) which has the highest expected total cost (£24,841). Expected costs are similar across all treatments, and there is a high degree of uncertainty around the costs for all treatments.

Apixaban (5 mg bd) has the highest expected QALYs (5.49), followed by rivaroxaban (20 mg od) (5.45), dabigatran (150 mg bd) and edoxaban (60 mg od) (both with 5.41), and warfarin (INR 2–3) (5.16). The NOACs have similar expected QALYs, all of which are higher than for warfarin (INR 2–3). There is a high degree of uncertainty around the QALY estimates.

At a willingness-to-pay threshold of £20,000 per QALY, all NOACs have positive expected incremental net benefit (INB) compared with warfarin (INR 2–3), suggesting that they may be a cost-effective use of NHS resources. Apixaban (5 mg bd) has the highest expected INB (£7533), followed by dabigatran (150 mg bd; £6365), rivaroxaban (20 mg od; £5279) and edoxaban (60 mg od; £5212). Apixaban (5 mg bd) is the only NOAC for which the 95% CI around INB is positive, suggesting that apixaban is cost-effective compared with warfarin. These conclusions also hold at the higher threshold of £30,000.

TABLE 67 Cost-effectiveness of first-line treatment strategies for patients with AF

Estimated costs and outcomes	Warfarin (INR 2–3): mean (95% CI)	Apixaban (5 mg bd): mean (95% CI)	Dabigatran (150 mg bd): mean (95% CI)	Edoxaban (60 mg od): mean (95% CI)	Rivaroxaban (20 mg od): mean (95% CI)
Expected total costs (£)	24,418 (12,189 to 50,365)	23,340 (12,842 to 45,753)	23,064 (12,674 to 46,075)	23,985 (13,098 to 46,319)	24,841 (13,198 to 47,603)
Expected QALYs	5.166 (3.629 to 6.541)	5.488 (3.841 to 6.795)	5.416 (3.817 to 6.701)	5.405 (3.819 to 6.678)	5.451 (3.824 to 6.797)
Expected incremental total costs (£)	(– to –)	–1078 (–7626 to 2568)	–1354 (–8049 to 2273)	–433.4 (–6430 to 3619)	422.5 (–4730 to 5104)
Incremental expected QALYs	(– to –)	0.3227 (–0.01486 to 0.8142)	0.2505 (–0.08034 to 0.7025)	0.2389 (–0.1122 to 0.6841)	0.2851 (–0.06816 to 0.8096)
Incremental expected net benefit (£20,000)	(– to –)	7533 (489.9 to 18,228)	6365 (–167.7 to 17,039)	5212 (–893.8 to 14,826)	5279 (–1097 to 15,180)
Incremental expected net benefit (£30,000)	(– to –)	10,760 (576.2 to 25,861)	8871 (–597.3 to 23,402)	7601 (–1556 to 20,987)	8130 (–1399 to 22,819)
Incremental results are relative to warfarin (INR 2–3). Figures are presented as mean (CI).					

The key drivers of the results are the lower rates of MI, ICH and other CRB for apixaban (see *Table 59*), as found in the NMA of *Chapter 5*. The high cost and disutility of ICH has a great influence on total costs, total QALYs and net benefits. Apixaban also has a low rate of TIA, but the uncertainty surrounding the other treatment effects, and the minimal impact of this event, means that it is not a driving factor in the results. Dabigatran also has a low rate of ICH but the higher rate of MI offsets this benefit.

The uncertainty in the estimated total costs and QALYs is illustrated in the cost-effectiveness plane (*Figure 17*). The CEAC (*Figure 18*) plots the probability of each intervention having the highest net benefit against a willingness to pay per QALY. It indicates that apixaban (5 mg bd) has the highest probability of being the most cost-effective first-line therapy for AF – close to 60% in the £20,000–30,000 range of willingness-to-pay thresholds generally considered by NICE. Dabigatran (150 mg bd) has the highest probability of being cost-effective if the willingness-to-pay threshold is very low, as a result of having the lowest expected total costs. Warfarin (INR 2–3) and edoxaban (60 mg od) are unlikely to be cost-effective. These results are further highlighted by the CEAF (*Figure 19*), which plots the probability of having the highest net benefit against a willingness to pay per QALY for the intervention with the highest expected net benefit. Apixaban (5 mg bd) has the highest expected net benefit at a wide range of willingness-to-pay thresholds. Apixaban (5 mg bd) is likely to be the most cost-effective first-line therapy for AF, under the assumptions of our model.

The per-person EVPI (*Figure 20*) estimated was £608 at a willingness-to-pay of £20,000 and £938 at £30,000. Assuming an incidence of 1%,¹⁴⁷ and that there are 500,000 70-year-olds in England and Wales,¹⁴⁸ there are 5000 new cases of AF every year. Extrapolating the EVPI over 10 years for 5000 patients, and discounting at 3.5%, gives a population EVPI of approximately £26M at a willingness to pay of £20,000, and £40M at £30,000. This suggests that there may be value in conducting further research to inform this decision.

Expected value of partial perfect information (*Figure 21*) was estimated for various groups of parameters using the SAVI tool.⁷⁶ Note that this is an approximation only, with large standard errors. We therefore interpret the results cautiously but as indicative of the *relative* impact of the different groups of parameters on decision uncertainty. The optimal decision is most sensitive to the HRs for the NOACs, suggesting that a head-to-head trial may be of value. The decision is also sensitive to costs, the effect of past events on future HRs and probabilities of treatment switching. The decision is less sensitive to utilities and event rates on the reference treatment (warfarin). The estimated EVPPI for a trial comparing apixaban and dabigatran (the two NOACs with highest probability of being most cost-effective at willingness to pay per QALY of £20,000), with a warfarin control arm, indicated that such a trial could potentially be of value, particularly




FIGURE 17 Incremental cost-effectiveness plane, warfarin (INR 2–3) is reference. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 18 Cost-effectiveness acceptability curves. The probability each first-line treatment is most cost-effective against willingness-to-pay-per-QALY threshold. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 19 Cost-effectiveness acceptability frontier. For each willingness-to-pay-per-QALY threshold, the probability of being most cost-effective is plotted for the treatment that has the highest expected net benefit at that willingness-to-pay threshold. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 20 Per-person EVPI over range of willingness-to-pay thresholds.




FIGURE 21 Expected value of partial perfect information for subsets of parameters. SAVI-estimated EVPPI scaled by EVPPI of all parameters as estimated by SAVI. 95% intervals are $\pm 1.96 \times$ standard error and are truncated above at 1 and below at 0. 'A vs. D' is apixaban vs. dabigatran vs. warfarin trial.

if it were designed to inform baseline event rates on warfarin, costs and switching probabilities. However, a study powered to measure all of these outcomes with sufficient precision would require a very large sample size, which may be prohibitively expensive.

Expected (mean) values are reported with 95% CIs. Incremental values are relative to warfarin (INR 2–3). INB is the difference in QALYs and costs for willingness-to-pay thresholds of £20,000 and £30,000 per QALY.

Results of sensitivity analyses

We used 1000 simulations of the model for each sensitivity analysis. To explore whether or not results were sensitive to the assumed costs of warfarin, we began with the extreme case in which there is no administration or monitoring costs for warfarin. We found that this had little effect on the conclusion that apixaban 5 mg bd is the most cost-effective strategy (Figure 22). Clearly, if warfarin is not cost-effective with zero monitoring costs then it will not be cost-effective with monitoring costs greater than this. We therefore omit the sensitivity analyses with higher monitoring costs. Similarly, the assumption that ICH and other CRBs have no effect on future mortality risk did not alter the conclusion that apixaban 5 mg bd is most likely to be cost-effective (Figure 23).

Different treatment switching strategies were also explored. If patients switch to no treatment only when they experience an ICH or a MI (if on dabigatran), the results are similar to our primary analysis (Figure 24). If all patients switch treatments after ischaemic stroke, bleed, SE and TIA, in addition to the switching after ICH and MI (for dabigatran) then patients spend only a short time on a NOAC before switching to warfarin. In this scenario, it is perhaps unsurprising that warfarin is the most cost-effective strategy (Figure 25). We also considered a switching strategy by which all patients switch after an ischaemic stroke or clinically relevant bleed, and none switches after a TIA or SE, and found that the results are similar to our primary analysis (Figure 26). Excluding the BAATAF study¹³⁹ has no effect on the conclusion that apixaban 5 mg bd is likely to be the most cost-effective treatment (Figure 27).




FIGURE 22 Cost-effectiveness acceptability curves for sensitivity analysis assuming that the cost of warfarin treatment is zero. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 23 Cost-effectiveness acceptability curves for sensitivity analysis assuming no effect of bleed or ICH on mortality risk. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.

Different initial ages for the cohort were also explored. Apixaban 5 mg bd is the strategy that is most likely to be cost-effective, assuming an initial cohort age of 60 years (*Figure 28*) or 80 years (*Figure 29*). Lower doses of apixaban (2.5 mg bd) and dabigatran (110 mg bd) are recommended for elderly patients, and were compared in a sensitivity analysis (*Figure 30*). The uncertainty is much greater in this comparison, but apixaban (2.5 mg bd) is most likely to be the most cost-effective first-line therapy for the prevention of stroke in AF. Results were robust to assuming that the hazard of ICH is the same for no treatment as for warfarin (*Figure 31*).

Summary of cost-effectiveness findings

We found that although there was a high degree of uncertainty in the inputs to our model, apixaban (5 mg bd) was identified with the highest probability of being the most cost-effective first-line treatment over a range of willingness-to-pay-per-QALY thresholds. The driver of this result is the generally lower rates of MI, ICH and other CRB on apixaban (5 mg bd) than the other NOACs.




FIGURE 24 Cost-effectiveness acceptability curves for sensitivity analysis assuming that no patients switch treatment following stroke, bleed, SE or TIA. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 25 Cost-effectiveness acceptability curves for sensitivity analysis assuming that all patients switch treatment following stroke, bleed, SE or TIA. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 26 Cost-effectiveness acceptability curves for sensitivity analysis assuming that all patients switch treatment following stroke or bleed, and none switches following SE or TIA. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 27 Cost-effectiveness acceptability curves for sensitivity analysis excluding the BAATAF study¹³⁹ from meta-analysis of the treatment effect of warfarin compared with no treatment. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 28 Cost-effectiveness acceptability curves for sensitivity analysis assuming that the cohort starts at age 60 years, rather than 70 years. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 29 Cost-effectiveness acceptability curves for sensitivity analysis assuming that the cohort starts at age 80 years, rather than 70 years. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 30 Cost-effectiveness acceptability curves for sensitivity analysis comparing lower doses of apixaban and dabigatran, as would be administered in older patients with AF. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 31 Cost-effectiveness acceptability curves for sensitivity analysis assuming that the hazard of ICH is the same on warfarin and no treatment.

Our model makes several assumptions (summarised in *Table 68*). However, the conclusion was robust to a wide range of sensitivity analyses. The only sensitivity analysis found to affect the conclusion was the assumption about treatment switching strategy; if treatment switching is assumed to always occur after stroke, bleed, SE or TIA then warfarin was identified as most cost-effective treatment. However, our clinical advice was that this extreme switching strategy was not considered realistic in practice. We have taken the costs of warfarin from the NICE costing report⁶⁸ but there is uncertainty in this estimate, which is difficult to quantify. We therefore conducted an extreme case scenario analysis in which we assumed zero cost for warfarin treatment and monitoring. Apixaban 5 mg bd was still the most cost-effective treatment under this assumption. Apixaban and dabigatran may be given in lower doses to the elderly. We assumed that all patients would receive the higher dose, and remain on it, even as they age. However, results were robust to a sensitivity analysis assuming only the lower doses of apixaban (2.5 mg bd) and dabigatran (110 mg bd) were administered.

TABLE 68 Main assumptions in the AF model

1.	Does not include minor non-clinically relevant bleeds as transient events
2.	No distinction between severity of ischaemic strokes SE assumed to be a transient event without long-term consequences
3.	Dose of apixaban and dabigatran given does not reduce as patients age
4.	Bleeds and ICH (and with it, haemorrhagic stroke) have same effect on future risk of death as stroke
5.	Patients on dabigatran who experience a MI will always switch to warfarin
6.	Patients switch to no treatment after ICH/haemorrhagic stroke
7.	Patients may switch (with an assumed probability) from NOAC to warfarin or warfarin to no treatment after ischaemic stroke, bleed, SE or TIA
8.	Patients may (with an assumed probability) discontinue warfarin treatment or switch from a NOAC to warfarin, even if they do not experience an event (due to lack of compliance)
9.	Warfarin arms from the RCTs identified in our systematic review are representative of the AF population in England and Wales
10.	Events rate and relative treatment effects are assumed not to vary with age
11.	Relative mortality rate in patients with AF relative to the general population does not vary with age
12.	Warfarin treatment costs over 3 months are taken from the NICE costing report. Uncertainty in this is represented using a uniform distribution from 50% to 150% of the NICE costing report estimate
14.	Assumes no monitoring or administration costs for NOACs
15.	Assumes post-ICH management costs to be similar to post-ischaemic stroke management costs
16.	Combined management costs for post-multiple event states (e.g. MI + stroke) to be the maximum of management costs for constituent events
17.	Assumed quality of life for patients with a history of multiple events to be multiplicative combination of quality of life for constituent events

We were unable to include betrixaban due to lack of evidence, and are therefore unable to draw any conclusions about the relative cost-effectiveness of betrixaban or other unlicensed treatments. We have assumed that age determines mortality rate, but that other event rates and relative treatment effects do not depend on age. We have not distinguished between minor and major stroke in our model. Some previous models have done so^{34,37,149} but we found that there was insufficient evidence to be able to estimate rates differently. We have assumed that SE is a transient event with no long-term consequences. Although there can be long-term consequences, such as limb loss, these are very rare, and we would not expect inclusion of these to affect the results.

One notable limitation of our model is that we have not distinguished between different types of AF. There is emerging evidence that there may be a 'dose-response' relationship in stroke risk with increasing 'persistence' of AF,¹⁵⁰ although others have suggested that risk of stroke is as high in paroxysmal patients with AF as with persistent or permanent AF.¹⁵¹ The RCTs included in our review are likely to have recruited mostly persistent or permanent patients with AF, and so our conclusions may not extend to patients with paroxysmal AF.

There have been few CEAs of NOACs for the prevention of stroke in AF in the UK population. Kansal *et al.*⁴² found dabigatran to be cost-effective compared with warfarin and aspirin in the UK setting, as in our model. However, they did not include any other NOACs. The Bayer submission to NICE on rivaroxaban³³ found it be cost-effective compared with warfarin. This submission also found rivaroxaban and dabigatran to have equivalent effects but dabigatran to have higher costs, thus concluding that rivaroxaban is the most cost-effective. Their CEACs compared only rivaroxaban with warfarin but found close to a 60% probability

that rivaroxaban was cost-effective in the £20,000–30,000 threshold range, similar to our probability that a NOAC (apixaban) was most cost-effective. The Harrington *et al.*³⁸ model in the US setting compared apixaban (5 mg bd), dabigatran (110 mg bd), rivaroxaban (20 mg od), and warfarin, and found that apixaban had the highest expected QALYs, followed by dabigatran, rivaroxaban and warfarin. Our model also found apixaban to have the highest expected QALYs and that dabigatran and rivaroxaban would have higher expected QALYs than warfarin, although the high degree of uncertainty in our results renders them compatible with the order found by Harrington *et al.*³⁸ Harrington *et al.*³⁸ also found apixaban and dabigatran to be cost-effective compared with warfarin, and other US studies found apixaban,³⁶ rivaroxaban³⁷ and dabigatran³⁴ to be cost-effective compared with warfarin. Although costs in the USA are not strictly comparable with those in the UK setting, our results are in line with these earlier findings.

Chapter 7 Clinical results (2): primary prevention of venous thromboembolism

Included studies

A total of 2727 unique records were identified from various data sources for the three VTE reviews (Figure 32).

Forty-three completed eligible RCTs were identified for inclusion in the review of primary prevention of VTE, with a total of 46 associated references.^{152–197} One further trial¹⁹⁸ contained insufficient detail to include in the quantitative synthesis. Three additional ongoing trials^{199–201} were also identified; two trials^{199,200} in knee surgery patient population and one trial²⁰¹ in medical patient population. A summary of the characteristics of the completed trials included in the analyses is presented in Table 69. There were 18 trials in hip surgery




FIGURE 32 The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow chart for reviews of primary prevention, acute treatment and secondary prevention of VTE.

TABLE 69 Characteristics of 43 included randomised trials in primary prevention of VTE

Study (centre type) [countries]	Study type, sponsor (sponsor's role)	Age eligibility, years (mean age), [% male]	Clinical condition	No. randomised	Interventions compared	Treatment duration (days)	Outcomes	Time of outcome assessment (days)
ADOPT¹⁸⁸ (Multicentre) [North and South America, Europe, Russia, Ukraine, Israel, Australia, Asia and South Africa]	Phase III Bristol-Myers Squibb and Pfizer (NR)	≥ 40 (66.8) [49.1]	Acute medical conditions	6528	Apixaban 1. 2.5 mg bd LMWH 2. Enoxaparin 40 mg od	14.9–34.9 Apixaban 3.3–11.3 LMWH	<i>Efficacy:</i> Major VTE, symptomatic DVT, proximal DVT, symptomatic proximal DVT, symptomatic distal DVT, symptomatic non-fatal PE <i>Safety:</i> All bleeding, major bleeding, composite CRB, intracranial bleeding	30 (for efficacy outcomes) 2–30 (for safety outcomes)
ADVANCE-1¹⁷¹ (Multicentre) [North and South America, Europe, Russia, Israel and Australia]	Phase III Bristol-Myers Squibb and Pfizer (Data were collected and analysed by the study sponsors)	≥ 18 (65.8) [37.9]	TKR surgery for one or both knees, including revision of a previously inserted artificial joint	3195	Apixaban 1. 2.5 mg bd LMWH 2. Enoxaparin 30 mg bd	10–14	<i>Efficacy:</i> DVT, Symptomatic DVT, proximal DVT, symptomatic PE, fatal PE, all stroke <i>Safety:</i> All bleeding, major bleeding, minor bleeding, fatal bleeding, CRNM bleeding, composite CRB, fatal bleeding, thrombocytopenia, MI, death (all causes)	10–14 (for the efficacy outcomes) 16 (for the safety outcomes)
ADVANCE-2¹⁷⁸ (Multicentre) [South America, Europe, Russia, Ukraine, Israel, Australia, Asia and South Africa]	Phase III Bristol-Myers Squibb and Pfizer (NR)	≥ 18 (67) [27.5]	Either elective unilateral or same-day bilateral TKR surgery or a revision of at least one component of a TKR	3057	Apixaban 1. 2.5 mg bd LMWH 2. Enoxaparin 40 mg od	10–14	<i>Efficacy:</i> Major VTE, DVT, symptomatic proximal DVT, symptomatic PE, fatal PE, all stroke <i>Safety:</i> All bleeding, major bleeding, minor bleeding, CRNM bleeding, composite CRB, bleeding from surgical site, thrombocytopenia, MI, death (all causes)	2–14

Study (centre type) [countries]	Study type, sponsor (sponsor's role)	Age eligibility, years (mean age), [% male]	Clinical condition	No. randomised	Interventions compared	Treatment duration (days)	Outcomes	Time of outcome assessment (days)
ADVANCE-3 ¹⁷⁶ (Multicentre) [North and South America, Europe, Russia, Ukraine, Israel, Australia and Asia]	Phase III Bristol-Myers Squibb and Pfizer (The sponsor was involved in data collection and analyse)	≥ 18 (60.8) [46.7]	Elective unilateral THR or a revision of at least one component of a THR	5407	Apixaban 1. 2.5 mg bd LMWH 2. Enoxaparin 40 mg od	32–38	Efficacy: Major VTE, DVT, proximal DVT, symptomatic DVT, fatal PE, symptomatic PE, symptomatic non-fatal PE, all stroke Safety: All bleeding, major bleeding, minor bleeding, CRNM bleeding, bleeding from surgical site, thrombocytopenia, MI, death (all causes)	32–38 (for efficacy outcomes and thrombocytopenia) 38 (for other safety outcomes and all stroke)
APROPOS ¹⁶² (Multicentre) [North America, Argentina, Denmark, Poland, Israel and Australia]	Phase II Bristol-Myers Squibb (NR)	18–90 (66.7) [36.7]	Elective unilateral THR surgery and who are willing and able to undergo bilateral ascending contrast venography	1238	Apixaban 1. 5 mg od 2. 10 mg od 3. 20 mg od 4. 2.5 mg bd 5. 5 mg bd 6. 10 mg bd LMWH 7. Enoxaparin 30 mg bd Warfarin 8. INR 1.8–3	10–14	Efficacy: VTE, symptomatic DVT, symptomatic proximal DVT, symptomatic PE, fatal PE Safety: All bleeding, major bleeding, minor bleeding, fatal bleeding, MI, all stroke, death (all causes)	10–14 [42 for major bleeding and death (all cause)]

continued

TABLE 69 Characteristics of 43 included randomised trials in primary prevention of VTE (continued)

Study (centre type) [countries]	Study type, sponsor (sponsor's role)	Age eligibility, years (mean age), [% male]	Clinical condition	No. randomised	Interventions compared	Treatment duration (days)	Outcomes	Time of outcome assessment (days)
ARDEPARIN ARTHROPLASTY STUDY ¹⁹⁶ (Multicentre) [USA]	Phase II Supported by a grant from Wyeth-Ayerst Research, Philadelphia, PA, USA (NR)	≥ 18 (68.6) [42.1]	Primary unilateral, simultaneous bilateral or unilateral revision TKR surgery	860	LMWH 1. Ardeparin 25 anti-Xa units/kg bd 2. Ardeparin 35 anti-Xa units/kg bd 3. Ardeparin 50 anti-Xa units/kg bd	14 Or at discharge post-op	<i>Efficacy:</i> VTE, DVT, proximal DVT, symptomatic PE <i>Safety:</i> Major bleeding, bleeding from surgical site, thrombocytopenia, death (all causes)	5–14 (for efficacy outcomes except symptomatic PE, which was prior to discharge) Unclear for safety outcomes
BISTRO II ¹⁹⁵ (Multicentre) [Europe and South Africa]	Phase II Boehringer Ingelheim (The sponsor was responsible for the overall planning and conduct of the study, and statistical analyses)	≥ 18 (66) [39]	THR or TKR surgery	1973	Warfarin 4. INR 2–3 Dabigatran 1. 50 mg bd 2. 150 mg bd 3. 300 mg od 4. 225 mg bd LMWH 5. Enoxaparin 40 mg od	6–10	<i>Efficacy:</i> VTE, symptomatic VTE, DVT, symptomatic DVT, proximal DVT, distal DVT, symptomatic PE <i>Safety:</i> Major bleeding, minor bleeding, CRNM bleeding, composite CRB	6–10

Study (centre type) [countries]	Study type, sponsor (sponsor's role)	Age eligibility, years (mean age), [% male]	Clinical condition	No. randomised	Interventions compared	Treatment duration (days)	Outcomes	Time of outcome assessment (days)
EXPERT ¹⁸⁸ (Multicentre) [USA and Canada]	Phase II Portola Pharmaceuticals Inc., South San Francisco, CA, USA (NR)	18–75 (63.3) [39.7]	Elective primary unilateral total knee arthroplasty	215	Betrixaban 1. 15 mg bd 2. 40 mg bd LMWH 3. Enoxaparin 30 mg bd	10–14	<i>Efficacy:</i> VTE, symptomatic VTE, symptomatic distal DVT, symptomatic proximal DVT, symptomatic DVT, non-symptomatic DVT, symptomatic PE <i>Safety:</i> All bleeding, major bleeding, CRNM bleeding, composite CRB	10–14
LIFENOX ¹⁸⁵ (Multicentre) [Asia, Mexico and Tunisia]	Phase III Sanofi (The data were gathered by the sponsor)	≥ 40 (65.5) [62.7]	Acute medical conditions	8323	LMWH 1. Enoxaparin 40 mg od 2. Placebo od	6–14	<i>Safety:</i> All bleeding, major bleeding, minor bleeding, CRNM bleeding, death (cardiovascular), death (all causes)	14 (for bleeding outcomes) 14, 30, 90 (for death outcomes)
MAGELLAN ^{184,191} (Multicentre) [North and South America, Europe, Israel, Australia, New Zealand and Asia]	Phase III Bayer HealthCare Pharmaceuticals and Janssen Research & Development (The data were collected and analysed by the sponsors)	≥ 40 (71.1) [54.2]	Acute medical conditions	8101	Rivaroxaban 1. 10 mg od LMWH 2. Enoxaparin 40 mg od	31–39 Rivaroxaban 6–14 LMWH	<i>Efficacy:</i> Major VTE, symptomatic DVT, symptomatic non-fatal PE <i>Safety:</i> Major bleeding, composite CRB, fatal bleeding, death (all causes)	10 and 35

continued

TABLE 69 Characteristics of 43 included randomised trials in primary prevention of VTE (continued)

Study (centre type) [countries]	Study type, sponsor (sponsor's role)	Age eligibility, years (mean age), [% male]	Clinical condition	No. randomised	Interventions compared	Treatment duration (days)	Outcomes	Time of outcome assessment (days)
ODIXa-HIP¹⁸⁴ (Multicentre) [Europe and Israel]	Phase II Bayer (The sponsor was involved in the study but the exact contributions are NR)	≥ 18 (65.1) [40.9]	THR surgery	641	Rivaroxaban 1. 2.5 mg bd 2. 5 mg bd 3. 10 mg bd 4. 30 mg od 5. 20 mg bd 6. 30 mg bd LMWH	5-9 Mean – rivaroxaban 7.5 ± 1.0 LMWH 7.6 ± 1.5	<i>Efficacy:</i> Major VTE, DVT, symptomatic DVT, proximal DVT, symptomatic PE, symptomatic non-fatal PE, fatal PE <i>Safety:</i> Major bleeding, minor bleeding, CRNM bleeding, composite CRB, fatal bleeding, death (all causes)	5-9
ODIXa-HIP2¹⁵⁹ (Multicentre) [Europe and Israel]	Phase II Bayer HealthCare AG (NR)	≥ 18 (65.3) [40.3]	Elective primary THR	722	7. Enoxaparin 40 mg od Rivaroxaban 1. 2.5 mg bd 2. 5 mg bd 3. 10 mg bd 4. 20 mg bd 5. 30 mg bd LMWH 6. Enoxaparin 40 mg od	5-9	<i>Efficacy:</i> Major VTE, DVT, proximal DVT, symptomatic PE <i>Safety:</i> Major bleeding, minor bleeding, CRNM bleeding, bleeding from surgical site	5-9

Study (centre type) [countries]	Study type, sponsor (sponsor's role)	Age eligibility, years (mean age), [% male]	Clinical condition	No. randomised	Interventions compared	Treatment duration (days)	Outcomes	Time of outcome assessment (days)
ODIXa-KNEE ¹⁵⁷ (Multicentre) [USA and Canada]	Phase II Bayer HealthCare AG, Germany (NR)	≥ 18 (66.5) [38.5]	Elective TKR	621	Rivaroxaban 1. 2.5 mg bd 2. 5 mg bd 3. 10 mg bd 4. 20 mg bd 5. 30 mg bd LMWH 6. Enoxaparin 30 mg bd	5–9	<i>Efficacy:</i> Major VTE, DVT, distal DVT, proximal DVT, symptomatic DVT, symptomatic PE <i>Safety:</i> Major bleeding, minor bleeding, CRNM bleeding, composite CRB, death (all causes)	5–9 (for efficacy outcomes) 11 (for safety outcomes)
ODIXa-OD.HIP ¹⁵⁸ (Multicentre) [Europe and Israel according to study report, but protocol says Japan]	Phase II Bayer HealthCare (NR)	≥ 18 (64.9) [41.1]	Primary THR surgery	873	Rivaroxaban 1. 5 mg od 2. 10 mg od 3. 20 mg od 4. 30 mg od 5. 40 mg od LMWH 6. Enoxaparin 40 mg od	5–9	<i>Efficacy:</i> Major VTE, DVT, distal DVT, proximal DVT, symptomatic distal DVT, symptomatic PE <i>Safety:</i> Major bleeding, minor bleeding, CRNM bleeding, death (all causes)	10

continued

TABLE 69 Characteristics of 43 included randomised trials in primary prevention of VTE (continued)

Study (centre type) [countries]	Study type, sponsor (sponsor's role)	Age eligibility, years (mean age), [% male]	Clinical condition	No. randomised	Interventions compared	Treatment duration (days)	Outcomes	Time of outcome assessment (days)
PROTECHT¹⁷⁰ (Multicentre) [Japan]	Phase III Italfarmaco SpA, Milan, Italy (NR)	≥ 18 (62.9) [51.7]	Metastatic or locally advanced cancer	1166	LMWH 1. Nadroparin 3800 IU anti-Xa od 2. Placebo od	110–130	Efficacy: Symptomatic VTE, symptomatic DVT, symptomatic PE Safety: All bleeding, major bleeding, minor bleeding, death (all causes)	111–113 (median)
RECORD 1¹⁶⁵ (Multicentre) [North and South America, Europe, Israel, Australia and South Africa]	Phase III Bayer HealthCare and Johnson & Johnson (The data were collected and analysed by the sponsors)	≥ 18 (63.2) [44.5]	Elective total hip arthroplasty	4541	Rivaroxaban 1. 10 mg od LMWH 2. Enoxaparin 40 mg od	35 (31–39)	Efficacy: Major VTE, symptomatic VTE, DVT, distal DVT, proximal DVT, symptomatic non-fatal PE, ischaemic stroke Safety: All bleeding, major bleeding, minor bleeding, CRNM bleeding, composite CRB, MI, death (cardiovascular), death (all causes)	36 (30–42) for all efficacy outcomes 37 (for all safety outcomes)
RECORD 2¹⁶⁶ (Multicentre) [North and South America, Europe, Australia, New Zealand, Asia and South Africa]	Phase III Bayer HealthCare AG, Johnson & Johnson Pharmaceutical Research and Development LLC (The study sponsors were involved in the study design, data collection and analysed)	≥ 18 (61.5) [46.4]	Elective total hip arthroplasty	2509	Rivaroxaban 1. 10 mg od LMWH 2. Enoxaparin 40 mg od	31–39 Rivaroxaban 10–14 LMWH	Efficacy: Symptomatic VTE, major VTE, DVT, distal DVT, proximal DVT, symptomatic non-fatal PE, fatal PE, ischaemic stroke Safety: All bleeding, major bleeding, CRNM bleeding, composite CRB, fatal bleeding, MI, death (cardiovascular), death (all causes)	30–42 (32–42 for major VTE, DVT, symptomatic non-fatal PE and composite CRB)

Study (centre type) [countries]	Study type, sponsor (sponsor's role)	Age eligibility, years (mean age), [% male]	Clinical condition	No. randomised	Interventions compared	Treatment duration (days)	Outcomes	Time of outcome assessment (days)
RECORD 3 ¹⁶³ (Multicentre) [North and South America, Europe, Israel, China and South Africa]	Phase III Bayer HealthCare and Johnson & Johnson Pharmaceutical Research & Development (Data were collected and analysed by the study sponsors)	≥ 18 (67.6) [31.8]	Total knee arthroplasty	2531	Rivaroxaban 1. 10 mg od LMWH 2. Enoxaparin 40 mg od	10–14	Efficacy: Major VTE, symptomatic VTE, DVT, distal DVT, proximal DVT, symptomatic non-fatal PE, ischaemic stroke Safety: All bleeding, major bleeding, CRNM bleeding, fatal bleeding, MI, death (cardiovascular), death (all causes)	17 (for all efficacy outcomes excluding ischaemic stroke) 16 (for bleeding outcomes) 15 (for MI, ischaemic stroke and death outcomes)
RECORD 4 ¹⁷³ (Multicentre) [North America, Europe, Israel, India and Sri Lanka]	Phase III Bayer Schering Pharma AG, Johnson & Johnson Pharmaceutical Research & Development (The study sponsors were involved in the design of the trial and collected and analysed the data)	≥ 18 (64.6) [34.9]	Total knee arthroplasty	3148	Rivaroxaban 1. 10 mg od LMWH 2. Enoxaparin 30 mg bd	10–14	Efficacy: Major VTE, symptomatic VTE, DVT, symptomatic DVT, non-symptomatic DVT, symptomatic PE, symptomatic non-fatal PE, fatal PE, ischaemic stroke Safety: Major bleeding, fatal bleeding, CRNM bleeding, composite CRB, fatal bleeding, MI, death (cardiovascular), death (all causes)	17 (for all efficacy outcomes excluding ischaemic stroke) 16 (for all safety outcomes and ischaemic stroke)
RE-MOBILISE ¹⁶⁷ (Multicentre) [North America and UK]	Phase III Boehringer Ingelheim (The sponsor was responsible for data collection and statistical analysis)	≥ 18 (66.1) [42.3]	Primary elective unilateral total knee arthroplasty	2615	Dabigatran 1. 150 mg od 2. 220 mg od LMWH 3. Enoxaparin 30 mg bd	12–15, median 14	Efficacy: VTE, major VTE, distal DVT, proximal DVT, symptomatic DVT, symptomatic PE, symptomatic non-fatal PE Safety: All bleeding, major bleeding, death (all causes)	12–15

continued

TABLE 69 Characteristics of 43 included randomised trials in primary prevention of VTE (continued)

Study (centre type) [countries]	Study type, sponsor (sponsor's role)	Age eligibility, years (mean age), [% male]	Clinical condition	No. randomised	Interventions compared	Treatment duration (days)	Outcomes	Time of outcome assessment (days)
RE-MODEL ¹⁶¹ (Multicentre) [Europe, Australia and South Africa]	Phase III Boehringer Ingelheim, Copenhagen, Denmark (The sponsor was responsible for data collection and statistical analysis)	≥ 18 (67.7) [34]	Primary elective unilateral TKR	2101	Dabigatran 1. 150 mg od 2. 220 mg od LMWH 3. Enoxaparin 40 mg od	6–10	<i>Efficacy:</i> VTE, symptomatic DVT, symptomatic PE <i>Safety:</i> All bleeding, major bleeding, minor bleeding, CRNM bleeding, composite CRB, death (all causes)	6–10
RE-NOVATE ¹⁶⁰ (Multicentre) [Europe, Australia and South Africa]	Phase III Boehringer Ingelheim, Alkmaar, The Netherlands (Data collection and analysis were done by the sponsor)	≥ 18 (64) [43.5]	Primary elective unilateral THR	3494	Dabigatran 1. 150 mg od 2. 220 mg od LMWH 3. Enoxaparin 40 mg od	28–35	<i>Efficacy:</i> Symptomatic DVT, symptomatic PE, fatal PE <i>Safety:</i> All bleeding, major bleeding, minor bleeding, CRNM bleeding, composite CRB	31–38
RE-NOVATE ^{163,169} (Multicentre) [North America, Europe, Australia, New Zealand, India and South Africa]	Phase III Boehringer Ingelheim, Sweden (NR)	≥ 18 (62) [48.2]	Unilateral, elective total hip arthroplasty	2055	Dabigatran 1. 220 mg od LMWH 2. Enoxaparin 40 mg od	28–35	<i>Efficacy:</i> Major VTE, symptomatic VTE, DVT, distal DVT, proximal DVT, symptomatic DVT, symptomatic non-fatal PE, ischaemic stroke <i>Safety:</i> All bleeding, major bleeding, minor bleeding, CRNM bleeding, composite CRB, MI, death (all causes)	28–35

Study (centre type) [countries]	Study type, sponsor (sponsor's role)	Age eligibility, years (mean age), [% male] [NR]	Clinical condition	No. randomised	Interventions compared	Treatment duration (days)	Outcomes	Time of outcome assessment (days)
STARS E-3 ¹⁸² (Multicentre) [Japan and Taiwan]	Phase III Daiichi Sankyo Inc. (NR)	20–84 (NR) [NR]	Unilateral total knee arthroplasty	716	Edoxaban 1. 30 mg od LMWH 2. Enoxaparin 2000 IU (20 mg) bd	11–14	<i>Efficacy:</i> VTE, DVT, symptomatic PE <i>Safety:</i> Major bleeding, composite CRB	14
STARS J-1 ^{172,180} (Multicentre) [Japan]	Phase II Daiichi Sankyo Co., Ltd, Tokyo, Japan (NR)	20–84 (71.1) [21.2]	Unilateral total knee arthroplasty	523	Edoxaban 1. 5 mg od 2. 15 mg od 3. 30 mg od 4. 60 mg od 5. Placebo od	11–14	<i>Efficacy:</i> VTE, DVT, distal DVT, proximal DVT, symptomatic DVT, symptomatic PE <i>Safety:</i> All bleeding, major bleeding, CRNM bleeding, composite CRB	14
STARS J-2 ¹⁷⁴ (Multicentre) [Japan and Taiwan]	Phase II Daiichi Sankyo Inc. (NR)	20–84 (NR) [NR]	Unilateral total hip arthroplasty	264	Edoxaban 1. 15 mg od 2. 30 mg od LMWH 3. Enoxaparin 20 mg bd	11–14	<i>Efficacy:</i> VTE, distal DVT <i>Safety:</i> Composite CRB	14

continued

TABLE 69 Characteristics of 43 included randomised trials in primary prevention of VTE (continued)

Study (centre type) [countries]	Study type, sponsor (sponsor's role)	Age eligibility, years (mean age), [% male]	Clinical condition	No. randomised	Interventions compared	Treatment duration (days)	Outcomes	Time of outcome assessment (days)
STARS J-4 ^{181,193} (Multicentre) [Japan]	Phase III Daiichi Sankyo Co., Ltd. Tokyo, Japan (NR)	≥ 20 (76) [20.5]	Hip surgery – for inner or outer femoral neck (trochanteric or subtrochanteric) fracture	92	Edoxaban 1. 30 mg od LMWH 2. Enoxaparin 2000 IU (20 mg) bd	11–14	<i>Efficacy:</i> VTE, major VTE, symptomatic DVT, non-symptomatic DVT, symptomatic PE <i>Safety:</i> All bleeding, major bleeding, minor bleeding, CRNM bleeding, composite CRB, death (all causes)	14
STARS J-V ¹⁷⁹ (Multicentre) [Japan]	Phase III Daiichi Sankyo Ltd. Tokyo, Japan (NR)	20–84 (62.8) [NR]	Unilateral total hip arthroplasty	610	Edoxaban 1. 30 mg od LMWH 2. Enoxaparin 20 mg bd	11–14	<i>Efficacy:</i> VTE, symptomatic DVT, non-symptomatic DVT, symptomatic PE <i>Safety:</i> Major bleeding, composite CRB	14
TOPIC-1 ¹⁹⁷ (Multicentre) [Germany, Czech Republic, Ukraine, Romania and Belarus]	Phase III Novartis Pharma GmbH Germany (NR)	Adults (55.6) [NR]	Metastatic breast cancer	353	LMWH 1. Certoparin 3000 IU od 2. Placebo od	182.6	<i>Efficacy:</i> VTE, DVT, symptomatic VTE, symptomatic DVT, non-symptomatic DVT, symptomatic PE <i>Safety:</i> All bleeding, major bleeding, minor bleeding, thrombocytopenia, death (all causes)	182.6

Study (centre type) [countries]	Study type, sponsor (sponsor's role)	Age eligibility, years (mean age), [% male]	Clinical condition	No. randomised	Interventions compared	Treatment duration (days)	Outcomes	Time of outcome assessment (days)
TOPIC-2 ¹⁹⁷ (Multicentre) [Germany, Czech Republic, Ukraine, Romania and Belarus]	Phase III Novartis Pharma GmbH Germany (NR)	Adults (60.6) [NR]	Inoperable disseminated primary non-small cell lung carcinoma	547	LMWH 1. Certoparin 3000 IU od 2. Placebo od	182.6	<i>Efficacy:</i> VTE, DVT, symptomatic VTE, symptomatic DVT, non-symptomatic DVT, symptomatic PE <i>Safety:</i> All bleeding, major bleeding, minor bleeding, thrombocytopenia, death (all causes)	182.6
VTE-APIX-PLACEBO-USACAN ⁹⁰ (Multicentre) [USA and Canada]	Phase II Bristol-Myers Squibb and Pfizer Inc. (NR)	≥ 18 (60) [50.4]	Receiving either first- or second-line chemotherapy for advanced or metastatic cancer	125	Apixaban 1. 5 mg od 2. 10 mg od 3. 20 mg od 4. Placebo od	84 (16–90)	<i>Efficacy:</i> Symptomatic VTE <i>Safety:</i> Major bleeding, CRNM bleeding, composite CRB	114–121
VTE-DABIG-LMWH-GREECE ¹⁸⁷ (Single centre) [NR]	Phase III Not declared (NR)	Adults (NR) [13.1]	Total knee arthroplasty	160	LMWH 1. Dalteparin 2.5 mg od 2. Enoxaparin 40 mg od 3. Tinzaparin 0.45 ml od Dabigatran 4. 110 mg od	Not given	<i>Efficacy:</i> VTE, DVT, PE, ischaemic stroke <i>Safety:</i> All bleeding	Not given

continued

TABLE 69 Characteristics of 43 included randomised trials in primary prevention of VTE (continued)

Study (centre type) [countries]	Study type, sponsor (sponsor's role)	Age eligibility, years (mean age), [% male]	Clinical condition	No. randomised	Interventions compared	Treatment duration (days)	Outcomes	Time of outcome assessment (days)
VTE-DABIG-PLAC-JAPAN ¹⁷⁵ (Multicentre) [Japan]	Phase III Boehringer Ingelheim Co, Ltd Kawanishi, Japan (NR)	≥ 20 (71.6) [17]	Primary, unilateral, elective total knee arthroplasty	512	Dabigatran 1. 110 mg od 2. 150 mg od 3. 220 mg od 4. Placebo od	11–14	<i>Efficacy:</i> Major VTE, DVT, proximal DVT, symptomatic DVT, symptomatic PE <i>Safety:</i> All bleeding, major bleeding, minor bleeding, CRNM bleeding, composite CRB, fatal bleeding, bleeding from surgical site, death (all causes)	14
VTE-EDOX-LMWH-MULTI ¹⁷⁷ (Multicentre) [North and South America, Europe, Russian and Ukraine]	Phase II Daiichi Sankyo Pharma Development (NR)	≥ 18 (57.8) [39.9]	Primary, unilateral THR surgery	903	Edoxaban 1. 15 mg od 2. 30 mg od 3. 60 mg od 4. 90 mg od LMWH 5. Dalteparin 5000 IU od	7–10	<i>Efficacy:</i> VTE, major VTE, proximal DVT <i>Safety:</i> All bleeding, major bleeding, CRNM bleeding, composite CRB, death (all causes)	7–10 (for efficacy outcomes) 10 (for safety outcomes)
VTE-LMWH-PLAC-CAN ¹⁶⁹ (Multicentre) [Canada]	Phase III Fragmin, Pharmacia, Pfizer Global Pharmaceuticals, Kirkland, QC, Canada (NR)	18–75 (41) [62]	Unilateral isolated fractures below the knee, which required operative fixation (patients with minor simultaneous injuries were also included if they were able to mobilise)	305	LMWH 1. Dalteparin 5000 IU od 2. Placebo od	14	<i>Efficacy:</i> Non-symptomatic DVT <i>Safety:</i> All bleeding, major bleeding, minor bleeding, thrombocytopenia, death (all causes)	14

Study (centre type) [countries]	Study type, sponsor (sponsor's role)	Age eligibility, years (mean age), [% male]	Clinical condition	No. randomised	Interventions compared	Treatment duration (days)	Outcomes	Time of outcome assessment (days)
VTE-LMWH-PLAC-JAPAN ¹⁸⁶ (Single centre) [Japan]	Phase III None declared (NR)	≥ 20 (NR) [18.4]	Unilateral THR surgery	255	LMWH 1. Fondaparinux 2.5 mg od 2. Enoxaparin 20 mg bd 3. Placebo od	10	<i>Efficacy:</i> VTE, symptomatic VTE, DVT, distal DVT, proximal DVT, symptomatic DVT, symptomatic PE <i>Safety:</i> All bleeding, major bleeding, minor bleeding	11
VTE-RIVAROX-LMWH-BRAZIL ¹⁶⁴ (Single centre) [Brazil]	Phase III Bayer HealthCare (NR)	≥ 18 (57.9) [55.4]	Elective total hip arthroplasty	67	Rivaroxaban 1. 10 mg od LMWH 2. Enoxaparin 40 mg od	32–36	<i>Efficacy:</i> DVT, symptomatic PE	32–36
VTE-RIVAROX-LMWH-CHINA ¹⁹² (Single centre) [China]	Phase III Not declared (NR)	> 50 (64.6) [56.6]	Unilateral hip arthroplasty	106	Rivaroxaban 1. 10 mg od LMWH 2. 4100 IU od (type NR)	35	<i>Efficacy:</i> DVT	182.6
VTE-VKA-LMWH-CANADA ¹⁹² (Multicentre) [NR]	Phase III Rhône-Poulenc Rorer Canada (NR)	Adults (68.8) [36.9]	Knee arthroplasty	670	Warfarin 1. INR 2–3 LMWH 2. Enoxaparin 30 mg bd	5.9–11.5 (mean)	<i>Efficacy:</i> Symptomatic VTE, DVT, proximal DVT, symptomatic PE <i>Safety:</i> All bleeding, major bleeding, minor bleeding, thrombocytopenia, death (all causes)	14

continued

TABLE 69 Characteristics of 43 included randomised trials in primary prevention of VTE (continued)

Study (centre type) [countries]	Study type, sponsor (sponsor's role)	Age eligibility, years (mean age), [% male]	Clinical condition	No. randomised	Interventions compared	Treatment duration (days)	Outcomes	Time of outcome assessment (days)
VTE-VKA-LMWH-US ¹⁵³ (Multicentre) [USA]	Phase III National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA, and a grant from Pharmacia & Upjohn, Kalamazoo, MI, USA (NR)	≥ 18 (63) [47.1]	Unilateral primary or revision total hip arthroplasty	580	Warfarin 1. INR 2.0–3.0 LMWH 2. Dalteparin 5000 IU od	5–9	<i>Efficacy:</i> DVT, distal DVT, proximal DVT <i>Safety:</i> Major bleeding	5–9 Unclear for major bleeding
VTE-VKA-LMWH-US-2 ¹⁵⁴ (Multicentre) [NR]	Phase III Rhône-Poulenc Rorer Pharmaceuticals (NR)	≥ 18 (64) [44.4]	Elective unilateral primary hip arthroplasty	3011	Warfarin 1. INR 2–3 LMWH 2. Enoxaparin 30 mg bd	14	<i>Efficacy:</i> Symptomatic VTE, symptomatic DVT, symptomatic PE, fatal PE <i>Safety:</i> All bleeding, major bleeding, minor bleeding, bleeding from surgical site, thrombocytopenia, death (all causes)	14

Study (centre type) [countries]	Study type, sponsor (sponsor's role)	Age eligibility, years (mean age), [% male]	Clinical condition	No. randomised	Interventions compared	Treatment duration (days)	Outcomes	Time of outcome assessment (days)
VTE-VKA-LMWH-US-3 ¹⁵⁵ (Multicentre) [USA and Canada]	Phase III Grant-in-aid by Pharmacia & Upjohn to the University of Calgary (NR)	≥ 18 (63.3) [48.2]	Elective unilateral total hip arthroplasty (primary or revision)	1501	Warfarin 1. INR 2–3 LMWH 2. Dalteparin 5000 IU – started pre-operatively and then od 3. Dalteparin 5000 IU – started post-operatively and then od	4–8	<i>Efficacy:</i> DVT, symptomatic DVT, proximal DVT, symptomatic PE <i>Safety:</i> Major bleeding, minor bleeding, death (all causes)	5–9 (for efficacy outcomes) 8 (for safety outcomes)
VTE-VKA-LMWH-US-4 ¹⁵⁶ (Multicentre) [USA]	Phase III Aventis Pharmaceuticals, Inc., Bridgewater, NJ, USA (NR)	≥ 38 (NR) [44]	Unilateral total knee arthroplasty	349	Warfarin 1. INR 2–3 LMWH 2. Enoxeparin 30 mg bd	4–14	<i>Efficacy:</i> VTE, DVT, distal DVT, proximal DVT, symptomatic PE <i>Safety:</i> All bleeding, major bleeding, minor bleeding, death (all causes)	5–15
NR, not reported.								

patient population (with 20 associated references^{153–155,158–160,164–166,174,176,177,179,181,183,186,189,192–194}), 17 trials in knee surgery patient population (with 18 associated references^{152,156,157,161–163,167–169,171–173,175,178,180,182,187,196}), seven trials in medical patient population (with seven associated references^{170,184,185,188,190,191,197}) and one trial (with one associated reference¹⁹⁵) involving both hip and knee surgery patients. Thirty-nine of the trials were multicentre and four were single-centre trials. Most of the multicentre trials were conducted across several countries mainly in North and South America, Europe, Asia, Russia and Israel, Australia and South Africa. Three of the single-centre studies were conducted in Japan, Brazil and China, and one study did not report the country where it was conducted. Thirty-one of the trials were Phase III studies and 12 were Phase II studies. The number of patients randomised ranged from 67 to 5407 patients across the 18 trials on hip surgery; 160 to 3195 patients across the 17 trials on knee surgery (one trial was below-knee fracture patient population); 125 to 8823 patients across the seven trials on medical cases; 1973 patients in the trial involving both hip and knee surgery patients; and 67 to 8323 patients across the whole trials, with a total of 77,563 patients of whom 88.9% (68,953 patients) were from Phase III studies. Thirty-one studies (19 Phase III and 12 Phase II) examined a NOAC. Overall, 11 studies examined rivaroxaban, seven studies examined dabigatran, six studies each examined apixaban and edoxaban, and one study examined betrixaban. Apart from two studies without sponsor information, all studies on NOACs were sponsored by one or more pharmaceutical companies. The role of sponsor was not declared in some of the studies, but, where the sponsor role was declared, the sponsor was commonly involved in the study design, data management and analysis.

Eligibility criteria for patient participation were similar across surgical studies of the same type, with all patients in hip surgery studies having elective unilateral hip arthroplasty, and all patients in knee surgery studies having elective unilateral knee arthroplasty. Patients in medical studies were selected based on specific clinical conditions, either having a metastatic cancer or one or more acute medical conditions, so the criteria varied slightly across the medical studies. The minimum age for inclusion in a majority of the studies was 18 years, the mean age across studies (where reported) ranged from 41 years to 76 years. The percentage of male patients, reported in 88% of the studies, ranged from 13.1% to 62.7%. Mean BMI and mean weight ranged from 23 to 32.4 kg/m² and from 52.3 to 90.9 kg, respectively, across studies, when reported. Proportions of comorbidities were poorly reported across studies. When reported, the proportion of patients with a previous thromboembolic event, chronic heart failure and cancer ranged from 0.1% to 10.2%, 0.6% to 34.8% (higher of the range from medical patient population studies), and 6% to 100% (100% in cancer patient studies), respectively.

Of the 31 studies that examined NOACs, a NOAC was compared with a LMWH in 27 studies, with placebo in three studies, and with both a LMWH and warfarin in one study. Fourteen of the 31 studies were on hip surgery patients, 12 on knee surgery patients, one on below knee fracture patients, one on both hip and knee surgery patients, and three on medical patients. The doses of NOACs examined were apixaban 5 mg, 10 mg and 20 mg od, and 2.5 mg, 5 mg and 10 mg bd; edoxaban 5 mg, 15 mg, 30 mg, 60 mg and 90 mg od; rivaroxaban 5 mg, 10 mg, 20 mg, 30 mg and 40 mg od, and 2.5 mg, 5 mg, 10 mg, 20 mg and 30 mg bd; betrixaban 15 mg and 40 mg bd; and dabigatran 110 mg, 150 mg, 220 mg and 300 mg od, and 50 mg, 150 mg and 225 mg bd. Among the studies that did not examine a NOAC, six studies each compared LMWH with warfarin, and with placebo. Standard intensity warfarin (INR 2–3) was examined in all studies involving a warfarin arm, although in one study the lower end of the INR range was 1.8. None of these studies that examined warfarin reported mean TTR. LMWHs varied in type and dose across studies. Start of treatment with LMWH varied across surgical patient studies with pre-op treatment start in 11 studies in hip surgery, four studies in knee surgery, and one study involving both hip and knee surgery patients, and post-op treatment start in eight studies in hip surgery and 11 studies in knee surgery. In one (hip surgery) study, pre- and post-op LMWH treatment start were compared.

Treatment duration varied greatly across hip surgery, knee surgery and medical patient studies, from 4 to 130 days. There is less variation in treatment duration within the knee and hip surgery studies, with

treatment duration ranging from 10 to 14 days in most of the knee surgery studies, and from 5 to 14 days and 28 to 35 days in most of the hip surgery studies. Treatment duration was the same for the interventions compared with studies, except in three studies where the LMWH comparator was given for a shorter duration than the NOAC (rivaroxaban in two studies and apixaban in one study). However, time to outcome assessment was the same in all studies including those with different treatment durations for the interventions compared.

Reported efficacy and safety outcome types were similar across studies irrespective of the patient group, and were reported at the end of the treatment periods. Two rivaroxaban studies reported only efficacy outcomes: in both cases few outcomes were reported. One study reported only safety outcomes. Overall, 29 studies reported data on symptomatic VTE; 25 on symptomatic DVT, 35 on symptomatic PE, nine on MI, 39 on major bleeding, 27 on CRB, and 28 on all-cause mortality. Diagnosis of VTE was predominantly by compression ultrasonography or venography for DVT, and by spiral computerised tomography scan or ventilation/perfusion lung scan for PE.

Time in therapeutic range for warfarin interventions

Seven studies of primary prevention of VTE included a warfarin intervention arm, but none of these reported mean TTR.

Risk of bias in included studies

Detailed risk-of-bias assessments for each included study for each domain of the Cochrane assessment tool are provided in *Table 70*. Overall, the studies were judged to be at low risk of bias. Assessment of a few studies was based on abstract information only, in which case risk of bias for most domains was judged to be unclear. The majority of the studies were judged to be at low risk of bias for blinding of outcome assessment and incomplete outcome data. The risk of bias in these two domains differed slightly in a few studies because of differences in blinding of outcome assessment and the number of patients included in analysis according to outcome type, mainly whether an outcome is for efficacy or for safety. Most studies were judged to be at low risk of bias for selective outcome reporting. Among those not judged to be at low risk, the main reason for the judgement was either unavailability of the study protocol or insufficient information to enable a judgement of low risk. Randomisation sequence generation and allocation concealment were predominantly by computer generation and central allocation, respectively. In some studies, randomisation was used a standard permuted block and some of the studies were stratified according to study centre. A few studies,^{153,154,156,168,174,193,194} predominantly of open-label design, were judged to be at high risk of bias for blinding of participants. The risk-of-bias judgements for studies contributing to analyses of each outcome are presented graphically in the sections that follow.

Results of clinical effectiveness and safety

Three trials (TOPIC-1,¹⁹⁷ TOPIC-2¹⁹⁷ and ARDEPARIN ARTHROPLASTY STUDY¹⁹⁶) were not included in any of the networks. They used non-standard variants of heparin that could not be assumed to be comparable with standard heparin, so these studies do not contribute information on the comparisons of interest.

The 38 trials included in these analyses implemented a total of 35 interventions, listed in *Table 71*. The interventions labelled as 'standard dose' for LMWH included tinzaparin (0.45 ml od), enoxaparin (40 mg od or 30 mg bd) and dalteparin (5000 IU). The 'warfarin variable' node included interventions in which a subtherapeutic INR range had been considered for some patients, and for that reason this node was included only in sensitivity analyses in which it was merged with the warfarin (INR 2–3 node). *Tables 72* and *73* show the numbers of events for each outcome reported in each trial. We performed NMAs for

TABLE 70 Risk-of-bias assessments for 43 included randomised trials in primary prevention of VTE

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting
ADOPT ¹⁸⁸	L: 'Randomization was performed through a central telephone system with the use of a computer-generated randomization list'	L: 'Randomization was performed through a central telephone system with the use of a computer-generated randomization list'	L: 'The study medications were packaged in identical-appearing dispensing kits. Patients who were randomly assigned to apixaban received daily injections of an enoxaparin placebo' 'Patients who were randomly assigned to enoxaparin received tablets containing an apixaban placebo'	L: 'All components of the primary efficacy outcome were adjudicated by the independent central adjudication committee. All compression ultrasound examinations were recorded for submission to an independent central adjudication committee whose members were unaware of the treatment assignments'	L: <i>For efficacy outcomes:</i> All patients were included in the analyses L: <i>For safety outcomes:</i> Some missing data; reasons given; unlikely to be related to true outcome	L: All outcomes are reported as per protocol
ADVANCE-1 ¹⁷¹	U: 'The randomization was stratified according to study site and whether a patient was undergoing replacement of one or both knees, with a block size of 4'	U: No information to enable judgement	L: One group of patients received 2.5 mg of apixaban orally bd as well as an injection of placebo that mimicked injection with enoxaparin. The other group received 30 mg of enoxaparin subcutaneously every 12 hours along with placebo tablets that were identical in appearance to apixaban tablets	L: 'All venograms and all episodes of suspected symptomatic VTE, bleeding, MI, stroke, thrombocytopenia, or death were adjudicated, without knowledge of the patient's assigned treatment, by an independent central adjudication committee'	L: No missing outcome data except for DVT outcomes U: <i>For DVT outcomes:</i> Some missing outcome data; not entirely balanced in numbers across intervention groups Not clear if missing data are unlikely to be related to true outcome	L: All outcomes are reported as per protocol

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting
ADVANCE-2 ¹⁷⁸	L: 'The randomisation schedule was generated by the Bristol-Myers Squibb randomisation centre with SAS and was stratified by study site and by unilateral or bilateral surgery with a block size of four'	L: 'The randomisation schedule was generated by the Bristol-Myers Squibb randomisation centre with SAS and was stratified by study site and by unilateral or bilateral surgery with a block size of four'	L: 'Investigators, patients, statisticians, adjudicators, and the steering committee were masked to treatment allocation'	L: 'Investigators, patients, statisticians, adjudicators, and the steering committee were masked to treatment allocation'	U: <i>For safety outcomes:</i> High proportion of missing outcome data; reasons for missing data given and reasons are similar across intervention groups and appear to be balanced in number across intervention groups However, it is not clear whether the reasons are related to true outcome or not L: <i>For safety outcomes:</i> Missing outcome data, however few reasons for missing data given and reasons balance in number across intervention groups; it is unlikely that that reason for missing data are related to true outcome L: <i>For death outcome:</i> All patients were included in the analyses	L: All outcomes are reported as per protocol

continued

TABLE 70 Risk-of-bias assessments for 43 included randomised trials in primary prevention of VTE (continued)

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting
ADVANCE-3 ¹⁷⁶	L: 'The randomization schedule was generated at the randomisation centre of Bristol-Myers Squibb with the use of SAS software and was stratified according to study site, with a block size of four'	L: 'Potentially eligible patients were identified during a screening period of up to 14 days before surgery and were randomly assigned, with the use of an interactive telephone system'	L: 'The study was a randomized, double-blind, double-dummy clinical trial'. Patients were assigned to receive apixaban at a dose of 2.5 mg orally bd plus placebo injections od or enoxaparin at a dose of 40 mg subcutaneously od plus placebo tablets bd'	L: 'All venograms and all episodes of suspected symptomatic VTE, bleeding, MI, stroke, thrombocytopenia, and death were adjudicated by an independent central adjudication committee whose members were unaware of the treatment assignments'	L: For symptomatic DVT and symptomatic PE: All patients were included in the analyses U: For other efficacy outcomes and safety outcomes: Some missing outcome data; similar reasons for missing data across groups but not balanced in numbers. Reasons for missing outcome data may be related to true outcome	L: All outcomes are reported as per protocol
APROPOS ⁶²	L: 'Randomization was done by computer generated allocation'	U: Not enough information to enable judgement. 'Patients were randomly assigned to one of the following eight treatment groups'	U: 'The study was conducted in a blinded fashion with regards to apixaban dosing and enoxaparin; the warfarin arm was open-label. In order to maintain blinding, apixaban and enoxaparin were administered in a double-dummy fashion'	L: 'Efficacy, bleeding events and cause of death were adjudicated by an independent central committee whose members were unaware of treatment assignments'	L: For efficacy outcomes: Some missing data but reasonable reasons for the missing data were provided and it is unlikely that missing data could influence the result L: For safety outcomes: Minimal missing data unlikely to affect result Also, reasons were provided for the missing data	L: All outcomes are reported as per protocol

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting
ARDEPARIN ARTHROPLASTY STUDY ¹⁹⁶	U: 'The study utilized a randomized, multicenter, stratified, parallel, double blind design' 'Eligible patients were randomly assigned to one of three ardeparin doses or oral warfarin prophylaxis in a 1 : 1 : 2 : 2 ratio'	U: Not enough information to enable judgement. 'Eligible patients were randomly assigned to one of three ardeparin doses or oral warfarin prophylaxis in a 1 : 1 : 2 : 2 ratio'	L: 'To maintain blinding of prophylaxis assignment, all patients received bd injections (either ardeparin or placebo), daily tablets (either placebo or warfarin) and daily prothrombin time measurement'	L: 'The efficacy endpoint measures (mandatory venography of the operated leg, or lung scan or pulmonary angiogram for clinically suspected PE) were determined by objective testing and were interpreted by experts blinded to treatment assignment' 'All other members of the clinical team, the patient, the pharmacist, and the sponsor, were blinded to prophylaxis treatment'	L: <i>For efficacy outcomes:</i> 'Twenty one percent of randomized patients failed to complete the study. The number of patients who did not complete the study was evenly distributed among the four prophylaxis groups in proportion to the randomization ratio' L: <i>For safety outcomes:</i> 'All patients who received at least one dose of the study drug were included in the analysis'	L: All outcomes are reported as per protocol
BISTRO II ¹⁹⁵	L: 'On the day before surgery, patients were assigned randomly to five treatment groups, stratified by the study center and surgical procedure (hip or knee replacement), using a computer-generated scheme' Separate medication kits for hip and knee replacement were provided to each site in blocks of 10'	U: 'On the day before surgery, patients were assigned randomly to five treatment groups, stratified by the study center and surgical procedure (hip or knee replacement), using a computer-generated scheme. Separate medication kits for hip and knee replacement were provided to each site in blocks of 10'	L: 'Patients were assigned to either oral dabigatran etexilate with doses of 50 and 150 mg bd, 300 mg od and 225 mg bd, or 40 mg of enoxaparin (Aventis Pharma, Bridgewater, NJ, USA) subcutaneously, od. Both study groups received active or matching placebo medications'	L: <i>For efficacy outcomes:</i> 'All tests for VTE during the treatment period were first evaluated locally and subsequently by an independent central adjudication committee blinded to the treatment allocation. The results of the central adjudication were used in the primary analysis' L: <i>For safety outcomes:</i> 'A centralized independent committee classified all bleeding events'	L: <i>For efficacy outcomes:</i> Of 1973 randomised patients, only 1464 were included in efficacy outcome analysis However, missing outcome data are balanced in numbers across the trial arms and the reasons for missing data in the dabigatran arms have a similar spread to those of the enoxaparin arm L: <i>For safety outcomes:</i> '1973 were randomized to either dabigatran etexilate (1576) or enoxaparin (397). Of these, 24 were not treated The safety population comprised 1949 patients who received at least one dose of study drug'	L: All outcomes are reported as per protocol

continued

TABLE 70 Risk-of-bias assessments for 43 included randomised trials in primary prevention of VTE (continued)

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting
EXPERT ¹⁶⁸	L: 'The computer-generated randomization code provided assignments in a 2 : 2 : 1 ratio to either betrixaban 15 mg, betrixaban 40 mg, or enoxaparin 30 mg, respectively'	U: Not enough information to judge allocation concealment. 'The computer-generated randomization code provided assignments in a 2 : 2 : 1 ratio to either betrixaban 15 mg, betrixaban 40 mg, or enoxaparin 30 mg, respectively'	H: 'Randomization was either to enoxaparin or one of two dose levels (15 or 40 mg bid) of betrixaban; patients and physicians were blinded to the betrixaban dose level, but unblinded to enoxaparin versus betrixaban'	L: 'All primary efficacy data and suspected bleeding events were evaluated centrally by an Independent Central Adjudication Committee (ICAC) blinded to treatment allocation'	U: <i>For efficacy outcomes:</i> There are missing data and although reasons for the missing data are provided, they do not balance in numbers across intervention groups and may be related to true outcome L: <i>For safety outcomes:</i> All patients were included in the analyses	L: All outcomes are reported as per protocol
LIFENOX ¹⁸⁵	L: 'The treatment-code list of random permuted blocks was generated by an independent contract research organization and was stratified according to center'	U: 'The investigators assigned the patients to a group in the sequential order of the treatment numbers available at the site'	L: 'The investigators, patients, and research personnel, as well as the members of the steering committee and of the data and safety monitoring committee, were unaware of the group assignments'	L: 'The investigators, patients, and research personnel, as well as the members of the steering committee and of the data and safety monitoring committee, were unaware of the group assignments'	L: A negligible number of participants did not receive study drug and had no follow-up data This reason is the same in both arms. All patients who received study drug were included in the analyses	L: All outcomes are reported as per protocol
MAGELLAN ^{184,191}	L: 'Randomization was performed in permuted blocks with the use of an interactive voice response system, with stratification according to centre'	L: 'Randomization was performed in permuted blocks with the use of an interactive voice response system, with stratification according to centre'	L: 'Eligible patients were randomly assigned to receive subcutaneous enoxaparin, 40 mg od, for 10 ± 4 days and oral placebo, od, for 35 ± 4 days or to receive subcutaneous placebo, od, for 10 ± 4 days and oral rivaroxaban, 10 mg od, for 35 ± 4 days'	L: 'All outcomes were assessed by an independent, central adjudication committee whose members were unaware of the study assignments'	L: Missing data; reasons provided with similarity between the treatment groups; reasons also balance in number in the treatment groups	L: All outcomes are reported as per protocol

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting
ODiXa-HIP ¹⁹⁴	U: 'In this dose-escalation study, patients were randomized to receive rivaroxaban (Bayer HealthCare AG) or enoxaparin (Clexane®/Lovenox®, Sanofi-Aventis), in a 3 : 1 ratio'	U: 'In this dose-escalation study, patients were randomized to receive rivaroxaban (Bayer HealthCare AG) or enoxaparin (Clexane®/Lovenox®, Sanofi-Aventis), in a 3 : 1 ratio'	H: 'This was a randomized, open-label, active-comparator-controlled, European, multinational, dose-escalation study'	L: 'All symptomatic events, including deaths, were assessed centrally by the VTE Adjudication Committee. Study drug allocation was not revealed to the adjudication committees, who performed their assessments in a blinded manner'	H: <i>For efficacy outcomes:</i> Analysis was per protocol, n = 466; 14, 21, 13, 18, 20, 34, and 55 patients were excluded from the randomised numbers in arms 1 to 7, respectively, of which 16 patients did not receive allocated drug treatment U: 'A patient was valid for the per-protocol (PP) analysis if they were valid for the ITT analysis, had no major protocol deviations and had adequate assessment of VTE no more than 1 day after stopping study medication'	L: All outcomes are reported as per protocol
					U: <i>For safety outcomes:</i> Analysis was based on n = 625; 1, 4, 3, 2 and 6 patients did not receive allocated drug treatment in arms 1, 2, 4, 5 and 6, respectively '16 patients did not receive allocated drug treatment'	

continued

TABLE 70 Risk-of-bias assessments for 43 included randomised trials in primary prevention of VTE (continued)

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting
ODiXa-HIP2 ¹⁵⁹	<p>U: Not enough information to enable judgement</p> <p>'In this double-blind, double-dummy, dose-ranging study, patients were randomized to oral BAY 59-7939 (2.5, 5, 10, 20, or 30 mg b.i.d.), starting 6-8 h after surgery, or s.c. enoxaparin 40 mg od, starting on the evening before surgery'</p>	<p>U: Not enough information to enable judgement</p> <p>'This was a prospective, randomized, double-blind, double-dummy, active-comparator-controlled, multicentre, multinational study. All patients received matching placebo injections or tablets'</p>	<p>L: 'This was a prospective, randomized, double-blind, double-dummy, active-comparator-controlled, multicentre, multinational study. All patients received matching placebo injections or tablets'</p>	<p>L: 'All adjudication committees were independent and blinded to treatment allocation'</p>	<p>U: <i>For efficacy outcomes:</i> Large numbers of outcome missing data</p> <p>The number of missing data seem to be balanced in the treatment groups, with similar reasons for missing data</p> <p>However, it is not clear whether or not missing data could be related to the true outcome</p> <p>L: <i>For safety outcomes:</i> Very few numbers of missing data; however, number is balanced in the treatment groups</p>	<p>L: All outcomes are reported as per protocol</p>
					Reason for missing data are unlikely to be related to the true outcome	

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting
ODIXa-KNEE ¹⁵⁷	L: 'Patients were randomly assigned to six treatment groups, using a computer-generated randomization list'	L: 'Patients were randomly assigned to six treatment groups, using a computer-generated randomization list and interactive voice response system'	L: 'This was a randomized, double-blind, double-dummy, active comparator controlled, parallel-group, dose-ranging study. All patients received matching placebo injections or tablets'	L: <i>For efficacy outcomes:</i> 'The assessment of the efficacy endpoints was based solely on the analysis made by two independent central adjudication committees (Venography and VTE) blinded to the treatment allocation'	L: <i>For efficacy outcomes:</i> Some missing outcome data and reasons for missing data are provided but missing outcome data do not balance in numbers across intervention groups Not clear whether or not reason for missing data are unrelated to true outcome L: <i>For safety outcomes:</i> All patients were included in the analyses	L: All outcomes are reported as per protocol
ODIXa-OD.HIP ¹⁵⁸	U: Not enough information to enable judgement 'The ODIXa-OD-HIP study was a randomized, double-blind, double-dummy, active-comparator-controlled, multinational, dose-ranging study'	U: Not enough information to enable judgement 'The ODIXa-OD-HIP study was a randomized, double-blind, double-dummy, active-comparator-controlled, multinational, dose-ranging study.'	L: 'The ODIXa-OD-HIP study was a randomized, double-blind, double-dummy, active-comparator-controlled, multinational, dose-ranging study. Patients received matching placebo tablets or injections, so that each patient received 2 tablets and an injection every evening'	L: 'All venograms were assessed centrally by the Venography Adjudication Committee. All adjudication committees were independent and blinded to treatment allocation'	U: <i>For efficacy outcomes:</i> Fairly large proportions of missing data; reasons for missing data are given but the reasons and numbers do not balance across the groups Reasons for missing outcome data may be related to the true outcome L: <i>For safety outcomes:</i> Small number of missing data with similar reasons Unlikely that reasons are related to the true outcome	U: Symptomatic VTE was not reported

continued

TABLE 70 Risk-of-bias assessments for 43 included randomised trials in primary prevention of VTE (continued)

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting
PROTECHT ¹⁷⁰	L: 'The randomisation list was generated by an independent statistician who used a standard permuted block of six without stratification. The list was generated with SAS version 8.2.'	L: 'The allocation sequence was available online to the investigators using the Hypernet web-based system'	L: 'Treatment assignments were masked from all study participants for the duration of the study'	L: 'All study outcomes were assessed by a central independent adjudication committee whose members were unaware of patients' study-group allocation'	L: Almost 99% of the randomised patients were included in the efficacy and safety analysis Reason for the minimal loss unlikely related to the outcome	L: All outcomes are reported as per protocol
RECORD 1 ¹⁶⁵	L: 'Before surgery, patients were randomly assigned to a study group with the use of permuted blocks and stratification according to center by means of a central telephone system with a computer-generated randomization list'	L: 'Before surgery, patients were randomly assigned to a study group with the use of permuted blocks and stratification according to center by means of a central telephone system with a computer-generated randomization list'	U: 'In a double-blind fashion, patients were assigned to receive either once-daily oral rivaroxaban in 10-mg tablets (Xarelto, Bayer HealthCare) or 40 mg of enoxaparin sodium administered by subcutaneous injection (Clexane/Lovenox, Sanofi-Aventis)'	L: 'All outcomes were assessed by central committees whose members were unaware of the patients' study-group assignments'	L: There is a substantial amount of missing data with reasons However, missing data appear to be balanced in numbers across intervention groups	L: All outcomes are reported as per protocol
RECORD 2 ¹⁶⁶	L: 'Patients were randomly assigned to study medication before surgery, using permuted blocks (size four) with stratification according to centre, via a central telephone system using a computer-generated randomisation code'	L: 'Patients were randomly assigned to study medication before surgery, using permuted blocks (size four) with stratification according to centre, via a central telephone system using a computer-generated randomisation code'	U: 'Patients were randomly assigned to receive double-blind, oral rivaroxaban 10 mg tablets od (Xarelto, Bayer HealthCare AG, Wuppertal, Germany) or subcutaneous injections of enoxaparin sodium 40 mg od (Clexane/Lovenox, Sanofi-Aventis, Frankfurt am Main, Germany)'	L: 'All outcomes were assessed by independent, central adjudication committees blinded to treatment allocation'	U: For efficacy outcomes: Some missing data (about 31 %); missing data seem balanced in number across intervention groups with similar reasons for missing data across groups but not sure if missing data are related to true outcome or not L: For safety outcomes: Few missing data; missing data seem balanced in number across intervention groups with similar reasons for missing data across groups and missing data are unlikely related to true outcome	L: All outcomes are reported as per protocol

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting
RECORD 3 ¹⁶³	U: 'On a double-blind and double-dummy basis, before surgery, patients were randomly assigned through a central telephone system' L: 'Before surgery, participants were randomly assigned to study drug through a central telephone system, stratified by centre with permuted blocks of four patients, on a double-blind and double-dummy basis'	L: 'On a double-blind and double-dummy basis, before surgery, patients were randomly assigned through a central telephone system to receive once-daily oral rivaroxaban (Bayer HealthCare), in a 10-mg tablet, or a once-daily injection of enoxaparin sodium (Clexane or Lovenox, Sanofi-Aventis), in a 40-mg dose'	U: 'On a double-blind and double-dummy basis, before surgery, patients were randomly assigned through a central telephone system to receive once-daily oral rivaroxaban (Bayer HealthCare), in a 10-mg tablet, or a once-daily injection of enoxaparin sodium (Clexane or Lovenox, Sanofi-Aventis), in a 40-mg dose'	L: 'All outcomes were assessed by central, independent adjudication committees who were unaware of the treatment assignments'	U: <i>For efficacy outcomes:</i> Some missing outcome data; reasons for missing data provided However, it is not clear whether or not missing data are unlikely to be related to true outcome L: <i>For safety outcomes:</i> Few missing outcomes data; reasons for missing data provided and appears to be the same in both intervention arms; it is unlikely that missing data are related to true outcome	L: All outcomes are reported as per protocol
RECORD 4 ¹⁷³	L: 'Before surgery, participants were randomly assigned to study drug through a central telephone system, stratified by centre with permuted blocks of four patients, on a double-blind and double-dummy basis'	L: 'Before surgery, participants were randomly assigned to study drug through a central telephone system, stratified by centre with permuted blocks of four patients, on a double-blind and double-dummy basis'	U: 'Before surgery, participants were randomly assigned to study drug through a central telephone system, stratified by centre with permuted blocks of four patients, on a double-blind and double-dummy basis'	L: 'Central independent adjudication committees masked to allocation assessed all outcomes'	L: <i>For efficacy outcomes:</i> 'Proportions of patients with venograms adequate for assessment for the primary efficacy analysis were lower than anticipated but similar (including the underlying reasons) in the two treatment groups (965 [60.9%] of 1584 patients in the rivaroxaban group and 959 [61.3%] of 1564 patients in the enoxaparin group). The groups were well balanced in terms of baseline demographic and surgery characteristics' L: <i>For safety outcomes:</i> All patients were included in the analyses	L: All outcomes are reported as per protocol

continued

TABLE 70 Risk-of-bias assessments for 43 included randomised trials in primary prevention of VTE (continued)

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting
RE-MOBILISE ¹⁶⁷	L: 'An Interactive Voice Response System was used for randomization in blocks of 6 and was based on an independently generated scheme'	L: 'This was a double-blind, centrally randomized trial' 'An Interactive Voice Response System was used for randomization'	L: 'This was a randomized, double-blind, active controlled, noninferiority study'. 'All 3 groups received one active and one placebo treatment (i.e., double-dummy blinding)'	L: <i>For efficacy outcomes:</i> 'Diagnostic tests for VTE events were initially evaluated locally and subsequently reviewed by an independent central adjudication committee blinded to treatment allocation' L: <i>For safety outcomes:</i> 'An independent expert adjudication committee blinded to treatment allocation classified and reviewed all bleeding events'	L: Missing data were accounted for and similar across study groups It is unlikely that missing data and reasons are related to the outcomes	L: All outcomes are reported as per protocol
RE-MODEL ¹⁶¹	L: 'Patients were randomly assigned to one of three treatment groups, using a computer-generated central scheme stratified by study centre'	L: 'Patients were randomly assigned to one of three treatment groups, using a computer-generated central scheme stratified by study centre'	U: 'This was a randomized, double-blind, active controlled, noninferiority study conducted at 105 centers in Europe, Australia, and South Africa'	L: <i>For efficacy outcomes:</i> 'Diagnostic tests for VTE events were initially evaluated locally, and subsequently reviewed by an independent central adjudication committee blinded to treatment allocation' U: <i>For safety outcomes:</i> 'An independent expert adjudication committee classified all bleeding events'	L: Missing data almost balanced across intervention groups and clear reasons given as to why data was missing	L: All outcomes are reported as per protocol

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting
RE-NOVATE ¹⁶⁰	L: 'Patients were randomly assigned to one of three treatment groups, stratified by study centre with a central computer generated scheme'	L: 'Patients were randomly assigned to one of three treatment groups, stratified by study centre with a central computer generated scheme'	L: 'All three groups received one active and one placebo medication identical in appearance to the other active treatment'	L: <i>For efficacy outcomes:</i> 'Diagnostic tests for venous thromboembolic events were initially assessed locally, then by an independent central adjudication committee blinded to treatment allocation. The results of the independent committee were used in the primary analysis'. Other outcomes were also reviewed by independent committees, masked to treatment allocation	U: <i>For efficacy outcomes:</i> Data for a substantial number of participants in the three groups – missing! Reasons for the missing data were provided. Proportion of missing data are not the same for the groups L: <i>For safety outcomes:</i> All patients were included in the analyses	L: All outcomes are reported as per protocol
RE-NOVATE II ^{163,189}	L: 'Up to three days before surgery, eligible patients were randomised in accordance with a computer-generated scheme using a central telephone randomisation procedure'	L: 'Up to three days before surgery, eligible patients were randomised in accordance with a computer-generated scheme using a central telephone randomisation procedure'	L: 'Treatment-group assignment was concealed from the investigators and their staff and the clinical monitors'. 'Patients were assigned to either once-daily oral dabigatran 220 mg (2 x 110 mg capsules) or enoxaparin 40 mg subcutaneous injection, together with a placebo of the other study drug (double-dummy design). Active and placebo medications were identical in appearance'	L: <i>For efficacy outcomes:</i> 'Diagnostic tests for thromboembolic events were initially evaluated locally, and subsequently by an independent central adjudication committee who were blinded to treatment allocation' U: <i>For safety outcomes:</i> Not clear. 'Perioperative and post-operative blood loss that was considered normal by the investigator was not recorded as a bleeding event'	L: For symptomatic DVT, symptomatic non-fatal PE and all safety outcomes, no missing outcome data However, missing data for other efficacy outcomes but with reasons Reasons for missing data are balanced in number across intervention groups; unlikely that reasons are related to true outcome	L: All outcomes are reported as per protocol

continued

TABLE 70 Risk-of-bias assessments for 43 included randomised trials in primary prevention of VTE (continued)

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting
STARS E-3 ¹⁸²	U: Abstract; not enough information 'This was a double-blind, double-dummy, centrally randomized trial'	L: 'This was a double-blind, double-dummy, centrally randomized trial'	U: Abstract; not enough information 'This was a double-blind, double-dummy, centrally randomized trial'	U: Abstract; not enough information 'This was a double-blind, double-dummy, centrally randomized trial'	U: Abstract; not enough information 'This was a double-blind, double-dummy, centrally randomized trial'	U: Study protocol not found
STARS J-1 ^{172,180}	L: 'Patients were randomized via an allocation table containing random numbers according to the Excel Visual Basic program using the permuted block method, and a pre-treatment examination was then performed'	U: Not enough information to enable judgement. 'Patients were randomized via an allocation table containing random numbers according to the Excel Visual Basic program using the permuted block method, and a pre-treatment examination was then performed'	U: 'This was a multicenter, randomized, double-blind, placebo controlled, dose-ranging study'	L: 'All venograms were assessed centrally by The Venous Thromboembolic Event Adjudication Committee under blinded conditions'	L: For efficacy outcomes: Some missing outcome data was provided and it is unlikely that missing outcome is related to true outcome L: For safety outcomes: All patients were included in the analyses	L: All outcomes are reported as per protocol
STARS J-2 ¹⁷⁴	U: Abstract information; not enough information to enable judge 'This was a randomized, enoxaparin-controlled, multicenter, parallel group study'	U: Abstract information; not enough information to enable judge 'This was a randomized, enoxaparin-controlled, multicenter, parallel group study'	H: 'Double-blind edoxaban 15 mg or 30 mg od or open-label, subcutaneous enoxaparin 20 mg BID was administered for 11 to 14 days'	U: 'Outcome assessors were blinded to treatment allocation but not for enoxaparin allocation which was open-blinded'	U: Some missing outcome data (substantial proportion) Reasons for missing outcome data not available Unclear if reasons for missing data are related to true outcome	L: All outcomes are reported as per protocol

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting
STARS J-4 ^{1,81,193}	<p>U: Not enough information to enable judgement</p> <p>'Japanese patients were randomized 2:1 to receive an oral dose of edoxaban 30 mg od or the active control, enoxaparin 2000 IU sc every 12 hours (BID), which is the approved dosing regimen in Japan'</p>	<p>U: Not enough information to enable judgement</p> <p>'Japanese patients were randomized 2:1 to receive an oral dose of edoxaban 30 mg od or the active control, enoxaparin 2000 IU sc every 12 hours (BID), which is the approved dosing regimen in Japan'</p>	<p>H: 'This was a multicenter, open-label, active-comparator, Phase 3 trial'</p>	<p>L: 'To ensure objectivity, independent committees assessed bleeding events and thromboembolic events under blinded conditions'</p>	<p>U: <i>For efficacy outcomes:</i> Some missing outcome data, although with reasons; the number of missing data is not balanced between the arms</p> <p>The reasons for missing data may be related to the true outcome</p> <p>L: <i>For safety outcomes:</i> Small number of missing outcome data with reasons; the number of missing data is balanced between the arms</p> <p>Unlikely that the reasons for missing data are related to the true outcome</p>	<p>L: All outcomes are reported as per protocol</p>
STARS J-V ⁷⁹	<p>U: Abstract; not enough information to enable judgement</p> <p>'This was a randomized, double-blind, double-dummy, enoxaparin-controlled, multicentre trial'</p>	<p>U: Abstract; not enough information to enable judgement</p> <p>'This was a randomized, double-blind, double-dummy, enoxaparin-controlled, multicentre trial'</p>	<p>U: Abstract; not enough information to enable judgement</p> <p>'This was a randomized, double-blind, double-dummy, enoxaparin-controlled, multicentre trial'</p>	<p>U: Abstract; not enough information to enable judgement</p> <p>'This was a randomized, double-blind, double-dummy, enoxaparin-controlled, multicentre trial'</p>	<p>U: <i>For efficacy outcomes:</i> Some missing outcome data, although with reasons; not enough information to judge whether or not the number of missing data are balanced between the arms</p> <p>The reasons for missing data may be related to the true outcome</p> <p>L: <i>For safety outcomes:</i> Minimal number of missing outcome data and, although not enough information to judge the balance between the groups, it is unlikely that the reasons for missing data are related to the true outcome</p>	<p>L: All outcomes are reported as per protocol</p>

continued

TABLE 70 Risk-of-bias assessments for 43 included randomised trials in primary prevention of VTE (continued)

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting
TOPIC-1 ¹⁹⁷	L: 'Patients were randomly assigned to placebo or certoparin sodium (Mono Embolex, Novartis GmbH, Nürnberg, Germany) using a computer-generated randomization list'	L: 'Randomization numbers were allocated sequentially as patients were enrolled at each centre. Only the external statistician from the Safety Committee had access to the randomization codes'	U: 'These were randomized, double-blind, adaptive group sequential, placebo controlled trials'	L: <i>For efficacy outcomes:</i> 'Validated by a blinded, independent Central Thrombosis Evaluation Team' L: <i>For safety outcomes:</i> 'Validated by a Data Safety Monitoring Committee consisting of 2 clinicians (blinded to treatment) and an independent statistician with access to the treatment assignments'	L: Only one and two patients were not included in the efficacy and safety analyses, respectively	U: Study protocol not found
TOPIC-2 ¹⁹⁷	L: 'Patients were randomly assigned to placebo or certoparin sodium (Mono Embolex, Novartis GmbH, Nürnberg, Germany) using a computer-generated randomization list'	L: 'Randomization numbers were allocated sequentially as patients were enrolled at each centre. Only the external statistician from the Safety Committee had access to the randomization codes'	U: 'These were randomized, double-blind, adaptive group sequential, placebo controlled trials'	L: <i>For efficacy outcomes:</i> 'Validated by a blinded, independent Central Thrombosis Evaluation Team' L: <i>For safety outcomes:</i> 'Validated by a Data Safety Monitoring Committee consisting of 2 clinicians (blinded to treatment) and an independent statistician with access to the treatment assignments'	L: Some missing outcome data; reasons not given and missing data are not exactly balanced in both arms However, the numbers are quite small and reasons unlikely to be related to the outcome	U: Study protocol not found

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting
VTE-APIX-PLACEBO-USACAN ¹⁹⁰	L: 'Randomization was performed centrally by contacting a computerized telephone voice response system provided by Bristol-Myers Squibb (BMS) (Lawrenceville, NJ, USA). Treatment assignments were implemented with a randomization schedule of size four; blocks were stratified by the presence (or not) of metastatic liver disease and clinical center'	L: 'Randomization was performed centrally by contacting a computerized telephone voice response system provided by Bristol-Myers Squibb (BMS) (Lawrenceville, NJ, USA). Treatment assignments were implemented with a randomization schedule with blocks of size four; blocks were stratified by the presence (or not) of metastatic liver disease and clinical center'	L: 'All subjects took four tablets orally od; these consisted of a combination of apixaban and matching placebo tablets for the apixaban treatment groups, or all placebo tablets for the placebo treatment group, such that the study supplies for subjects in all treatment groups were identical in appearance'	L: Outcome assessors were blinded to treatment allocation	L: Missing data are of the same quantity (minimal) in all groups and reasons unlikely to be related to the true outcome	L: All outcomes are reported as per protocol
VTE-DABIG-LMWH-GREECE ⁸⁷	U: Abstract; not enough information to enable judgement 'The patients were randomly assigned in the first group, that fondaparinux 2.5 mg were used for thromboprophylaxis, in the enoxaparin 40 mg group, in the Tinzaparin 0.45 group and in the forth Dabigatran 110 mg group (75 mg over 75 years old)'	U: Abstract; not enough information to enable judgement 'The patients were randomly assigned in the first group, that fondaparinux 2.5 mg were used for thromboprophylaxis, in the enoxaparin 40 mg group, in the Tinzaparin 0.45 group and in the forth Dabigatran 110 mg group (75 mg over 75 years old)'	U: Abstract; there is no information on blinding of participants and personnel	U: Abstract; there is no information on blinding of outcome assessment	U: Abstract; there is no information on the number of participants included in the analyses, for comparison with the number randomised to treatments	U: Study protocol not found

continued

TABLE 70 Risk-of-bias assessments for 43 included randomised trials in primary prevention of VTE (continued)

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting
VTE-DABIG-PLAC-JAPAN ¹⁷⁵	L: 'Patients were randomly assigned to 1 of 4 treatment groups using a computer-generated scheme stratified by study center'	U: Not enough information to enable judgement 'Randomization was performed in blocks of 4'	U: 'This was a double-blind, multicenter, randomized, parallel-group, placebo-controlled study conducted at 38 centers in Japan'	L: <i>For efficacy outcomes:</i> 'Diagnostic tests for VTE were evaluated centrally by an independent adjudication committee blinded to treatment allocation' U: <i>For safety outcomes:</i> 'Two medical experts reviewed all cases of bleeding'	L: There were missing data but missing data appear to balance in numbers across intervention groups, with similar reasons for missing data across groups	L: All outcomes are reported as per protocol
VTE-EDOX-LMWH-MULTI ¹⁷⁷	L: 'The study was a multicentre study that used a randomized, parallel- group, multi-dose, active-controlled, double-blind, and double-dummy design'	L: 'randomly allocated, using an interactive voice recognition system'	L: 'Eligible patients who provided written informed consent were randomly allocated, using an interactive voice recognition system to receive either oral edoxaban and subcutaneous injections of placebo, or subcutaneous dalteparin and oral placebo'	L: 'All venograms were interpreted by a central independent adjudication committee blinded to treatment allocation and were categorised as proximal DVT (with or without associated distal thrombosis), distal DVT only, normal, or non-evaluable. All episodes of suspected bleeding, suspected symptomatic DVT or PE, and all deaths were reviewed by a blinded central independent clinical events committee and classified according to the definitions provided'	U: <i>For efficacy outcomes:</i> Some missing outcome data and reasons for missing data are provided but missing outcome data do not balance in numbers across intervention groups Not clear whether or not reason for missing data are unrelated to true outcome L: <i>For safety outcomes:</i> Very few missing outcome data; reasons for missing outcome data are provided and it is likely that reasons are unrelated to true outcome	L: All outcomes are reported as per protocol

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting
VTE-LMWH-PLAC-CAN ¹⁶⁹	L: 'A statistician and pharmacist at the co-ordinating centre randomised a total of 305 patients via computer generation in a ratio of 1:1 to receive either LMWH or a placebo for 14 days'	U: 'A statistician and pharmacist at the co-ordinating centre randomised a total of 305 patients via computer generation in a ratio of 1:1 to receive either LMWH or a placebo for 14 days'	U: 'Owing to the double-blind nature of the study, all patients received a general anaesthetic for surgical fixation to avoid any potential adverse reaction to spinal anaesthesia in those patients receiving Fragmin'	L: <i>For efficacy outcomes:</i> 'Three senior interventional radiologists reviewed the venograms, with any difference of opinion resolved by consensus. All the radiologists were blinded to the study group' U: <i>For safety outcomes:</i> Not enough information to enable judgement 'All adverse events were monitored and recorded with clinical examination and regular haematological, biochemical and urinary investigations during the routine management of the patients while in hospital'	L: The number randomised is not the number analysed However, participants removed from the analyses are those who did not meet baseline venography eligibility after randomisation even though they met the study inclusion criteria prior to randomisation All finally included participants were accounted for in the analysis	U: Study protocol not found

continued

TABLE 70 Risk-of-bias assessments for 43 included randomised trials in primary prevention of VTE (continued)

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting
VTE-LMWH-PLAC-JAPAN ¹⁸⁶	<p>U: Not enough information to enable judgement</p> <p>'A randomised controlled trial was performed to evaluate whether the incidence of postoperative VTE was reduced by using pharmacological anticoagulation with either fondaparinux or enoxaparin in addition to our prophylactic mechanical regimen'</p>	<p>U: Not enough information to enable judgement</p> <p>'The 255 patients were randomly assigned into three Groups'</p>	<p>U: Not enough information to enable judgement</p> <p>'The 255 patients were randomly assigned into three groups (each of 85) to receive postoperative subcutaneous injections of fondaparinux (Arixtra; GlaxoSmithKline, London, United Kingdom: 2.5 mg od), enoxaparin (Clexane; Sanofi-Aventis, Paris, France: 40 mg, 20 mg twice daily) or placebo (0.5 ml of isotonic saline) for ten consecutive days'</p>	<p>L: All of the scans were performed by experienced vascular technicians and were read by experienced radiologists who were blinded to the patient's randomisation</p>	<p>L: For efficacy outcomes: Very few missing data, < 1%, missing data unlikely to be related to the outcome</p> <p>L: For safety outcomes: All patients were included in the analyses</p>	<p>U: Study protocol not found</p>
VTE-RIVAROX-LMWH-BRAZIL ¹⁶⁴	<p>U: Not enough information to enable judgement</p> <p>'From September 2006 to April 2007, at the Orthopedics and Traumatology Clinic of the Hospital Complex of the Santa Casa of Porto Alegre, State of Rio Grande do Sul, a randomized, double-blind clinical trial was carried out'</p>	<p>U: Not enough information to enable judgement</p> <p>'From September 2006 to April 2007, at the Orthopedics and Traumatology Clinic of the Hospital Complex of the Santa Casa of Porto Alegre, State of Rio Grande do Sul, a randomized, double-blind clinical trial was carried out'</p>	<p>L: One of the groups was given subcutaneous 40 mg enoxaparin 6 hours to 8 hours before surgery, and after surgery a placebo pill was added, for once a day oral intake, during the first 32 to 36 days</p> <p>The other group was given oral 10 mg rivaroxaban, once a day, during the first 32–36 post-op days</p>	<p>U: There is no specific information on blinding of outcome assessors</p> <p>This may have been done but not stated</p>	<p>L: All patients were included in the analyses</p>	<p>U: Study protocol not found</p>

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting
VTE-RIVAROX- LMWH-CHINA ¹⁹²	U: 'The patients were randomly divided into rivaroxaban group and low-molecular-weight heparin group'	H: No information and no indication of concealment of treatment allocation	In order to have the double-blind feature of the study, a subcutaneous placebo injection was given 6–8 hours before surgery and on the 32–36 days following surgery U: Not enough information 'The patients in two groups were given drugs at 6 hours after replacement, the patients in the rivaroxaban group were given rivaroxaban 10 mg/d with the course of 5 weeks; the patients in the LMWH group were given LMWH 4 100 U/d with the course of 2 weeks'	H: No information and no indication of blinding of outcome assessors	L: All patients were included in the analyses	U: Study protocol not found
VTE-VKA- LMWH- CANADA ¹⁵²	L: 'The 670 eligible and consenting patients were randomly allocated after surgery to receive either warfarin sodium (334 patients) or enoxaparin (336 patients) in a 1:1 ratio in blocks of four. A computer generated the randomization schedule'	U: Not enough information to enable judgement. 'We stratified randomization by study center, history of VTE, and use of a cemented or uncemented prosthesis'	L: 'Patients in the warfarin group also received subcutaneous saline placebo every 12 hours. Patients in the enoxaparin group received 30 mg of enoxaparin subcutaneously every 12 hours and warfarin placebo od'	L: 'All diagnostic tests and bleeding episodes were adjudicated by a central committee that was unaware of treatment allocation or clinical findings'	L: Missing outcome data with reasons which are balance between the treatment arms Unlikely to be related to the true outcome	U: Study protocol not found

continued

TABLE 70 Risk-of-bias assessments for 43 included randomised trials in primary prevention of VTE (continued)

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting
VTE-VKA-LMWH-US ¹⁵³	<p>U: Not enough information to enable judgement</p> <p>'The effectiveness and safety of warfarin were compared with those of a low-molecular-weight heparin (dalteparin) for the prevention of DVT after total hip arthroplasty in a prospective, randomized, multi-institutional trial'</p>	<p>U: Not enough information to enable judgement</p> <p>'The patients were randomly assigned to receive prophylaxis with either warfarin or LMWH'</p>	<p>H: The study used an open-label design</p>	<p>L: For efficacy outcomes: 'All venograms were evaluated by a radiologist who had no knowledge of the treatment-group assignment'</p> <p>U: For safety outcomes: No information is reported about who assessed major bleeding and if the assessor was blinded</p>	<p>L: 'Thirty patients (seventeen who were randomized to treatment with dalteparin and thirteen who were randomized to treatment with warfarin) were excluded from the intent-to-treat population because they had never received the drug (twenty-seven patients) or they had received the drug but the operation had been cancelled (three patients). All patients in the intent-to-treat population were included in the per-protocol analysis if they had at least one evaluable venogram'</p>	<p>U: Study protocol not found</p>
VTE-VKA-LMWH-US-2 ¹⁵⁴	<p>U: 'The study was a randomized, open-label, parallel group clinical trial conducted in 156 centres and divided into two phases'</p>	<p>U: Not enough information to enable judgement</p> <p>'The study was a randomized, open-label, parallel group clinical trial conducted in 156 centres and divided into two phases'</p>	<p>H: The study was a randomized, open-label, parallel group clinical trial conducted in 156 centres and divided into two phases</p>	<p>U: Not enough information to enable judgement. 'Each patient was examined for clinical signs and symptoms of DVT (pain, inflammation, swelling, and redness of the lower extremity) and PE (chest pain and difficulty breathing)'</p>	<p>L: 'As already stated, the results and conclusions are based on the intent-to-treat analysis, including all patients who received at least one dose of a study medication'</p>	<p>U: Study protocol not found</p>

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting
VTE-VKA-LMWH-US-3 ¹⁵⁵	L: 'We used a randomized, computer-derived treatment schedule to assign treatment regimens. To obtain continuing balance of treatments, the randomization list was divided into consecutive blocks'	U: Not enough information to enable judgement. Allocation sequence was generated by computer but not clear if allocation was done centrally	L: 'Patients randomized to receive warfarin also received subcutaneous placebo injections. Patients randomized to receive dalteparin also received placebo capsules (warfarin and its placebo were encapsulated to maintain blinding)'	L: 'Venograms were interpreted by the local radiologist and an independent, blinded central reader. Disagreements between the local radiologist and the central reader were resolved by a second blinded independent central interpretation; this second reading was decisive' 'Thus the use of placebo capsules and injections and the assignment of an independent anticoagulant monitor to adjust INR values maintained double blinding throughout the study'	L: 'Twenty nine patients were randomized but did not receive study medication; this occurred because of traumatic spinal tap (1,3, and 3 patients per group respectively), cancelled operation (0,2 and 1 patients), presence of exclusion criteria (1, 1, and 1 patient), withdrawn consent (2, 1, and 3 patients), or miscellaneous reasons making the patient ineligible (4,2, and 4 patients)'	U: Study protocol not found
VTE-VKA-LMWH-US-4 ¹⁵⁶	U: 'Randomization numbers generated by the study sponsor were affixed to the exterior of each kit; randomization was performed by the investigator allocating the kits in ascending order'	L: 'Each center was provided with sealed medication kits containing either syringes filled with enoxaparin or warfarin tablets' 'Randomization numbers generated by the study sponsor were affixed to the exterior of each kit; randomization was performed by the investigator allocating the kits in ascending order'	H: 'We report the results of a prospective, randomized, multicenter, open-label, inpatient, parallel-group study'	L: 'In addition to the assessment by the investigator, a blinded, independent review of all venograms and ultrasonograms was carried out by a panel of vascular imaging specialists'	L: All patients were included in the analyses	U: Study protocol not found

H, high risk; L, low risk; U, unclear risk.
Quotations are denoted by inverted commas.

TABLE 71 List of distinct interventions examined by included randomised trials of primary prevention of VTE

1	LMWH	Post-op (standard dose)
2		Pre-op (standard dose)
3		Standard dose
4		Noxaparin 20 mg bd
5		(100 IU od)
6		(ardeparin 3800 IU anti-Xa od
7	Warfarin	(INR 2–3)
8		Variable
9	Placebo	
10	Apixaban	2.5 mg bd
11		5 mg od
12		5 mg bd
13		10 mg od
14		10 mg bd
15		20 mg od
16	Betrixaban	15 mg bd
17		40 mg bd
18	Dabigatran	110 mg od
19		150 mg od
20		220 mg od
21	Edoxaban	5 mg od
22		15 mg od
23		30 mg od
24		60 mg od
25		90 mg od
26	Rivaroxaban	2.5 mg bd
27		5 mg od
28		5 mg bd
29		10 mg od
30		10 mg bd
31		20 mg od
32		30 mg od
33		20 mg bd
34		40 mg od
35		30 mg bd

TABLE 72 Efficacy outcomes reported by 38 included randomised trials in primary prevention of VTE: number of events for each outcome in each trial

Study	Study size	DVT	Symp. DVT	Non-symp. DVT	Proximal DVT	Distal DVT	Symp. proximal DVT	Symp. distal DVT	PE	Symp. PE	Fatal PE	Symp. non-fatal PE	VTE	Symp. VTE	Major VTE
ADOPT ¹⁸⁸	6401		21		110		17	5				15			130
ADVANCE-1 ¹⁷¹	3184	181	10		20					23	4				
ADVANCE-2 ¹⁷⁸	3009	385			10		35			4	1				39
ADVANCE-3 ¹⁷⁶	4394	90	6		27					8	1	7			35
APROPOS ¹⁶²	856		5				13			4	1		100		
EXPERT ¹⁶⁸	215		2	24			1	1		2			28	4	
LIFENOX ¹⁸⁵	8307														
MAGELLAN ^{184,191}	7998		28									24			160
ODiXa-HIP2 ¹⁵⁹	548	81			14					0					14
ODiXa-KNEE ¹⁵⁷	613	121	4		12	109				2					14
ODiXa-OD.HIP ¹⁵⁸	618	82			18	64		1		0					18
PROTECHT ¹⁷⁰	1150		16							6				22	
RE-MOBILISE ¹⁶⁷	1896		26		44	513				15		11	569		56
RE-MODEL ¹⁶¹	2076		12							2			587		
RE-NOVATE ¹⁶⁰	3463		16							9	1				
RE-NOVATE II ^{183,189}	2013	127	4		48	78						3		7	51
RECORD 1 ¹⁶⁵	4433	65			32	33						5		22	37
RECORD 2 ¹⁶⁶	2457	85									1	5		21	55
RECORD 3 ¹⁶³	1833	239			29	210						4		40	33
RECORD 4 ¹⁷³	3034	147	16	131						13	1	12		35	35

continued

TABLE 72 Efficacy outcomes reported by 38 included randomised trials in primary prevention of VTE: number of events for each outcome in each trial (continued)

Study	Study size	DVT	DVT	Symp. DVT	Non-symp. DVT	Proximal DVT	Distal DVT	Symp. proximal DVT	Symp. distal DVT	PE	Symp. PE	Fatal PE	Symp. non-fatal PE	VTE	Symp. VTE	Major VTE
STARS E-3 ¹⁸²	706	63									0			63		
STARS J-1 ^{172,180}	520	111	1			6	110				0			112		
STARS J-2 ¹⁷⁴	261						8							8		
STARS J-4 ^{181,193}	88	0	0	4	4						0			4		0
STARS J-V ¹⁷⁹	604	0	0	23	23						0			23		
VTE-APIX-PLACEBO-USACAN ¹⁹⁰	122												3			
VTE-DABIG-LMWH-GREECE ¹⁸⁷	120	0								0				0		
VTE-DABIG-PLAC-JAPAN ¹⁷⁵	512	156	6		10						0					10
VTE-EDOX-LMWH-MULTI ¹⁷⁷	896				40									183		41
VTE-LMWH-PLAC-CAN ¹⁶⁹	237				25											
VTE-LMWH-PLAC-JAPAN ¹⁸⁶	170	11	0		0		11				0			11	0	
VTE-RIVAROX-LMWH-BRAZIL ¹⁶⁴	65	5									0					
VTE-RIVAROX-LMWH-CHINA ¹⁹²	106	7														
VTE-VKA-LMWH-CANADA ¹⁵²	670	185			46						4				4	
VTE-VKA-LMWH-US ¹⁵³	550	77			26		64									
VTE-VKA-LMWH-US-2 ¹⁵⁴	3011		96								27	1			111	
VTE-VKA-LMWH-US-3 ¹⁵⁵	1472	161	30		17						0					
VTE-VKA-LMWH-US-4 ¹⁵⁶	349	123			23		100				1					124

Symp., symptomatic.

TABLE 73 Safety outcomes reported by 38 included randomised trials in primary prevention of VTE: number of events for each outcome in each trial

Study	Study size	MI	TCP	All bleeds	Minor bleeds	Major bleeds	Fatal bleeds	IC bleeds	Bleeds from surgical site	CRNIM bleeding	CRB	CV death	All-cause mortality
ADOPT ¹⁸⁸	6401			465		21		2			152		
ADVANCE-1 ¹⁷¹	3184	5	2	193	79	33	1	1		82	115		9
ADVANCE-2 ¹⁷⁸	3009	2	1	230	105	23		0	95	102	125		2
ADVANCE-3 ¹⁷⁶	4394	8	5	647	384	40		0	201	229	269		4
APROPOS ¹⁶²	856	4		78	57	18	0						1
EXPERT ¹⁶⁸	215			5		1				4	5		
LIFENOX ¹⁸⁵	8307			151	120	27				32	59	425	703
MAGELLAN ^{184,191}	7998					58	8	2			231		312
ODIXa-HIP ¹⁵⁹	548				42	17		0	15	20	37		
ODIXa-KNEE ¹⁵⁷	613				43	16		0		21	37		0
ODIXa-OD.HIP ¹⁵⁸	618				44	27		0		18	45		0
PROTECHT ¹⁷⁰	1150			92	87	5		1					49
RE-MOBILISE ¹⁶⁷	1896			88		22							7
RE-MODEL ¹⁶¹	2076			341	188	28				125	153		3
RE-NOVATE ¹⁶⁰	3463			415	216	56				143	199		
RE-NOVATE II ^{183,189}	2013	2		181	115	23				43	66		1
RECORD 1 ¹⁶⁵	4433	22		264	148	8				119	127	5	9
RECORD 2 ¹⁶⁶	2457	7		149		2	0				72		10
RECORD 3 ¹⁶³	1833	3		120		13	0			61	74	1	6
RECORD 4 ¹⁷³	3034	10				14	1	2		69	83	8	12
STARS E-3 ¹⁸²	706					5		0			35		
STARS J-1 ^{172,180}	520			53		1				18	19		

continued

TABLE 73 Safety outcomes reported by 38 included randomised trials in primary prevention of VTE: number of events for each outcome in each trial (*continued*)

Study	Study size	MI	TCP	All bleeds	Minor bleeds	Major bleeds	Fatal bleeds	IC bleeds	Bleeds from surgical site	CRNM bleeding	CRB	CV death	All-cause mortality
STARS J-2 ¹⁷⁴	261										5		
STARS J-4 ^{181,193}	88			20	16	2		0		2	4		0
STARS J-V ¹⁷⁹	604					8					19		
VTE-APIX-PLACEBO-USACAN ¹⁹⁰	122					3				4	7		
VTE-DABIG-LMWH-GREECE ¹⁸⁷	120			0									
VTE-DABIG-PLAC-JAPAN ¹⁷⁵	512			50	39	5	0		3	6	11		0
VTE-EDOX-LMWH-MULTI ¹⁷⁷	896			24		5				10	14		4
VTE-LMWH-PLAC-CAN ¹⁶⁹	237		0	0	0	0							0
VTE-LMWH-PLAC-JAPAN ¹⁸⁶	170			8	8	0							
VTE-RIVAROX-LMWH-BRAZIL ¹⁶⁴	65												
VTE-RIVAROX-LMWH-CHINA ¹⁹²	106												
VTE-VKA-LMWH-CANADA ¹⁵²	670		2	190	177	13							2
VTE-VKA-LMWH-US ¹⁵³	550					10							
VTE-VKA-LMWH-US-2 ¹⁵⁴	3011		0	262	249	26		0	19				19
VTE-VKA-LMWH-US-3 ¹⁵⁵	1472				60	98							4
VTE-VKA-LMWH-US-4 ¹⁵⁶	349			99	86	13							4

CV, cardiovascular; IC, intracranial; TCP, thrombocytopenia.

seven outcomes: symptomatic VTE, symptomatic DVT, symptomatic PE, MI, major bleeding, CRB and all-cause mortality. For the first three outcomes, hip surgery, knee surgery and non-surgical patients were analysed separately, whereas for each of the four remaining outcomes all patients were combined in a single network.

Results are presented as follows for each of the seven outcomes. First, we provide network plots to illustrate the comparisons of interventions made in the different trials. Second, we illustrate the risk-of-bias assessments that were specific to the outcome for each trial included in the network. Third, we present results tables for each intervention compared with the reference treatment (standard dose of LMWH administered before surgery for hip surgery patients, after surgery for knee surgery patients, or at start of treatment for other patients). Fourth, we present results tables for pairwise comparisons among licensed doses of the NOACs. For both sets of results tables, posterior median ORs and 95% credible intervals from Bayesian fixed-effects analyses are shown, although we refer to the latter as CIs for convenience. In these tables we present results separately for any available direct evidence, for any indirect comparisons that can be made (excluding the direct evidence) and for the NMA (which combines the direct and the indirect evidence). Comparisons from the NMA with a ratio between interval limits exceeding nine were considered 'imprecisely estimated' and are presented at the bottom of each table (note that calculation of indirect evidence was not undertaken for imprecisely estimated comparisons). A summary of results across outcomes is provided at the end in the form of a 'rankogram', which illustrates the probability that each treatment is best, second best, and so on, for each outcome. Last, forest plots of all contributing data, with ORs calculated using standard frequentist methods, are included in *Appendix 3*.

Symptomatic venous thromboembolism

Of 28 studies that contributed data to analyses of symptomatic VTE, 11 reported direct data on symptomatic VTE events (see *Table 72*). *Table 74* shows risk-of-bias judgements for these studies. They were generally judged to be at low risk of bias, although with some concerns about allocation concealment and blinding of participants and personnel.

Nine studies of hip surgery patients reported 231 symptomatic VTE events, leading to a network of 13 interventions (*Figure 33*). This network was disconnected so that two interventions could not be included in the analysis. Most comparisons were imprecisely estimated, but there was evidence that risk of symptomatic VTE is lower with rivaroxaban (10 mg od) than LMWH (pre-op, standard dose) but higher with LMWH (post-op, standard dose) and warfarin (INR 2–3) than LMWH (pre-op, standard dose) (*Table 75*). Indirect evidence about warfarin (INR 2–3) versus LMWH (pre-op, standard dose) pointed in the opposite direction to the direct evidence, but was extremely imprecisely estimated.

Comparisons between licensed doses of NOACs were imprecisely estimated (*Table 76*). In addition, there was some heterogeneity in the direction of effects among studies of dabigatran (150 mg od) compared with post-op LMWH (standard dose) and of dabigatran (220 mg od) compared with post-op LMWH (standard dose) (see *Appendix 3*).

Ten trials including knee surgery patients reported 186 symptomatic VTE events, leading to a network of 21 interventions (*Figure 34*). There was little evidence that risk of symptomatic VTE differed between apixaban (2.5 mg bd), dabigatran (220 mg od) or rivaroxaban (10 mg od) compared with LMWH (post-op, standard dose) (*Table 77*). Comparisons between licensed doses of NOACs were imprecisely estimated (*Table 78*).

TABLE 74 Included trials and risk-of-bias assessment for symptomatic VTE (primary prevention of VTE)

Study	Interventions compared	SG	AC	BPP	BOA	IOD	SR
ADOPT ¹⁸⁸	3, 10	+	+	+	+	+	+
ADVANCE-1 ¹⁷¹	1, 10	?	?	+	+	+	+
ADVANCE-3 ¹⁷⁶	2, 10	+	+	+	+	+	+
APROPOS ¹⁶²	1, 7, 10, 11, 12, 13, 14, 15	+	?	?	+	+	+
EXPERT ¹⁶⁸	1, 16, 17	+	?	-	+	?	+
MAGELLAN ^{184,191}	3, 29	+	+	+	+	+	+
ODiXa-KNEE ¹⁵⁷	1, 26, 28, 30, 33, 35	+	+	+	+	?	+
ODiXa-OD.HIP ¹⁵⁸	2, 27, 29, 31, 32, 34	?	?	+	+	?	?
PROTECHT ¹⁷⁰	6, 9	+	+	+	+	+	+
RECORD 1 ¹⁶⁵	2, 29	+	+	?	+	+	+
RECORD 2 ¹⁶⁶	2, 29	+	+	?	+	?	+
RECORD 3 ¹⁶³	2, 29	?	+	?	+	?	+
RECORD 4 ¹⁷³	1, 29	+	+	?	+	+	+
RE-MOBILISE ¹⁶⁷	1, 19, 20	+	+	+	+	+	+
RE-MODEL ¹⁶¹	2, 19, 20	+	+	?	+	+	+
RE-NOVATE ¹⁶⁰	2, 19, 20	+	+	+	+	?	+
RE-NOVATE II ^{183,189}	2, 20	+	+	+	+	+	+
VTE-APIX-PLACEBO-USACAN ¹⁹⁰	9, 11, 13, 15	+	+	+	+	+	+
VTE-DABIG-PLAC-JAPAN ¹⁷⁵	9, 18, 19, 20	+	?	?	+	+	+
VTE-LMWH-PLAC-JAPAN ¹⁸⁶	1, 4, 9	?	?	?	+	+	?
VTE-VKA-LMWH-CANADA ¹⁵²	1, 7	+	?	+	+	+	?
VTE-VKA-LMWH-US-2 ¹⁵⁴	1, 7	?	?	-	?	+	?
VTE-VKA-LMWH-US-3 ¹⁵³	1, 2, 7	+	?	+	+	+	?

-, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation; SR, selective reporting.




FIGURE 33 Network plot for symptomatic VTE in hip surgery patients (primary prevention of VTE).

TABLE 75 Results for symptomatic VTE in hip surgery patients (primary prevention of VTE): comparisons with LMWH

Comparisons with LMWH (pre-op, standard dose)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
LMWH post-op (standard dose)	2.16 (0.73 to 7.03)	6.49 (0.50 to 83.8)	2.59 (1.03 to 8.36)
Warfarin (INR 2–3)	3.33 (1.21 to 10.4)	0.29 (0 to 19.5)	2.87 (1.14 to 9.25)
Dabigatran (150 mg od)	1.46 (0.57 to 3.75)	–	1.46 (0.57 to 3.75)
Dabigatran (220 mg od)	1.20 (0.51 to 2.86)	–	1.20 (0.51 to 2.86)
Rivaroxaban (10 mg od)	0.33 (0.16 to 0.64)	–	0.33 (0.16 to 0.64)
<i>Imprecisely estimated comparisons</i>			
Apixaban (2.5 mg bd)	0.38 (0.10 to 1.16)	–	0.38 (0.10 to 1.16)
Rivaroxaban (5 mg od)	0.22 (0 to 4.76)	–	0.22 (0 to 4.76)
Rivaroxaban (20 mg od)	0.19 (0 to 4.01)	–	0.19 (0 to 4.01)
Rivaroxaban (30 mg od)	0.19 (0 to 4.19)	–	0.19 (0 to 4.19)
Rivaroxaban (40 mg od)	0.21 (0 to 4.62)	–	0.21 (0 to 4.62)

TABLE 76 Results for symptomatic VTE in hip surgery patients (primary prevention of VTE): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Rivaroxaban (10 mg od) vs. dabigatran (220 mg od)	–	0.28 (0.09 to 0.81)	0.28 (0.09 to 0.81)
<i>Imprecisely estimated comparisons</i>			
Dabigatran (220 mg od) vs. apixaban (2.5 mg bd)	–	3.21 (0.77 to 15.5)	3.21 (0.77 to 15.5)
Rivaroxaban (10 mg od) vs. apixaban (2.5 mg bd)	–	0.89 (0.23 to 3.90)	0.89 (0.23 to 3.90)


**FIGURE 34** Network plot for symptomatic VTE in knee surgery patients (primary prevention of VTE).

TABLE 77 Results for symptomatic VTE in knee surgery patients (primary prevention of VTE): comparisons with LMWH

Comparisons with LMWH (post-op, standard dose)	Direct evidence	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
LMWH pre-op (standard dose)	–	1.96 (0.91 to 4.27)	1.96 (0.91 to 4.27)
Apixaban (2.5 mg bd)	1.24 (0.64 to 2.43)	–	1.24 (0.64 to 2.43)
Dabigatran (150 mg od)	0.82 (0.40 to 1.67)	–	0.82 (0.40 to 1.67)
Dabigatran (220 mg od)	0.92 (0.45 to 1.86)	–	0.92 (0.45 to 1.86)
Rivaroxaban (10 mg od)	0.80 (0.43 to 1.46)	–	0.80 (0.43 to 1.46)
<i>Imprecisely estimated comparisons</i>			
<i>Warfarin (INR 2–3)</i>	<i>0.25 (0.01 to 2.34)</i>	–	<i>0.25 (0.01 to 2.34)</i>
<i>Placebo</i>	–	<i>1.14 (0.12 to 8.36)</i>	<i>1.14 (0.12 to 8.36)</i>
<i>Apixaban (5 mg od)</i>	<i>0.12 (0 to 1.84)</i>	–	<i>0.12 (0 to 1.84)</i>
<i>Apixaban (5 mg bd)</i>	<i>0.11 (0 to 1.66)</i>	–	<i>0.11 (0 to 1.66)</i>
<i>Apixaban (10 mg od)</i>	<i>1.11 (0.17 to 5.41)</i>	–	<i>1.11 (0.17 to 5.41)</i>
<i>Apixaban (10 mg bd)</i>	<i>0.57 (0.05 to 3.43)</i>	–	<i>0.57 (0.05 to 3.43)</i>
<i>Apixaban (20 mg od)</i>	<i>0.57 (0.04 to 3.45)</i>	–	<i>0.57 (0.04 to 3.45)</i>
<i>Betrixaban (15 mg bd)</i>	<i>1.34 (0.10 to 44.6)</i>	–	<i>1.34 (0.10 to 44.6)</i>
<i>Betrixaban (40 mg bd)</i>	<i>0.59 (0.01 to 22.8)</i>	–	<i>0.59 (0.01 to 22.8)</i>
<i>Dabigatran (110 mg od)</i>	–	<i>0.43 (0.01 to 4.41)</i>	<i>0.43 (0.01 to 4.41)</i>
<i>Rivaroxaban (2.5 mg bd)</i>	<i>0.59 (0.04 to 5.21)</i>	–	<i>0.59 (0.04 to 5.21)</i>
<i>Rivaroxaban (5 mg bd)</i>	<i>1.24 (0.17 to 9.07)</i>	–	<i>1.24 (0.17 to 9.07)</i>
<i>Rivaroxaban (10 mg bd)</i>	<i>0.12 (0 to 2.36)</i>	–	<i>0.12 (0 to 2.36)</i>
<i>Rivaroxaban (20 mg bd)</i>	<i>0.66 (0.05 to 5.93)</i>	–	<i>0.66 (0.05 to 5.93)</i>
<i>Rivaroxaban (30 mg bd)</i>	<i>0.12 (0 to 2.3)</i>	–	<i>0.12 (0 to 2.33)</i>

TABLE 78 Results for symptomatic VTE in knee surgery patients (primary prevention of VTE): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Dabigatran (220 mg od) vs. apixaban (2.5 mg bd)	–	0.74 (0.28 to 1.95)	0.74 (0.28 to 1.95)
Rivaroxaban (10 mg od) vs. apixaban (2.5 mg bd)	–	0.64 (0.26 to 1.56)	0.64 (0.26 to 1.56)
Rivaroxaban (10 mg od) vs. dabigatran (220 mg od)	–	0.87 (0.37 to 2.01)	0.87 (0.37 to 2.01)

Four trials in non-surgical patients reported 45 symptomatic VTE events, leading to a network of eight interventions (*Figure 35*). Because the network was disconnected we excluded two Phase II trials (PROTECHT¹⁷⁰ and VTE-APIX-PLACEBO-USACAN¹⁹⁰) so that analyses were of the connected network. This enabled us to compare two licensed doses of NOACs. There was weak evidence that risk of symptomatic VTE is lower with apixaban (2.5 mg bd) than LMWH (standard dose) (*Table 79*), and also when compared with rivaroxaban (10 mg od) (*Table 80*), although these comparisons were imprecisely estimated.




FIGURE 35 Network plot for symptomatic VTE in medical patients (primary prevention of VTE).

TABLE 79 Results for symptomatic VTE in medical patients (primary prevention of VTE): comparisons with LMWH

Comparisons with LMWH (standard dose)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Apixaban (2.5 mg bd)	0.50 (0.24 to 0.97)	–	0.50 (0.24 to 0.97)
Rivaroxaban (10 mg od)	1.53 (0.73 to 3.28)	–	1.53 (0.73 to 3.28)

TABLE 80 Results for symptomatic VTE in medical patients (primary prevention of VTE): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Rivaroxaban (10 mg od) vs. apixaban (2.5 mg bd)	–	3.09 (1.13 to 8.87)	3.09 (1.13 to 8.87)

Symptomatic deep-vein thrombosis

Twenty studies contributed data to analyses of symptomatic DVT. *Table 81* shows risk-of-bias judgements for these studies. Most were judged to be at low risk of bias, although with a few concerns about blinding of participants and personnel.

Eight studies of hip surgery patients provided data on 157 symptomatic DVT events, leading to a network of nine interventions (*Figure 36*). Because the resulting network was disconnected, we excluded several interventions from the analysis. All comparisons were imprecisely estimated (*Tables 82 and 83*), but there was evidence that risk of symptomatic DVT is higher for that LMWH (post-op, standard dose) and warfarin (INR 2–3) than LMWH (pre-op, standard dose).

Nine studies of knee surgery patients reported 81 symptomatic DVT events, leading to a network of 24 interventions (*Figure 37*). All comparisons were imprecisely estimated (*Tables 84 and 85*). Indirect evidence about warfarin (INR 2–3) compared with LMWH (pre-op, standard dose) pointed in the opposite direction to the direct evidence, but was very imprecisely estimated.

Three studies of medical patients provided data on 65 symptomatic DVT events, leading to a network of five interventions. Because the resulting network was disconnected (*Figure 38*), we excluded the PROTECT trial,¹⁷⁰ which allowed us to make an indirect comparison between two licensed NOAC doses. All comparisons were imprecisely estimated, although there was evidence that risk of symptomatic DVT is lower for apixaban (2.5 mg bd) than LMWH (standard dose) (*Table 86*). The comparison between apixaban (2.5 mg bd) and rivaroxaban (10 mg od) was imprecisely estimated (*Table 87*).

TABLE 81 Included trials and risk-of-bias assessment for symptomatic DVT (primary prevention of VTE)

Study	Interventions compared	SG	AC	BPP	BOA	IOD	SR
ADOPT ¹⁸⁸	3, 10	+	+	+	+	+	+
ADVANCE-1 ¹⁷¹	1, 10	?	?	+	+	+	+
ADVANCE-3 ¹⁷⁶	2, 10	+	+	+	+	+	+
APROPOS ¹⁶²	1, 7, 10, 11, 12, 13, 14, 15	+	?	?	+	+	+
EXPERT ¹⁶⁸	1, 16, 17	+	?	-	+	?	+
MAGELLAN ^{184,191}	3, 29	+	+	+	+	+	+
ODiXa-KNEE ¹⁵⁷	1, 26, 28, 30, 33, 35	+	+	+	+	?	+
PROTECHT ¹⁷⁰	6, 9	+	+	+	+	+	+
RECORD 4 ¹⁷³	1, 29	+	+	?	+	+	+
RE-MOBILISE ¹⁶⁷	1, 19, 20	+	+	+	+	+	+
RE-MODEL ¹⁶¹	2, 19, 20	+	+	?	+	+	+
RE-NOVATE ¹⁶⁰	2, 19, 20	+	+	+	+	?	+
RE-NOVATE II ^{183,189}	2, 20	+	+	+	+	+	+
STARS J-1 ^{172,180}	9, 21, 22, 23, 24	+	?	?	+	+	+
STARS J-4 ^{181,193}	4, 23	?	?	-	+	?	+
STARS J-V ¹⁷⁹	4, 23	?	?	?	?	?	+
VTE-DABIG-PLAC-JAPAN ¹⁷⁵	9, 18, 19, 20	+	?	?	+	+	+
VTE-LMWH-PLAC-JAPAN ¹⁸⁶	1, 4, 9	?	?	?	+	+	?
VTE-VKA-LMWH-US-2 ¹⁵⁴	1, 7	?	?	-	?	+	?
VTE-VKA-LMWH-US-3 ¹⁵³	1, 2, 7	+	?	+	+	+	?

-, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation; SR, selective reporting.





FIGURE 36 Network plot for symptomatic DVT in hip surgery patients (primary prevention of VTE).

TABLE 82 Results for symptomatic DVT in hip surgery patients (primary prevention of VTE): comparisons with LMWH

Comparisons with LMWH (pre-op, standard dose)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
LMWH post-op (standard dose)	2.14 (0.72 to 7.34)	4.95 (0.57 to 42.8)	2.58 (1.03 to 7.94)
Warfarin (INR 2–3)	3.31 (1.21 to 10.8)	0.84 (0.05 to 13.1)	2.74 (1.10 to 8.39)
Imprecisely estimated comparisons			
Apixaban (2.5 mg bd)	0.15 (0.01 to 1.09)	–	0.15 (0.01 to 1.09)
Dabigatran (150 mg od)	2.90 (0.93 to 10.5)	–	2.90 (0.93 to 10.5)
Dabigatran (220 mg od)	1.19 (0.37 to 4.05)	–	1.19 (0.37 to 4.05)

TABLE 83 Results for symptomatic DVT in hip surgery patients (primary prevention of VTE): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Imprecisely estimated comparisons			
Dabigatran (220 mg od) vs. apixaban (2.5 mg bd)	–	8.37 (0.79 to 286)	8.37 (0.79 to 286)

**FIGURE 37** Network plot for symptomatic DVT in knee surgery patients (primary prevention of VTE).

Symptomatic pulmonary embolism

Thirty studies contributed data to analyses of symptomatic PE: few reported directly on symptomatic PE events (see *Table 72*) so we inferred these by summing symptomatic non-fatal and fatal PE events if that information was available. Most studies were judged to be at low risk of bias (*Table 88*), although there were some concerns about sequence generation, lack of allocation concealment, blinding of participants and personnel, and incomplete outcome data.

TABLE 84 Results for symptomatic DVT in knee surgery patients (primary prevention of VTE): comparisons with LMWH

Comparisons with LMWH (post-op, standard dose)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Dabigatran (150 mg od)	1.58 (0.64 to 4.31)	–	1.58 (0.64 to 4.31)
Dabigatran (220 mg od)	1.21 (0.46 to 3.43)	–	1.21 (0.46 to 3.43)
Rivaroxaban (10 mg od)	0.58 (0.19 to 1.59)	–	0.58 (0.19 to 1.59)
Imprecisely estimated comparisons			
LMWH pre-op (standard dose)	–	6.06 (1.38 to 31.0)	6.06 (1.38 to 31.0)
Placebo	–	1.82 (0.18 to 15.1)	1.82 (0.18 to 15.1)
Apixaban (2.5 mg bd)	0.50 (0.14 to 1.55)	–	0.50 (0.14 to 1.55)
Apixaban (5 mg od)	0.15 (0 to 2.64)	–	0.15 (0 to 2.64)
Apixaban (5 mg bd)	0.13 (0 to 2.48)	–	0.13 (0 to 2.48)
Apixaban (10 mg od)	1.32 (0.18 to 8.59)	–	1.32 (0.18 to 8.59)
Apixaban (10 mg bd)	0.13 (0 to 2.37)	–	0.13 (0 to 2.37)
Apixaban (20 mg od)	0.13 (0 to 2.37)	–	0.13 (0 to 2.37)
Betrixaban (15 mg bd)	0.57 (0.04 to 8.47)	–	0.57 (0.04 to 8.47)
Betrixaban (40 mg bd)	0.12 (0 to 3.43)	–	0.12 (0 to 3.43)
Dabigatran (110 mg od)	–	0.69 (0.02 to 8.04)	0.69 (0.02 to 8.04)
Edoxaban (5 mg od)	9.54 (0.15 to 3760)	–	9.54 (0.15 to 3760)
Edoxaban (15 mg od)	1.60 (0 to 894)	–	1.60 (0 to 894)
Edoxaban (30 mg od)	1.72 (0 to 978)	–	1.72 (0 to 978)
Edoxaban (60 mg od)	1.69 (0 to 1010)	–	1.69 (0 to 1010)
Rivaroxaban (2.5 mg bd)	0.60 (0.04 to 5.56)	–	0.60 (0.04 to 5.56)
Rivaroxaban (5 mg bd)	0.12 (0 to 2.52)	–	0.12 (0 to 2.52)
Rivaroxaban (10 mg bd)	0.12 (0 to 2.36)	–	0.12 (0 to 2.36)
Rivaroxaban (20 mg bd)	0.66 (0.05 to 5.99)	–	0.66 (0.05 to 5.99)
Rivaroxaban (30 mg bd)	0.12 (0 to 2.41)	–	0.12 (0 to 2.41)

TABLE 85 Results for symptomatic DVT in knee surgery patients (primary prevention of VTE): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Imprecisely estimated comparisons			
Dabigatran (220 mg od) vs. apixaban (2.5 mg bd)	–	2.43 (0.54 to 12.6)	2.43 (0.54 to 12.6)
Edoxaban (30 mg od) vs. apixaban (2.5 mg bd)	–	3.47 (0 to 2150)	3.47 (0 to 2150)
Rivaroxaban (10 mg od) vs. apixaban (2.5 mg bd)	–	1.16 (0.24 to 5.84)	1.16 (0.24 to 5.84)
Edoxaban (30 mg od) vs. dabigatran (220 mg od)	–	1.41 (0 to 779)	1.41 (0 to 779)
Rivaroxaban (10 mg od) vs. dabigatran (220 mg od)	–	0.47 (0.11 to 1.97)	0.47 (0.11 to 1.97)
Rivaroxaban (10 mg od) vs. edoxaban (30 mg od)	–	0.33 (0 to 295)	0.33 (0 to 295)




FIGURE 38 Network plot for symptomatic DVT in medical patients (primary prevention of VTE).

TABLE 86 Results for symptomatic DVT in medical patients (primary prevention of VTE): comparisons with LMWH

Comparisons with LMWH (standard dose)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Apixaban (2.5 mg bd)	0.30 (0.10 to 0.78)	–	0.30 (0.10 to 0.78)
Rivaroxaban (10 mg od)	0.89 (0.41 to 1.89)	–	0.89 (0.41 to 1.89)

TABLE 87 Results for symptomatic DVT in medical patients (primary prevention of VTE): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
<i>Imprecisely estimated comparisons</i>			
<i>Rivaroxaban (10 mg od) vs. apixaban (2.5 mg bd)</i>	–	<i>3.01 (0.87 to 11.6)</i>	<i>3.01 (0.87 to 11.6)</i>

TABLE 88 Included trials and risk-of-bias assessment for symptomatic PE (primary prevention of VTE)

Study	Interventions compared	SG	AC	BPP	BOA	IOD	SR
ADOPT ¹⁸⁸	3, 10	+	+	+	+	+	+
ADVANCE-1 ¹⁷¹	1, 10	?	?	+	+	+	+
ADVANCE-2 ¹⁷⁸	2, 10	+	+	+	+	?	+
ADVANCE-3 ¹⁷⁶	2, 10	+	+	+	+	+	+
APROPOS ¹⁶²	1, 7, 10, 11, 12, 13, 14, 15	+	?	?	+	+	+
EXPERT ¹⁶⁸	1, 16, 17	+	?	–	+	?	+
MAGELLAN ^{184,191}	3, 29	+	+	+	+	+	+
ODiXa-HIP2 ¹⁵⁹	2, 26, 28, 30, 33, 35	?	?	+	+	?	+
ODiXa-KNEE ¹⁵⁷	1, 26, 28, 30, 33, 35	+	+	+	+	?	+
ODiXa-OD.HIP ¹⁵⁸	2, 27, 29, 31, 32, 34	?	?	+	+	?	?
PROTECHT ¹⁷⁰	6, 9	+	+	+	+	+	+

continued

TABLE 88 Included trials and risk-of-bias assessment for symptomatic PE (primary prevention of VTE) (continued)

Study	Interventions compared	SG	AC	BPP	BOA	IOD	SR
RECORD 1 ¹⁶⁵	2, 29	+	+	?	+	+	+
RECORD 2 ¹⁶⁶	2, 29	+	+	?	+	?	+
RECORD 3 ¹⁶³	2, 29	?	+	?	+	?	+
RECORD 4 ¹⁷³	1, 29	+	+	?	+	+	+
RE-MOBILISE ¹⁶⁷	1, 19, 20	+	+	+	+	+	+
RE-MODEL ¹⁶¹	2, 19, 20	+	+	?	+	+	+
RE-NOVATE ¹⁶⁰	2, 19, 20	+	+	+	+	?	+
RE-NOVATE II ^{183,189}	2, 20	+	+	+	+	+	+
STARS E-3 ¹⁸²	1, 23	?	+	?	?	?	?
STARS J-1 ^{172,180}	9, 21, 22, 23, 24	+	?	?	+	+	+
STARS J-4 ^{181,193}	4, 23	?	?	-	+	?	+
STARS J-V ¹⁷⁹	4, 23	?	?	?	?	?	+
VTE-DABIG-PLAC-JAPAN ¹⁷⁵	9, 18, 19, 20	+	?	?	+	+	+
VTE-LMWH-PLAC-JAPAN ¹⁸⁶	1, 4, 9	?	?	?	+	+	?
VTE-RIVAROX-LMWH-BRAZIL ¹⁶²	2, 29	?	?	+	?	+	?
VTE-VKA-LMWH-CANADA ¹⁵²	1, 7	+	?	+	+	+	?
VTE-VKA-LMWH-US-2 ¹⁵⁴	1, 7	?	?	-	?	+	?
VTE-VKA-LMWH-US-3 ¹⁵³	1, 2, 7	+	?	+	+	+	?
VTE-VKA-LMWH-US-4 ¹⁵⁴	1, 7	?	+	-	+	+	?

-, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation; SR, selective reporting.

Thirteen studies in hip surgery patients provided data on 58 symptomatic PE events, leading to a network of 19 interventions (Figure 39). However, most interventions were either disconnected from the network or considered only in trials in which there were no events in any arm, so that only five interventions were included in the analysis. All comparisons were imprecisely estimated (Tables 89 and 90).

Fourteen studies in knee surgery patients reported 74 symptomatic PE events, leading to a network of 26 interventions (Figure 40). We excluded three trials with zero events in each arm, hence some interventions were not part of the analysis. All comparisons were imprecisely estimated (Table 91) but there was some evidence that risk of symptomatic PE is lower with dabigatran (150 mg od) and higher with apixaban (2.5 mg bd) than LMWH (post-op, standard dose). Among licensed doses of NOACs the risk of symptomatic PE may be lower for rivaroxaban (10 mg od) than apixaban (2.5 mg bd) (Table 92).

Three studies in medical patients reported 45 symptomatic PE events. Because the resulting network was disconnected (Figure 41), we excluded the PROTECHT trial.¹⁷⁰ This led to a connected network that enabled an indirect comparison among two licensed NOACs. All comparisons were imprecisely estimated (Tables 93 and 94).

Myocardial infarction

Nine studies provided data on 63 MI events, leading to a network of 11 interventions (Figure 42). The included studies were mainly judged to be at low risk of bias (Table 95), although there were some concerns about blinding of participants and personnel.




FIGURE 39 Network plot for symptomatic PE in hip surgery patients (primary prevention of VTE).

TABLE 89 Results for symptomatic PE in hip surgery patients (primary prevention of VTE): comparisons with LMWH

Comparisons with LMWH (pre-op, standard dose)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Imprecisely estimated comparisons			
Apixaban (2.5 mg bd)	0.57 (0.11 to 2.40)	–	0.57 (0.11 to 2.40)
Dabigatran (150 mg od)	0.20 (0.01 to 1.56)	–	0.20 (0.01 to 1.56)
Dabigatran (220 mg od)	1.22 (0.35 to 4.31)	–	1.22 (0.35 to 4.31)
Rivaroxaban (10 mg od)	0.82 (0.22 to 2.84)	–	0.82 (0.22 to 2.84)

TABLE 90 Results for symptomatic PE in hip surgery patients (primary prevention of VTE): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Imprecisely estimated comparisons			
Dabigatran (220 mg od) vs. apixaban (2.5 mg bd)	–	2.16 (0.32 to 16.7)	2.16 (0.32 to 16.7)
Rivaroxaban (10 mg od) vs. apixaban (2.5 mg bd)	–	1.46 (0.21 to 11.1)	1.46 (0.21 to 11.1)
Rivaroxaban (10 mg od) vs. dabigatran (220 mg od)	–	0.67 (0.11 to 3.95)	0.67 (0.11 to 3.95)

All comparisons were imprecisely estimated (Tables 96 and 97), although there was some evidence that rivaroxaban (10 mg od) may reduce the risk of MI compared with LMWH (post-op, standard dose).

Major bleeding

Thirty-four studies reported 706 major bleeding events, leading to a network of 32 interventions (Figure 43). The studies were mainly judged to be at low risk of bias (Table 98), although there were some concerns about sequence generation and blinding of participants and personnel.





FIGURE 40 Network plot for symptomatic PE in knee surgery patients (primary prevention of VTEs).

TABLE 91 Results for symptomatic PE in knee surgery patients (primary prevention of VTE): comparisons with LMWH

Comparisons with LMWH (post-op, standard dose)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Apixaban (2.5 mg bd)	2.14 (1.00 to 4.94)	–	2.14 (1.00 to 4.94)
Dabigatran (220 mg od)	1.05 (0.39 to 2.85)	–	1.05 (0.39 to 2.85)
Imprecisely estimated comparisons			
LMWH pre-op (standard dose)	–	0.90 (0.23 to 3.39)	0.90 (0.23 to 3.39)
Warfarin (INR 2–3)	3.44 (0.58 to 44.0)	–	3.44 (0.58 to 44.0)
Apixaban (5 mg od)	0.31 (0 to 5.87)	–	0.31 (0 to 5.87)
Apixaban (5 mg bd)	0.28 (0 to 5.31)	–	0.28 (0 to 5.31)
Apixaban (10 mg od)	0.29 (0 to 5.32)	–	0.29 (0 to 5.32)
Apixaban (10 mg bd)	1.43 (0.10 to 11.6)	–	1.43 (0.10 to 11.6)
Apixaban (20 mg od)	1.42 (0.11 to 11.8)	–	1.42 (0.11 to 11.8)
Betrixaban (15 mg bd)	2.99 (0.10 to 1930)	–	2.99 (0.10 to 1930)
Betrixaban (40 mg bd)	3.23 (0.11 to 2070)	–	3.23 (0.11 to 2070)
Dabigatran (150 mg od)	0.19 (0.02 to 0.80)	–	0.19 (0.02 to 0.80)
Rivaroxaban (2.5 mg bd)	1.03 (0 to 759)	–	1.03 (0 to 759)
Rivaroxaban (5 mg bd)	11.0 (0.61 to 6860)	–	11.0 (0.61 to 6860)
Rivaroxaban (10 mg od)	0.41 (0.12 to 1.17)	–	0.41 (0.12 to 1.17)
Rivaroxaban (10 mg bd)	1.08 (0 to 769)	–	1.08 (0 to 769)
Rivaroxaban (20 mg od)	1.13 (0 to 887)	–	1.13 (0 to 887)
Rivaroxaban (30 mg bd)	1.10 (0 to 781)	–	1.10 (0 to 781)

TABLE 92 Results for symptomatic PE in knee surgery patients (primary prevention of VTE): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
<i>Imprecisely estimated comparisons</i>			
Dabigatran (220 mg od) vs. apixaban (2.5 mg bd)	–	0.49 (0.14 to 1.66)	0.49 (0.14 to 1.66)
Rivaroxaban (10 mg od) vs. apixaban (2.5 mg bd)	–	0.19 (0.05 to 0.67)	0.19 (0.05 to 0.67)
Rivaroxaban (10 mg od) vs. dabigatran (220 mg od)	–	0.39 (0.09 to 1.58)	0.39 (0.09 to 1.58)

**FIGURE 41** Network plot for symptomatic PE in medical patients (primary prevention of VTE).**TABLE 93** Results for symptomatic PE in medical patients (primary prevention of VTE): comparisons with LMWH

Comparisons with LMWH (post-op, standard dose)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Apixaban (2.5 mg bd)	0.88 (0.30 to 2.48)	–	0.88 (0.30 to 2.48)
Rivaroxaban (10 mg od)	0.73 (0.31 to 1.64)	–	0.73 (0.31 to 1.64)

TABLE 94 Results for symptomatic PE in medical patients (primary prevention of VTE): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
<i>Imprecisely estimated comparisons</i>			
Rivaroxaban (10 mg od) vs. apixaban (2.5 mg bd)	–	0.83 (0.22 to 3.18)	0.83 (0.22 to 3.18)

There was little evidence that risk of major bleeding differs between pre-op and post-op LMWH (standard dose). There was evidence that risk of major bleeding is lower with warfarin (INR 2–3) and higher with rivaroxaban (10 mg od) than LMWH (post-op, standard dose) (Table 99). We observed statistical inconsistency between the direct and indirect estimates comparing dabigatran (220 mg od) with post-op LMWH (standard dose). The direct evidence indicated a reduction in bleeding with dabigatran and the indirect evidence indicated an increase. The estimated OR from the NMA was 1.20 (95% CI 0.75 to 1.92). All three of these results had CIs compatible with increases and decreases in risk. There was evidence that risk of major bleeding is higher with rivaroxaban (10 mg od) than with LMWH (post-op, standard dose) and than apixaban (2.5 mg bd) and dabigatran (220 mg od) (Table 100).




FIGURE 42 Network plot for MI (primary prevention of VTE). a, Excluded interventions that were included in sensitivity analyses.

TABLE 95 Included trials and risk-of-bias assessment for MI (primary prevention of VTE)

Study	Interventions compared	SG	AC	BPP	BOA	IOD	SR
ADVANCE-1 ¹⁷¹	1, 10	?	?	+	+	+	+
ADVANCE-2 ¹⁷⁸	2, 10	+	+	+	+	+	+
ADVANCE-3 ¹⁷⁶	2, 10	+	+	+	+	?	+
APROPOS ¹⁶²	1, 7, 10, 11, 12, 13, 14, 15	+	?	?	+	+	+
RECORD 1 ¹⁶⁵	2, 29	+	+	?	+	+	+
RECORD 2 ¹⁶⁶	2, 29	+	+	?	+	+	+
RECORD 3 ¹⁶³	2, 29	?	+	?	+	+	+
RECORD 4 ¹⁷³	1, 29	+	+	?	+	+	+
RE-NOVATE II ^{183,189}	2, 20	+	+	+	?	+	+


–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation; SR, selective reporting.

TABLE 96 Results for MI (primary prevention of VTE): comparisons with LMWH

Comparisons with LMWH (post-op, standard dose)	Direct evidence	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Imprecisely estimated comparisons			
LMWH pre-op (standard dose)	–	0.37 (0.09 to 1.25)	0.37 (0.09 to 1.25)
Apixaban (2.5 mg bd)	0.65 (0.18 to 2.11)	–	0.65 (0.18 to 2.11)
Apixaban (5 mg od)	0.75 (0.05 to 6.23)	–	0.75 (0.05 to 6.23)
Apixaban (5 mg bd)	0.14 (0 to 2.63)	–	0.14 (0 to 2.63)
Apixaban (10 mg od)	0.14 (0 to 2.61)	–	0.14 (0 to 2.61)
Apixaban (10 mg bd)	0.14 (0 to 2.64)	–	0.14 (0 to 2.64)
Apixaban (20 mg od)	0.14 (0 to 2.69)	–	0.14 (0 to 2.69)
Dabigatran (220 mg od)	0.37 (0.01 to 17.5)	–	0.37 (0.01 to 17.5)
Rivaroxaban (10 mg od)	0.27 (0.07 to 0.88)	–	0.27 (0.07 to 0.88)

TABLE 97 Results for MI (primary prevention of VTE): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
<i>Imprecisely estimated comparisons</i>			
Dabigatran (220 mg od) vs. apixaban (2.5 mg bd)	–	0.57 (0.01 to 26.4)	0.57 (0.01 to 26.4)
Rivaroxaban (10 mg od) vs. apixaban (2.5 mg bd)	–	0.42 (0.12 to 1.44)	0.42 (0.12 to 1.44)
Rivaroxaban (10 mg od) vs. dabigatran (220 mg od)	–	0.74 (0.02 to 31.0)	0.74 (0.02 to 31.0)

**FIGURE 43** Network plot for major bleeding (primary prevention of VTE). a, Excluded interventions that were included in sensitivity analyses.**TABLE 98** Included trials and risk-of-bias assessment for major bleeding (primary prevention of VTE)

Study	Interventions compared	SG	AC	BPP	BOA	IOD	SR
ADOPT ¹⁸⁸	3, 10	+	+	+	+	+	+
ADVANCE-1 ¹⁷¹	1, 10	?	?	+	+	+	+
ADVANCE-2 ¹⁷⁸	2, 10	+	+	+	+	+	+
ADVANCE-3 ¹⁷⁶	2, 10	+	+	+	+	?	+
APROPOS ¹⁶²	1, 7, 10, 11, 12, 13, 14, 15	+	?	?	+	+	+
EXPERT ¹⁶⁸	1, 16, 17	+	?	-	+	+	+
LIFENOX ¹⁸⁵	3, 9	+	?	+	+	+	+
MAGELLAN ^{184,191}	3, 29	+	+	+	+	+	+
ODiXa-HIP2 ¹⁵⁹	2, 26, 28, 30, 33, 35	?	?	+	+	+	+
ODiXa-KNEE ¹⁵⁷	1, 26, 28, 30, 33, 35	+	+	+	+	+	+
ODiXa-OD.HIP ¹⁵⁸	2, 27, 29, 31, 32, 34	?	?	+	+	+	?
PROTECHT ¹⁷⁰	6, 9	+	+	+	+	+	+
RECORD 1 ¹⁶⁵	2, 29	+	+	?	+	+	+

continued

TABLE 98 Included trials and risk-of-bias assessment for major bleeding (primary prevention of VTE) (continued)

Study	Interventions compared	SG	AC	BPP	BOA	IOD	SR
RECORD 2 ¹⁶⁶	2, 29	+	+	?	+	+	+
RECORD 3 ¹⁶³	2, 29	?	+	?	+	+	+
RECORD 4 ¹⁷³	1, 29	+	+	?	+	+	+
RE-MOBILISE ¹⁶⁷	1, 19, 20	+	+	+	+	+	+
RE-MODEL ¹⁶¹	2, 19, 20	+	+	?	?	+	+
RE-NOVATE ¹⁶⁰	2, 19, 20	+	+	+	+	+	+
RE-NOVATE II ^{183,189}	2, 20	+	+	+	?	+	+
STARS E-3 ¹⁸²	4, 23	?	+	?	?	?	?
STARS J-1 ^{172,180}	9, 21, 22, 23, 24	+	?	?	+	+	+
STARS J-4 ^{181,193}	4, 23	?	?	-	+	+	+
STARS J-V ¹⁷⁹	4, 23	?	?	?	?	+	+
VTE-APIX-PLACEBO-USACAN ¹⁹⁰	9, 11, 13, 15	+	+	+	+	+	+
VTE-DABIG-PLAC-JAPAN ¹⁷⁵	9, 18, 19, 20	+	?	?	?	+	+
VTE-EDOX-LMWH-MULTI ¹⁷⁷	1, 22, 23, 24, 25	+	+	+	+	+	+
VTE-LMWH-PLAC-CAN ¹⁶⁹	2, 9	+	?	?	?	+	?
VTE-LMWH-PLAC-JAPAN ¹⁸⁶	1, 4, 9	?	?	?	+	+	?
VTE-VKA-LMWH-CANADA ¹⁵²	1, 7	+	?	+	+	+	?
VTE-VKA-LMWH-US ¹⁵³	2, 7	?	?	-	+	+	?
VTE-VKA-LMWH-US-2 ¹⁵⁴	1, 7	?	?	-	?	+	?
VTE-VKA-LMWH-US-3 ¹⁵³	1, 2, 7	+	?	+	+	+	?
VTE-VKA-LMWH-US-4 ¹⁵⁴	1, 7	?	+	-	+	+	?

-, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation; SR, selective reporting.

TABLE 99 Results for major bleeding (primary prevention of VTE): comparisons with LMWH

Comparisons with LMWH (post-op, standard dose)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
LMWH pre-op (standard dose)	1.32 (0.85 to 2.06)	0.90 (0.58 to 1.40)	1.09 (0.79 to 1.49)
Warfarin (INR 2–3)	0.59 (0.39 to 0.88)	0.47 (0.18 to 1.23)	0.57 (0.39 to 0.82)
Placebo	0.68 (0.31 to 1.50)	1.75 (0.36 to 8.54)	0.82 (0.41 to 1.64)
Apixaban (2.5 mg bd)	0.93 (0.55 to 1.58)	1.02 (0.57 to 1.82)	0.97 (0.65 to 1.45)
Dabigatran (150 mg od)	0.39 (0.13 to 1.16)	1.00 (0.53 to 1.89)	0.79 (0.465 to 1.35)
Dabigatran (220 mg od)	0.39 (0.13 to 1.17)	1.55 (0.92 to 2.60)	1.20 (0.755 to 1.92)
Rivaroxaban (10 mg od)	2.86 (1.67 to 4.88)	1.41 (0.61 to 3.26)	2.33 (1.515 to 3.68)
Imprecisely estimated comparisons			
LMWH (enoxaparin 20 mg bd)	–	2.98 (0.18 to 93.9)	2.98 (0.185 to 93.9)
LMWH (nadroparin 3800 IU anti-Xa od)	–	9.42 (0.61 to 4420)	9.42 (0.615 to 4420)
Apixaban (5 mg od)	3.53 (0.75 to 23.1)	–	3.53 (0.755 to 23.1)

TABLE 99 Results for major bleeding (primary prevention of VTE): comparisons with LMWH (*continued*)

Comparisons with LMWH (post-op, standard dose)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Apixaban (5 mg bd)	4.66 (0.93 to 31.3)	–	4.66 (0.935 to 31.3)
Apixaban (10 mg od)	1.25 (0.14 to 10.0)	–	1.25 (0.14 to 10.0)
Apixaban (10 mg bd)	4.65 (0.95 to 30.9)	–	4.65 (0.95 to 30.9)
Apixaban (20 mg od)	5.94 (1.49 to 37.4)	–	5.94 (1.49 to 37.4)
Betrixaban (15 mg bd)	0.09 (0 to 2.90)	–	0.09 (0 to 2.90)
Betrixaban (40 mg bd)	0.10 (0 to 3.02)	–	0.10 (0 to 3.02)
Dabigatran (110 mg od)	–	0.63 (0.05 to 3.72)	0.63 (0.05 to 3.72)
Edoxaban (5 mg od)	–	0.85 (0 to 51.4)	0.85 (0 to 51.4)
Edoxaban (15 mg od)	–	2.03 (0.16 to 55.4)	2.03 (0.165 to 55.4)
Edoxaban (30 mg od)	–	2.24 (0.17 to 61.1)	2.24 (0.17 to 61.1)
Edoxaban (60 mg od)	–	3.32 (0.36 to 87.5)	3.32 (0.36 to 87.5)
Edoxaban (90 mg od)	–	4.80 (0.42 to 135)	4.80 (0.42 to 135)
Rivaroxaban (2.5 mg bd)	–	0.56 (0.09 to 2.78)	0.56 (0.09 to 2.78)
Rivaroxaban (5 mg od)	–	2.90 (0.52 to 14.2)	2.90 (0.52 to 14.2)
Rivaroxaban (5 mg bd)	0.79 (0.16 to 3.53)	–	0.79 (0.16 to 3.53)
Rivaroxaban (10 mg bd)	1.31 (0.36 to 5.32)	–	1.31 (0.36 to 5.32)
Rivaroxaban (20 mg od)	–	5.77 (1.53 to 24.4)	5.77 (1.53 to 24.4)
Rivaroxaban (30 mg od)	–	6.69 (1.87 to 27.7)	6.69 (1.87 to 27.7)
Rivaroxaban (20 mg bd)	2.41 (0.77 to 9.05)	–	2.41 (0.77 to 9.05)
Rivaroxaban (40 mg od)	–	6.98 (1.92 to 28.6)	6.98 (1.92 to 28.6)
Rivaroxaban (30 mg bd)	4.46 (1.43 to 16.9)	–	4.46 (1.43 to 16.9)

TABLE 100 Results for major bleeding (primary prevention of VTE): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Dabigatran (220 mg od) vs. apixaban (2.5 mg bd)	–	1.23 (0.72 to 2.12)	1.23 (0.72 to 2.12)
Rivaroxaban (10 mg od) vs. apixaban (2.5 mg bd)	–	2.40 (1.37 to 4.29)	2.40 (1.37 to 4.29)
Rivaroxaban (10 mg od) vs. dabigatran (220 mg od)	–	1.95 (1.06 to 3.61)	1.95 (1.06 to 3.61)
<i>Imprecisely estimated comparisons</i>			
Edoxaban (30 mg od) vs. apixaban (2.5 mg bd)	–	2.31 (0.16 to 64.3)	2.31 (0.16 to 64.3)
Edoxaban (30 mg od) vs. dabigatran (220 mg od)	–	1.87 (0.13 to 52.5)	1.87 (0.13 to 52.5)
Rivaroxaban (10 mg od) vs. edoxaban (30 mg od)	–	1.04 (0.04 to 14.5)	1.04 (0.04 to 14.5)

Clinically relevant bleeding

Twenty-five studies reported 1973 CRB events, leading to a network of 29 interventions (*Figure 44*). The studies were mostly judged to be at low risk of bias (*Table 101*), although there were some concerns about lack of blinding of participants and personnel.




FIGURE 44 Network plot for CRB (primary prevention of VTE).

TABLE 101 Included trials and risk-of-bias assessment for CRB (primary prevention of VTE)

Study	Interventions compared	SG	AC	BPP	BOA	IOD	SR
ADOPT ¹⁸⁸	3, 10	+	+	+	+	+	+
ADVANCE-1 ¹⁷¹	1, 10	?	?	+	+	+	+
ADVANCE-2 ¹⁷⁸	2, 10	+	+	+	+	+	+
ADVANCE-3 ¹⁷⁶	2, 10	+	+	+	+	+	+
EXPERT ¹⁶⁸	1, 16, 17	+	?	-	+	+	+
LIFENOX ¹⁸⁵	3, 9	+	?	+	+	+	+
MAGELLAN ^{184,191}	3, 29	+	+	+	+	+	+
ODiXa-HIP2 ¹⁵⁹	2, 26, 28, 30, 33, 35	?	?	+	+	+	+
ODiXa-KNEE ¹⁵⁷	1, 26, 28, 30, 33, 35	+	+	+	+	+	+
ODiXa-OD.HIP ¹⁵⁸	2, 27, 29, 31, 32, 34	?	?	+	+	+	?
RECORD 1 ¹⁶⁵	2, 29	+	+	?	+	+	+
RECORD 2 ¹⁶⁶	2, 29	+	+	?	+	+	+
RECORD 3 ¹⁶³	2, 29	?	+	?	+	+	+
RECORD 4 ¹⁷³	1, 29	+	+	?	+	+	+
RE-MODEL ¹⁶¹	2, 19, 20	+	+	?	?	+	+
RE-NOVATE ¹⁶⁰	2, 19, 20	+	+	+	+	+	+
RE-NOVATE II ^{183,189}	2, 20	+	+	+	?	+	+
STARS E-3 ¹⁸²	4, 23	?	+	?	?	?	?
STARS J-1 ^{172,180}	9, 21, 22, 23, 24	+	?	?	+	+	+
STARS J-2 ¹⁷⁴	4, 22, 23	?	?	-	+	+	+
STARS J-4 ^{181,193}	4, 23	?	?	-	+	+	+
STARS J-V ¹⁷⁹	4, 23	?	?	?	?	?	+
VTE-APIX-PLACEBO-USACAN ¹⁹⁰	9, 11, 13, 15	+	+	+	+	+	+
VTE-DABIG-PLAC-JAPAN ¹⁷⁵	9, 18, 19, 20	+	?	?	?	+	+
VTE-EDOX-LMWH-MULTI ¹⁷⁷	1, 22, 23, 24, 25	+	+	+	+	+	+

-, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation; SR, selective reporting.

There was evidence that risk of CRB is higher for pre-op LMWH (standard dose) than post-op LMWH (standard dose), and higher for dabigatran (150 mg or 220 mg od) and rivaroxaban (10 mg od) than LMWH (post-op, standard dose) (Table 102). We observed statistical inconsistency between direct and indirect estimates comparing rivaroxaban with post-op LMWH (standard dose). In particular, the direct evidence for rivaroxaban (5 mg bd) indicated a reduction in bleeding with rivaroxaban, whereas the indirect evidence indicated an increase. The combined estimate for this comparison from the NMA suggested a small increase with OR 1.53 (95% CI 0.54 to 4.47); all three of these results had CIs compatible with increases and decreases in risk. There was evidence that risk of CRB is higher for dabigatran (220 mg od) and rivaroxaban (10 mg od) than apixaban (2.5 mg bd) (Table 103).

TABLE 102 Results for CRB (primary prevention of VTE): comparisons with LMWH

Comparisons with LMWH (post-op, standard dose)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
LMWH pre-op (standard dose)	–	1.30 (1.03 to 1.62)	1.30 (1.03 to 1.62)
Placebo	0.71 (0.45 to 1.12)	–	0.71 (0.45 to 1.12)
Apixaban (2.5 mg bd)	0.97 (0.76 to 1.24)	1.16 (0.74 to 1.82)	1.06 (0.86 to 1.30)
Dabigatran (150 mg od)	–	1.53 (1.09 to 2.15)	1.53 (1.09 to 2.15)
Dabigatran (220 mg od)	–	1.55 (1.12 to 2.15)	1.55 (1.12 to 2.15)
Rivaroxaban (10 mg od)	1.85 (1.52 to 2.26)	1.30 (0.91 to 1.85)	1.85 (1.52 to 2.26)
Rivaroxaban (5 mg bd)	0.56 (0.11 to 2.54)	5.94 (1.76 to 20.0)	2.45 (0.97 to 6.73)
Rivaroxaban (10 mg bd)	0.55 (0.11 to 2.49)	3.55 (0.85 to 14.9)	1.53 (0.54 to 4.47)
Rivaroxaban (20 mg od)	1.93 (0.68 to 5.07)	–	1.93 (0.68 to 5.07)
Rivaroxaban (30 mg od)	2.81 (1.13 to 6.88)	–	2.81 (1.13 to 6.88)
Rivaroxaban (20 mg bd)	1.84 (0.57 to 6.44)	10.5 (2.47 to 44.4)	3.73 (1.57 to 9.98)
Rivaroxaban (40 mg od)	3.26 (1.34 to 7.89)	–	3.26 (1.34 to 7.89)
Rivaroxaban (30 mg bd)	3.53 (1.25 to 11.1)	32.5 (4.47 to 236)	5.94 (2.39 to 16.4)
Imprecisely estimated comparisons			
LMWH (enoxaparin 20 mg bd)	–	1.25 (0.35 to 4.95)	1.25 (0.35 to 4.95)
Apixaban (5 mg od)	–	0.64 (0.02 to 32.0)	0.64 (0.02 to 32.0)
Apixaban (10 mg od)	–	0.71 (0.02 to 36.0)	0.71 (0.02 to 36.0)
Apixaban (20 mg od)	–	3.78 (0.41 to 150)	3.78 (0.41 to 150)
Betrixaban (15 mg bd)	0.03 (0 to 0.54)	–	0.03 (0 to 0.54)
Betrixaban (40 mg bd)	0.33 (0.05 to 1.88)	–	0.33 (0.05 to 1.88)
Dabigatran (110 mg od)	–	0.25 (0.01 to 1.63)	0.25 (0.01 to 1.63)
Edoxaban (5 mg od)	0.54 (0.06 to 3.04)	–	0.54 (0.06 to 3.04)
Edoxaban (15 mg od)	1.40 (0.43 to 5.03)	–	1.40 (0.43 to 5.03)
Edoxaban (30 mg od)	1.42 (0.44 to 5.17)	–	1.42 (0.44 to 5.17)
Edoxaban (60 mg od)	1.77 (0.56 to 6.33)	–	1.77 (0.56 to 6.33)
Edoxaban (90 mg od)	2.13 (0.49 to 9.24)	–	2.13 (0.49 to 9.24)
Rivaroxaban (2.5 mg bd)	1.01 (0.31 to 3.18)	–	1.01 (0.31 to 3.18)
Rivaroxaban (5 mg od)	1.46 (0.43 to 4.16)	–	1.46 (0.43 to 4.16)

TABLE 103 Results for CRB (primary prevention of VTE): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Dabigatran (220 mg od) vs. apixaban (2.5 mg bd)	–	1.47 (1.09 to 1.98)	1.47 (1.09 to 1.98)
Rivaroxaban (10 mg od) vs. apixaban (2.5 mg bd)	–	1.75 (1.40 to 2.20)	1.75 (1.40 to 2.20)
Rivaroxaban (10 mg od) vs. dabigatran (220 mg od)	–	1.19 (0.88 to 1.63)	1.19 (0.88 to 1.63)
Imprecisely estimated comparisons			
Edoxaban (30 mg od) vs. apixaban (2.5 mg bd)	–	1.34 (0.41 to 5.00)	1.34 (0.41 to 5.00)
Edoxaban (30 mg od) vs. dabigatran (220 mg od)	–	0.92 (0.27 to 3.44)	0.92 (0.27 to 3.44)
Rivaroxaban (10 mg od) vs. edoxaban (30 mg od)	–	1.30 (0.35 to 4.32)	1.30 (0.35 to 4.32)

All-cause mortality

Twenty-four studies reported 1161 all-cause mortality events, leading to a network of 29 interventions (Figure 45). The studies were mostly judged to be at low risk of bias (Table 104), with some concerns about lack of blinding of participants and personnel.

Rates of all-cause mortality were substantially higher in studies of patients with cancer than in studies of surgical patients (see Table 73). There was little evidence that risk of all-cause mortality differed for any intervention compared with LMWH (post-op, standard dose) (Table 105). We observed statistical inconsistency between the direct and indirect estimates comparing apixaban (2.5 mg bd) with post-op LMWH (standard dose). The direct evidence indicated a reduction in bleeding with apixaban and the indirect evidence showed an increase. The combined estimate from the NMA suggested a small increase with OR 1.57 (95% CI 0.6 to 4.37). Comparisons between licensed doses of NOACs were imprecisely estimated (Table 106).

Summary of results and ranking of interventions

Despite the substantial number of patients randomised to trials of primary prevention of VTE, low numbers of clinically relevant outcome events meant that most comparisons were imprecisely estimated. Conclusions can mainly be drawn from analyses of symptomatic VTE, major bleeding and CRB. There was evidence that




FIGURE 45 Network plot for all-cause mortality (primary prevention of VTE). a, Excluded interventions that were included in sensitivity analyses.

TABLE 104 Included trials and risk-of-bias assessment for all-cause mortality (primary prevention of VTE)

Study	Interventions compared	SG	AC	BPP	BOA	IOD	SR
ADVANCE-1 ¹⁷¹	1, 10	?	?	+	+	+	+
ADVANCE-2 ¹⁷⁸	2, 10	+	+	+	+	+	+
ADVANCE-3 ¹⁷⁶	2, 10	+	+	+	+	?	+
APROPOS ¹⁶²	1, 7, 10, 11, 12, 13, 14, 15	+	?	?	+	+	+
LIFENOX ¹⁸⁵	3, 9	+	?	+	+	+	+
MAGELLAN ^{184,191}	3, 29	+	+	+	+	+	+
ODiXa-KNEE ¹⁵⁷	1, 26, 28, 30, 33, 35	+	+	+	+	+	+
ODiXa-OD.HIP ¹⁵⁸	2, 27, 29, 31, 32, 34	?	?	+	+	+	?
PROTECHT ¹⁷⁰	6, 9	+	+	+	+	+	+
RECORD 1 ¹⁶⁵	2, 29	+	+	?	+	+	+
RECORD 2 ¹⁶⁶	2, 29	+	+	?	+	+	+
RECORD 3 ¹⁶³	2, 29	?	+	?	+	+	+
RECORD 4 ¹⁷³	1, 29	+	+	?	+	+	+
RE-MOBILISE ¹⁶⁷	1, 19, 20	+	+	+	+	+	+
RE-MODEL ¹⁶¹	2, 19, 20	+	+	?	?	+	+
RE-NOVATE II ^{183,189}	2, 20	+	+	+	?	+	+
STARS J-4 ^{181,193}	4, 23	?	?	-	+	+	+
VTE-DABIG-PLAC-JAPAN ¹⁷⁵	9, 18, 19, 20	+	?	?	?	+	+
VTE-EDOX-LMWH-MULTI ¹⁷⁷	1, 22, 23, 24, 25	+	+	+	+	+	+
VTE-LMWH-PLAC-CAN ¹⁶⁹	2, 9	+	?	?	?	+	?
VTE-VKA-LMWH-CANADA ¹⁵²	1, 7	+	?	+	+	+	?
VTE-VKA-LMWH-US-2 ¹⁵⁴	1, 7	?	?	-	?	+	?
VTE-VKA-LMWH-US-3 ¹⁵³	1, 2, 7	+	?	+	+	+	?
VTE-VKA-LMWH-US-4 ¹⁵⁴	1, 7	?	+	-	+	+	?

–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation; SR, selective reporting.

TABLE 105 Results for all-cause mortality (primary prevention of VTE): comparisons with LMWH

Comparisons	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
LMWH pre-op (standard dose)	2.00 (0.30 to 13.47)	1.79 (0.86 to 3.74)	1.82 (0.93 to 3.62)
LMWH (nadroparin 3800 IU anti-Xa od)	–	1.06 (0.57 to 2.05)	1.06 (0.57 to 2.05)
Warfarin (INR 2–3)	1.44 (0.69 to 3.06)	–	1.44 (0.69 to 3.06)
Placebo	1.03 (0.88 to 1.20)	–	1.03 (0.88 to 1.20)
Apixaban (2.5 mg bd)	0.66 (0.18 to 2.29)	6.29 (1.25 to 31.5)	1.57 (0.6 to 4.37)
Rivaroxaban (10 mg od)	1.06 (0.85 to 1.33)	0.80 (0.35 to 1.83)	1.04 (0.83 to 1.29)

continued

TABLE 105 Results for all-cause mortality (primary prevention of VTE): comparisons with LMWH (*continued*)

Comparisons	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Imprecisely estimated comparisons			
<i>Apixaban (5 mg od)</i>	0.41 (0 to 9.80)	–	0.41 (0 to 9.80)
<i>Apixaban (5 mg bd)</i>	0.37 (0 to 9.27)	–	0.37 (0 to 9.27)
<i>Apixaban (10 mg od)</i>	0.38 (0 to 9.42)	–	0.38 (0 to 9.42)
<i>Apixaban (10 mg bd)</i>	0.36 (0 to 8.91)	–	0.36 (0 to 8.91)
<i>Apixaban (20 mg od)</i>	0.36 (0 to 8.71)	–	0.36 (0 to 8.71)
<i>Dabigatran (150 mg od)</i>	1.49 (0.31 to 7.13)	–	1.49 (0.31 to 7.13)
<i>Dabigatran (220 mg od)</i>	1.04 (0.21 to 4.86)	–	1.04 (0.21 to 4.86)
<i>Edoxaban (15 mg od)</i>	4.37 (0.15 to 1610)	–	4.37 (0.15 to 1610)
<i>Edoxaban (30 mg od)</i>	13.6 (0.87 to 4510)	–	13.6 (0.87 to 4510)
<i>Edoxaban (60 mg od)</i>	0.88 (0 to 421)	–	0.88 (0 to 421)
<i>Edoxaban (90 mg od)</i>	0.93 (0 to 423)	–	0.93 (0 to 423)

TABLE 106 Results for all-cause mortality (primary prevention of VTE): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Rivaroxaban (10 mg od) vs. apixaban (2.5 mg bd)	–	0.66 (0.23 to 1.76)	0.66 (0.23 to 1.76)
Imprecisely estimated comparisons			
<i>Dabigatran (220 mg od) vs. apixaban (2.5 mg bd)</i>	–	0.66 (0.10 to 3.85)	0.66 (0.10 to 3.85)
<i>Edoxaban (30 mg od) vs. apixaban (2.5 mg bd)</i>	–	8.79 (0.44 to 3220)	8.79 (0.44 to 3220)
<i>Edoxaban (30 mg od) vs. dabigatran (220 mg od)</i>	–	13.8 (0.53 to 5360)	13.8 (0.53 to 5360)
<i>Rivaroxaban (10 mg od) vs. dabigatran (220 mg od)</i>	–	0.99 (0.21 to 4.95)	0.99 (0.21 to 4.95)
<i>Rivaroxaban (10 mg od) vs. edoxaban (30 mg od)</i>	–	0.08 (0 to 1.22)	0.08 (0 to 1.22)

risk of symptomatic VTE is lower with rivaroxaban (10 mg od) than LMWH (pre-op, standard dose) in hip surgery patients, but that risk of major bleeding and CRB is higher with rivaroxaban (10 mg od) than LMWH (post-op, standard dose).

We conducted sensitivity analyses merging warfarin interventions with variable INR range with those with INR range 2–3. Results, which are available from the authors up request, were similar to those presented above. With regard to model appraisal, we did not identify any instance of lack of convergence among the Markov chains or poor model fit. There were some instances of inconsistency between direct and indirect estimates of the same effect, although in most instances these results were accompanied by wide CIs. Few of the comparisons were replicated across studies; when there were multiple estimates we did not find evidence of statistical heterogeneity.

Because of the substantial imprecision in comparisons of efficacy outcomes, we present only one rankogram containing the bleeding and death outcomes for which all patients were jointly analysed (*Figure 46*). Warfarin was ranked with high probability as the best intervention for major bleeding events, and LMWH (post-op, standard dose) was ranked with high probability as best, or second-best, intervention for CRB. Rivaroxaban (10 mg od) was ranked among the worst interventions for bleeding outcomes.




FIGURE 46 Rankogram for licensed interventions examined in primary prevention of VTE.

Chapter 8 Clinical results (3): acute treatment of venous thromboembolism

Included studies

Nine completed RCTs with 10 references²⁰²⁻²¹¹ were identified for inclusion in the review of acute treatment of VTE (see *Figure 32*), as well as one ongoing trial.²¹² A summary of the characteristics of the nine included studies²⁰²⁻²¹¹ is presented in *Table 107*. All studies were multicentre and many were conducted across countries in North and South America, Europe, Asia, Australia, New Zealand, South Africa, Russia and Israel. Six were Phase III²⁰⁵⁻²¹¹ studies and three were Phase II²⁰²⁻²⁰⁴ studies. The number of patients randomised ranged from 520 to 8292, with a total of 28,803 patients across the nine studies. The Phase III studies examined edoxaban, apixaban, dabigatran and rivaroxaban, and these studies randomised 27,127 patients (94% of the total). The Phase II studies,²⁰²⁻²⁰⁴ which examined apixaban and rivaroxaban, contributed 1676 patients (6%).

Eligibility criteria were similar across studies: all patients had acute symptomatic and objectively confirmed DVT and/or PE. The mean ages of included patients were similar, ranging from 54.7 to 59.1 years. The percentage of males across studies ranged from 51% to 62%. Mean BMI was reported by four studies,^{202,203,205,211} ranged from 27 to 28.9 kg/m², and was comparable between study arms. Five studies^{203,204,209-211} reported percentages of cancer cases, which were comparable between study arms and ranged from 2% to 12%.

All of the studies compared a NOAC with standard intensity warfarin (INR 2–3): mean TTR ranged from 50.3% to 62.7%. Of the studies that examined rivaroxaban, two Phase III studies administered 15 mg bd and two Phase II studies examined six dosing strategies. Two studies examined apixaban: one Phase III study administered 5 mg bd and one Phase II study compared this with two alternative dosing strategies. Two Phase III studies examined dabigatran 150 mg bd; and one Phase III study examined edoxaban 60 mg od.

Treatment duration ranged from 12 to 48 weeks in the rivaroxaban studies, from 12 to 24 weeks in the apixaban studies, from 12 to 48 weeks in the edoxaban study and was 24 weeks in the dabigatran studies. Reported efficacy and safety outcome types were similar across studies and reported at the end of the treatment periods. All nine studies²⁰²⁻²¹¹ reported symptomatic DVT, symptomatic PE and major bleeding. Eight studies reported all-cause mortality and CRB, seven reported symptomatic VTE and five reported MI. Each of the studies was sponsored by one or more pharmaceutical companies. In almost all studies the sponsor(s) was responsible for the study design and data collection, and in some cases data analysis.

Time in therapeutic range for warfarin interventions

Table 108 shows the comparator interventions, target INR and (where reported) mean TTR for the nine studies²⁰²⁻²¹¹ that included a warfarin intervention arm. Eight^{202,204-211} (89%) of these studies reported mean TTR, which varied between 56.9% and 63.5%.

TABLE 107 Characteristics of nine included randomised trials in acute treatment of VTE

Study (centre type) [countries]	Study type, sponsor (sponsor's role)	Age eligibility (mean age, years) [% male]	Clinical condition	No. randomised	Interventions compared	Treatment duration (weeks)	Outcomes	Time of outcome assessment (weeks)
AMPLIFY²¹⁰ (Multicentre) [North and South America, Europe, Russia, Israel, Australia, Asia and South Africa]	Phase III Pfizer and Bristol-Myers Squibb <i>(The sponsors collected and maintained the data; the academic authors had full access to the data through the sponsors)</i>	≥ 18 (57) [58.7]	Acute objectively confirmed, symptomatic proximal DVT or PE (with or without DVT)	5400	Apixaban 1. 5 mg bd Warfarin 2. INR 2–3 (Mean TTR: 61%)	24	<i>Efficacy:</i> Symptomatic VTE, symptomatic DVT, symptomatic non-fatal PE, fatal PE <i>Safety:</i> Major bleeding, CRNM bleeding, composite CRB, fatal bleeding, MI, death (all causes)	24
BOTTICELLI DVT²⁰⁴ (Multicentre) [USA, European, Israel, Australia and South Africa]	Phase II Bristol-Myers Squibb (Not declared)	≥ 18 (58.5) [62.1]	Acute symptomatic and objectively confirmed proximal DVT or extensive calf-vein thrombosis involving at least the upper third of the deep calf veins	520	Apixaban 1. 5 mg bd 2. 10 mg bd 3. 20 mg bd Warfarin 4. INR 2–3 (Mean TTR: 57%)	12–13	<i>Efficacy:</i> Symptomatic DVT, symptomatic PE <i>Safety:</i> Major bleeding, minor bleeding, CRNM bleeding, composite CRB, death (all causes)	12–13
EINSTEIN DVT²⁰⁶ (Multicentre) [North and South America, Europe, Israel, Australia, New Zealand, Asia and South Africa]	Phase III Bayer Schering Pharma and Ortho-McNeil <i>(The data were collected and maintained by the sponsor)</i>	≥ 18 (56.1) [56.8]	Acute, objectively confirmed proximal DVT without symptomatic PE	3449	Rivaroxaban 1. 15 mg bd (then 20 mg od) Warfarin 2. INR 2–3 (Mean TTR: 57.7%)	12–48	<i>Efficacy:</i> Symptomatic VTE, symptomatic DVT, fatal PE, symptomatic non-fatal PE <i>Safety:</i> Major bleeding, CRNM bleeding, composite CRB, MI, death (cardiovascular), death (all causes)	12–48

Study (centre type) [countries]	Study type, sponsor (sponsor's role)	Age eligibility (mean age, years) [% male]	Clinical condition	No. randomised	Interventions compared	Treatment duration (weeks)	Outcomes	Time of outcome assessment (weeks)
EINSTEIN DVT dose-ranging study ²⁰³ (Multicentre) [North and South America, Europe, Israel, Australia and South Africa]	Phase II Bayer HealthCare <i>(The data were gathered and maintained by the sponsor)</i>	≥ 18 (58) [51.1]	Acute symptomatic and objectively confirmed DVT (proximal or isolated extensive calf vein thrombosis involving at least the upper one-third of the calf veins)	543	Rivaroxaban 1. 20 mg od 2. 30 mg od 3. 40 mg od Warfarin 4. INR 2–3 (Mean TTR: NR)	12	<i>Efficacy:</i> Symptomatic DVT, symptomatic non-fatal PE, symptomatic VTE <i>Safety:</i> All bleeding, major bleeding, CRNM bleeding, CRB, death (all causes)	12
EINSTEIN PE ²⁰⁷ (Multicentre) [North and South America, Europe, Israel, Australia, New Zealand, Asia and South Africa]	Phase III Bayer HealthCare and Janssen Pharmaceuticals <i>(The data were collected and maintained by the sponsor)</i>	≥ 18 (57.7) [52.9]	Acute symptomatic PE, objectively confirmed, with or without DVT	4833	Rivaroxaban 1. 15 mg bd (then 20 mg od) Warfarin 2. INR 2–3 (Mean TTR: 62.7%)	31 (mean)	<i>Efficacy:</i> Symptomatic VTE, Symptomatic DVT, fatal PE, symptomatic non-fatal PE <i>Safety:</i> Major bleeding, CRNM bleeding, composite CRB, death (all causes)	12–48
HOKUSAI-VTE ^{208,209} (Multicentre) [North and South America, Europe, Russia, Israel, Australia, Asia and South Africa]	Phase III Daiichi Sankyo <i>(The sponsor was responsible for the collection and maintenance of the data)</i>	≥ 18 (55.8) [57.2]	Acute objectively confirmed, symptomatic DVT involving the popliteal, femoral, or iliac veins, or acute, symptomatic PE (with or without DVT)	8292	Edoxaban 1. 60 mg od ^a Warfarin 2. INR 2–3 (Mean TTR: 63.5%)	12–48	<i>Efficacy:</i> Symptomatic VTE, symptomatic DVT, symptomatic non-fatal PE, fatal PE <i>Safety:</i> All bleeding, major bleeding, fatal bleeding, CRNM bleeding, composite CRB, MI, death (all causes)	48

continued

TABLE 107 Characteristics of nine included randomised trials in acute treatment of VTE (continued)

Study (centre type) [countries]	Study type, sponsor (sponsor's role)	Age eligibility (mean age, years) [% male]	Clinical condition	No. randomised	Interventions compared	Treatment duration (weeks)	Outcomes	Time of outcome assessment (weeks)
ODIXa-DVT ²⁰² (Multicentre) [Canada, South America, Europe, Israel, Australia, New Zealand and South Africa]	Phase II Bayer HealthCare AG (The statistical analysis was performed by the sponsor)	≥ 18 (59.1) [60.9]	Acute symptomatic and objectively confirmed thrombosis of the popliteal or more proximal veins, who have no symptoms of PE	613	Rivaroxaban 1. 10 mg bd 2. 20 mg bd 3. 30 mg bd 4. 40 mg od Warfarin 5. INR 2–3 (Mean TTR: 60%)	12	<i>Efficacy:</i> Symptomatic VTE, symptomatic DVT, symptomatic non-fatal PE <i>Safety:</i> All bleeding, major bleeding, minor bleeding	12
RE-COVER ²⁰⁵ (Multicentre) [North and South America, Europe, Russia, Israel, Australia, New Zealand, India and South Africa]	Phase III Boehringer Ingelheim (The study was funded, designed, conducted, and the data analysed by the sponsor in conjunction with the steering committee)	≥ 18 (54.7) [58.4]	Acute, symptomatic, objectively confirmed proximal DVT of the legs or PE, and for whom 6 months of anticoagulant therapy was considered to be an appropriate treatment	2564	Dabigatran 1. 150 mg bd Warfarin 2. INR 2–3 (Mean TTR: 59.9%)	24	<i>Efficacy:</i> Symptomatic VTE, symptomatic DVT, symptomatic non-fatal PE <i>Safety:</i> All bleeding, major bleeding, composite CRB, MI, death (all causes)	24

Study (centre type) [countries]	Study type, sponsor (sponsor's role)	Age eligibility (mean age, years) [% male]	Clinical condition	No. randomised	Interventions compared	Treatment duration (weeks)	Outcomes	Time of outcome assessment (weeks)
RE-COVER II ¹¹ (Multicentre)	Phase III Boehringer Ingelheim	≥ 18 (54.9) [60.6]	Acute symptomatic unilateral or bilateral DVT of the leg involving proximal veins, and/or PE	2589	Dabigatran 1. 150 mg bd Warfarin 2. INR 2–3 (Mean TTR: 56.9%)	24	Efficacy: Symptomatic VTE, symptomatic non-fatal PE Safety: All bleeding, major bleeding, CRNM bleeding, composite CRB, fatal bleeding, MI, death (all causes)	24
<p>NR, not reported.</p> <p>a Note that 17.6% of the patients in the edoxaban 60 mg od arm received a lower dose of 30 mg od.</p> <p>Note: In warfarin arms, participants also received LMWH (treatment duration 5 days; except in the BOTTICELLI DVT study,²⁰⁴ for which treatment was continued until a stable INR of > 2 was observed on two measurements at least 24 hours apart, and minimum duration of treatment was 5 days).</p>								

TABLE 108 Mean TTR for warfarin in acute treatment of VTE

Study	Interventions that were compared with warfarin	Warfarin INR	Mean time (%) in therapeutic range (INR)
AMPLIFY ²¹⁰	Apixaban 5 mg bd	2–3	61
BOTTICELLI DVT ²⁰⁴	Apixaban 5 mg, 10 mg, 20 mg bd	2–3	57
EINSTEIN DVT ²⁰⁶	Rivaroxaban 15 mg bd (then 20 mg od)	2–3	57.7
EINSTEIN DVT dose-ranging study ²⁰³	Rivaroxaban 20 mg, 30 mg, 40 mg od	2–3	NR
EINSTEIN PE ²⁰⁷	Rivaroxaban 15 mg bd (then 20 mg od)	2–3	62.7
HOKUSAI-VTE ^{208,209}	Edoxaban 60 mg od	2–3	63.5
ODiXa-DVT ²⁰²	Rivaroxaban 10 mg, 20 mg, 30 mg bd, 40 mg od	2–3	60
RE-COVER ²⁰⁵	Dabigatran 150 mg bd	2–3	59.9
RE-COVER II ²¹¹	Dabigatran 150 mg bd	2–3	56.9

NR, not reported.

Risk of bias in included studies

Table 109 shows the detailed risk-of-bias assessments for each included study for each domain. Generally, the studies were judged to be at low risk of bias. The randomisation sequence was predominantly computer generated. The studies were judged to be at low risk of bias for sequence generation, blinding of outcome assessment and selective reporting, although one study did not explain how randomisation was performed, stating only that a veiled randomisation process was carried out. In all studies, concealed allocation to intervention arms was achieved through central allocation, either an interactive voice or a web-based system. Five studies were of open-label design and, as such, were judged to be of high risk of bias for blinding of participants and personnel. Completeness of the data analysed depended – in a few studies – on whether the outcome was for efficacy or safety. For the majority of outcomes all patients were accounted for in the analysis or, in some situations, a small number of patients were not included in the analysis but reasons were provided and judged to be similar across intervention arms and unlikely to be related to the outcome. These studies were therefore judged to be at low risk of bias as a result of incomplete outcome data. In one study the reasons for not including some patients in the efficacy analyses were judged to be similar across study arms but were judged to be potentially related to the outcome, and the study was therefore considered at high risk of bias for the domain. Outcomes were reported as stated in the protocols in all studies, which were therefore judged to be at low risk of bias because of selective reporting. Risk-of-bias judgements for studies contributing to analyses of each outcome are presented graphically in the sections that follow.

Results of clinical effectiveness and safety

The nine trials of acute treatment for VTE examined 13 distinct interventions (Table 110). Tables 111 and 112 show the number of outcome events for each outcome as reported in each trial. We performed NMAs for seven outcomes: symptomatic DVT, symptomatic PE, symptomatic VTE, MI, major bleeding, CRB and all-cause mortality.

Results are presented as follows for each of the seven outcomes. First, we provide network plots to illustrate the comparisons of interventions made in the different trials. Second, we illustrate the risk-of-bias assessments specific to the outcome for each trial included in the network. Third, we present results tables

TABLE 109 Risk-of-bias assessments for nine included randomised trials in acute treatment of VTE

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting
AMPLIFY ²¹⁰	L: 'Randomisation was performed with the use of an interactive voice-response system'	L: 'Randomisation was performed with the use of an interactive voice-response system'	L: 'Patients were assigned to receive apixaban tablets plus placebo enoxaparin injections and placebo warfarin tablets or conventional therapy with enoxaparin injections and warfarin tablets plus placebo apixaban tablets'	L: 'An independent committee, whose members were unaware of the study-group assignments, adjudicated the qualifying diagnosis, the anatomical extent of the initial DVT or PE, and all suspected outcomes'	U: 'For efficacy and safety outcomes except symptomatic DVT: There are missing outcome data with reasons. Although missing outcome data seem to be balanced in numbers across intervention groups, it is not quite clear whether or not the reasons could be related to true outcome L: For symptomatic DVT: All patients were included in the analyses	L: Outcomes reported as stated in the study protocol
BOTTICELLI DVT ²⁰⁴	U: 'The Botticelli study was a veiled randomised, parallel group dose-ranging study'	L: 'An interactive voice response system was used for randomisation. The study was conducted according to current methodological standards; that is, consecutive patients were centrally randomised'	H: 'The Botticelli study was a veiled randomised, parallel group dose-ranging study that was double-blind for the different doses of apixaban and open-label for the LMWH/KA comparator'	L: 'All potential study outcomes were assessed by an independent committee, whose members were unaware of treatment assignment'	L: There are missing data; however numbers missing in each arm are almost the same; also reasons for missing data unlikely to be related to the outcomes	L: Outcomes reported according to study protocol
EINSTEIN DVT ²⁰⁶	L: 'Patients were randomly assigned to a study group with the use of a computerised voice-response system, with stratification by country'	L: 'Patients were randomly assigned to a study group with the use of a computerised voice-response system'	H: 'The Acute DVT Study was a randomised, open-label study'	L: 'All suspected outcome events were classified by a central adjudication committee whose members were unaware of the treatment assignments'	L: Few missing data with reasons and number of missing data similar in the two groups; reasons for missing data unlikely to be related to true outcome. Analysis by intention to treat	L: Outcomes reported according to study protocol

continued

TABLE 109 Risk-of-bias assessments for nine included randomised trials in acute treatment of VTE (continued)

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting
EINSTEIN DVT dose-ranging study ²⁰³	L: 'Patients were randomised, via an interactive voice response system'	L: 'Patients were randomised, via an interactive voice response system' – a central allocation system	H: 'The Einstein–DVT study was a randomised, dose-ranging study that was double-blind for rivaroxaban doses and open-label for the LMWH/VKA'	L: 'An independent adjudication committee, unaware of treatment allocation, evaluated all suspected thromboembolic complications, deaths, baseline and repeat ultrasound and perfusion lung scans, as well as all episodes of suspected bleeding'	H: <i>For efficacy outcomes:</i> Missing data but with reasons. Reasons are similar across all rivaroxaban arms. Numbers are similar across rivaroxaban arm but differ significantly when each is compared with the comparator arm. Reasons for missing data may be related to the outcome L: <i>For safety outcomes:</i> All patients were included in the analyses	L: Outcomes reported according to study protocol
EINSTEIN PE ²⁰⁷	L: 'Randomisation was performed with the use of a computerised voice-response system'	L: 'Randomisation was performed with the use of a computerised voice-response system'	H: 'The EINSTEIN–PE study was a randomised, open-label trial'	L: 'All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment'	L: Few missing data; missing data are balanced in numbers across groups. Reasons for missing data given, unlikely to be related to true outcome	L: Outcomes reported according to study protocol
HOKUSAI-VTE ^{208,209}	L: 'Randomisation was performed with the use of an interactive Web-based system'	L: 'Randomisation was performed with the use of an interactive Web-based system' – a central allocation	L: 'Edoxaban or warfarin was administered in a double-blind, double-dummy fashion'	L: 'An independent committee, whose members were unaware of the study-group assignments, adjudicated all suspected outcomes'	L: Small numbers of missing data; however, balanced in the treatment groups. Reason for missing data are unlikely to be related to the true outcome. Data analysis was by intention to treat	L: Outcomes reported as stated in the study protocol

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting
ODIXa-DVT²⁰²	L: 'The ODIXa-DVT study was a multinational, multicentre, partially blinded, parallel-group study in which patients were randomised by central computer'	L: 'The ODIXa-DVT study was a multinational, multicentre, partially blinded, parallel-group study in which patients were randomised by central computer' – a Central allocation system	H: 'The ODIXa-DVT study was a multinational, multicentre, partially blinded, parallel-group study' 'Patients in the oral rivaroxaban treatment groups received double blinded doses of 10, 20, or 30 mg bd (BID) or 40 mg od, with food, for 12 weeks. Patients in the open-label, standard-anticoagulant group received enoxaparin 1 mg/kg BID by subcutaneous injection and a VKA'	L: 'All clinically suspected VTE, bleeding events, perfusion lung scans were adjudicated, without knowledge of the treatment group, by an independent central adjudication committee'	L: All patients were included in the analyses	L: Outcomes reported according to study protocol
RE-COVER²⁰⁵	L: 'We used a computer generated randomisation scheme with variable block sizes, stratified according to presentation'	L: 'Staff members at the clinical centres called an interactive voice-response system that randomly assigned subjects to one of the supplied medication kits' – a central allocation system	L: 'Active dabigatran and warfarin-like placebo or active warfarin and dabigatran-like placebo were then given for 6 months ('double-dummy phase')	L: 'All suspected outcome events and deaths were classified by central adjudication committees, whose members were unaware of the treatment assignments'	L: All patients were included in the analyses	L: Outcomes reported according to study protocol
RE-COVER II²¹¹	L: 'Patients were randomised using an interactive voice response system and a computer generated randomisation scheme in blocks of 4'	L: 'Patients were randomised using an interactive voice response system'	L: 'Patients were assigned in a 1:1 ratio to receive active fixed dose dabigatran 150 mg bd and warfarin-like placebo, or active warfarin and dabigatran-like placebo'	L: 'All suspected outcome events and deaths were classified by central adjudication committees, whose members were unaware of the treatment assignments'	L: All patients were included in the analyses	L: Outcomes reported as stated in the study protocol

H, high risk; L, low risk; U, unclear risk.
Note: quotations are denoted by inverted commas.

TABLE 110 List of distinct interventions examined by included randomised trials in acute treatment of VTE

1.	Warfarin (INR 2–3)
2.	Apixaban (5 mg bd)
3.	Apixaban (10 mg bd)
4.	Apixaban (20 mg od)
5.	Dabigatran (150 mg bd)
6.	Edoxaban [60 or 30 (17.6%) mg od] ^a
7.	Rivaroxaban (10 mg bd)
8.	Rivaroxaban (20 mg od)
9.	Rivaroxaban (15 mg bd then 20 mg od)
10.	Rivaroxaban (30 mg od)
11.	Rivaroxaban (20 mg bd)
12.	Rivaroxaban (40 mg od)
13.	Rivaroxaban (30 mg bd)

a The planned edoxaban dose in the HOKUSAI-VTE study^{208,209} was 60 mg od, but 17.6% of the patients in that intervention arm received a lower dose of 30 mg od. This intervention is denoted 'Edoxaban [60 or 30 (17.6%) mg od]'.

for each intervention compared with the reference treatment (warfarin with a target INR range of 2–3). Fourth, we present results tables for pairwise comparisons among licensed doses of the NOACs. For both sets of results tables, posterior median ORs and 95% credible intervals from Bayesian fixed-effects analyses are shown, although we refer to the latter as CIs for convenience. In these tables we present results separately for any available direct evidence, for any indirect comparisons that can be made (excluding the direct evidence) and for the NMA (which combines the direct and the indirect evidence). Comparisons from the NMA with a ratio between interval limits exceeding nine were considered 'imprecisely estimated' and are presented at the bottom of each table (note that calculation of indirect evidence was not undertaken for imprecisely estimated comparisons). A summary of results across outcomes is provided at the end in the form of a 'rankogram', which illustrates the probability that each treatment is best, second best, and so on, for each outcome. Last, forest plots of all contributing data, with ORs calculated using standard frequentist methods, are included in *Appendix 4*.

Symptomatic venous thromboembolism

Eight studies reported 728 symptomatic VTE events, leading to a network of 11 interventions (*Figure 47*). *Table 113* shows risk-of-bias judgements for these studies. They were mostly judged to be at low risk of bias, although there were some concerns about lack of blinding of participants and personnel. There was little evidence that risk of symptomatic VTE differed for any of the NOAC interventions compared with warfarin (INR 2–3) (*Table 114*). Neither was there evidence that risk of symptomatic VTE differed between licensed doses of NOACs (*Table 115*).

Symptomatic deep-vein thrombosis

Nine studies reported 351 symptomatic DVT events, leading to a network of 13 interventions (*Figure 48*). The studies were mostly judged to be at low risk of bias (*Table 116*), with some concerns about lack of blinding of participants and personnel. There was little evidence that risk of symptomatic DVT differed for any of the NOAC interventions compared with warfarin (INR 2–3) (*Table 117*). Neither was there evidence that risk of symptomatic VTE differed between licensed doses of NOACs (*Table 118*).

TABLE 111 Efficacy outcomes reported by nine included randomised trials in acute treatment of VTE: number of events for each outcome in each trial

Study	Study size	Symptomatic DVT	Symptomatic proximal DVT	Symptomatic PE	Fatal PE	Symptomatic non-fatal PE	Symptomatic VTE	Cardiovascular deaths	All-cause mortality
AMPLIFY ²¹⁰	5365	53			3	50	130	10	93
BOTTICELLI DVT ²⁰⁴	511	10	1						5
EINSTEIN DVT ²⁰⁶	3429	42			1	38	87	6	87
EINSTEIN DVT dose-ranging study ²⁰³	542	10			0	3	16		19
EINSTEIN PE ²⁰⁷	4817	35			3	41	94		108
HOKUSAI-VTE ^{208,209}	8240	120			7	108	276	27	258
ODIXa-DVT ²⁰²	543	5	6		2	3	10		
RE-COVER ²⁰⁵	2539	34				20	57		42
RE-COVER II ²¹¹	2568	42				20	58		50

TABLE 112 Safety outcomes reported by nine included randomised trials in acute treatment of VTE: number of events for each outcome in each trial

Study	Study size	MI	All bleeding	Minor bleeding	Major bleeding	Fatal bleeding	Intracranial bleeding	CRNM bleeding	CRB
AMPLIFY ²¹⁰	5365	6	1110		64	3	9	318	376
BOTTICELLI DVT ²⁰⁴	511			29	3	0		35	38
EINSTEIN DVT ²⁰⁶	3429	6			34		4	245	277
EINSTEIN DVT dose-ranging study ²⁰³	542		127		5	1		26	31
EINSTEIN PE ²⁰⁷	4817				78		14	463	523
HOKUSAI-VTE ^{208,209}	8240	33					23		
ODIXa-DVT ²⁰²	543		52	44	10	0			
RE-COVER ²⁰⁵	2539	6	482		44	2	3		182
RE-COVER II ²¹¹	2568	6	485		37	1	4	129	166




FIGURE 47 Network plot for symptomatic VTE (acute treatment of VTE).

TABLE 113 Included trials and risk-of-bias assessment for symptomatic VTE (acute treatment of VTE)

Study	Interventions compared	SG	AC	BPP	BOA	IOD	SR
AMPLIFY ²¹⁰	1, 2	+	+	+	+	?	+
EINSTEIN DVT ²⁰⁶	1, 9	+	+	-	+	+	+
EINSTEIN DVT dose-ranging study ²⁰³	1, 8, 10, 12	+	+	-	+	-	+
EINSTEIN PE ²⁰⁷	1, 9	+	+	-	+	+	+
HOKUSAI-VTE ^{208,209}	1, 2	+	+	+	+	+	+
ODiXa-DVT ²⁰²	1, 7, 11, 12, 13	+	+	?	+	+	+
RE-COVER ²⁰⁵	1, 5	+	+	+	+	+	+
RE-COVER II ²¹¹	1, 5	+	+	+	+	+	+


–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation; SR, selective reporting.

TABLE 114 Results for symptomatic VTE (acute treatment of VTE): comparisons with warfarin (INR 2–3)

Comparisons	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
With warfarin (INR 2–3)			
Apixaban (5 mg bd)	0.83 (0.58 to 1.18)	–	0.83 (0.58 to 1.18)
Dabigatran (150 mg bd)	1.09 (0.75 to 1.58)	–	1.09 (0.75 to 1.58)
Edoxaban [60 or 30 (17.6%) mg od]	0.89 (0.70 to 1.13)	–	0.89 (0.70 to 1.13)
Rivaroxaban (15 mg bd then 20 mg od)	0.90 (0.67 to 1.20)	–	0.90 (0.67 to 1.20)
Imprecisely estimated comparisons			
Rivaroxaban (10 mg bd)	0.77 (0.09 to 4.53)	–	0.77 (0.09 to 4.53)
Rivaroxaban (20 mg od)	0.44 (0.09 to 1.76)	–	0.44 (0.09 to 1.76)
Rivaroxaban (30 mg od)	0.63 (0.15 to 2.29)	–	0.63 (0.15 to 2.29)
Rivaroxaban (20 mg bd)	0.81 (0.09 to 4.81)	–	0.81 (0.09 to 4.81)
Rivaroxaban (40 mg od)	0.52 (0.15 to 1.65)	–	0.52 (0.15 to 1.65)
Rivaroxaban (30 mg bd)	0.73 (0.09 to 4.42)	–	0.73 (0.09 to 4.42)

TABLE 115 Results for symptomatic VTE (acute treatment of VTE): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd)	–	1.31 (0.79 to 2.19)	1.31 (0.79 to 2.19)
Edoxaban [60 or 30 (17.6%) mg od] vs. apixaban (5 mg bd)	–	1.06 (0.70 to 1.63)	1.06 (0.70 to 1.63)
Rivaroxaban (15 mg bd then 20 mg od) vs. apixaban (5 mg bd)	–	1.08 (0.68 to 1.71)	1.08 (0.68 to 1.71)
Edoxaban [60 or 30 (17.6%) mg od] vs. dabigatran (150 mg bd)	–	0.81 (0.52 to 1.27)	0.81 (0.52 to 1.27)
Rivaroxaban (15 mg bd then 20 mg od) vs. dabigatran (150 mg bd)	–	0.82 (0.51 to 1.33)	0.82 (0.51 to 1.33)
Rivaroxaban (15 mg bd then 20 mg od) vs. edoxaban [60 or 30 (17.6%) mg od]	–	1.01 (0.69 to 1.48)	1.01 (0.69 to 1.48)

**FIGURE 48** Network plot for symptomatic DVT (acute treatment of VTE).**TABLE 116** Included trials and risk-of-bias assessment for symptomatic DVT (acute treatment of VTE)

Study	Interventions compared	SG	AC	BPP	BOA	IOD	SR
AMPLIFY ²¹⁰	1, 2	+	+	+	+	+	+
BOTTICELLI DVT ²⁰⁴	1, 2, 3, 4	?	+	–	+	+	+
EINSTEIN DVT ²⁰⁶	1, 9	+	+	–	+	+	+
EINSTEIN DVT dose-ranging study ²⁰³	1, 8, 10, 12	+	+	–	+	–	+
EINSTEIN PE ²⁰⁷	1, 9	+	+	–	+	+	+
HOKUSAI-VTE ^{206,207}	1, 2	+	+	+	+	+	+
ODiXa-DVT ²⁰²	1, 7, 11, 12, 13	+	+	?	+	+	+
RE-COVER ²⁰⁵	1, 5	+	+	+	+	+	+
RE-COVER II ²¹¹	1, 5	+	+	+	+	+	+

–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation; SR, selective reporting.

TABLE 117 Results for symptomatic DVT (acute treatment of VTE): comparisons with warfarin (INR 2–3)

Comparisons with warfarin (INR 2–3)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Apixaban (5 mg bd)	0.66 (0.38 to 1.11)	–	0.66 (0.38 to 1.11)
Dabigatran (150 mg bd)	1.18 (0.75 to 1.86)	–	1.18 (0.75 to 1.86)
Edoxaban [60 or 30 (17.6%) mg od]	0.91 (0.63 to 1.30)	–	0.91 (0.63 to 1.30)
Rivaroxaban (15 mg bd then 20 mg od)	0.70 (0.44 to 1.10)	–	0.70 (0.44 to 1.10)
<i>Imprecisely estimated comparisons</i>			
<i>Apixaban (10 mg bd)</i>	<i>1.27 (0.29 to 5.11)</i>	–	<i>1.27 (0.29 to 5.11)</i>
<i>Apixaban (20 mg od)</i>	<i>0.25 (0.01 to 1.87)</i>	–	<i>0.25 (0.01 to 1.87)</i>
<i>Rivaroxaban (10 mg bd)</i>	<i>0.56 (0.02 to 7.51)</i>	–	<i>0.56 (0.02 to 7.51)</i>
<i>Rivaroxaban (20 mg od)</i>	<i>0.28 (0.03 to 1.33)</i>	–	<i>0.28 (0.03 to 1.33)</i>
<i>Rivaroxaban (30 mg od)</i>	<i>0.12 (0 to 0.86)</i>	–	<i>0.12 (0 to 0.86)</i>
<i>Rivaroxaban (20 mg bd)</i>	<i>0.59 (0.02 to 8.08)</i>	–	<i>0.59 (0.02 to 8.08)</i>
<i>Rivaroxaban (40 mg od)</i>	<i>0.21 (0.03 to 0.94)</i>	–	<i>0.21 (0.03 to 0.94)</i>
<i>Rivaroxaban (30 mg bd)</i>	<i>0.53 (0.02 to 7.27)</i>	–	<i>0.53 (0.02 to 7.27)</i>

TABLE 118 Results for symptomatic DVT (acute treatment of VTE): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd)	–	1.80 (0.90 to 3.64)	1.80 (0.90 to 3.64)
Edoxaban [60 or 30 (17.6%) mg od] vs. apixaban (5 mg bd)	–	1.38 (0.73 to 2.65)	1.38 (0.73 to 2.65)
Rivaroxaban (15 mg bd then 20 mg od) vs. apixaban (5 mg bd)	–	1.07 (0.53 to 2.18)	1.07 (0.53 to 2.18)
Edoxaban [60 or 30 (17.6%) mg od] vs. dabigatran (150 mg bd)	–	0.77 (0.43 to 1.38)	0.77 (0.43 to 1.38)
Rivaroxaban (15 mg bd then 20 mg od) vs. dabigatran (150 mg bd)	–	0.60 (0.31 to 1.13)	0.60 (0.31 to 1.13)
Rivaroxaban (15 mg bd then 20 mg od) vs. edoxaban [60 or 30 (17.6%) mg od]	–	0.77 (0.43 to 1.39)	0.77 (0.43 to 1.39)
<i>Imprecisely estimated comparisons</i>			
<i>Apixaban (10 mg bd) vs. apixaban (5 mg bd)</i>	<i>1.94 (0.44 to 7.95)</i>	–	<i>1.94 (0.44 to 7.95)</i>
<i>Dabigatran (150 mg bd) vs. apixaban (10 mg bd)</i>	–	<i>0.93 (0.21 to 4.36)</i>	<i>0.93 (0.21 to 4.36)</i>
<i>Edoxaban [60 or 30 (17.6%) mg od] vs. apixaban (10 mg bd)</i>	–	<i>0.71 (0.17 to 3.27)</i>	<i>0.71 (0.17 to 3.27)</i>
<i>Rivaroxaban (15 mg bd then 20 mg od) vs. apixaban (10 mg bd)</i>	–	<i>0.55 (0.13 to 2.60)</i>	<i>0.55 (0.13 to 2.60)</i>

Symptomatic pulmonary embolism

One study reported direct data on symptomatic PE events (see *Table 111*), whereas for the remaining eight studies, we derived symptomatic PE events by adding fatal PE and symptomatic non-fatal PE events, leading to a total of 300 symptomatic PE events across the network, which is displayed in *Figure 49*. The studies were mostly judged to be at low risk of bias (*Table 119*), with some concerns about lack of




FIGURE 49 Network plot for symptomatic PE (acute treatment of VTE).

TABLE 119 Included trials and risk-of-bias assessment for symptomatic PE (acute treatment of VTE)

Study	Interventions compared	SG	AC	BPP	BOA	IOD	SR
AMPLIFY ²¹⁰	1, 2	+	+	+	+	?	+
BOTTICELLI DVT ²⁰⁴	1, 2, 3, 4	?	+	-	+	+	+
EINSTEIN DVT ²⁰⁶	1, 9	+	+	-	+	+	+
EINSTEIN DVT dose-ranging study ²⁰³	1, 8, 10, 12	+	+	-	+	-	+
EINSTEIN PE ²⁰⁷	1, 9	+	+	-	+	+	+
HOKUSAI-VTE ^{206,207}	1, 2	+	+	+	+	+	+
ODiXa-DVT ²⁰²	1, 7, 11, 12, 13	+	+	?	+	+	+
RE-COVER ²⁰⁵	1, 5	+	+	+	+	+	+
RE-COVER II ²¹¹	1, 5	+	+	+	+	+	+

–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation; SR, selective reporting.

blinding of participants and personnel. There was little evidence that risk of symptomatic PE differed for any of the NOAC interventions compared with warfarin (INR 2–3) (Table 120). Neither was there evidence that risk of symptomatic PE differed between licensed doses of NOACs (Table 121).

Myocardial infarction

Five studies reported 57 MI events, leading to a network of five interventions (Figure 50). These studies were judged to be at low risk of bias (Table 122). All comparisons were imprecisely estimated (Tables 123 and 124).

Major bleeding

The nine trials^{200–209} reported 228 major bleeding events, leading to a network of 13 interventions (Figure 51). These studies^{200–209} were judged to be at low risk of bias (Table 125). There was strong evidence that apixaban (5 mg bd) and rivaroxaban (15 mg bd then 20 mg od) reduce risk of major bleeding compared with warfarin (INR 2–3) (Table 126). There was evidence that risk of major bleeding was higher for edoxaban [60 or 30 (17.6%) mg od] and dabigatran (150 mg bd) than apixaban (5 mg bd) (Table 127).

TABLE 120 Results for symptomatic PE (acute treatment of VTE): comparisons with warfarin (INR 2–3)

Comparisons with warfarin (INR 2–3)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Apixaban (5 mg bd)	1.09 (0.64 to 1.87)	–	1.09 (0.64 to 1.87)
Dabigatran (150 mg bd)	1.00 (0.53 to 1.89)	–	1.00 (0.53 to 1.89)
Edoxaban [60 or 30 (17.6%) mg od]	0.85 (0.59 to 1.23)	–	0.85 (0.59 to 1.23)
Rivaroxaban (15 mg bd then 20 mg od)	1.18 (0.77 to 1.83)	–	1.18 (0.77 to 1.83)
<i>Imprecisely estimated comparisons</i>			
<i>Apixaban (10 mg bd)</i>	<i>0.28 (0 to 6.40)</i>	–	<i>0.28 (0 to 6.40)</i>
<i>Apixaban (20 mg od)</i>	<i>0.29 (0 to 6.53)</i>	–	<i>0.29 (0 to 6.53)</i>
<i>Rivaroxaban (10 mg bd)</i>	<i>0.73 (0.02 to 11.6)</i>	–	<i>0.73 (0.02 to 11.6)</i>
<i>Rivaroxaban (20 mg od)</i>	<i>1.10 (0.07 to 14.9)</i>	–	<i>1.10 (0.07 to 14.9)</i>
<i>Rivaroxaban (30 mg od)</i>	<i>1.12 (0.07 to 15.6)</i>	–	<i>1.12 (0.07 to 15.6)</i>
<i>Rivaroxaban (20 mg bd)</i>	<i>0.78 (0.02 to 12.2)</i>	–	<i>0.78 (0.02 to 12.2)</i>
<i>Rivaroxaban (40 mg od)</i>	<i>0.49 (0.04 to 4.19)</i>	–	<i>0.49 (0.04 to 4.19)</i>
<i>Rivaroxaban (30 mg bd)</i>	<i>0.69 (0.02 to 11.3)</i>	–	<i>0.69 (0.02 to 11.3)</i>

TABLE 121 Results for symptomatic PE (acute treatment of VTE): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd)	–	0.92 (0.40 to 2.09)	0.92 (0.40 to 2.09)
Edoxaban [60 or 30 (17.6%) mg od] vs. apixaban (5 mg bd)	–	0.78 (0.41 to 1.49)	0.78 (0.41 to 1.49)
Edoxaban [60 or 30 (17.6%) mg od] vs. dabigatran (150 mg bd)	–	0.85 (0.41 to 1.77)	0.85 (0.41 to 1.77)
Rivaroxaban (15 mg bd then 20 mg od) vs. apixaban (5 mg bd)	–	1.09 (0.54 to 2.16)	1.09 (0.54 to 2.16)
Rivaroxaban (15 mg bd then 20 mg od) vs. dabigatran (150 mg bd)	–	1.18 (0.55 to 2.54)	1.18 (0.55 to 2.54)
Rivaroxaban (15 mg bd then 20 mg od) vs. edoxaban [60 or 30 (17.6%) mg od]	–	1.39 (0.79 to 2.46)	1.39 (0.79 to 2.46)
<i>Imprecisely estimated comparisons</i>			
<i>Apixaban (10 mg bd) vs. apixaban (5 mg bd)</i>	<i>0.25 (0 to 5.86)</i>	–	<i>0.25 (0 to 5.86)</i>
<i>Dabigatran (150 mg bd) vs. apixaban (10 mg bd)</i>	–	<i>3.66 (0.15 to 1860)</i>	<i>3.66 (0.15 to 1860)</i>
<i>Edoxaban [60 or 30 (17.6%) mg od] vs. apixaban (10 mg bd)</i>	–	<i>3.10 (0.13 to 1530)</i>	<i>3.10 (0.13 to 1530)</i>
<i>Rivaroxaban (15 mg bd then 20 mg od) vs. apixaban (10 mg bd)</i>	–	<i>4.32 (0.18 to 2160)</i>	<i>4.32 (0.18 to 2160)</i>




FIGURE 50 Network plot for MI (acute treatment of VTE).

TABLE 122 Included trials and risk-of-bias assessment for MI (acute treatment of VTE)

Study	Interventions compared	SG	AC	BPP	BOA	IOD	SR
AMPLIFY ²¹⁰	1, 2	+	+	+	+	?	+
EINSTEIN DVT ²⁰⁶	1, 9	+	+	-	+	+	+
HOKUSAI-VTE ^{206,207}	1, 2	+	+	+	+	+	+
RE-COVER ²⁰⁵	1, 5	+	+	+	+	+	+
RE-COVER II ²¹¹	1, 5	+	+	+	+	+	+

–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation; SR, selective reporting.

TABLE 123 Results for MI (acute treatment of VTE): comparisons with warfarin (INR 2–3)

Comparisons with warfarin (INR 2–3)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Edoxaban [60 or 30 (17.6%) mg od]	1.56 (0.78 to 3.24)	–	1.56 (0.78 to 3.24)
Imprecisely estimated comparisons			
Apixaban (5 mg bd)	2.18 (0.40 to 17.9)	–	2.18 (0.40 to 17.9)
Dabigatran (150 mg bd)	2.11 (0.64 to 8.12)	–	2.11 (0.64 to 8.12)
Rivaroxaban (15 mg bd then 20 mg od)	6.81 (0.90 to 219)	–	6.81 (0.90 to 219)

Clinically relevant bleeding

Eight studies^{201–209} reported 2365 CRB events, leading to a network of 10 interventions (Figure 52). These studies were mostly judged to be at low risk of bias (Table 128), with some concerns about lack of blinding of participants and personnel. There was evidence that apixaban (5 mg bd), dabigatran (150 mg bd) and edoxaban [60 or 30 (17.6%) mg od] reduce risk of CRB compared with warfarin (INR 2–3) (Table 129). There was some evidence that rivaroxaban (15 mg bd then 20 mg od) reduces risk of CRB compared with warfarin (INR 2–3). There was evidence that risk of CRB is higher with dabigatran (150 mg bd), edoxaban [60 or 30 (17.6%) mg od] and rivaroxaban (15 mg bd then 20 mg od) than apixaban (5 mg bd) (Table 130). There was evidence that risk of CRB is higher with edoxaban [60 or 30 (17.6%) mg od] and rivaroxaban (15 mg bd then 20 mg od) than dabigatran (150 mg bd).

TABLE 124 Results for MI (acute treatment of VTE): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Imprecisely estimated comparisons			
Dabigatran (150 mg bd) vs. apixaban (5 mg bd)	–	0.96 (0.09 to 8.47)	0.96 (0.09 to 8.47)
Edoxaban [60 or 30 (17.6%) mg od] vs. apixaban (5 mg bd)	–	0.71 (0.08 to 4.49)	0.71 (0.08 to 4.49)
Rivaroxaban (15 mg bd then 20 mg od) vs. apixaban (5 mg bd)	–	3.17 (0.17 to 145)	3.17 (0.17 to 145)
Edoxaban [60 or 30 (17.6%) mg od] vs. dabigatran (150 mg bd)	–	0.74 (0.16 to 3.03)	0.74 (0.16 to 3.03)
Rivaroxaban (15 mg bd then 20 mg od) vs. dabigatran (150 mg bd)	–	3.27 (0.29 to 124)	3.27 (0.29 to 124)
Rivaroxaban (15 mg bd then 20 mg od) vs. edoxaban [60 or 30 (17.6%) mg od]	–	4.44 (0.50 to 143)	4.44 (0.50 to 143)




FIGURE 51 Network plot for major bleeding (acute treatment of VTE).

TABLE 125 Included trials and risk-of-bias assessment for major bleeding (acute treatment of VTE)

Study	Interventions compared	SG	AC	BPP	BOA	IOD	SR
AMPLIFY ²¹⁰	1, 2	+	+	+	+	?	+
BOTTICELLI DVT ²⁰⁴	1, 2, 3, 4	?	+	–	+	+	+
EINSTEIN DVT ²⁰⁶	1, 9	+	+	–	+	+	+
EINSTEIN DVT dose-ranging study ²⁰³	1, 8, 10, 12	+	+	–	+	+	+
EINSTEIN PE ²⁰⁷	1, 9	+	+	–	+	+	+
HOKUSAI-VTE ^{206,207}	1, 2	+	+	+	+	+	+
ODiXa-DVT ²⁰²	1, 7, 11, 12, 13	+	+	?	+	+	+
RE-COVER ²⁰⁵	1, 5	+	+	+	+	+	+
RE-COVER II ²¹¹	1, 5	+	+	+	+	+	+

–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation; SR, selective reporting.

TABLE 126 Results for major bleeding (acute treatment of VTE): comparisons with warfarin (INR 2–3)

Comparisons with warfarin (INR 2–3)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Apixaban (5 mg bd)	0.33 (0.18 to 0.56)	–	0.33 (0.18 to 0.56)
Dabigatran (150 mg bd)	0.76 (0.48 to 1.18)	–	0.76 (0.48 to 1.18)
Edoxaban [60 or 30 (17.6%) mg od]	0.85 (0.59 to 1.22)	–	0.85 (0.59 to 1.22)
Rivaroxaban (15 mg bd then 20 mg od)	0.55 (0.37 to 0.80)	–	0.55 (0.37 to 0.80)
<i>Imprecisely estimated comparisons</i>			
<i>Apixaban (10 mg bd)</i>	<i>0.18 (0 to 3.84)</i>	–	<i>0.18 (0 to 3.84)</i>
<i>Apixaban (20 mg od)</i>	<i>1.79 (0.23 to 15.8)</i>	–	<i>1.79 (0.23 to 15.8)</i>
<i>Rivaroxaban (10 mg bd)</i>	<i>1.86 (0.23 to 16)</i>	–	<i>1.86 (0.23 to 16)</i>
<i>Rivaroxaban (20 mg od)</i>	<i>0.97 (0.07 to 9.40)</i>	–	<i>0.97 (0.07 to 9.40)</i>
<i>Rivaroxaban (30 mg od)</i>	<i>1.81 (0.24 to 14.8)</i>	–	<i>1.81 (0.24 to 14.8)</i>
<i>Rivaroxaban (20 mg bd)</i>	<i>1.90 (0.24 to 15.4)</i>	–	<i>1.90 (0.24 to 15.4)</i>
<i>Rivaroxaban (40 mg od)</i>	<i>1.03 (0.18 to 6.02)</i>	–	<i>1.03 (0.18 to 6.02)</i>
<i>Rivaroxaban (30 mg bd)</i>	<i>3.58 (0.65 to 26.6)</i>	–	<i>3.58 (0.65 to 26.6)</i>

TABLE 127 Results for major bleeding (acute treatment of VTE): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Rivaroxaban (15 mg bd then 20 mg od) vs. apixaban (5 mg bd)	–	1.68 (0.85 to 3.40)	1.68 (0.85 to 3.40)
Edoxaban [60 or 30 (17.6%) mg od] vs. apixaban (5 mg bd)	–	2.60 (1.35 to 5.21)	2.60 (1.35 to 5.21)
Edoxaban [60 or 30 (17.6%) mg od] vs. dabigatran (150 mg bd)	–	1.12 (0.63 to 1.98)	1.12 (0.63 to 1.98)
Rivaroxaban (15 mg bd then 20 mg od) vs. dabigatran (150 mg bd)	–	0.72 (0.40 to 1.30)	0.72 (0.40 to 1.30)
Rivaroxaban (15 mg bd then 20 mg od) vs. edoxaban [60 or 30 (17.6%) mg od]	–	0.64 (0.38 to 1.10)	0.64 (0.38 to 1.10)
<i>Imprecisely estimated comparisons</i>			
<i>Apixaban (10 mg bd) vs. apixaban (5 mg bd)</i>	<i>0.54 (0 to 12.1)</i>	–	<i>0.54 (0 to 12.1)</i>
<i>Dabigatran (150 mg bd) vs. apixaban (5 mg bd)</i>	–	<i>2.32 (1.15 to 4.86)</i>	<i>2.32 (1.15 to 4.86)</i>
<i>Dabigatran (150 mg bd) vs. apixaban (10 mg bd)</i>	–	<i>4.31 (0.19 to 2090)</i>	<i>4.31 (0.19 to 2090)</i>
<i>Edoxaban [60 or 30 (17.6%) mg od] vs. apixaban (10 mg bd)</i>	–	<i>4.84 (0.22 to 2300)</i>	<i>4.84 (0.22 to 2300)</i>
<i>Rivaroxaban (15 mg bd then 20 mg od) vs. apixaban (10 mg bd)</i>	–	<i>3.12 (0.14 to 1470)</i>	<i>3.12 (0.14 to 1470)</i>




FIGURE 52 Network plot for CRB (acute treatment of VTE).

TABLE 128 Included trials and risk-of-bias assessment for CRB (acute treatment of VTE)

Study	Interventions compared	SG	AC	BPP	BOA	IOD	SR
AMPLIFY ²¹⁰	1, 2	+	+	+	+	?	+
BOTTICELLI DVT ²⁰⁴	1, 2, 3, 4	?	+	-	+	+	+
EINSTEIN DVT ²⁰⁶	1, 9	+	+	-	+	+	+
EINSTEIN DVT dose-ranging study ²⁰³	1, 8, 10, 12	+	+	-	+	+	+
EINSTEIN PE ²⁰⁷	1, 9	+	+	-	+	+	+
HOKUSAI-VTE ^{206,207}	1, 2	+	+	+	+	+	+
RE-COVER ²⁰⁵	1, 5	+	+	+	+	+	+
RE-COVER II ²¹¹	1, 5	+	+	+	+	+	+

–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation; SR, selective reporting.

TABLE 129 Results for CRB (acute treatment of VTE): comparisons with warfarin (INR 2–3)

Comparisons with warfarin (INR 2–3)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Apixaban (5 mg bd)	0.44 (0.35 to 0.55)	–	0.44 (0.35 to 0.55)
Apixaban (10 mg bd)	0.36 (0.12 to 0.87)	–	0.36 (0.12 to 0.87)
Apixaban (20 mg od)	0.76 (0.34 to 1.61)	–	0.76 (0.34 to 1.61)
Dabigatran (150 mg bd)	0.61 (0.49 to 0.76)	–	0.61 (0.49 to 0.76)
Edoxaban [60 or 30 (17.6%) mg od]	0.81 (0.70 to 0.94)	–	0.81 (0.70 to 0.94)
Rivaroxaban (15 mg bd then 20 mg od)	0.93 (0.80 to 1.08)	–	0.93 (0.80 to 1.08)
Rivaroxaban (20 mg od)	0.54 (0.20 to 1.39)	–	0.54 (0.20 to 1.39)
Rivaroxaban (30 mg od)	0.56 (0.21 to 1.43)	–	0.56 (0.21 to 1.43)
Imprecisely estimated comparisons			
Rivaroxaban (40 mg od)	0.17 (0.04 to 0.58)	–	0.17 (0.04 to 0.58)

TABLE 130 Results for CRB (acute treatment of VTE): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Apixaban (10 mg bd) vs. apixaban (5 mg bd)	0.81 (0.28 to 2.00)	–	0.81 (0.28 to 2.00)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd)	–	1.39 (1.02 to 1.90)	1.39 (1.02 to 1.90)
Edoxaban [60 or 30 (17.6%) mg od] vs. apixaban (5 mg bd)	–	1.84 (1.41 to 2.40)	1.84 (1.41 to 2.40)
Rivaroxaban (15 mg bd then 20 mg od) vs. apixaban (5 mg bd)	–	2.12 (1.63 to 2.76)	2.12 (1.63 to 2.76)
Dabigatran (150 mg bd) vs. apixaban (10 mg bd)	–	1.72 (0.68 to 5.02)	1.72 (0.68 to 5.02)
Edoxaban [60 or 30 (17.6%) mg od] vs. apixaban (10 mg bd)	–	2.27 (0.91 to 6.56)	2.27 (0.91 to 6.56)
Rivaroxaban (15 mg bd then 20 mg od) vs. apixaban (10 mg bd)	–	2.62 (1.05 to 7.55)	2.62 (1.05 to 7.55)
Edoxaban [60 or 30 (17.6%) mg od] vs. dabigatran (150 mg bd)	–	1.32 (1.01 to 1.73)	1.32 (1.01 to 1.73)
Rivaroxaban (15 mg bd then 20 mg od) vs. dabigatran (150 mg bd)	–	1.52 (1.17 to 1.99)	1.52 (1.17 to 1.99)
Rivaroxaban (15 mg bd then 20 mg od) vs. edoxaban [60 or 30 (17.6%) mg od]	–	1.15 (0.93 to 1.42)	1.15 (0.93 to 1.42)

All-cause mortality

Eight studies^{201–209} reported 662 all-cause mortality events, leading to a network of 10 interventions (*Figure 53*). These studies^{201–209} were mostly judged to be at low risk of bias (*Table 131*), with some concerns about lack of blinding of participants and personnel. There was little evidence that risk of all-cause mortality differed for any of the NOAC interventions compared with warfarin (INR 2–3) (*Table 132*). Neither was there evidence that risk of all-cause mortality differed between licensed doses of NOACs (*Table 133*).


**FIGURE 53** Network plot for all-cause mortality (acute treatment of VTE).

TABLE 131 Included trials and risk-of-bias assessment for all-cause mortality (acute treatment of VTE)

Study	Interventions compared	SG	AC	BPP	BOA	IOD	SR
AMPLIFY ²¹⁰	1, 2	+	+	+	+	?	+
BOTTICELLI DVT ²⁰⁴	1, 2, 3, 4	?	+	-	+	+	+
EINSTEIN DVT ²⁰⁶	1, 9	+	+	-	+	+	+
EINSTEIN DVT dose-ranging study ²⁰³	1, 8, 10, 12	+	+	-	+	+	+
EINSTEIN PE ²⁰⁷	1, 9	+	+	-	+	+	+
HOKUSAI-VTE ^{206,207}	1, 2	+	+	+	+	+	+
RE-COVER ²⁰⁵	1, 5	+	+	+	+	+	+
RE-COVER II ²¹¹	1, 5	+	+	+	+	+	+

–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation; SR, selective reporting.

TABLE 132 Results for all-cause mortality (acute treatment of VTE): comparisons with warfarin (INR 2–3)

Comparisons with warfarin (INR 2–3)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Apixaban (5 mg bd)	0.85 (0.57 to 1.27)	–	0.85 (0.57 to 1.27)
Dabigatran (150 mg bd)	1.00 (0.66 to 1.52)	–	1.00 (0.66 to 1.52)
Edoxaban [60 or 30 (17.6%) mg od]	1.05 (0.82 to 1.35)	–	1.05 (0.82 to 1.35)
Rivaroxaban (15 mg bd then 20 mg od)	0.96 (0.73 to 1.29)	–	0.96 (0.73 to 1.29)
<i>Imprecisely estimated comparisons</i>			
Apixaban (10 mg bd)	0.58 (0.05 to 3.74)	–	0.58 (0.05 to 3.74)
Apixaban (20 mg od)	0.61 (0.05 to 3.87)	–	0.61 (0.05 to 3.87)
Rivaroxaban (20 mg od)	0.80 (0.18 to 3.16)	–	0.80 (0.18 to 3.16)
Rivaroxaban (30 mg od)	1.73 (0.55 to 5.88)	–	1.73 (0.55 to 5.88)
Rivaroxaban (40 mg od)	0.35 (0.04 to 1.82)	–	0.35 (0.04 to 1.82)

TABLE 133 Results for all-cause mortality (acute treatment of VTE): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd)	–	1.18 (0.66 to 2.12)	1.18 (0.66 to 2.12)
Edoxaban [60 or 30 (17.6%) mg od] vs. apixaban (5 mg bd)	–	1.24 (0.77 to 1.99)	1.24 (0.77 to 1.99)
Rivaroxaban (15 mg bd then 20 mg od) vs. apixaban (5 mg bd)	–	1.14 (0.70 to 1.87)	1.14 (0.70 to 1.87)
Edoxaban [60 or 30 (17.6%) mg od] vs. dabigatran (150 mg bd)	–	1.05 (0.65 to 1.70)	1.05 (0.65 to 1.70)
Rivaroxaban (15 mg bd then 20 mg od) vs. dabigatran (150 mg bd)	–	0.97 (0.58 to 1.59)	0.97 (0.58 to 1.59)
Rivaroxaban (15 mg bd then 20 mg od) vs. edoxaban [60 or 30 (17.6%) mg od]	–	0.92 (0.63 to 1.34)	0.92 (0.63 to 1.34)


TABLE 133 Results for all-cause mortality (acute treatment of VTE): NOACs (licensed doses only) (continued)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
<i>Imprecisely estimated comparisons</i>			
Apixaban (10 mg bd) vs. apixaban (5 mg bd)	0.68 (0.05 to 4.47)	–	0.68 (0.05 to 4.47)
Dabigatran (150 mg bd) vs. apixaban (10 mg bd)	–	1.73 (0.25 to 22.6)	1.73 (0.25 to 22.6)
Edoxaban [60 or 30 (17.6%) mg od] vs. apixaban (10 mg bd)	–	1.82 (0.27 to 23.2)	1.82 (0.27 to 23.2)
Rivaroxaban (15 mg bd then 20 mg od) vs. apixaban (10 mg bd)	–	1.67 (0.25 to 21.4)	1.67 (0.25 to 21.4)

Summary of results and ranking of interventions

There was little evidence that risk of symptomatic VTE, symptomatic DVT or symptomatic PE differed for any of the NOAC interventions compared with warfarin (INR 2–3). Neither was there evidence that risk of these outcomes differed between licensed doses of NOACs. However, there was evidence of substantial reductions in risk of both major bleeding and CRB for apixaban (5 mg bd) compared with warfarin (INR 2–3). There was also evidence that other NOACs reduced bleeding compared with warfarin (INR 2–3). In comparisons between licensed doses of NOACs, there was evidence that apixaban (5 mg bd) reduced major bleeding risk compared with some other NOACs. With regard to model appraisal, we did not identify any instance of lack of convergence among the Markov chains, poor model fit or inconsistency.

Figure 54 presents the rankogram for all licensed interventions and all seven outcomes examined in this review. There was a high probability that warfarin (INR 2–3) is ranked worst for major bleeding and CRB. There was a high probability that apixaban 5 mg bd is ranked best for major bleeding and CRB, and this intervention also had a high probability of being ranked best or second best for symptomatic DVT, symptomatic VTE and all-cause mortality.

**FIGURE 54** Rankogram for licensed interventions examined in acute treatment of VTE. CR, clinically relevant. (continued)




FIGURE 54 Rankogram for licensed interventions examined in acute treatment of VTE. CR, clinically relevant. (continued)




FIGURE 54 Rankogram for licensed interventions examined in acute treatment of VTE. CR, clinically relevant.

Chapter 9 Clinical results (4): secondary prevention of venous thromboembolism

Included studies

Ten completed RCTs with 11 references,^{206,213–222} one ongoing trial²²³ and one trial²²⁴ reported in insufficient detail to include in the quantitative synthesis met the eligibility criteria for the review (see *Figure 32*). A summary of the characteristics of the 10 studies included in the analyses is presented in *Table 134*. All were multicentre and many were conducted across countries in North and South America, Europe, Asia, and Australia, New Zealand, South Africa, Russia and Israel. All were Phase III trials. A total of 10,390 patients were included; the number of patients randomised ranged from 162 to 2866. Four studies, with a randomised total of 7902 patients, examined a NOAC (against placebo in three studies and against warfarin in one study). Four studies, with a randomised total of 1263 patients, examined warfarin (against placebo in two studies and against no treatment in two studies). Two studies, with a randomised total of 1225 patients, examined aspirin against placebo.

Eligibility criteria were similar across the studies, all patients having already been treated for first-ever objectively confirmed symptomatic DVT and/or PE. The mean age of patients was similar across studies that compared NOACs, ranging from 54.7 to 58 years. The mean age of patients across all the 10 included studies^{206,213–222} ranged from 53 to 67.3 years. The percentage of male patients was similar across studies that compared NOACs, ranging from 55.5% to 61%. The percentage of males across the 10 studies^{206,213–222} ranged from 52.8% to 63.9%. Mean BMI was reported in only three studies^{216,219,221} and ranged from 27.1 to 29.9 kg/m² across study arms. Mean body weight ranged from 83.7 to 86.1 kg across study arms when data were reported. The proportion of patients with comorbidities was not well reported. Three studies^{216,222} reported the proportion of patients who were diabetic, which ranged from 6.7% to 10.5%. Two studies^{221,222} reported proportions with hypertension and cancer, which ranged from 36.3% to 41.3% and from 1% to 4%, respectively. Half of the studies that reported each comorbidity examined a NOAC.

Two studies examined dabigatran 150 mg bd: against standard intensity warfarin (INR 2–3) in one study and against placebo in the other. One study examined each of apixaban 2.5 mg and 5 mg bd, and rivaroxaban 20 mg od, against placebo in both studies. Two studies examined aspirin 100 mg od against placebo. Four studies examined warfarin: against placebo in two studies and against no treatment in two studies. Three of these four studies examined standard intensity warfarin and one study examined low intensity warfarin (INR 1.5–2). Mean TTR for standard intensity warfarin arms was reported in only one study²¹⁵ and was 83%.

The duration of treatment varied across studies, ranging from 6 to 36 months in the NOAC studies, from 24 to 48 months in the aspirin studies and from 3 to 51.6 months in the warfarin studies. Efficacy and safety outcomes reported across studies were similar irrespective of the intervention examined, and were reported at the end of the treatment periods. All 10 studies^{206,213–222} reported data on symptomatic VTE and major bleeding. Nine studies each reported data on symptomatic DVT, symptomatic PE and all-cause mortality. Six studies reported data on CRB, and five studies reported data on MI. Only the four NOACs studies were sponsored by a pharmaceutical company. Four other studies were conducted with funding from more than one source: mainly medical research councils or institutes. In all sponsored studies, the sponsors were responsible for study design and data collection, and in the majority of cases data analysis (particularly the pharmaceutical company funded studies). Funding source was not declared in two studies.

TABLE 134 Characteristics of 10 included randomised trials in secondary prevention of VTE

Study (centre type) [countries]	Sponsor (sponsor's role)	Age eligibility (mean age, years) [% male]	Clinical condition	No. randomised	Interventions compared	Treatment duration (months)	Outcomes	Time of outcome assessment (months)
AMPLIFY-EXT ²¹ (Multicentre) [North and South America, Europe, Russia, Israel, Australia, Asia and South Africa]	Pfizer and Bristol-Myers Squibb <i>(The sponsors collected and maintained the data; the academic authors had access to the data at all times, through the sponsors)</i>	≥ 18 (56.7) [57.4]	Already treated for a first-ever objectively confirmed, symptomatic DVT or PE (with or without DVT)	2486	Apixaban 1. 2.5 mg bd 2. 5 mg bd 3. Placebo bd	12	Efficacy: Symptomatic VTE, symptomatic DVT, symptomatic non-fatal PE, fatal PE Safety: Major bleeding, CRNM bleeding, composite CRB, fatal bleeding, MI, death (cardiovascular), death (all causes)	12
ASPIRE ²⁰ (Multicentre) [Argentina, Australia, New Zealand and Asia]	National Health and Medical Research Council Australia and others (not specified) <i>(The funder was responsible for the collection, maintenance, integrity, and confidentiality of all data)</i>	≥ 18 (54.5) [54.4]	Already treated for a first-ever unprovoked episode of objectively diagnosed symptomatic DVT or an acute PE	822	Aspirin 1. 100 mg od 2. Placebo od	Up to 48	Efficacy: Symptomatic VTE, symptomatic DVT, symptomatic distal DVT, symptomatic proximal DVT, symptomatic PE, fatal PE Safety: All bleeding, major bleeding, CRNM bleeding, composite CRB, fatal bleeding, MI, all stroke, death (cardiovascular), death (all causes)	37.2 (median)
EINSTEIN-EXTENSION ^{206,217,218} (Multicentre) [North and South America, Europe, Israel, Australia, New Zealand, Asia and South Africa]	Bayer Healthcare <i>(The data were collected and maintained by the sponsor)</i>	≥ 18 (58.3) [58]	Already treated for mixed (first ever and ≥ 1 previous VTE) confirmed symptomatic PE or DVT	1197	Rivaroxaban 1. 20 mg od 2. Placebo od	6–12	Efficacy: Symptomatic VTE, symptomatic DVT, symptomatic non-fatal PE, fatal PE Safety: Major bleeding, CRNM bleeding, composite CRB, fatal bleeding, death (all causes)	6.2 (mean)

Study (centre type) [countries]	Sponsor (sponsor's role)	Age eligibility (mean age, years) [% male]	Clinical condition	No. randomised	Interventions compared	Treatment duration (months)	Outcomes	Time of outcome assessment (months)
LAFIT ²¹³ (Multicentre) [Canada and USA]	Supported by a grant from DuPont Pharma, Wilmington, DE, USA, and by the Medical Research Council of Canada, the Heart and Stroke Foundation of Canada and the Ministry of Health of Ontario	Adults (59) [60]	Already treated for a first-ever episode of idiopathic VTE	162	Warfarin 1. INR 2–3 (mean TTR: 64%) 2. Placebo od	24	Efficacy: Symptomatic VTE, symptomatic DVT, symptomatic non-fatal PE, fatal PE Safety: All bleeding, major bleeding, minor bleeding, death (all causes)	24
PREVENT ²¹⁶ (Multicentre) [USA]	(Not declared) National Heart, Lung, and Blood Institute, USA (Note: Study drug and placebo were supplied without fee by Bristol-Myers Squibb) <i>(The funder appointed an independent data and safety monitoring committee that monitored the primary end point of recurrent venous thromboembolism)</i>	≥30 (median 53) [52.8]	Already treated for idiopathic VTE. VTE episode is not clearly reported but texts suggest this may be a first-ever event	508	Warfarin 1. INR 1.5–2 (mean TTR: NR) 2. Placebo od	51.6 (mean 25.2)	Efficacy: Symptomatic VTE, fatal PE Safety: Major bleeding, minor bleeding, MI, death (all causes)	51.6 (mean 25.2)

continued

TABLE 134 Characteristics of 10 included randomised trials in secondary prevention of VTE (continued)

Study (centre type) [countries]	Sponsor (sponsor's role)	Age eligibility (mean age, years) [% male]	Clinical condition	No. randomised	Interventions compared	Treatment duration (months)	Outcomes	Time of outcome assessment (months)
RE-MEDY ²²² (Multicentre) [North and South America, Europe, Russia, Israel, Australia, New Zealand, Asia, New Zealand and South Africa]	Boehringer Ingelheim <i>(Study was designed, conducted, and data analysed by the funder in conjunction with the steering committee)</i>	≥ 18 (54.7) [61]	Already treated for mixed (first-ever and ≥ 1 previous) objectively confirmed, symptomatic, proximal DVT or PE	2866	Dabigatran 1. 150 mg bd Warfarin 2. INR 2–3 (median TTR: 65.3%)	6–36	<i>Efficacy:</i> Symptomatic VTE, symptomatic DVT, symptomatic non-fatal PE <i>Safety:</i> All bleeding, major bleeding, composite CRB, intracranial bleeding, MI, death (all causes)	36
RE-SONATE ²²² (Multicentre) [North America, Europe, Russia, Australia, New Zealand, Asia and South Africa]	Boehringer Ingelheim <i>(Study was designed, conducted, and data analysed by the funder in conjunction with the steering committee)</i>	≥ 18 (55.8) [55.5]	Already treated for mixed (first-ever and ≥ 1 previous) objectively confirmed, symptomatic, proximal DVT or PE. A small proportion (< 1%) had ≥ 1 previous	1353	Dabigatran 1. 150 mg bd 2. Placebo bd	6	<i>Efficacy:</i> Symptomatic VTE, symptomatic DVT, symptomatic non-fatal PE <i>Safety:</i> All bleeding, major bleeding, CRNIM bleeding, composite CRB, MI	6
WARFASA ²¹⁹ (Multicentre) [Austria and Italy]	University of Perugia, Italy, and others (not specified) <i>(Data were collected, maintained, and analysed by the Clinical Research Unit of the University of Perugia)</i>	≥ 18 (62) [63.9]	Already treated for a first-ever, objectively confirmed, symptomatic, unprovoked, proximal DVT, PE, or both	403	Aspirin 1. 100 mg od 2. Placebo od	24	<i>Efficacy:</i> Symptomatic VTE, symptomatic DVT, symptomatic PE, fatal PE, arterial event <i>Safety:</i> Major bleeding, CRNIM bleeding, composite CRB, death (all causes)	24

Study (centre type) [countries]	Sponsor (sponsor's role)	Age eligibility (mean age, years) [% male]	Clinical condition	No. randomised	Interventions compared	Treatment duration (months)	Outcomes	Time of outcome assessment (months)
WODIT-DVT ²¹⁴ (Multicentre) [Italy]	Not declared	15–85 (67.3) [57.9]	Already treated for a first-ever episode of symptomatic objectively confirmed idiopathic proximal DVT	267	Warfarin 1. INR 2–3 (mean TTR: 81%) 2. No treatment	9	<i>Efficacy:</i> Symptomatic VTE, symptomatic DVT, symptomatic non-fatal PE, fatal PE <i>Safety:</i> Major bleeding, fatal bleeding, death (cardiovascular), death (all causes)	33
WODIT-PE ²¹⁵ (Multicentre) [Italy]	Not declared	15–85 (62) [59.5]	Already treated for a first-ever episode of symptomatic, objectively confirmed PE	326	Warfarin 1. INR 2–3 (mean TTR: NR) 2. No treatment	3	<i>Efficacy:</i> Symptomatic VTE, symptomatic PE, symptomatic non-fatal PE, symptomatic DVT, fatal PE <i>Safety:</i> All bleeding, major bleeding, fatal bleeding, death (cardiovascular), death (all causes)	3
NR, not reported.								

Time in therapeutic range for warfarin interventions

Table 135 shows the comparator interventions, target INR and (where reported) mean TTR for the five studies^{213–216,222} that included a warfarin intervention arm. Three (60%) of these studies^{213,214,222} reported mean TTR, which was 64% in LAFIT,²¹³ 65.3% in RE-MEDY²²² and 81% in WODIT-DVT.²¹⁴

Risk of bias in included studies

Table 136 shows detailed risk-of-bias assessments for each included study for each domain of the Cochrane assessment tool. Generally, the studies were judged to be at low risk of bias for sequence generation, blinding of outcome assessment and incomplete outcome data. However, one study did not describe how the randomisation sequence was generated. Eight studies described how treatment allocation was concealed: these studies were judged to be at low risk of bias for this domain. One study provided insufficient information to enable a judgement on allocation concealment, and one study provided no information on this domain: these studies were judged to be at unclear and high risk of bias, respectively. Overall, the risk of bias due to selective reporting was judged to be low. Three studies were open-label and so were judged to be at a high risk of bias for blinding of participants and personnel.

Results of clinical effectiveness and safety

This review included 10 trials comparing a total number of nine interventions (Table 137). The outcomes reported in the 10 studies, along with the number of events per outcome, are displayed in Tables 138 and 139. We performed NMAs for seven outcomes: symptomatic DVT, symptomatic PE, symptomatic VTE, MI, major bleeding, CRB and all-cause mortality.

Results are presented as follows for each of the six outcomes. First, we provide network plots to illustrate the comparisons of interventions made in the different trials. Second, we illustrate the risk-of-bias assessments that were specific to the outcome for each trial included in the network. Third, we present results tables for each intervention compared with the reference treatment (placebo). Fourth, we present for each NOAC intervention compared with aspirin and warfarin. Fifth, we present results tables for pairwise comparisons among licensed doses of the NOACs. For all sets of results tables, posterior median ORs and 95% credible intervals from Bayesian fixed-effects analyses are shown, although we refer to the latter as CIs for convenience. In these tables, we present results separately for any available direct evidence, for any indirect comparisons that can be made (excluding the direct evidence) and for the NMA (which combines the direct and the indirect evidence). Comparisons from the NMA with a ratio between

TABLE 135 Mean TTR for warfarin in secondary prevention of VTE

Study	Interventions that were compared with warfarin	Warfarin INR	Mean TTR (INR)
LAFIT ²¹³	Placebo od, warfarin	2–3	64%
PREVENT ²¹⁶	Placebo od	1.5–2	NR
RE-MEDY ²²²	Dabigatran 150 mg bd	2–3	65.3% (median)
WODIT-DVT ²¹⁴	No treatment	2–3	81%
WODIT-PE ²¹⁵	No treatment	2–3	NR

NR, not reported.

TABLE 136 Risk-of-bias assessments for 10 included randomised trials in secondary prevention of VTE

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting
AMPLIFY-EXT ²²¹	L: 'Randomization was performed with the use of an interactive voice-response system and was stratified according to the initial diagnosis (DVT or PE) and participation or no participation in the AMPLIFY trial'	L: 'Randomization was performed with the use of an interactive voice-response system AMPLIFY trial'	U: 'We conducted a randomized, double-blind study.' 'Patients were assigned, in a 1:1:1 ratio, to receive 2.5 mg of apixaban, 5 mg of apixaban, or placebo, all given bd'	L: 'An independent committee, whose members were unaware of the study-group assignments, adjudicated the qualifying initial diagnosis (DVT or PE) and all suspected outcomes'	L: All patients were included in the analyses	L: All outcomes reported as per study protocol
ASPIRE ²²⁰	L: 'Randomization was performed through a central Web-based randomization system, with stratification according to centre and duration of initial oral anticoagulation therapy (≤ 26 weeks or > 26 weeks)'	L: 'Randomization was performed through a central web-based randomization system'	L: 'Enteric-coated aspirin, in 100-mg tablets, and matching placebo were provided without charge by Bayer Health-Care Pharmaceuticals'	L: 'All primary and secondary events were adjudicated by an independent event adjudication committee whose members were unaware of the group assignments'	L: Very few missing outcome data but these almost balance out across intervention groups, with similar reasons for missing data. However, analysis was by intention to treat	L: All outcomes reported as per study protocol

continued

TABLE 136 Risk-of-bias assessments for 10 included randomised trials in secondary prevention of VTE (continued)

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting
EINSTEIN-EXTENSION ^{206,217,218}	<p>L: 'This was a randomized, double-blind, placebo-controlled superiority study in which patients who completed the first 6–12 months of oral anticoagulant treatment with VKA or with rivaroxaban (if previously enrolled in the EINSTEIN-DVT or EINSTEIN-PE studies)'</p> <p>As this study is related to EINSTEIN DVT²⁰⁶ and PE studies, for which randomisation was by use of computerised voice-response system, it is assumed that randomisation was done</p>	<p>L: As this study is related to EINSTEIN DVT²⁰⁶ and PE studies, it is assumed that there was central allocation of treatment</p>	<p>H: As this study is related to EINSTEIN DVT²⁰⁶ and PE studies, both of open-label type, it is assumed that participants and personnel may not have been blinded</p>	<p>L: 'All suspected outcome events were classified by a central adjudication committee whose members were unaware of the treatment assignments'</p>	<p>L: For all outcomes (except bleeding outcomes): No missing outcome data – analysis was by intention to treat</p> <p>L: For bleeding outcomes: Very minimal missing data – unlikely to influence outcome</p>	<p>L: All outcomes reported as per study protocol</p>
LAFIT ²¹³	<p>L: 'A computer algorithm, with a randomly determined block size of two or four within each stratum, had previously determined whether the patient received warfarin or placebo'</p>	<p>L: 'Patients were provided with consecutively numbered supplies of study drug'</p>	<p>L: 'We performed a double-blind, randomized trial. Patients were provided with consecutively numbered supplies of study drug either tablets containing 5 mg of warfarin or identical-appearing placebo'</p>	<p>L: 'Information on all suspected outcome events and deaths was reviewed and classified by a central adjudication committee whose members were unaware of the treatment assignments'</p>	<p>L: All patients were included in the analyses</p>	<p>U: Study protocol not found</p>

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting
PREVENT ²¹⁶	L: 'Randomization was stratified according to clinical site, time since the index event (≤ 6 months or > 6 months) and whether or not the index event was the patient's first venous thromboembolism'	L: Randomization to low-intensity warfarin (coumadin, provided without charge by Bristol-Myers Squibb; target INR, 1.5 to 2.0) or to matching placebo was performed centrally	L: 'To ensure blinding, sham dose adjustments were made in the placebo group. These devices were altered electronically to provide a coded INR value that was transmitted in a double-blind fashion to the data coordinating centre'	L: 'All end points were reviewed by a committee of physicians who were unaware of treatment-group assignments'	L: All patients were included in the analyses	L: All outcomes reported as per study protocol
RE-MEDY ²²²	L: 'Patients underwent randomization by means of an interactive voice-response system' The true or sham INR was then obtained by means of an interactive voice-response system with a central computer that had been programmed with the randomization schedule'	L: 'Patients underwent randomization by means of an interactive voice-response system'	L: 'A randomized, double-blind design. Patients were assigned in a 1:1 ratio to receive active dabigatran (at a fixed dose of 150 mg bd) and a warfarin-like placebo or active warfarin and a dabigatran-like placebo'	L: 'Central committees, whose members were not aware of the treatment assignments, adjudicated suspected cases of recurrent VTE, bleeding, death, acute coronary events, and liver function abnormalities'	L: All patients were included in the analyses	L: All outcomes reported as per study protocol

continued

TABLE 136 Risk-of-bias assessments for 10 included randomised trials in secondary prevention of VTE (continued)

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting
RE-SONATE ²²	L: 'Patients underwent randomization by means of an interactive voice-response system. Randomization was stratified according to the presence or absence of active cancer' and according to study centre in the placebo-control study	L: 'Patients underwent randomization by means of an interactive voice-response system'	U: 'A randomized, double-blind design' 'Patients were assigned in a 1:1 ratio to receive dabigatran (at a fixed dose of 150 mg bd) or a matching placebo'	L: 'Central committees, whose members were not aware of the treatment assignments, adjudicated suspected cases of recurrent VTE, bleeding, death, acute coronary, and liver function abnormalities'	L: All patients were included in the analyses	L: All outcomes reported as per study protocol
WARFASA ²¹⁹	L: 'WARFASA was a multicenter, investigator-initiated, randomized, double-blind clinical trial Eligible patients were randomly assigned to aspirin, 100 mg od, or placebo for 2 years, with the option of extending the study treatment Randomization occurred within 2 weeks after VKAs had been withdrawn'	U: Not enough information on whether or not treatment allocation was concealed. 'Eligible patients were randomly assigned to aspirin, 100 mg od, or placebo for 2 years, with the option of extending the study treatment'	U: 'WARFASA was a multicenter, investigator-initiated, randomized, double-blind clinical trial'	L: 'All suspected study outcome events were assessed by a central, independent adjudication committee whose members were unaware of the group assignments and who reviewed the imaging results'	L: All patients were included in the analyses	L: All outcomes reported as per study protocol

Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting
WODIT-DVT ²¹⁴	U: 'The Warfarin Optimal Duration Italian Trial was a randomized, multicentre, open trial'	H: No information on allocation concealment	H: 'The Warfarin Optimal Duration Italian Trial was a randomized, multicentre, open trial'	L: 'All suspected outcome events and all deaths were reviewed centrally, for both the interim and final analyses, by an independent, external adjudication committee whose members were unaware of the treatment group assignments'	L: All patients were included in the analyses	U: Study protocol not found
WODIT-PE ²¹⁵	L: 'Randomization was performed centrally in permuted blocks of six'	L: 'Randomization was performed centrally in permuted blocks of six'	H: 'Our study, like other studies with oral anticoagulant therapy, was not a placebo-controlled, double-blind trial'	L: 'All suspected outcome events and all deaths were reviewed centrally by an independent, external adjudication committee whose members were unaware of the treatment group assignments'	L: All patients were included in the analyses	U: Study protocol not found

H, high risk; L, low risk; U, unclear risk.
Note: Quotations are denoted by inverted commas.

TABLE 137 List of distinct interventions examined by included randomised trials in secondary prevention of VTE

No.	Intervention
1	Placebo
2	No treatment
3	Aspirin (100 mg od)
4	Warfarin (INR 1.5–2)
5	Warfarin (INR 2–3)
6	Apixaban (2.5 mg bd)
7	Apixaban (5 mg bd)
8	Dabigatran (150 mg bd)
9	Rivaroxaban (20 mg od)

interval limits exceeding nine were considered ‘imprecisely estimated’ and are presented at the bottom of each table (note that calculation of indirect evidence was not undertaken for imprecisely estimated comparisons). A summary of results across outcomes is provided at the end, in the form of a ‘rankogram’, which illustrates the probability that each treatment is best, second best, and so on, for each outcome. Lastly, forest plots of all contributing data, with ORs calculated using standard frequentist methods, are included in *Appendix 5*.

Symptomatic venous thromboembolism

All 10 studies^{206,213–222} reported on symptomatic VTE (578 events), leading to a network of all nine interventions (*Figure 55*). The included studies were judged to be at mostly low risk of bias, with concerns about only lack of blinding of participants and personnel in some studies (*Table 140*). There was evidence that aspirin (100 mg od) decreased the risk of symptomatic VTE compared with placebo (*Table 141*). Both warfarin (INR 1.5–2) and warfarin (INR 2–3) substantially reduced risk of symptomatic VTE compared with placebo. All NOACs at the doses included in the network substantially reduced risk of symptomatic VTE compared with placebo. Risk of symptomatic VTE was lower for all NOACs at doses included in the network compared with aspirin (*Table 142*). However, there was no clear evidence that risk of symptomatic VTE differed between these NOAC interventions and warfarin (INR 2–3), although most comparisons were imprecisely estimated (*Table 143*). There was no clear evidence that risk of symptomatic VTE differed between licensed doses of NOACs (*Table 144*), although all comparisons were imprecisely estimated.

We conducted a supplementary analysis using HRs for symptomatic recurrent VTE. The structure of the network was exactly the same as that presented in *Figure 55*. Results, presented in *Tables 145–148*, were similar to those based on ORs.

Symptomatic deep-vein thrombosis

Nine studies^{204,211–213,215–220} reported 342 symptomatic DVT events, leading to a network of eight interventions (*Figure 56*). These studies were mostly judged to be at low risk of bias (*Table 149*), with some concerns about lack of blinding of participants and personnel. There was no clear evidence that aspirin (100 mg od) reduced risk of symptomatic DVT compared with placebo (*Table 150*). There was evidence that warfarin (INR 2–3) and all NOACs at doses included in the network substantially reduced risk of symptomatic DVT compared with placebo. These NOAC interventions substantially reduced risk of symptomatic DVT compared with aspirin (*Table 151*). By contrast, there was no clear evidence that risk of symptomatic DVT differed between these NOACs and warfarin (INR 2–3), although comparisons were imprecisely estimated (*Table 152*). There was no clear evidence that risk of symptomatic DVT differed between NOACs at licensed doses, although all comparisons were imprecisely estimated (*Table 153*).

TABLE 138 Efficacy outcomes reported by 10 included randomised trials in secondary prevention of VTE: number of events for each outcome in each trial

Study	Study size	Symptomatic DVT	Symptomatic proximal DVT	Symptomatic distal DVT	Symptomatic PE	Fatal PE	Symptomatic non-fatal PE	Symptomatic VTE	Cardiovascular deaths	All-cause mortality
AMPLIFY-EXT ²²¹	2482	67				0	27	101	15	25
ASPIRE ²²⁰	822	82	68	25	48	2		130	12	34
EINSTEIN-EXTENSION ^{206,217,218}	1188	36				1	15	50		3
LAFIT ²¹³	162	11				1	6	18		4
PREVENT ²¹⁶	508					2		51		12
RE-MEDY ²²²	2856	30					15	44		36
RE-SONATE ²²²	1343	24					15	38		
WARFASA ²¹⁹	402	44			25	2		71		11
WODIT-DVT ²¹⁴	267	34				0	8	42	6	14
WODIT-PE ²¹⁵	326	14			12	2	10	33	3	19

TABLE 139 Safety outcomes reported by 10 included randomised trials in secondary prevention of VTE: number of events for each outcome in each trial

Study	Study size	MI	Arterial event	All bleeding	Minor bleeding	Major bleeding	Fatal bleeding	Intracranial bleeding	CRNM bleeding	CRB
AMPLIFY-EXT ²²¹	2482	9				7	0		78	84
ASPIRE ²²⁰	822	8		22		14	2		8	22
EINSTEIN-EXTENSION ^{206,217,218}	1188					4	0		39	43
LAFIT ²¹³	162			10	7	3				
PREVENT ²¹⁶	508	5			94	7				
RE-MEDY ²²²	2856	11		650		38		6		225
RE-SONATE ²²²	1343	2		111		2			46	48
WARFASA ²¹⁹	402		13			2			6	8
WODIT-DVT ²¹⁴	267					6	2			
WODIT-PE ²¹⁵	326			11		4	0			




FIGURE 55 Network plot for symptomatic VTE (secondary prevention of VTE).

TABLE 140 Included trials and risk-of-bias assessment for symptomatic VTE (secondary prevention of VTE)

Study	Interventions compared	SG	AC	BPP	BOA	IOD	SR
AMPLIFY-EXT ²²¹	1, 6, 7	+	+	?	+	+	+
ASPIRE ²²⁰	1, 3	+	+	+	+	+	+
EINSTEIN-EXTENSION ^{206,217,218}	1, 9	+	+	-	+	+	+
LAFIT ²¹¹	1, 5	+	+	+	+	+	?
PREVENT ²¹⁶	1, 4	+	+	+	+	+	+
RE-MEDY ²²²	5, 8	+	+	+	+	+	+
RE-SONATE ²²²	1, 8	+	+	?	+	+	+
WARFASA ²¹⁹	1, 3	+	?	?	+	+	+
WODIT-DVT ²¹⁴	2, 5	?	-	-	+	+	?
WODIT-PE ²¹⁵	2, 5	+	+	-	+	+	?

–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation; SR, selective reporting.

TABLE 141 Results for symptomatic VTE (secondary prevention of VTE): comparisons with placebo

Comparisons with placebo	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Aspirin (100 mg od)	0.68 (0.50 to 0.92)	–	0.68 (0.50 to 0.92)
Warfarin (INR 1.5–2)	0.33 (0.17 to 0.63)	–	0.33 (0.17 to 0.63)
Apixaban (2.5 mg bd)	0.17 (0.09 to 0.30)	–	0.17 (0.09 to 0.30)
Apixaban (5 mg bd)	0.18 (0.09 to 0.31)	–	0.18 (0.09 to 0.31)
Dabigatran (150 mg bd)	0.07 (0.02 to 0.18)	–	0.07 (0.02 to 0.18)
Rivaroxaban (20 mg od)	0.17 (0.07 to 0.35)	–	0.17 (0.07 to 0.35)
Imprecisely estimated comparisons			
No treatment	–	0.05 (0.01 to 0.17)	0.05 (0.01 to 0.17)
Warfarin (INR 2–3)	0.05 (0.01 to 0.14)	–	0.05 (0.01 to 0.14)

TABLE 142 Results for symptomatic VTE (secondary prevention of VTE): comparisons with aspirin

Comparisons with aspirin	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Apixaban (2.5 mg bd)	–	0.25 (0.13 to 0.48)	0.25 (0.13 to 0.48)
Apixaban (5 mg bd)	–	0.26 (0.13 to 0.50)	0.26 (0.13 to 0.50)
Rivaroxaban (20 mg od)	–	0.25 (0.10 to 0.55)	0.25 (0.10 to 0.55)
<i>Imprecisely estimated comparisons</i>			
<i>Dabigatran (150 mg bd)</i>	–	<i>0.10 (0.03 to 0.28)</i>	<i>0.10 (0.03 to 0.28)</i>

TABLE 143 Results for symptomatic VTE (secondary prevention of VTE): comparisons with warfarin (INR 2–3)

Comparisons with warfarin (INR 2–3)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Dabigatran (150 mg bd)	1.36 (0.67 to 2.80)	–	1.36 (0.67 to 2.80)
<i>Imprecisely estimated comparisons</i>			
<i>Apixaban (2.5 mg bd)</i>	–	<i>2.10 (0.42 to 14.0)</i>	<i>2.10 (0.42 to 14.0)</i>
<i>Apixaban (5 mg bd)</i>	–	<i>2.96 (0.64 to 19.1)</i>	<i>2.96 (0.64 to 19.1)</i>
<i>Rivaroxaban (20 mg od)</i>	–	<i>3.01 (0.55 to 20.4)</i>	<i>3.01 (0.55 to 20.4)</i>

TABLE 144 Results for symptomatic VTE (secondary prevention of VTE): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)	1.04 (0.48 to 2.22)	–	1.04 (0.48 to 2.22)
Rivaroxaban (20 mg od) vs. apixaban (2.5 mg bd)	–	0.99 (0.36 to 2.6)	0.99 (0.36 to 2.6)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd)	–	0.96 (0.35 to 2.48)	0.96 (0.35 to 2.48)
<i>Imprecisely estimated comparisons</i>			
<i>Dabigatran (150 mg bd) vs. apixaban (2.5 mg bd)</i>	–	<i>0.41 (0.11 to 1.29)</i>	<i>0.41 (0.11 to 1.29)</i>
<i>Dabigatran (150 mg bd) vs. apixaban (5 mg bd)</i>	–	<i>0.40 (0.11 to 1.25)</i>	<i>0.40 (0.11 to 1.25)</i>
<i>Rivaroxaban (20 mg od) vs. dabigatran (150 mg bd)</i>	–	<i>2.41 (0.67 to 9.93)</i>	<i>2.41 (0.67 to 9.93)</i>

TABLE 145 Results for recurrent VTE (secondary prevention of VTE): comparisons with placebo

Comparisons with placebo	HR (95% CI)
Aspirin (100 mg od)	0.68 (0.51 to 0.90)
Warfarin (INR 1.5–2)	0.36 (0.19 to 0.68)
Warfarin (INR 2–3)	0.05 (0.02 to 0.16)
Apixaban (2.5 mg bd)	0.17 (0.10 to 0.31)
Apixaban (5 mg bd)	0.18 (0.10 to 0.32)
Dabigatran (150 mg bd)	0.08 (0.03 to 0.22)
Rivaroxaban (20 mg od)	0.18 (0.09 to 0.37)
<i>Imprecisely estimated comparisons</i>	
<i>No treatment</i>	<i>0.06 (0.02 to 0.23)</i>

TABLE 146 Results for recurrent VTE (secondary prevention of VTE): comparisons with aspirin

Comparisons with aspirin	HR (95% CI)
Apixaban (2.5 mg bd)	0.25 (0.13 to 0.49)
Apixaban (5 mg bd)	0.26 (0.14 to 0.51)
Dabigatran (150 mg bd)	0.11 (0.04 to 0.34)
Rivaroxaban (20 mg od)	0.27 (0.12 to 0.58)

TABLE 147 Results for recurrent VTE (secondary prevention of VTE): comparisons with warfarin (INR 2–3)

Comparisons with warfarin (INR 2–3)	HR (95% CI)
Dabigatran (150 mg bd)	1.45 (0.80 to 2.60)
<i>Imprecisely estimated comparisons</i>	
<i>Apixaban (2.5 mg bd)</i>	<i>3.24 (0.92 to 11.4)</i>
<i>Apixaban (5 mg bd)</i>	<i>3.36 (0.95 to 11.7)</i>
<i>Rivaroxaban (20 mg od)</i>	<i>3.41 (0.88 to 12.6)</i>

TABLE 148 Results for recurrent VTE (secondary prevention of VTE): NOACs (licensed doses only)

Licensed NOACs only	HR (95% CI)
<i>Imprecisely estimated comparisons</i>	
<i>Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)</i>	<i>0.57 (0.14 to 1.94)</i>
<i>Dabigatran (150 mg bd) vs. apixaban (2.5 mg bd)</i>	<i>0.48 (0.01 to 6.79)</i>
<i>Rivaroxaban (20 mg od) vs. apixaban (2.5 mg bd)</i>	<i>0.86 (0.02 to 13.0)</i>
<i>Dabigatran (150 mg bd) vs. apixaban (5 mg bd)</i>	<i>0.85 (0.02 to 13.4)</i>
<i>Rivaroxaban (20 mg od) vs. apixaban (5 mg bd)</i>	<i>1.54 (0.04 to 25.7)</i>
<i>Rivaroxaban (20 mg od) vs. dabigatran (150 mg bd)</i>	<i>1.79 (0.03 to 121)</i>




FIGURE 56 Network plot for symptomatic DVT (secondary prevention of VTE).

TABLE 149 Included trials and risk-of-bias assessment for symptomatic DVT (secondary prevention of VTE)

Study	Interventions compared	SG	AC	BPP	BOA	IOD	SR
AMPLIFY-EXT ²²¹	1, 6, 7	+	+	?	+	+	+
ASPIRE ²²⁰	1, 3	+	+	+	+	+	+
EINSTEIN-EXTENSION ^{206,217,218}	1, 9	+	+	-	+	+	+
LAFIT ²¹¹	1, 5	+	+	+	+	+	?
RE-MEDY ²²²	5, 8	+	+	+	+	+	+
RE-SONATE ²²²	1, 8	+	+	?	+	+	+
WARFASA ²¹⁹	1, 3	+	?	?	+	+	+
WODIT-DVT ²¹⁴	2, 5	?	-	-	+	+	?
WODIT-PE ²¹⁵	2, 5	+	+	-	+	+	?

–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation; SR, selective reporting.

TABLE 150 Results for symptomatic DVT (secondary prevention of VTE): comparisons with placebo

Comparisons with placebo	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Aspirin (100 mg od)	0.74 (0.51 to 1.07)	–	0.74 (0.51 to 1.07)
Apixaban (2.5 mg bd)	0.1 (0.04 to 0.22)	–	0.1 (0.04 to 0.22)
Apixaban (5 mg bd)	0.14 (0.06 to 0.28)	–	0.14 (0.06 to 0.28)
Rivaroxaban (20 mg od)	0.14 (0.05 to 0.34)	–	0.14 (0.05 to 0.34)
<i>Imprecisely estimated comparisons</i>			
No treatment	–	0.05 (0.01 to 0.22)	0.05 (0.01 to 0.22)
Warfarin (INR 2–3)	0.05 (0.01 to 0.17)	–	0.05 (0.01 to 0.17)
Dabigatran (150 mg bd)	0.07 (0.01 to 0.21)	–	0.07 (0.01 to 0.21)

TABLE 151 Results for symptomatic DVT (secondary prevention of VTE): comparisons with aspirin

Comparisons with aspirin	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Apixaban (2.5 mg bd)	–	0.14 (0.05 to 0.32)	0.14 (0.05 to 0.32)
Apixaban (5 mg bd)	–	0.19 (0.08 to 0.42)	0.19 (0.08 to 0.42)
Rivaroxaban (20 mg od)	–	0.19 (0.06 to 0.51)	0.19 (0.06 to 0.51)
<i>Imprecisely estimated comparisons</i>			
Dabigatran (150 mg bd)	–	0.09 (0.02 to 0.30)	0.09 (0.02 to 0.30)

TABLE 152 Results for symptomatic DVT (secondary prevention of VTE): comparisons with warfarin (INR 2–3)

Comparisons with warfarin (INR 2–3)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Imprecisely estimated comparisons			
Apixaban (2.5 mg bd)	–	2.10 (0.42 to 14.0)	2.10 (0.42 to 14.0)
Apixaban (5 mg bd)	–	2.96 (0.64 to 19.1)	2.96 (0.64 to 19.1)
Dabigatran (150 mg bd)	1.36 (0.67 to 2.80)	–	1.36 (0.67 to 2.80)
Rivaroxaban (20 mg od)	–	3.01 (0.55 to 20.4)	3.01 (0.55 to 20.4)

TABLE 153 Results for symptomatic DVT (secondary prevention of VTE): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Imprecisely estimated comparisons			
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)	1.40 (0.48 to 4.37)	–	1.40 (0.48 to 4.37)
Dabigatran (150 mg bd) vs. apixaban (2.5 mg bd)	–	0.65 (0.10 to 3.04)	0.65 (0.10 to 3.04)
Rivaroxaban (20 mg od) vs. apixaban (2.5 mg bd)	–	1.44 (0.37 to 5.36)	1.44 (0.37 to 5.36)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd)	–	0.46 (0.07 to 1.98)	0.46 (0.07 to 1.98)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd)	–	1.02 (0.28 to 3.46)	1.02 (0.28 to 3.46)
Rivaroxaban (20 mg od) vs. dabigatran (150 mg bd)	–	2.21 (0.43 to 14.2)	2.21 (0.43 to 14.2)

Symptomatic pulmonary embolism

Three studies reported symptomatic PE events, and a further six studies reported symptomatic non-fatal and fatal PE events, which were added together. The studies reported a total 173 symptomatic PE events, leading to a network comparing eight interventions (*Figure 57*). The included studies were mostly judged to be at low risk of bias (*Table 154*), with some concerns about lack of blinding of participants and personnel. There was evidence that warfarin (INR 2–3), apixaban (5 mg bd), dabigatran (150 mg bd) and rivaroxaban (20 mg od) substantially reduce the risk of symptomatic PE compared with placebo (*Table 155*).




FIGURE 57 Network plot for symptomatic PE (secondary prevention of VTE).

TABLE 154 Included trials and risk-of-bias assessment for symptomatic PE (secondary prevention of VTE)

Study	Interventions compared	SG	AC	BPP	BOA	IOD	SR
AMPLIFY-EXT ²²¹	1, 6, 7	+	+	?	+	+	+
ASPIRE ²²⁰	1, 3	+	+	+	+	+	+
EINSTEIN-EXTENSION ^{206,217,218}	1, 9	+	+	-	+	+	+
LAFIT ²¹¹	1, 5	+	+	+	+	+	?
RE-MEDY ²²²	5, 8	+	+	+	+	+	+
RE-SONATE ²²²	1, 8	+	+	?	+	+	+
WARFASA ²¹⁹	1, 3	+	?	?	+	+	+
WODIT-DVT ²¹⁴	2, 5	?	-	-	+	+	?
WODIT-PE ²¹⁵	2, 5	+	+	-	+	+	?

–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation; SR, selective reporting.

TABLE 155 Results for symptomatic PE (secondary prevention of VTE): comparisons with placebo

Comparisons with placebo	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Aspirin (100 mg od)	0.63 (0.38 to 1.02)	–	0.63 (0.38 to 1.02)
<i>Imprecisely estimated comparisons</i>			
No treatment	–	0.05 (0.01 to 0.32)	0.05 (0.01 to 0.32)
Warfarin (INR 2–3)	0.05 (0.01 to 0.24)	–	0.05 (0.01 to 0.24)
Apixaban (2.5 mg bd)	0.51 (0.20 to 1.21)	–	0.51 (0.20 to 1.21)
Apixaban (5 mg bd)	0.25 (0.07 to 0.71)	–	0.25 (0.07 to 0.71)
Dabigatran (150 mg bd)	0.09 (0.01 to 0.35)	–	0.09 (0.01 to 0.35)
Rivaroxaban (20 mg od)	0.12 (0.02 to 0.45)	–	0.12 (0.02 to 0.45)

There was evidence that dabigatran (150 mg bd) and rivaroxaban (20 mg od) reduce the risk of symptomatic PE compared with aspirin (Table 156). There was evidence that risk of symptomatic PE was higher for apixaban (2.5 mg bd) than warfarin (INR 2–3) (Table 157). There was weak evidence that risk of symptomatic PE was lower for dabigatran (150 mg bd) and rivaroxaban (20 mg od) than apixaban (2.5 mg bd) (Table 158).

TABLE 156 Results for symptomatic PE (secondary prevention of VTE): comparisons with aspirin

Comparisons with aspirin	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Apixaban (2.5 mg bd)	–	0.81 (0.29 to 2.19)	0.81 (0.29 to 2.19)
<i>Imprecisely estimated comparisons</i>			
Apixaban (5 mg bd)	–	0.40 (0.10 to 1.28)	0.40 (0.10 to 1.28)
Dabigatran (150 mg bd)	–	0.14 (0.02 to 0.61)	0.14 (0.02 to 0.61)
Rivaroxaban (20 mg od)	–	0.19 (0.03 to 0.78)	0.19 (0.03 to 0.78)

TABLE 157 Results for symptomatic PE (secondary prevention of VTE): comparisons with warfarin (INR 2–3)

Comparisons with warfarin (INR 2–3)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Dabigatran (150 mg bd)	1.76 (0.64 to 5.24)	–	1.76 (0.64 to 5.24)
Imprecisely estimated comparisons			
Apixaban (2.5 mg bd)	–	10.1 (1.66 to 102)	10.1 (1.66 to 102)
Apixaban (5 mg bd)	–	4.94 (0.66 to 53.6)	4.94 (0.66 to 53.6)
Rivaroxaban (20 mg od)	–	2.29 (0.19 to 28.4)	2.29 (0.19 to 28.4)

TABLE 158 Results for symptomatic PE (secondary prevention of VTE): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Imprecisely estimated comparisons			
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)	0.49 (0.13 to 1.62)	–	0.49 (0.13 to 1.62)
Dabigatran (150 mg bd) vs. apixaban (2.5 mg bd)	–	0.18 (0.02 to 0.92)	0.18 (0.02 to 0.92)
Rivaroxaban (20 mg od) vs. apixaban (2.5 mg bd)	–	0.23 (0.03 to 1.18)	0.23 (0.03 to 1.18)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd)	–	0.36 (0.04 to 2.38)	0.36 (0.04 to 2.38)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd)	–	0.47 (0.05 to 3.04)	0.47 (0.05 to 3.04)
Rivaroxaban (20 mg od) vs. dabigatran (150 mg bd)	–	1.31 (0.12 to 14.0)	1.31 (0.12 to 14.0)

Myocardial infarction

Five studies^{214,218–220} reported 35 MI events, leading to a network of seven interventions (*Figure 58*). These studies were judged to be at low risk of bias (*Table 159*). All comparisons were imprecisely estimated (*Tables 160–163*).

Major bleeding

All 10 studies^{204,212–220} reported on major bleeding (87 events), leading to a network of nine interventions (*Figure 59*). These studies^{204,212–220} were mostly judged to be at low risk of bias (*Table 164*), with some concerns about lack of blinding of participants and personnel. There was evidence that risk of major bleeding




FIGURE 58 Network plot for MI (secondary prevention of VTE).

TABLE 159 Included trials and risk-of-bias assessment for MI (secondary prevention of VTE)

Study	Interventions compared	SG	AC	BPP	BOA	IOD	SR
AMPLIFY-EXT ²²¹	1, 6, 7	+	+	?	+	+	+
ASPIRE ²²⁰	1, 3	+	+	+	+	+	+
PREVENT ²¹⁶	1, 4	+	+	+	+	+	+
RE-MEDY ²²²	5, 8	+	+	+	+	+	+
RE-SONATE ²²²	1, 8	+	+	?	+	+	+

–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation; SR, selective reporting.

TABLE 160 Results for MI (secondary prevention of VTE): comparisons with placebo

Comparisons with placebo	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
<i>Imprecisely estimated comparisons</i>			
<i>Aspirin (100 mg od)</i>	0.29 (0.04 to 1.37)	–	0.29 (0.04 to 1.37)
<i>Warfarin (INR 1.5–2)</i>	1.57 (0.24 to 14.0)	–	1.57 (0.24 to 14.0)
<i>Warfarin (INR 2–3)</i>	0.06 (0 to 3.26)	–	0.06 (0 to 3.26)
<i>Apixaban (2.5 mg bd)</i>	0.45 (0.06 to 2.51)	–	0.45 (0.06 to 2.51)
<i>Apixaban (5 mg bd)</i>	0.74 (0.13 to 3.59)	–	0.74 (0.13 to 3.59)
<i>Dabigatran (150 mg bd)</i>	0.90 (0.02 to 29.8)	–	0.90 (0.02 to 29.8)

TABLE 161 Results for MI (secondary prevention of VTE): comparisons with aspirin

Comparisons with aspirin	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
<i>Imprecisely estimated comparisons</i>			
<i>Apixaban (2.5 mg bd)</i>	–	1.57 (0.12 to 21.7)	1.57 (0.12 to 21.7)
<i>Apixaban (5 mg bd)</i>	–	2.60 (0.26 to 33.1)	2.60 (0.26 to 33.1)
<i>Dabigatran (150 mg bd)</i>	–	3.19 (0.05 to 174)	3.19 (0.05 to 174)

TABLE 162 Results for MI (secondary prevention of VTE): comparisons with warfarin (INR 2–3)

Comparisons with warfarin (INR 2–3)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
<i>Imprecisely estimated comparisons</i>			
<i>Apixaban (2.5 mg bd)</i>	–	7.48 (0.08 to 1220)	7.48 (0.08 to 1220)
<i>Apixaban (5 mg bd)</i>	–	12.6 (0.15 to 2000)	12.6 (0.15 to 2000)
<i>Dabigatran (150 mg bd)</i>	13.6 (2.26 to 409)	–	13.6 (2.26 to 409)

TABLE 163 Results for MI (secondary prevention of VTE): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Imprecisely estimated comparisons			
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)	1.65 (0.25 to 14.2)	–	1.65 (0.25 to 14.2)
Dabigatran (150 mg bd) vs. apixaban (2.5 mg bd)	–	2.06 (0.03 to 117)	2.06 (0.03 to 117)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd)	–	1.22 (0.02 to 57.5)	1.22 (0.02 to 57.5)




FIGURE 59 Network plot for major bleeding (secondary prevention of VTE).

TABLE 164 Included trials and risk-of-bias assessment for major bleeding (secondary prevention of VTE)

Study	Interventions compared	SG	AC	BPP	BOA	IOD	SR
AMPLIFY-EXT ²²¹	1, 6, 7	+	+	?	+	+	+
ASPIRE ²²⁰	1, 3	+	+	+	+	+	+
EINSTEIN-EXTENSION ^{206,217,218}	1, 9	+	+	–	+	+	+
LAFIT ²¹¹	1, 5	+	+	+	+	+	?
PREVENT ²¹⁶	1, 4	+	+	+	+	+	+
RE-MEDY ²²²	5, 8	+	+	+	+	+	+
RE-SONATE ²²²	1, 8	+	+	?	+	+	+
WARFASA ²¹⁹	1, 3	+	?	?	+	+	+
WODIT-DVT ²¹⁴	2, 5	?	–	–	+	+	?
WODIT-PE ²¹⁵	2, 5	+	+	–	+	+	?

–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation; SR, selective reporting.

is higher for warfarin (INR 2–3) and rivaroxaban (20 mg od) than placebo, although these comparisons were imprecisely estimated (Table 165). Comparisons of the risk of major bleeding for NOACs compared with aspirin were imprecisely estimated (Table 166). There was evidence that risk of major bleeding is lower with dabigatran (150 mg bd), apixaban (2.5 mg bd) and apixaban (5 mg bd) than warfarin (INR 2–3) (Table 167). There was evidence that risk of major bleeding is higher with dabigatran (150 mg bd) and rivaroxaban (20 mg od) than apixaban (2.5 mg bd and 5 mg bd) (Table 168).

TABLE 165 Results for major bleeding (secondary prevention of VTE): comparisons with placebo

Comparisons with placebo	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Aspirin (100 mg od)	1.3 (0.47 to 3.76)	–	1.3 (0.47 to 3.76)
Imprecisely estimated comparisons			
No treatment	–	4.93 (0.36 to 142)	4.93 (0.36 to 142)
Warfarin (INR 1.5–2)	2.78 (0.55 to 22.2)	–	2.78 (0.55 to 22.2)
Warfarin (INR 2–3)	12.0 (1.66 to 279)	–	12.0 (1.66 to 279)
Apixaban (2.5 mg bd)	0.45 (0.06 to 2.57)	–	0.45 (0.06 to 2.57)
Apixaban (5 mg bd)	0.19 (0.01 to 1.56)	–	0.19 (0.01 to 1.56)
Dabigatran (150 mg bd)	6.11 (0.83 to 145)	–	6.11 (0.83 to 145)
Rivaroxaban (20 mg od)	17.8 (1.25 to 8340)	–	17.8 (1.25 to 8340)

TABLE 166 Results for major bleeding (secondary prevention of VTE): comparisons with aspirin

Comparisons with aspirin	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Imprecisely estimated comparisons			
Apixaban (2.5 mg bd)	–	0.34 (0.03 to 2.60)	0.34 (0.03 to 2.60)
Apixaban (5 mg bd)	–	0.14 (0 to 1.54)	0.14 (0 to 1.54)
Dabigatran (150 mg bd)	–	4.81 (0.50 to 126)	4.81 (0.50 to 126)
Rivaroxaban (20 mg od)	–	13.9 (0.78 to 6690)	13.9 (0.78 to 6690)

TABLE 167 Results for major bleeding (secondary prevention of VTE): comparisons with warfarin (INR 2–3)

Comparisons with warfarin	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Dabigatran (150 mg bd)	0.51 (0.25 to 0.98)	–	0.51 (0.25 to 0.98)
Imprecisely estimated comparisons			
Apixaban (2.5 mg bd)	–	0.03 (0 to 0.53)	0.03 (0 to 0.53)
Apixaban (5 mg bd)	–	0.01 (0 to 0.29)	0.01 (0 to 0.29)
Rivaroxaban (20 mg od)	–	1.52 (0.03 to 712)	1.52 (0.03 to 712)

TABLE 168 Results for major bleeding (secondary prevention of VTE): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Imprecisely estimated comparisons			
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)	0.43 (0.01 to 5.42)	–	0.43 (0.01 to 5.42)
Dabigatran (150 mg bd) vs. apixaban (2.5 mg bd)	–	14.7 (0.96 to 582)	14.7 (0.96 to 582)
Rivaroxaban (20 mg od) vs. apixaban (2.5 mg bd)	–	44.8 (1.60 to 24,100)	44.8 (1.60 to 24,100)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd)	–	37.1 (1.70 to 2980)	37.1 (1.70 to 2980)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd)	–	116 (2.87 to 92,100)	116 (2.87 to 92,100)
Rivaroxaban (20 mg od) vs. dabigatran (150 mg bd)	–	3.01 (0.05 to 1390)	3.01 (0.05 to 1390)

Clinically relevant bleeding

Six studies^{204,215–220} reported 430 CRB events across trials, leading to a network of seven interventions (Figure 60). These studies^{204,215–220} were mostly judged to be at low risk of bias (Table 169) with some concerns about lack of blinding of participants and personnel. There was evidence that risk of CRB is substantially higher with warfarin (INR 2–3), dabigatran (150 mg od) and rivaroxaban (20 mg od) than placebo (Table 170) and that risk of CRB is higher with rivaroxaban (20 mg od) than aspirin (Table 171).




FIGURE 60 Network plot for CRB (secondary prevention of VTE).

TABLE 169 Included trials and risk-of-bias assessment for CRB (secondary prevention of VTE)

Study	Interventions compared	SG	AC	BPP	BOA	IOD	SR
AMPLIFY-EXT ²²¹	1, 6, 7	+	+	?	+	+	+
ASPIRE ²²⁰	1, 3	+	+	+	+	+	+
EINSTEIN-EXTENSION ^{206,217,218}	1, 9	+	+	-	+	+	+
RE-MEDY ²²²	5, 8	+	+	+	+	+	+
RE-SONATE ²²²	1, 8	+	+	?	+	+	+
WARFASA ²¹⁹	1, 3	+	?	?	+	+	+

–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation; SR, selective reporting.

TABLE 170 Results for CRB (secondary prevention of VTE): comparisons with placebo

Comparisons with placebo	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Aspirin (100 mg od)	1.51 (0.72 to 3.27)	–	1.51 (0.72 to 3.27)
Warfarin (INR 2–3)	5.85 (2.93 to 12.6)	–	5.85 (2.93 to 12.6)
Apixaban (2.5 mg bd)	1.22 (0.69 to 2.19)	–	1.22 (0.69 to 2.19)
Apixaban (5 mg bd)	1.66 (0.96 to 2.89)	–	1.66 (0.96 to 2.89)
Dabigatran (150 mg bd)	3.05 (1.62 to 6.25)	–	3.05 (1.62 to 6.25)
Rivaroxaban (20 mg od)	5.56 (2.58 to 14.0)	–	5.56 (2.58 to 14.0)

TABLE 171 Results for CRB (secondary prevention of VTE): comparisons with aspirin

Comparisons with aspirin	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Apixaban (2.5 mg bd)	–	0.81 (0.31 to 2.08)	0.81 (0.31 to 2.08)
Apixaban (5 mg bd)	–	1.10 (0.43 to 2.78)	1.10 (0.43 to 2.78)
Dabigatran (150 mg bd)	–	2.03 (0.75 to 5.66)	2.03 (0.75 to 5.66)
Rivaroxaban (20 mg od)	–	3.70 (1.25 to 12.0)	3.70 (1.25 to 12.0)

There was evidence that risk of CRB is lower with apixaban (2.5 mg or 5 mg bd) and dabigatran (150 mg bd) than warfarin (INR 2–3) (Table 172). All comparisons between NOACs at licensed doses were imprecisely estimated, but there was evidence that risk of CRB is higher with dabigatran (150 mg bd) and rivaroxaban (20 mg od) than apixaban (2.5 mg bd and 5 mg bd) (Table 173).

Bleeding (sensitivity analysis)

We conducted a supplementary analysis based on HRs for bleeding events reported in some studies. We extracted HRs for CRB, or for major bleeding if that was the only information available. The structure of this resulting network is presented in Figure 61. Results are similar to those for CRB (Tables 174–177).

TABLE 172 Results for CRB (secondary prevention of VTE): comparisons with warfarin (INR 2–3)

Comparisons with warfarin (INR 2–3)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Apixaban (2.5 mg bd)	–	0.21 (0.08 to 0.52)	0.21 (0.08 to 0.52)
Apixaban (5 mg bd)	–	0.28 (0.11 to 0.69)	0.28 (0.11 to 0.69)
Dabigatran (150 mg bd)	0.52 (0.39 to 0.69)	–	0.52 (0.39 to 0.69)
Rivaroxaban (20 mg od)	–	0.95 (0.32 to 3.01)	0.95 (0.32 to 3.01)

TABLE 173 Results for CRB (secondary prevention of VTE): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Imprecisely estimated comparisons			
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)	0.43 (0.01 to 5.42)	–	0.43 (0.01 to 5.42)
Dabigatran (150 mg bd) vs. apixaban (2.5 mg bd)	–	14.7 (0.96 to 582)	14.7 (0.96 to 582)
Rivaroxaban (20 mg od) vs. apixaban (2.5 mg bd)	–	44.8 (1.60 to 24,100)	44.8 (1.60 to 24,100)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd)	–	37.1 (1.70 to 2980)	37.1 (1.70 to 2980)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd)	–	116 (2.87 to 92,100)	116 (2.87 to 92,100)
Rivaroxaban (20 mg od) vs. dabigatran (150 mg bd)	–	3.01 (0.05 to 1390)	3.01 (0.05 to 1390)




FIGURE 61 Network plot for bleeding (secondary prevention of VTE).

TABLE 174 Results for bleeding (secondary prevention of VTE): comparisons with placebo

Comparisons with placebo	NMA
	HR (95% CI)
Aspirin (100 mg od)	1.48 (0.70 to 3.09)
Warfarin (INR 2–3)	5.39 (2.64 to 10.8)
Apixaban (2.5 mg bd)	1.29 (0.72 to 2.33)
Apixaban (5 mg bd)	1.82 (1.05 to 3.17)
Dabigatran (150 mg bd)	2.91 (1.51 to 5.54)
Rivaroxaban (20 mg od)	5.19 (2.28 to 11.6)
<i>Imprecisely estimated comparisons</i>	
Warfarin (INR 1.5–2)	2.54 (0.48 to 13.1)

TABLE 175 Results for bleeding (secondary prevention of VTE): comparisons with aspirin

Comparisons with aspirin	NMA
	HR (95% CI)
Apixaban (2.5 mg bd)	0.87 (0.34 to 2.25)
Apixaban (5 mg bd)	1.23 (0.48 to 3.14)
Dabigatran (150 mg bd)	1.97 (0.73 to 5.25)
Rivaroxaban (20 mg od)	3.51 (1.17 to 10.5)

TABLE 176 Results for bleeding (secondary prevention of VTE): comparisons with warfarin (INR 2–3)

Comparisons with warfarin (INR 2–3)	NMA
	HR (95% CI)
Apixaban (2.5 mg bd)	0.24 (0.09 to 0.61)
Apixaban (5 mg bd)	0.34 (0.14 to 0.84)
Dabigatran (150 mg bd)	0.54 (0.41 to 0.71)
Rivaroxaban (20 mg od)	0.96 (0.33 to 2.82)

TABLE 177 Results for bleeding (secondary prevention of VTE): NOACs (licensed doses only)

Licensed NOACs only	NMA
	HR (95% CI)
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)	1.65 (0.25 to 14.2)
Dabigatran (150 mg bd) vs. apixaban (2.5 mg bd)	2.06 (0.03 to 117)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd)	1.22 (0.02 to 57.5)

All-cause mortality

Nine studies^{204,211–220} reported 158 all-cause mortality events, leading to a network of nine interventions (*Figure 62*). These studies^{204,211–220} were mostly judged to be at low risk of bias (*Table 178*), with some concerns about lack of blinding of participants and personnel. All comparisons of risk of all-cause mortality with placebo, except that for aspirin (100 mg od), were imprecisely estimated (*Table 179*). However, there was evidence that risk of all-cause mortality was lower for apixaban (5 mg bd) than placebo. Comparisons of NOACs with aspirin were imprecisely estimated, although there was weak evidence that risk of all-cause mortality is lower with apixaban (5 mg bd) than aspirin (*Table 180*). There was no evidence that risk of all-cause mortality differed for NOACs compared with warfarin (INR 2–3), although all comparisons – except that with dabigatran (150 mg bd) – were imprecisely estimated (*Table 181*). Comparisons of risk of all-cause mortality between NOACs at licensed doses were imprecisely estimated (*Table 182*).


**FIGURE 62** Network plot for all-cause mortality (secondary prevention of VTE).

TABLE 178 Included trials and risk-of-bias assessment for all-cause mortality (secondary prevention of VTE)

Study	Interventions compared	SG	AC	BPP	BOA	IOD	SR
AMPLIFY-EXT ²²¹	1, 6, 7	+	+	?	+	+	+
ASPIRE ²²⁰	1, 3	+	+	+	+	+	+
EINSTEIN-EXTENSION ^{206,217,218}	1, 9	+	+	-	+	+	+
LAFIT ²¹¹	1, 5	+	+	+	+	+	?
PREVENT ²¹⁶	1, 4	+	+	+	+	+	+
RE-MEDY ²²²	5, 8	+	+	+	+	+	+
WARFASA ²¹⁹	1, 3	+	?	?	+	+	+
WODIT-DVT ²¹⁴	2, 5	?	-	-	+	+	?
WODIT-PE ²¹⁵	2, 5	+	+	-	+	+	?

–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation; SR, selective reporting.

TABLE 179 Results for all-cause mortality (secondary prevention of VTE): comparisons with placebo

Comparisons with placebo	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Aspirin (100 mg od)	0.94 (0.52 to 1.73)	–	0.94 (0.52 to 1.73)
Apixaban (2.5 mg bd)	0.48 (0.18 to 1.17)	–	0.48 (0.18 to 1.17)
Imprecisely estimated comparisons			
No treatment	–	0.20 (0.01 to 2.03)	0.20 (0.01 to 2.03)
Warfarin (INR 1.5–2)	0.47 (0.12 to 1.54)	–	0.47 (0.12 to 1.54)
Warfarin (INR 2–3)	0.28 (0.01 to 2.47)	–	0.28 (0.01 to 2.47)
Apixaban (5 mg bd)	0.27 (0.07 to 0.78)	–	0.27 (0.07 to 0.78)
Dabigatran (150 mg bd)	0.25 (0.01 to 2.50)	–	0.25 (0.01 to 2.50)
Rivaroxaban (20 mg od)	0.41 (0.01 to 5.21)	–	0.41 (0.01 to 5.21)

TABLE 180 Results for all-cause mortality (secondary prevention of VTE): comparisons with aspirin

Comparisons with aspirin	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Imprecisely estimated comparisons			
Apixaban (2.5 mg bd)	–	0.50 (0.16 to 1.49)	0.50 (0.16 to 1.49)
Apixaban (5 mg bd)	–	0.29 (0.07 to 0.98)	0.29 (0.07 to 0.98)
Dabigatran (150 mg bd)	–	0.26 (0.01 to 2.87)	0.26 (0.01 to 2.87)
Rivaroxaban (20 mg od)	–	0.43 (0.01 to 5.90)	0.43 (0.01 to 5.90)

TABLE 181 Results for all-cause mortality (secondary prevention of VTE): comparisons with warfarin (INR 2–3)

Comparisons with warfarin (INR 2–3)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Dabigatran (150 mg bd)	0.89 (0.45 to 1.73)	–	0.89 (0.45 to 1.73)
<i>Imprecisely estimated comparisons</i>			
Apixaban (2.5 mg bd)	–	1.71 (0.15 to 60.6)	1.71 (0.15 to 60.6)
Apixaban (5 mg bd)	–	0.97 (0.08 to 35.1)	0.97 (0.08 to 35.1)
Rivaroxaban (20 mg od)	–	1.52 (0.03 to 98.3)	1.52 (0.03 to 98.3)

TABLE 182 Results for all-cause mortality (secondary prevention of VTE): NOACs (licensed doses only)

Licensed NOACs only	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
<i>Imprecisely estimated comparisons</i>			
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)	–	0.57 (0.14 to 1.94)	0.57 (0.14 to 1.94)
Dabigatran (150 mg bd) vs. apixaban (2.5 mg bd)	–	0.51 (0.01 to 6.39)	0.51 (0.01 to 6.39)
Rivaroxaban (20 mg od) vs. apixaban (2.5 mg bd)	–	0.85 (0.02 to 12.9)	0.85 (0.02 to 12.9)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd)	–	0.91 (0.02 to 13.0)	0.91 (0.02 to 13.0)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd)	–	1.52 (0.04 to 26.3)	1.52 (0.04 to 26.3)
Rivaroxaban (20 mg od) vs. dabigatran (150 mg bd)	–	1.79 (0.03 to 121)	1.79 (0.03 to 121)

Summary of results

Our analyses of a network of 10 RCTs found evidence that warfarin (INR 2–3), apixaban (2.5 mg bd), apixaban (5 mg bd), dabigatran (150 mg bd) and rivaroxaban (20 mg od) reduce the risk of recurrent VTE, symptomatic DVT and symptomatic PE compared with placebo. Some of these reductions were substantial. We also found evidence that aspirin (100 mg od) and warfarin (INR 1.5–2) reduce the risk of recurrent VTE. The risk of recurrent VTE and symptomatic DVT is generally lower for NOACs at doses included in the network than for aspirin (100 mg od). However, there was little evidence that risks of recurrent VTE and symptomatic DVT differ comparing NOACs with warfarin (INR 2–3) or that the risk of these outcomes differs between licensed doses of NOACs. There was evidence that risk of symptomatic PE is higher with apixaban (2.5 mg bd) than warfarin (INR 2–3), and lower with dabigatran (150 mg bd) and rivaroxaban (20 mg od) than apixaban (2.5 mg bd).

By contrast, the risk of major bleeding and CRB is higher with warfarin (INR 2–3), dabigatran (150 mg od) and rivaroxaban (20 mg od) than placebo. However, the risk of these outcomes is lower for dabigatran (150 mg bd), apixaban (2.5 mg bd) and apixaban (5 mg bd) than warfarin (INR 2–3). There was evidence that the risk of major bleeding and CRB is higher with dabigatran (150 mg bd) and rivaroxaban (20 mg od) than apixaban (2.5 mg bd and 5 mg bd). However, results should be interpreted with caution because many comparisons were imprecisely estimated: for this reason it was not possible to derive a rankogram for this network.

For some outcomes there was evidence that patients who remained untreated had lower outcome risks than those on active interventions. This counterintuitive finding is based on the from WODIT-DVT²¹⁴ and WODIT-PE²¹⁵ trials. With regard to model appraisal, we did not identify any instance of lack of convergence among the Markov chains, poor model fit or inconsistency.

Chapter 10 Clinical results (5): combined safety analyses

In this chapter, we present network plots and pairwise comparisons from NMAs using the information from all four reviews. These should not be regarded as main results, but as a set of supplementary analyses in which we aimed to gain power by combining all databases in a single network for each of the following outcomes: MI, major bleeding, CRB and all-cause mortality.

A number of decisions were made in order to define the list of relevant nodes (e.g. interventions). We excluded the TOPIC-1,¹⁹⁷ TOPIC-2¹⁹⁷ and ARDEPARIN ARTHROPLASTY STUDY¹⁹⁶ trials, as for the analyses of primary prevention of VTE. We also excluded several individual interventions that were not considered to provide relevant information and were not necessary to keep our networks connected. These were warfarin arms with a subtherapeutic INR range, arms combined dabigatran and aspirin (considered only in PETRO¹⁰²), no treatment arms (only found in WODIT-DVT²¹⁴ and WODIT-PE²¹⁵ and compared with warfarin), LMWH (nadroparin 3800 IU anti-Xa od, implemented only in PROTECHT¹⁷⁰ and compared with placebo), and warfarin with INR range 3–4 (considered only in AFASAK⁹⁵ and compared with aspirin). If the intervention had been implemented in a two-arm trial then the trial was excluded from these analyses.

We also made several decisions in order to reduce the number of intervention arms compared. The reference treatment in our networks was warfarin (INR 2–3), which may include other VKA interventions, as was described for the analyses of AF. The antiplatelet interventions were defined as in the AF review (e.g. < 150 mg od and ≥ 150 mg od). The standard dose of LMWH was as in the review of primary prevention of VTE, and LMWH administered to non-surgical patients was combined with post-op LMWH. We merged some NOAC intervention doses and labelled these according to total daily dose. The edoxaban (60 mg) intervention included one arm from the review of acute VTE treatment in which 17% of patients received 30 mg instead. The list of interventions included in the networks is presented in *Table 183*.

Results are presented as follows for each outcome. First, we provide network plots. Second, we present results tables for each intervention compared with the reference treatment [warfarin (INR range 2–3)]. These tables show posterior median ORs and 95% credible intervals from Bayesian fixed-effects analyses are shown, but we refer to the latter as CIs for convenience. We present results separately for any available direct evidence, for any indirect comparisons that can be made and for the NMA (which combines the direct and the indirect evidence). Comparisons from the NMA with a ratio between interval limits exceeding nine were considered to be imprecisely estimated and are presented at the bottom of each table (back-calculation of indirect evidence was not done for imprecisely estimated comparisons).

Myocardial infarction

A total of 34 trials reported on MI across the four reviews, leading to a network of 18 interventions (*Figure 63*). The total number of events was 1489. Comparisons with the reference interventions [warfarin (INR 2–3)], presented in *Table 184*, suggest that the risk of MI is higher with dabigatran (220 mg daily), dabigatran (300–600 mg daily) and edoxaban (30–45 mg daily) than warfarin (INR 2–3).

TABLE 183 List of distinct interventions examined in the combined safety analyses

Warfarin	INR 2–3
LMWH post-op	Standard dose
LMWH pre-op	Standard dose
LMWH	Enoxaparin 20 mg bd
Antiplatelet	< 150 mg od ≥ 150 mg od
Placebo	
Apixaban	5 mg 10 mg 20 mg
Betrixaban	30–60 mg 80 mg
Dabigatran	100–150 mg 220 mg 300–600 mg
Edoxaban	5–15 mg 30–45 mg 60 mg 90–120 mg
Rivaroxaban	5 mg 10 mg 20–30 mg




FIGURE 63 Network plot for MI (combined analysis).

TABLE 184 Results for MI (combined analysis): comparisons with warfarin (INR 2–3)

Comparisons with warfarin (INR 2–3)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
Antiplatelet (< 150 mg)	1.01 (0.63 to 1.60)	–	1.01 (0.63 to 1.60)
Antiplatelet (≥ 150 mg)	1.36 (0.88 to 2.13)	–	1.36 (0.88 to 2.13)
Placebo	–	2.23 (0.79 to 6.72)	2.23 (0.79 to 6.72)
Apixaban (10 mg)	0.90 (0.69 to 1.18)	–	0.90 (0.69 to 1.18)
Dabigatran (220 mg)	1.39 (1.03 to 1.89)	–	1.39 (1.03 to 1.89)
Dabigatran (300–600 mg)	1.44 (1.08 to 1.91)	–	1.44 (1.08 to 1.91)
Edoxaban (30–45 mg)	1.25 (1.00 to 1.56)	–	1.25 (1.00 to 1.56)
Edoxaban (60 mg)	1.01 (0.81 to 1.26)	–	1.01 (0.81 to 1.26)
Rivaroxaban (20–30 mg)	0.84 (0.64 to 1.09)	–	0.84 (0.64 to 1.09)
Imprecisely estimated comparisons			
LMWH post-op (standard dose)	–	2.17 (0.50 to 9.72)	2.17 (0.50 to 9.72)
LMWH pre-op (standard dose)	–	0.82 (0.19 to 3.42)	0.82 (0.19 to 3.42)
Apixaban (5 mg)	–	1.33 (0.40 to 4.46)	1.33 (0.40 to 4.46)
Apixaban (20 mg)	–	0.46 (0.01 to 4.23)	0.46 (0.01 to 4.23)
Edoxaban (90–120 mg)	0.19 (0 to 2.61)	–	0.19 (0 to 2.61)
Rivaroxaban (10 mg)	–	0.60 (0.13 to 2.80)	0.60 (0.13 to 2.80)

Major bleeding

A total of 71 trials reported on major bleeding across the four reviews, leading to a network of 23 interventions (Figure 64). In total there were 5335 major bleeding events. The pairwise comparisons with warfarin, shown in Table 185, suggest that the risk of major bleeding is similar for both pre-op and post-op LMWH than warfarin (INR 2–3). However, there was notable inconsistency between the directly and indirectly estimated ORs. There was evidence that risk of major bleeding is lower for NOAC interventions than warfarin (INR 2–3), in agreement with the results from the AF review. This applies to the apixaban (10 mg daily), dabigatran (100–150 mg and 220 mg daily) and edoxaban interventions. Risk of major bleeding appeared higher with rivaroxaban (10 mg and 30–40 mg daily) than warfarin (INR 2–3), a finding that might stem from the evidence on primary prevention of VTE.


**FIGURE 64** Network plot for major bleeding (combined analysis).

TABLE 185 Results for major bleeding (combined analysis): comparisons with warfarin (INR 2–3)

Comparisons with warfarin (INR 2–3)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
LMWH post-op (standard dose)	1.65 (1.11 to 2.44)	0.61 (0.41 to 0.89)	0.99 (0.75 to 1.29)
LMWH pre-op (standard dose)	2.14 (1.36 to 3.36)	0.62 (0.45 to 0.89)	0.99 (0.75 to 1.3)
LMWH (enoxaparin 40 mg)	–	0.61 (0.21 to 1.84)	0.61 (0.21 to 1.84)
Antiplatelet (< 150 mg)	1.01 (0.57 to 1.80)	0.62 (0.41 to 0.93)	0.73 (0.52 to 1.03)
Antiplatelet (≥ 150 mg)	1.07 (0.82 to 1.41)	–	1.07 (0.82 to 1.41)
Placebo	0.60 (0.36 to 0.99)	–	0.60 (0.36 to 0.99)
Apixaban (5 mg)	–	0.89 (0.60 to 1.31)	0.89 (0.60 to 1.31)
Apixaban (10 mg)	0.67 (0.59 to 0.77)	–	0.67 (0.59 to 0.77)
Apixaban (20 mg)	1.77 (0.84 to 3.76)	–	1.77 (0.84 to 3.76)
Dabigatran (100–150 mg)	–	0.62 (0.39 to 0.97)	0.62 (0.39 to 0.97)
Dabigatran (220 mg)	0.82 (0.71 to 0.94)	–	0.82 (0.71 to 0.94)
Dabigatran (300–600 mg)	0.91 (0.80 to 1.04)	–	0.91 (0.80 to 1.04)
Edoxaban (30–45 mg)	0.47 (0.40 to 0.54)	–	0.47 (0.40 to 0.54)
Edoxaban (60 mg)	0.80 (0.70 to 0.90)	–	0.80 (0.70 to 0.90)
Edoxaban (90–120 mg)	2.43 (0.97 to 5.76)	–	2.43 (0.97 to 5.76)
Rivaroxaban (5 mg)	–	0.65 (0.22 to 1.55)	0.65 (0.22 to 1.55)
Rivaroxaban (10 mg)	–	1.71 (1.14 to 2.57)	1.71 (1.14 to 2.57)
Rivaroxaban (20–30 mg)	1.01 (0.88 to 1.15)	–	1.01 (0.88 to 1.15)
Rivaroxaban (40–60 mg)	1.18 (0.45 to 3.12)	3.53 (2.00 to 6.22)	2.67 (1.63 to 4.36)
<i>Imprecisely estimated comparisons</i>			
<i>Betrixaban (30–60 mg)</i>	–	<i>0.09 (0 to 2.87)</i>	<i>0.09 (0 to 2.87)</i>
<i>Betrixaban (80 mg)</i>	–	<i>0.10 (0 to 3.07)</i>	<i>0.10 (0 to 3.07)</i>
<i>Edoxaban (5–15 mg)</i>	–	<i>0.63 (0.10 to 2.64)</i>	<i>0.63 (0.10 to 2.64)</i>

Clinically relevant bleeding

A total of 51 trials reported on CRB, leading to a network of 22 interventions (*Figure 65*). These trials reported a total of 14,324 CRB events. Comparisons with the reference intervention [warfarin (INR 2–3)], presented in *Table 186*, suggest that risk of CRB was lower with LMWH than warfarin (INR 2–3). The risk of CRB was also lower for antiplatelets and placebo than warfarin (INR 2–3), as found in the AF and VTE secondary prevention reviews. Among the NOAC interventions, risk of CRB was lower with apixaban (5 mg and 10 mg daily), betrixaban (30–60 mg daily), dabigatran, edoxaban (30–45 mg and 60 mg daily) and rivaroxaban (5 mg and 10 mg daily) than warfarin (INR 2–3) but higher with edoxaban (90 mg daily). These findings are generally in agreement with those from the AF and VTE treatment reviews.

All-cause mortality

In total 59 trials reported on all-cause mortality, leading to a network of 23 interventions (*Figure 66*). The total number of deaths was 8508. Comparisons with the reference intervention [warfarin (INR 2–3)], shown in *Table 187*, suggest that risk of all-cause mortality was higher with antiplatelet therapy (≥ 150 mg daily) than warfarin (INR 2–3). Risk of all-cause mortality was generally lower among the NOAC interventions [estimated ORs compared with warfarin (INR 2–3) were between 0.87 and 0.93].




FIGURE 65 Network plot for CRB (combined analysis).

TABLE 186 Results for CRB (combined analysis): comparisons with warfarin (INR 2–3)

Comparisons with warfarin (INR 2–3)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
LMWH post-op (standard dose)	–	0.39 (0.29 to 0.53)	0.39 (0.29 to 0.53)
LMWH pre-op (standard dose)	–	0.48 (0.36 to 0.66)	0.48 (0.36 to 0.66)
LMWH (enoxaparin 40 mg)	–	0.52 (0.31 to 0.86)	0.52 (0.31 to 0.86)
Antiplatelet (< 150 mg)	–	0.52 (0.40 to 0.67)	0.52 (0.40 to 0.67)
Placebo	0.28 (0.21 to 0.37)	–	0.28 (0.21 to 0.37)
Apixaban (5 mg)	0.40 (0.30 to 0.54)	–	0.40 (0.30 to 0.54)
Apixaban (10 mg)	0.61 (0.55 to 0.67)	–	0.61 (0.55 to 0.67)
Apixaban (20 mg)	0.74 (0.40 to 1.38)	–	0.74 (0.40 to 1.38)
Betrixaban (30–60 mg)	0.24 (0.08 to 0.64)	–	0.24 (0.08 to 0.64)
Betrixaban (80 mg)	0.45 (0.16 to 1.21)	–	0.45 (0.16 to 1.21)
Dabigatran (100–150 mg)	0.54 (0.37 to 0.78)	–	0.54 (0.37 to 0.78)
Dabigatran (220 mg)	–	0.57 (0.39 to 0.82)	0.57 (0.39 to 0.82)
Dabigatran (300–600 mg)	0.62 (0.52 to 0.73)	–	0.62 (0.52 to 0.73)
Edoxaban (5–15 mg)	–	0.53 (0.25 to 1.08)	0.53 (0.25 to 1.08)
Edoxaban (30–45 mg)	0.59 (0.54 to 0.64)	–	0.59 (0.54 to 0.64)
Edoxaban (60 mg)	0.83 (0.78 to 0.89)	–	0.83 (0.78 to 0.89)
Edoxaban (90–120 mg)	2.04 (1.15 to 3.62)	0.82 (0.27 to 2.52)	1.69 (1.00 to 2.80)
Rivaroxaban (5 mg)	–	0.42 (0.21 to 0.80)	0.42 (0.21 to 0.80)
Rivaroxaban (10 mg)	–	0.72 (0.53 to 0.98)	0.72 (0.53 to 0.98)
Rivaroxaban (20–30 mg)	1.00 (0.93 to 1.07)	–	1.00 (0.93 to 1.07)
Rivaroxaban (40–60 mg)	0.23 (0.06 to 0.85)	1.46 (0.97 to 2.21)	1.24 (0.84 to 1.83)




FIGURE 66 Network plot for all-cause mortality (combined analysis).

TABLE 187 Results for all-cause mortality (combined analysis): comparisons with warfarin (INR 2–3)

Comparisons with warfarin (INR 2–3)	Direct evidence, OR (95% CI)	Indirect evidence, OR (95% CI)	NMA, OR (95% CI)
LMWH pre-op (standard dose)	–	1.70 (0.84 to 3.50)	1.70 (0.84 to 3.50)
LMWH post-op (standard dose)	0.68 (0.32 to 1.47)	1.26 (0.80 to 1.98)	1.07 (0.72 to 1.6)
Antiplatelet (< 150 mg)	1.02 (0.76 to 1.37)	1.13 (0.87 to 1.47)	1.08 (0.88 to 1.32)
Antiplatelet (≥ 150 mg)	1.23 (1.02 to 1.48)	–	1.23 (1.02 to 1.48)
Placebo	1.15 (0.77 to 1.71)	–	1.15 (0.77 to 1.71)
Apixaban (5 mg)	–	1.07 (0.54 to 2.08)	1.07 (0.54 to 2.08)
Apixaban (10 mg)	0.87 (0.78 to 0.97)	–	0.87 (0.78 to 0.97)
Dabigatran (220 mg)	0.92 (0.81 to 1.04)	–	0.92 (0.81 to 1.04)
Dabigatran (300–600 mg)	0.89 (0.79 to 1.01)	–	0.89 (0.79 to 1.01)
Edoxaban (30–45 mg)	0.88 (0.79 to 0.97)	–	0.88 (0.79 to 0.97)
Edoxaban (60 mg)	0.93 (0.85 to 1.02)	–	0.93 (0.85 to 1.02)
Rivaroxaban (10 mg)	–	1.10 (0.70 to 1.72)	1.10 (0.70 to 1.72)
Rivaroxaban (20–30 mg)	0.87 (0.75 to 1.02)	–	0.87 (0.75 to 1.02)
Imprecisely estimated comparisons			
Apixaban (20 mg)	0.67 (0.17 to 2.34)	–	0.67 (0.17 to 2.34)
Betrixaban (30–60 mg)	0.71 (0.07 to 10.2)	–	0.71 (0.07 to 10.2)
Betrixaban (80 mg)	0.19 (0 to 5.78)	–	0.19 (0 to 5.78)
Dabigatran (100–150 mg)	–	1.36 (0.32 to 5.00)	1.36 (0.32 to 5.00)
Edoxaban (5–15 mg)	–	0.76 (0.06 to 4.54)	0.76 (0.06 to 4.54)
Edoxaban (90–120 mg)	–	0.16 (0 to 2.30)	0.16 (0 to 2.30)
Rivaroxaban (40–60 mg)	0.27 (0.04 to 1.03)	–	0.27 (0.04 to 1.03)

Chapter 11 Cost-effectiveness results (2): venous thromboembolism

Introduction

In this chapter we present the results of the CEA for first-line secondary prevention, acute treatment and primary prevention of venous thromboembolic disease. The decision questions, populations, interventions, outcomes, model structures, cost and utility inputs have been previously described in *Chapter 4*. In this chapter we begin by describing clinical effectiveness inputs to the models, including relative treatment effects based on the evidence identified in the systematic reviews (see *Chapters 7–9*), transition probabilities on the reference treatment on which relative effects are applied, other state-transition probabilities based on evidence from longitudinal studies, and mortality. We then present the results from our cost-effectiveness model, together with sensitivity analyses to key assumptions made. Results are presented from Bayesian analyses with 95% credible intervals, although we refer to these as confidence intervals for convenience.

Model inputs: venous thromboembolism secondary prevention

Overview

The state-transition parameters that inform the secondary prevention model have two components. The relative effects of the different treatments come from the NMAs of the studies that were identified in the systematic review (see *Chapter 9*). The transition parameters under standard care (i.e. no pharmacological treatment) are taken from longitudinal studies that provide information on the natural history of VTE.

Relative treatment efficacy

Hazard ratios for the relative treatment effects of aspirin, warfarin and three NOACs (apixaban, dabigatran and rivaroxaban) compared with placebo are derived from the NMA (see *Table 145*). These HRs were applied to the risk of symptomatic VTE on the reference treatment (no pharmacotherapy) to estimate the efficacy of each intervention. The NMA revealed inconsistent results between the WODIT trials,^{212,213} which used a no-treatment control arm and other trials that used a placebo control arm. The estimated hazard for no treatment lacked face validity, as it was much lower than placebo and aspirin, and was similar to the NOACs. Therefore, we decided that aspirin, warfarin and NOAC efficacy relative to placebo was the more reliable estimate for the cost-effectiveness model.

Given a recurrent VTE event, we estimated the probability that it is a DVT, which can be subtracted from 1 to give the probability that it is a PE. If the recurrent VTE is a PE, we estimated the probability that it is a non-fatal PE. Owing to very small numbers of events in the secondary prevention RCTs, we are unable to estimate relative treatment effects for these conditional probabilities and assumed that they are treatment independent. We therefore treat each arm of each trial as an independent source of information on the probability of (1) a DVT only, given a recurrent VTE event, and (2) a non-fatal PE, given a PE event. Eight out of the 10 studies in the systematic review were included in this analysis; two studies did not record counts of DVT, non-fatal PE and fatal PE. The counts of VTE, DVT, non-fatal PE and fatal PE are in *Table 138*. Both fixed- and random-effects single-arm meta-analyses were explored (including study arms with zero events). The random-effects models did not show evidence of a better fit than the fixed-effects models. We therefore used the results from the fixed-effects meta-analysis to estimate conditional probabilities and uncertainty using beta distributions (*Table 188*).

TABLE 188 Estimated risk for DVT given VTE recurrence and non-fatal PE given PE

Event	Proportion	Alpha	Beta	Distribution
DVT given recurrent VTE	0.626	268	160	Beta
Non-fatal PE, given PE	0.919	147	13	Beta

Relative treatment safety

The criteria for and classification of bleeding events is not uniform across RCTs and is the subject of wider debate.²²⁵ Our model distinguishes between fatal bleeds, non-fatal ICH and other clinically relevant bleeds (those which require an intervention or hospital admission). Minor bleeds, identified through close monitoring in RCTs, which do not require intervention, are not considered clinically relevant and have not been included in the model because of the minimal impact on quality of life and costs.

The incidence of ICH was not commonly reported in the secondary prevention VTE RCTs. Therefore, the relative treatment effects of the NOACs compared with warfarin for ICH were derived from RCTs conducted in the AF population (see *Table 59*). These trials included all NOAC and dose combinations compared in the secondary prevention of VTE. We assumed that the relative treatment effects of no pharmacotherapy and aspirin compared with warfarin for ICH are similar to those estimated for CRB (see *Table 174*).

The VTE secondary prevention RCTs did not provide sufficient information to determine what proportion of ICHs are fatal. Therefore, the proportion of non-fatal ICHs was estimated from a study²²⁶ that investigated ICHs in patients with AF using data from the RE-LY¹⁰⁴ trial. In total there were 56 fatal and 98 non-fatal ICHs. The relative treatment effects for other CRB, compared with the reference group (no pharmacotherapy), for the interventions, were estimated in a NMA (see *Table 174*).

Transition probabilities with usual care (no pharmacotherapy)

A rapid literature review was conducted to identify long-term follow-up studies in a patient population with VTE to inform the natural history of VTE with usual care (no pharmacotherapy). The initial search identified 3915 abstracts. After abstract selection and full-paper review of the most relevant subset of papers, the following three studies,²²⁷⁻²²⁹ based in the same region of Italy, were selected as most relevant to parameterise the secondary prevention model.

Prandoni *et al.*²²⁷ recruited 528 patients with a first episode of venography proven DVT in a prospective cohort study conducted in a single centre in Italy. Patients were treated initially with unfractionated heparin or LMWH and then warfarin (INR target 2–3) for at least 3 months. Patients were advised to wear compression stockings for at least 2 years and followed up every 6 months for up to 8 years. The aim of the study was to assess VTE recurrence, PTS incidence and mortality. The results of this study were used to parameterise the rate of mild/moderate and severe PTS.

Prandoni *et al.*²²⁸ broadened their previous work and reported on a prospective cohort of 1626 patients, recruited in three centres in Italy. Patients with a previous, imaging confirmed, symptomatic proximal DVT or a PE after discontinuation of anticoagulation (warfarin for, on average, 3 months) treatment were eligible. Patients were followed up in clinic or by telephone at least once every 6 months for a maximum of 10 years (median 50 months). The study²²⁸ estimated the cumulative incidence of symptomatic recurrent VTE, confirmed by imaging, and we used these results to estimate the risk of recurrent VTE with no anticoagulation in our model.

Pengo *et al.*²²⁹ estimated the incidence of CTPH in a prospective cohort of 223 patients with a first episode of acute PE in one Italian centre. Patients initially received heparin and then oral anticoagulation for at least 6 months (target INR 2–3). Follow-up was performed at least every 6 months during the first 2 years and then annually for up to 10 years; mean follow-up was 94.3 months. CTPH was diagnosed in patients with

unexplained persistent dyspnoea, with supportive evidence on pulmonary angiography and mean pulmonary artery pressures. We used these findings to estimate transition from 'post PE' and 'post PE DVT' to CTPH in our model.

Parameters informing the risk of recurrent VTE in the usual care group (no long-term pharmacotherapy) were derived from Prandoni *et al.*²²⁸ Individual patient data were reconstructed from the cumulative risk plot, and exponential and Weibull parametric distributions were fitted to these data. The Akaike information criterion (AIC)²³⁰ was used to determine the best-fitting curve for the within-study period (preferring models with lower AIC) and a visual examination determined the validity of the extrapolation. The best-fitting curve for the within-study period was the Weibull distribution (*Figure 67* and *Table 189*).

The risk of a clinically relevant bleed in the reference group was estimated based on PREVENT.²¹⁶ The PREVENT trial²¹⁶ had a follow-up of up to 4.3 years, with a mean of 2.1 years. The observed rate of major bleeding – requiring hospitalisation or transfusion – in the placebo arm was 4 per 1000 person-years. Patients not receiving pharmacotherapy are assumed to be at equal risk of bleeds as placebo.

Future venous thromboembolism-related events

A proportion of patients develop PTS after a DVT. The incidence of PTS, stratified by mild/moderate or severe, was derived from Prandoni *et al.*,²²⁷ which provides a plot of the cumulative incidence of all PTS and severe PTS. Data from this plot were extracted using WebPlotDigitizer (<http://arohatgi.info/WebPlotDigitizer/>) to estimate the yearly incidence of severe PTS and mild/moderate PTS (*Table 190*). The cumulative incidence of PTS levels off 2 years after the index VTE event, and we assume that patients have no additional risk of PTS after that time. The rate of CTPH given a PE was taken from Pengo *et al.*²²⁹ In total, 7 of 223 patients developed symptoms of CTPH, and all seven events occurred in the initial 2 years (*Table 191*).




FIGURE 67 Parametric distributions for recurrent VTE baseline risk fitted to results reported in Prandoni *et al.*²²⁸

TABLE 189 Parameters and AIC for recurrent VTE baseline risk based on Prandoni *et al.*²²⁸

Distribution	Scale	Shape	AIC
Exponential	0.005487	–	2758.604
Weibull	0.016565	0.721213	2702.246

TABLE 190 Cumulative PTS rates, given DVT

Year	Cumulative incidence		Source
	PTS (95% CI)	Severe PTS (95% CI)	
1	0.172 (0.135 to 0.215)	0.029 (0.009 to 0.044)	Prandoni ²²⁷
2	0.231 (0.180 to 0.277)	0.062 (0.032 to 0.090)	

TABLE 191 Incidence of CTPH, given PE

Month	Cumulative incidence of CTPH	95% CI	Source
12	0.031	0.007 to 0.055	Pengo ²²⁹
24	0.038	0.011 to 0.065	

Mortality

In the model, patients can die from a fatal PE, an ICH or other, all-cause, mortality. The rates of recurrent VTE and ICH including fatal PE and ICH events are described previously. We assumed that ICH was the cause of all of the fatal bleeding events. Seven trials^{213-216,218,220,222} reported on fatal bleeds; all had low counts and four had zero events. We assumed that sudden fatal PEs do not accrue a cost and non-sudden fatal PEs accrue the full cost of treating a PE. This proportion of sudden fatal PEs was assumed to be 74.4% as recorded in Prandoni *et al.*²²⁸

All-cause mortality rates are applied to every health state in the model to incorporate other causes of death. These were obtained from the ONS,¹⁰ stratified by gender and age to match our population (see *Appendix 10*).

Model inputs: venous thromboembolism acute treatment

Overview

Relative treatment effects for the probabilities in the first-line acute treatment decision tree model have been derived from three NMAs and a pairwise meta-analysis (described below) for the following four events: (1) recurrent VTE; (2) non-fatal ICH (pairwise meta-analysis); (3) other CRB; and (4) non-VTE-related mortality.

Relative treatment efficacy

The ORs of four NOACs (apixaban, dabigatran, edoxaban, rivaroxaban) compared with warfarin were derived from the NMA (*Table 192*, and see *Table 114*). The probabilities of DVT given recurrent VTE and non-fatal PE given PE were, as with secondary prevention, assumed to be treatment independent and derived from single arms from all nine studies in the acute treatment review using a fixed-effects meta-analysis (*Table 193* and see *Table 111*).

TABLE 192 Odds ratios of VTE recurrence on acute treatment: all ORs are compared with warfarin

Intervention	OR	95% CI	Distribution
Dabigatran	1.09	0.75 to 1.59	MCMC posterior simulations
Rivaroxaban	0.90	0.67 to 1.21	
Apixaban	0.83	0.58 to 1.18	

TABLE 193 Estimated risk of DVT given VTE recurrence and non-fatal PE given PE

Event	Proportion	Alpha	Beta	Distribution
DVT given recurrent VTE	0.47	341	387	Beta
Non-fatal PE given a PE event	0.73	283	104	

Relative treatment safety

Four out of the nine studies identified in the literature review reported non-fatal ICH. The incidence was low: 38 patients out of 21,916 experienced an event, and there were not enough data to perform a NMA. Instead, we assumed that all NOACs have a similar risk, and performed a pairwise meta-analysis for all NOACs combined compared with warfarin. Fixed- and random-effects pairwise meta-analyses were explored resulting in DIC²³ values of 40.31 and 39.54, respectively. We preferred models with lower DIC, for which differences of at least '3' are considered to be meaningful. On this basis, the fixed-effects model was used to estimate the OR and uncertainty (*Table 194*). This assumption was explored in a sensitivity analysis, for which we assumed that the risk of non-fatal ICH for NOACs is the same as the risk for warfarin. The relative treatment effects for individual NOACs compared with warfarin for other clinically relevant bleeds were estimated in *Table 129* and are provided below (*Table 195*).

Mortality

To derive the mortality in the 6 months of acute treatment a NMA was performed. The counts are the reported all-cause mortality with VTE-related mortality deducted. Eight out of the nine studies identified in the literature review reported all-cause mortality and VTE-related mortality separately (see *Table 111*). The data used in the NMA are provided in *Appendix 9*. The results relative to warfarin are in *Table 196*.

Transition probabilities with usual care (warfarin)

The risks of experiencing recurrent VTE, non-fatal ICH, clinically relevant bleed and non-VTE-related mortality on usual care (warfarin) have been estimated from a single-arm, fixed-effects meta-analysis model for each outcome using all of the warfarin arms that were identified in the systematic review (including study arms with zero counts). The fixed-effects model was chosen over the random-effects model on the basis of lower DIC. Each of the outcomes is considered to be independent and so each is modelled separately to estimate parameters and beta distributions representing uncertainty (*Table 197*).

TABLE 194 Odds ratios of non-fatal ICH in the acute treatment: NOACs combined, compared with warfarin

Intervention	OR	95% CI	Distribution
NOACs	0.395	0.189 to 0.790	MCMC posterior simulations

TABLE 195 Odds ratios of clinically relevant bleeds in acute treatment: all ORs are compared with warfarin

Intervention	OR	95% CI	Distribution
Dabigatran	0.61	0.49 to 0.76	MCMC posterior simulations
Rivaroxaban	0.93	0.81 to 1.08	
Edoxaban	0.81	0.70 to 0.94	
Apixaban	0.44	0.35 to 0.55	

TABLE 196 Odds ratios of non-VTE/ICH-related mortality in acute treatment: all ORs are compared with warfarin

Intervention	OR	95% CI	Distribution
Dabigatran	0.98	0.64 to 4.84	MCMC posterior simulations
Rivaroxaban	0.96	0.71 to 1.30	
Edoxaban	1.06	0.81 to 1.39	
Apixaban	0.87	0.54 to 1.39	

TABLE 197 Estimated risk on warfarin for recurrent VTE, non-fatal ICH, CRB and non-VTE-related mortality

Event	Proportion	Alpha	Beta	Distribution
Recurrent VTE	0.027	378	13,474	Beta
Non-fatal ICH	0.002	27	10,930	
Clinically relevant bleed	0.097	1319	12,288	
Non-VTE-related mortality	0.018	244	13,496	

Model inputs: venous thromboembolism primary prevention

Overview

Absolute probabilities of VTE, clinically relevant bleeds and mortality on reference treatment (LMWH) are estimated from the LMWH arms of the primary prevention trials identified in our systematic review, and these probabilities differ between THR and TKR populations (due to different length of time on treatment). All of the relative effects of NOACs have been derived from NMAs, and the MCMC simulations are used directly as inputs to our probabilistic model, retaining all correlations between parameter estimates. We stratified relative effects of NOACs compared with LMWH by THR and TKR populations. However, as a result of sparse data for AEs, and for consistency with the clinical effectiveness results, we assumed that relative effects are common across THR and TKR populations for clinically relevant bleeds and all-cause mortality.

Relative treatment efficacy

The proportion of patients who experience a symptomatic VTE event was derived from NMAs stratified by post THR and TKR, reported in *Tables 75* and *Table 77*, respectively. The reference comparator for these two populations is post-op LMWH. We pooled relative treatment effects over the THR and TKR populations in a sensitivity analysis.

Relative treatment safety

Intracranial haemorrhage was reported in only 12 primary prevention studies. Within these studies, the total count of ICH is 6 out of 32,879 patients (it may also be the case that studies that did not report ICH did not observe any events, which would mean that the risk is even lower). Patients who are receiving primary prevention (for up to 35 days) are at much lower risk of ICH than patients who are receiving acute treatment (up to 6 months) or long-term secondary prevention. Owing to extremely low incidence, this outcome has not been incorporated into the primary prevention model. The relative treatment effects for CRB compared with post-op LMWH are reported in *Table 102*.

Mortality

Relative treatment effects for all-cause mortality have been derived from the NMA. This includes fatal VTE events, so to avoid double counting VTE-related mortality, only the rates from all-cause mortality informed

the transition to death in the model. The results relative to post-op LMWH are given in *Table 105*. The mortality rates for patients who do not experience a symptomatic VTE and enter the two-stage Markov model were taken from the ONS all-cause mortality (see *Appendix 10*).

Transition probabilities with usual care (low-molecular-weight heparin)

Usual care in the primary prevention model is post-op LMWH.⁸ The risk of experiencing each event (VTE, clinically relevant bleed and mortality) on the reference treatment was estimated from single-arm, fixed-effects meta-analyses for each outcome and population (THR or TKR), using reference treatment arms that were identified in the systematic review (including studies with zero events). The outcomes are considered to be independent and so are modelled separately. The absolute risk of recurrent VTE and all-cause mortality on LMWH was estimated separately for the THR and TKR populations, as THR patients remain on treatment for longer. There was not enough information on other CRB in the THR population to estimate an absolute risk; we therefore pooled over TKR and THR populations. We fitted a random-effects model over the pooled TKR and THR population for clinically relevant bleeds as a result of the substantial heterogeneity, with the random-effects model giving a DIC of 22.7 compared with 43.0 for a fixed-effects model. The resulting parameter estimates and beta distributions that represent the uncertainty in these estimates are given in *Table 198*.

Sensitivity analyses

We tested the robustness of the models' results to some of the model parameters in one-way sensitivity analyses, listed below.

Proportion of venous thromboembolism events that are fatal and non-fatal pulmonary embolism (secondary prevention)

We varied the proportion of DVT, non-fatal PE and fatal PE when a patient experienced a recurrent VTE event in the secondary prevention model. Having a large proportion of non-fatal recurrent VTE events has a small effect on quality of life compared with having a large proportion of fatal events. We used a beta distribution with proportions estimated in Prandoni *et al.*:²²⁷ 101 recurrent events consisting of 80 DVTs, 10 non-fatal PEs and 11 fatal PEs.

Risk of clinically relevant bleed on warfarin (secondary prevention)

The rate used in the base case was the observed rate for major bleeds in a secondary prevention RCT (PREVENT²¹⁶). This could be an underestimate as a result of including only major and not clinically relevant minor bleeds. In sensitivity analysis we use, instead, the odds of experience of a CRB taken from the AF population [see *Chapter 6, Transition probabilities with usual care (warfarin)*].

TABLE 198 Estimated risk on LMWH for VTE, CRB and mortality minus VTE-related mortality

Event	Proportion	Alpha	Beta	Distribution
Recurrent VTE THR	0.035	65	1,787	Beta
Recurrent VTE TKR	0.023	36	1,527	
Mortality THR	0.019	53	2,619	
Mortality TKR	0.004	16	4,342	
Event	Proportion	LB	UB	Distribution
Clinically relevant bleed	0.029	0.005	0.121	MCMC simulations

LB, lower bound; UB, upper bound.

Beta distributions, Beta (alpha,beta), representing uncertainty in the estimates are given.

Rate of non-fatal intracranial haemorrhage (acute treatment)

We did not have enough data to perform a NMA on this outcome. In the base case we assumed that all NOACs have the same relative treatment effect compared with warfarin. We tested this assumption by instead assuming that the rate of non-fatal ICH is equal among NOACs and warfarin in this sensitivity analysis.

Cost of edoxaban (acute treatment)

Edoxaban does not currently have a list price in the UK. For the base case we assume a cost similar to the list price of other NOACs, and test this assumption in a sensitivity analysis. We do this through a threshold analyses to see what the cost of edoxaban would have to be for it to be considered cost-effective at a willingness-to-pay threshold of £20,000 per QALY. We begin by assuming a zero drug cost for edoxaban, noting that if it is not found to be cost-effective at a zero cost then increasing the cost will not change our results.

Changing the time on treatment (acute treatment)

In the majority of trials in our review, patients receive acute treatment for 6 months; however, NICE guidance recommends 3 months in acute treatment, with an additional 3 months treatment if necessary. We assume 6 months' treatment in our base case, and reduce this to 3 months in a sensitivity analysis. Note that due to a lack of evidence, we assume that relative treatment efficacy is unchanged if given for 3 months rather than 6 months; however, absolute event rates for AEs decrease with time on treatment, and treatment costs are reduced.

Pooling post total hip replacement and post total knee replacement populations for relative treatment effect of venous thromboembolism (primary prevention)

We pooled THR and TKR populations to estimate relative treatment effects of VTE in primary prevention in this sensitivity analysis. The relative treatment effects are provide in *Appendix 11*.

Dabigatran dose for elderly patients (primary prevention)

In this sensitivity analysis we costed dabigatran at a lower dose in the primary prevention models to match the dose recommended in the BNF for elderly patients: 150 mg od.

Cost of treatment-related adverse events (all models)

We varied the cost of treatment-related AEs by $\pm 50\%$. These included clinically relevant bleeds, ICH and post ICH.

Cost of venous thromboembolism events (all models)

We varied the cost of VTE events by $\pm 50\%$. These included DVT, PE, mild moderate PTS, severe PTS and CTPH.

Utility decrements of treatment-related adverse events (all models)

We varied the utility decrement of treatment-related AEs by $\pm 50\%$. These included clinically relevant bleeds, ICH and post ICH.

Utility decrements of venous thromboembolism events (all models)

We varied the utility decrement of VTE events by $\pm 50\%$. These included DVT, PE, mild moderate PTS, severe PTS and CTPH.

Cost of warfarin (all models)

We assessed sensitivity of our results to administration and monitoring cost of warfarin through a threshold analysis to see what the cost of warfarin would have to be for it to be considered cost-effective at a willingness-to-pay threshold of £20,000 per QALY. We begin by assuming a zero cost for warfarin, noting that if it is not found to be cost-effective at a zero cost then increasing the cost will not change our results.

Results of the cost-effectiveness model: venous thromboembolism secondary prevention

We estimated expected costs, QALYs, incremental costs, incremental QALYs and incremental NMB at willingness to pay of £20,000 and £30,000 for first-line prevention therapy (*Table 199*). The cheapest comparator is aspirin (total expected cost £20,671). No pharmacotherapy is the next cheapest treatment, with benefits similar to aspirin. Warfarin and the NOACs all have substantially higher costs than aspirin and no pharmacotherapy, and the NOACs are more expensive than warfarin. Dabigatran and apixaban (5 mg) have marginally higher expected QALYs than no pharmacotherapy. Apixaban (2.5 mg) has the lowest expected QALYs, followed by warfarin. Apixaban (2.5 mg) has the highest HR for the risk of ICH, albeit estimated imprecisely. Although the NOACs and warfarin prevent more recurrent VTEs than no pharmacotherapy or aspirin, the rate of recurrent VTE is low and the rate of AEs (ICH and clinically relevant bleeds), which can have a long-term impact on quality of life, are generally higher for the NOACs than aspirin or no pharmacotherapy.

Aspirin has the highest expected net benefit at willingness-to-pay thresholds of £20,000 and £30,000 per QALY (see *Table 199*). However, the CI for the INB of aspirin includes zero, indicating uncertainty about whether or not it is more cost-effective than no pharmacotherapy. All NOACs have negative expected INBs at the £20,000 and £30,000 thresholds, and all CIs are negative at the £20,000 threshold, indicating that they are not cost-effective compared with no pharmacotherapy. Dabigatran, which had the lowest estimated HR for recurrent VTE and ICH of all the NOACs, also has the highest expected net benefit of any NOAC. However, dabigatran is not cost-effective relative to no pharmacotherapy, even at the £30,000 threshold, as the incremental NMB is negative (–£3402; 95% CI –£12,338 to £5424). *Figure 68* shows that although there is uncertainty in the estimated costs and QALYs, it is clear that aspirin has lower costs and similar benefits in the majority of the samples. Over a wide range of willingness-to-pay-per-QALY thresholds, aspirin has the highest expected net benefit (*Figure 69*), and also the highest probability of being the most cost-effective (*Figure 70*), although there is a non-negligible probability that no pharmacotherapy is the most cost-effective intervention for secondary prevention of VTE at a threshold of £20,000–30,000. These results suggest that it is not cost-effective to prescribe NOACs or warfarin for secondary prevention of VTE over the range of willingness-to-pay thresholds that we explored (up to £40,000 per QALY).

The estimated per-person EVPI was £757 at a willingness to pay of £20,000, and £1291 at £30,000. Assuming a VTE incidence of 183 per 100,000 in a European population,⁷ and a population of 65- to 70-year-olds in England and Wales of approximately 3 million (2011 Census), gives an estimated VTE incidence rate per year of 5490. Population EVPI over a 10-year time horizon, discounting at 3.5%, is approximately £36M and £61M at willingness-to-pay thresholds of £20,000 and £30,000, respectively.

Figure 71 shows the proportion of the EVPI that is attributable to different groups of parameters. The optimal decision is most sensitive to the relative treatment effects, suggesting that there may be value in running a large trial comparing a NOAC with aspirin and no pharmacotherapy. Note, however, that, as a result of low event rates, a study that is powered to capture VTE events may be prohibitive.

Results of the cost-effectiveness model: low-molecular-weight heparin acute treatment

We estimated expected costs, QALYs, incremental costs, incremental QALYs and incremental NMB at a willingness to pay of £20,000 and £30,000 for first-line therapy (*Table 200*). Expected costs and benefits are similar across all treatments because of the short (6-month) treatment duration and the small,

TABLE 199 Results of the secondary prevention CEA

Estimated costs and outcomes	No pharmacotherapy	Aspirin	Rivaroxaban	Dabigatran	Warfarin	Apixaban 2.5 mg	Apixaban 5 mg
Costs	£21,282 (£14,619 to £30,388)	£20,671 (£14,342 to £29,346)	£31,781 (£26,270 to £39,317)	£30,952 (£25,613 to £38,396)	£26,379 (£21,103 to £33,550)	£33,496 (£26,672 to £43,389)	£31,557 (£26,061 to £39,312)
QALYs	12.58 (12.16 to 12.94)	12.58 (12.05 to 12.99)	12.50 (11.97 to 12.91)	12.74 (12.32 to 13.09)	12.32 (11.67 to 12.78)	11.83 (8.1 to 13.07)	12.63 (12.17 to 13.00)
Incremental costs	-	-£611 (-£1834 to £939)	£10,498 (£8197 to £12,640)	£9670 (£7545 to £11,406)	£5097 (£2337 to £7829)	£12,213 (£8365 to £22,029)	£10,275 (£8429 to £11,810)
Incremental QALYs	-	0.00 (-0.27 to 0.15)	-0.08 (-0.42 to 0.16)	0.16 (-0.05 to 0.36)	-0.26 (-0.71 to 0.03)	-0.75 (-4.40 to 0.39)	0.06 (-0.18 to 0.25)
Incremental NMB (at £20,000)	-	£623 (-£6404 to £4602)	-£12,119 (-£19,983 to -£6238)	-£6536 (-£116,711 to £ -1513)	-£10,351 (-£20,582 to -£3256)	-£27,180 (-£109,197 to -£1272)	-£9171 (-£14,548 to -£4565)
Incremental NMB (at £30,000)	-	£629 (-£9176 to £6085)	-£13,740 (-£28,266 to -£3216)	-£3402 (-£12,388 to £5424)	-£15,606 (-£34,467 to -£2776)	-£42,146 (-£197,897 to £6442)	-£8067 (-£18,012 to £294)

Incremental results are relative to no pharmacotherapy. Figures are presented as mean (CI).




FIGURE 68 Incremental cost-effectiveness plane for secondary prevention (no pharmacotherapy: reference). See Chapter 4 (*Outcomes of atrial fibrillation and venous thromboembolism models*) for further details.




FIGURE 69 Cost-effectiveness acceptability frontier for secondary prevention. See Chapter 4 (*Outcomes of atrial fibrillation and venous thromboembolism models*) for further details.




FIGURE 70 Cost-effectiveness acceptability curve for secondary prevention. See Chapter 4 (*Outcomes of atrial fibrillation and venous thromboembolism models*) for further details.




FIGURE 71 Expected value of partial perfect information for subsets of model input parameters in the VTE secondary prevention model, presented as a proportion of the total EVPI. SAVI-estimated EVPPI scaled by EVPPI of all parameters as estimated by SAVI. 95% intervals are $\pm 1.96 \times$ standard error and are truncated above at 1 and below at 0.

and imprecisely estimated, effects of NOACs on VTE recurrence and AEs compared with warfarin. Warfarin has the lowest expected cost (£19,651), followed by dabigatran, edoxaban and apixaban, and rivaroxaban is the most expensive (£19,753). Apixaban had the highest expected QALYs (12.02) but this is only 0.04 QALYs greater than the interventions with the lowest expected QALYs (edoxaban, warfarin and dabigatran).

TABLE 200 Results of the acute treatment CEA: costs, QALYs, incremental costs, incremental QALYs and incremental NMB at willingness-to-pay thresholds of £20,000 and £30,000

Estimated costs and outcomes	Warfarin (95% CI)	Dabigatran (95% CI)	Rivaroxaban (95% CI)	Apixaban (95% CI)	Edoxaban (95% CI)
Costs	£19,651 (£13,543 to £27,667)	£19,663 (£13,522 to £27,695)	£19,753 (£13,579 to £27,819)	£19,683 (£13,543 to £27,801)	£19,675 (£13,557 to £27,732)
QALYs	11.98 (11.46 to 12.36)	11.98 (11.46 to 12.37)	11.99 (11.48 to 12.38)	12.02 (11.49 to 12.41)	11.98 (11.46 to 12.36)
Incremental costs		£12 (–£168 to £152)	£102 (–£22 to £211)	£31 (–£149 to £180)	£24 (–£99 to £133)
Incremental QALYs		0.00 (–0.10 to 0.08)	0.01 (–0.06 to 0.07)	0.04 (–0.07 to 0.12)	–0.01 (–0.07 to 0.05)
Incremental NMB (at £20,000)		£21 (–£1885 to £1498)	£196 (–£1123 to £1281)	£710 (–£1322 to £2185)	–£132 (–£1369 to £920)
Incremental NMB (at £30,000)		£38 (–£2903 to £2324)	£344 (–£1686 to £2018)	£1080 (–£2059 to £3351)	–£186 (–£2084 to £1434)

The expected net benefit is highest for apixaban at willingness-to-pay thresholds of £20,000 and £30,000 per QALY. This is due to the marginally lower risk of recurrent VTE, CRB and non-VTE-related mortality with apixaban relative to other NOACs. However, there is substantial uncertainty around this estimate. Rivaroxaban also has a positive INB compared with warfarin. CIs for INB are wide for all treatments, reflecting substantial uncertainty that is also seen in the incremental cost-effectiveness plane (*Figure 72*).

The CEACs (*Figure 73*) show that for very low willingness to pay per QALY, warfarin is the most cost-effective treatment (because it has lowest expected costs). For willingness-to-pay thresholds of > £1000, apixaban (5 mg) has the highest expected net benefit (*Figure 74*), with a probability of being most cost-effective at £20,000–30,000 per QALY thresholds of approximately 0.54. However, it is possible that rivaroxaban or dabigatran are the most cost-effective interventions, even at high willingness-to-pay thresholds.

The per-person EVPI was £365 at willingness-to-pay thresholds of £20,000 and £579 at £30,000. Assuming a VTE incidence rate per year of 5490 (as for secondary prevention). Population EVPI over a 10-year time horizon, discounting at 3.5%, is approximately £17M and £27M at willingness-to-pay thresholds of £20,000 and £30,000, respectively.

Figure 75 shows the proportion of the EVPI that is attributable to different groups of parameters. The optimal decision is most sensitive to uncertainty in the cost and utility model inputs. This suggests there may be value in conducting a study to estimate the utilities associated with VTE events and treatment-related events. As such a study is likely to be relatively inexpensive to conduct (compared with a RCT), and given the magnitude of likely benefits, this should be considered a research priority.




FIGURE 72 Incremental cost-effectiveness plane for acute treatment (warfarin: reference). See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 73 Cost-effectiveness acceptability curve for acute treatment. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 74 Cost-effectiveness acceptability frontier for acute treatment. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.

The optimal decision is not very sensitive to event rates on the reference comparator (baseline risk), relative treatment effects for all comparators, relative treatment effects of apixaban compared with warfarin (the two comparators with the highest probability of being cost-effective at a willingness to pay of £20,000 per QALY) and treatment-independent transition parameters.




FIGURE 75 Expected value of partial perfect information subsets of parameters in the VTE acute treatment model, as a proportion of the total EVPI. SAVI-estimated EVPPI scaled by EVPPI of all parameters as estimated by SAVI. 95% intervals are $\pm 1.96 \times$ standard error and are truncated above at 1 and below at 0.

Results of the cost-effectiveness model: low-molecular-weight heparin primary prevention

Total hip replacement

The expected total costs, QALYs, incremental costs, incremental QALYs and incremental NMB at willingness-to-pay thresholds of £20,000 and £30,000 per QALY for first-line prevention therapy are reported in *Table 201* and illustrated in *Figure 76*). The lowest expected total costs are for apixaban (£702) followed by rivaroxaban (£718) and then dabigatran (£893). LMWH has the highest expected cost (£1062). Expected benefits are highest for rivaroxaban and LMWH (9.10 QALYs), followed by dabigatran (9.04 QALYs) then apixaban (8.96 QALYs). At both willingness-to-pay thresholds of £20,000 and £30,000 per QALY, rivaroxaban has the highest expected INB, although CIs around net benefit are wide (particularly for dabigatran) and also skewed (apixaban).

TABLE 201 Results of the THR primary prevention CEA: costs, QALYs, incremental costs, incremental QALYs and incremental NMB

Estimated costs and outcomes	LMWH	Dabigatran	Rivaroxaban	Apixaban
Costs	£1062 (£888 to £1311)	£893 (£635 to £1495)	£718 (£571 to £1045)	£702 (£573 to £953)
QALYs	9.1 (8.85 to 9.35)	9.04 (8.44 to 9.40)	9.10 (8.84 to 9.36)	8.96 (8.47 to 9.31)
Incremental costs		−£169 (−£430 to £345)	−£344 (−£558 to −£99)	−£360 (−£559 to −£156)
Incremental QALYs		−0.06 (−0.61 to 0.15)	0.01 (−0.04 to 0.04)	−0.13 (−0.57 to 0.09)
Incremental NMB (at £20,000)		−£1066 (−£12,127 to £3191)	£453 (−£485 to £1312)	−£2284 (−£11,017 to £2085)
Incremental NMB (at £30,000)		−£1684 (−£18,241 to £4649)	£507 (−£883 to £1739)	−£3606 (−£16,704 to £2917)

Incremental results are relative to LMWH. Figures are presented as mean (CI).




FIGURE 76 Incremental cost-effectiveness plane for THR primary prevention (LMWH reference). See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.

Rivaroxaban has the highest expected net benefit over the range of willingness-to-pay thresholds that we explored (*Figure 77*) but with substantial uncertainty: its probability of being the most cost-effective was 0.35 for willingness-to-pay threshold of £30,000 per QALY (*Figure 78*). Because of the very wide confidence limits for dabigatran, there is an apparently contradictory finding that it has the highest probability of being the most cost-effective NOAC (see *Figure 77*) for thresholds of > £14,000 but does not have the highest expected net benefit (see *Figure 78* and *Table 201*). This phenomenon is documented




FIGURE 77 Cost-effectiveness acceptability curve for THR primary prevention. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 78 Cost-effectiveness acceptability frontier for THR primary prevention. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.

in the literature, and in these circumstances the CEAF (see *Figure 78*) is a better summary than the CEAC (see *Figure 77*).²³¹ Note the general high degree of uncertainty as to which treatment is the most cost-effective.

The per-person EVPI estimated was £730 at a willingness-to-pay threshold of £20,000, and £1138 at £30,000. Assuming an annual incidence of primary THR operations per year⁶⁹ of 76,000, population EVPI over a 10-year time horizon, discounting at 3.5%, is approximately £475M and £741M at willingness-to-pay thresholds of £20,000 and £30,000, respectively. These very high figures reflect the high per-person EVPI (driven by the uncertainty in the available evidence) and also the large volume of primary THR operations that are conducted.

Figure 79 shows the proportion of the EVPI that is attributable to different groups of parameters. The optimal decision is most sensitive to uncertainty in the treatment-independent transition parameters, and also sensitive to uncertainty in the cost parameters. The decision is not very sensitive to uncertainty in utility values, event rates on the reference comparator (baseline risk), relative treatment effects for all comparators, relative treatment effects of rivaroxaban compared with LMWH (the two comparators with the highest probability of being cost-effective at a willingness-to-pay threshold of £20,000 per QALY), and the proportion of VTE events. This suggests that there may be value in running a longitudinal study examining the treatment-independent transition parameters: rates of mild/moderate PTS, severe PTS, CTPH and the proportion split of VTE events.

Total knee replacement

The expected total costs, QALYs, incremental costs, incremental QALYs and incremental NMB at a willingness to pay of £20,000 and £30,000 for first-line prevention therapy are reported in *Table 202*. Both benefits and uncertainty in the benefits are similar across interventions. Rivaroxaban has the lowest expected total costs (£834), followed by post-op LMWH (£855) and dabigatran (£871), whereas apixaban has the highest expected total costs of £932. Rivaroxaban and LMWH had similar INB at willingness-to-pay thresholds of £20,000 and £30,000 per QALY. Dabigatran and apixaban have negative INB compared with post-op LMWH.




FIGURE 79 Expected value of partial perfect information for subsets of model input parameters in the VTE primary prevention THR model, presented as a proportion of the total EVPI. SAVI-estimated EVPI scaled by EVPI of all parameters as estimated by SAVI. 95% intervals are $\pm 1.96 \times$ standard error and are truncated above at 1 and below at 0.

TABLE 202 Results of the TKR primary prevention CEA: costs, QALYs, incremental costs, incremental QALYs and incremental NMB at willingness-to-pay thresholds of £20,000 and £30,000

Estimated costs and outcomes	LMWH	Dabigatran	Rivaroxaban	Apixaban
Costs	£855 (£706 to £1078)	£871 (£646 to £1252)	£834 (£632 to £1183)	£932 (£688 to £1388)
QALYs	9.25 (9.00 to 9.49)	9.24 (8.96 to 9.48)	9.25 (9.00 to 9.49)	9.22 (8.96 to 9.46)
Incremental costs		£16 (–£149 to £284)	–£20 (–£187 to £223)	£77 (–£113 to £417)
Incremental QALYs		–0.02 (–0.14 to 0.03)	0.00 (–0.01 to 0.01)	–0.03 (–0.12 to 0.01)
Incremental NMB (at £20,000)		–£320 (–£2844 to £638)	£16 (–£406 to £329)	–£686 (–£2458 to £266)
Incremental NMB (at £30,000)		–£472 (–£4214 to £919)	£13 (–£509 to £414)	–£991 (–£3658 to £375)

Incremental results are relative to LMWH.
Figures are presented as mean (CI).

The cost-effectiveness plane (*Figure 80*) and the CEACs (*Figure 81*) show substantial uncertainty around the relative costs and benefits of these interventions. Rivaroxaban has the highest expected net benefit over the range of willingness-to-pay thresholds that we explored (*Figure 82*), and the highest probability of being the most cost-effective treatment for willingness-to-pay thresholds of up to approximately £20,000 per QALY (see *Figure 81*). Beyond that, dabigatran has the highest probability of being the most cost-effective but not the highest expected net benefit because of the high level of uncertainty around the cost-effectiveness of dabigatran (as seen also in the THR population). As previously noted we prefer the CEAF summary (see *Figure 82*) in this situation. Note that there is a non-negligible chance that each of the treatments may be the most cost-effective, and this decision uncertainty increases as we increase our willingness to pay per QALY.

The per-person EVPI was £171 at a willingness-to-pay threshold of £20,000, and £249 at £30,000, which is lower than that seen in other populations, reflecting the larger number of studies on this population.




FIGURE 80 Incremental cost-effectiveness plane for TKR primary prevention (LMWH: reference). See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 81 Cost-effectiveness acceptability curve for TKR primary prevention. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.

Assuming an annual incidence of primary TKR operations per year⁶⁹ of 76,000, population EVPI over a 10-year time horizon, discounting at 3.5%, is approximately £111M and £161M at willingness-to-pay thresholds of £20,000 and £30,000, respectively. These high figures reflect the large volume of primary TKR operations that are conducted.




FIGURE 82 Cost-effectiveness acceptability frontier for TKR primary prevention. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.

Figure 83 shows the proportion of the EVPI that is attributable to different groups of parameters. The optimal decision is most sensitive to uncertainty in the utilities, relative treatment effects and treatment-independent transition parameters, and also sensitive to uncertainty in the cost parameters, but not to uncertainty in the risk on the reference comparator. This suggests that there may be value in running a large trial comparing NOACs and warfarin to reduce the uncertainty in the relative treatment effects. There may also be value in conducting a study to estimate the utility values associated with VTE events and treatment-related events, and a longitudinal study examining the treatment-independent transition parameters: rates of mild/moderate PTS, severe PTS, CTPH and the proportion split of VTE events.




FIGURE 83 Expected value of partial perfect information for subsets of parameters in the VTE primary prevention TKR model, as a proportion of the total EVPI. SAVI-estimated EVPPI scaled by EVPPI of all parameters as estimated by SAVI. 95% intervals are $\pm 1.96 \times$ standard error and are truncated above at 1 and below at 0.

Results of sensitivity analyses for secondary prevention model

We varied the proportion of recurrent VTEs that are DVT, non-fatal PE and fatal PE using the proportions estimated in the study by Prandoni *et al.*²²⁷ (79% DVT, 10% non-fatal PE and 11% fatal PE) rather than the proportions estimated from the RCTs included in the systematic review. At a willingness-to-pay threshold of > £25,000 per QALY dabigatran becomes the most cost-effective treatment (*Figure 84*). This indicates that NOACs are more likely to be cost-effective in secondary prevention if the risk of fatal VTE is higher than we assumed in our base-case analysis.

We varied the clinically relevant bleed rate to match that assumed in the AF model. The results were robust to this assumption, with aspirin having the highest expected net benefit over all willingness-to-pay thresholds that we explored. We explored sensitivity of results to a policy of switching patients to warfarin after a second VTE event, and the sensitivity to the cost of warfarin by reducing the cost to £0 in one-way sensitivity analyses. The results were robust to these assumptions (see *Appendix 12*).

The results were robust to the seven sensitivity analyses for which we varied the utilities of VTE and AEs by $\pm 50\%$, the AE costs by $\pm 50\%$ and the VTE costs by $+50\%$ (see *Appendix 12*). When we reduced the cost of VTE events by 50%, no pharmacotherapy has the highest expected net benefit over the willingness-to-pay thresholds that we explored (*Figure 85*).

When the rate of ICH for no pharmacotherapy was assumed to be zero, no pharmacotherapy then had the highest probability of being cost-effective and the highest net benefit over a willingness-to-pay range of £0–40,000 (*Figure 86*). In this analysis the risk of having an ICH while on aspirin and NOACs outweighed the benefit gained from reduced recurrent VTE.

Results of sensitivity analyses for acute treatment model

Changing the time on treatment from 6 months to 3 months and varying the cost and utilities by $\pm 50\%$ over VTE events and AEs did not alter the conclusion that apixaban was most likely to be cost-effective




FIGURE 84 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analysis: vary proportion of DVT, non-fatal PE and fatal PE of recurrent VTE. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 85 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analyses: reduction in VTE costs by 50%. See Chapter 4 (*Outcomes of atrial fibrillation and venous thromboembolism models*) for further details.




FIGURE 86 Cost-effectiveness acceptability frontier secondary prevention: risk of ICH for no pharmacotherapy is set to zero. See Chapter 4 (*Outcomes of atrial fibrillation and venous thromboembolism models*) for further details.

over a threshold of £1000 (see *Appendix 12*). The assumption that NOACs have the same non-fatal ICH rate as warfarin had little effect on the conclusion that apixaban has the highest expected net benefit at a willingness-to-pay thresholds of £20,000 and £30,000 per QALY (see *Appendix 12*).

Assuming a zero cost for edoxaban, we find that edoxaban has the highest expected net benefit and highest probability of being cost-effective at a willingness-to-pay threshold of < £10,000 per QALY. However, as willingness to pay per QALY increases to > £10,000, apixaban is the most cost-effective treatment because of the higher benefits (*Figure 87*, and see *Table 200*).




FIGURE 87 Cost-effectiveness acceptability frontier acute treatment model: assuming a zero cost for edoxaban. See Chapter 4 (*Outcomes of atrial fibrillation and venous thromboembolism models*) for further details.

Results of sensitivity analyses for primary prevention model

Total knee replacement

When we increased the AEs utilities by 50%, LMWH became the most cost-effective treatment at a willingness-to-pay threshold of > £27,000 per QALY (*Figure 88*). Increasing the AE costs by 50% changed the comparators with the highest average net benefit from rivaroxaban to LMWH over willingness-to-pay thresholds that we explored (*Figure 89*).




FIGURE 88 Cost-effectiveness acceptability frontier for TKR primary prevention sensitivity analysis: increasing AE costs by 50%. See Chapter 4 (*Outcomes of atrial fibrillation and venous thromboembolism models*) for further details.




FIGURE 89 Cost-effectiveness acceptability frontier for TKR primary prevention sensitivity analysis: increasing AE utilities by 50%. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.

Decreasing the VTE event costs by 50% changed the comparators with the highest average net benefit from rivaroxaban to LMWH over willingness-to-pay thresholds that we explored (*Figure 90*). When we decreased the VTE utilities by 50%, LMWH became the most cost-effective comparator above a willingness-to-pay threshold of £20,000 (*Figure 91*).

Our results were robust to all other sensitivity analyses that were conducted on the primary prevention populations: pooling post-THR and post-TKR populations for relative treatment effect of VTE; costing dabigatran at a lower dose to match the licensed dose for an elderly population; decreasing the costs and utilities for AEs; and increasing the costs and utilities for VTE events by 50% (see *Appendix 12*).




FIGURE 90 Cost-effectiveness acceptability frontier for TKR primary prevention sensitivity analysis: decreasing VTE costs by 50%. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 91 Cost-effectiveness acceptability frontier for TKR primary prevention sensitivity analysis: decreasing VTE utilities by 50%. See Chapter 4 (*Outcomes of atrial fibrillation and venous thromboembolism models*) for further details.

Total hip replacement

Our results were robust to all of the sensitivity analyses conducted on the primary prevention populations: pooling post-THR and post-TKR populations for relative treatment effect of VTE, costing dabigatran at a lower dose to match the licensed dose for an elderly population; and varying the costs and utilities for VTE and AEs by $\pm 50\%$ (see Appendix 12).

Summary of cost-effectiveness findings

The economic analyses of the use of NOACs in the prevention and treatment of VTE attempt to balance the costs of pharmacotherapy against the benefits of reducing VTE-related events and the risks of anti-coagulant-related AEs. To a large extent the findings of the economic analyses reflect the evidence and uncertainty identified by the NMAs in previous chapters.

In secondary prevention, we found no strong evidence that NOACs (apixaban, dabigatran and rivaroxaban) were more cost-effective than no pharmacotherapy or aspirin. The RCT evidence that NOACs reduce the risk of VTE was counterbalanced by the relatively low underlying risk of VTE, the low proportion of fatal VTE events and the potentially elevated risk of AEs as a result of bleeding. Our base-case analysis indicated that the relatively small benefits of NOACs compared with no pharmacotherapy or aspirin did not justify the high costs of long-term NOAC treatment. This finding was sensitive to assumptions about the incidence of fatal PE. We found that aspirin was most likely to be cost-effective for secondary prevention, although there was uncertainty whether or not no pharmacotherapy was more cost-effective, and choice between aspirin and no pharmacotherapy was particularly sensitive to assumptions around AEs (ICH) under no pharmacotherapy, and costs associated with VTEs. Further research on the relative cost-effectiveness of aspirin and no pharmacotherapy would be of value.

In acute treatment, we found that NOACs, particularly apixaban, are likely to be cost-effective compared with warfarin at conventional NICE willingness-to-pay thresholds of £20,000–30,000 per QALY. Although there was little evidence that NOACs substantially reduced the risk of VTE compared with warfarin, the reduced risk of ICH and CRB contributed to our finding that there was a relatively high probability (> 0.5)

that apixaban is the most cost-effective intervention in this setting. This finding was robust to sensitivity analyses on the model assumptions, although further research on the relative efficacy and safety of apixaban compared with other NOACs would be valuable to increase the strength of evidence.

For primary prevention of VTE following hip surgery, expected clinical benefits were similar for rivaroxaban and LMWH, whereas the lower costs of intervention with rivaroxaban meant that it was the most cost-effective intervention at the usual NICE thresholds. For primary prevention of VTE following knee surgery there was little difference in clinical benefit between the interventions, with rivaroxaban and LMWH being similarly cost-effective. There is a substantial potential value of further research in both THR and TKR populations, partly due to the large volume of these operations, meaning that a large population of patients may be given these treatments, but also because of the high levels of uncertainty in the relative treatment effects. This arises partly because of the fact that events are rare, and so very large studies are required to provide sufficient power to detect treatment differences when they exist, especially for AEs, which can have long-term consequences.

Our models make several assumptions (summarised in *Box 1*). In order to make the models tractable for each decision problem, we assumed that the most cost-effective comparator in secondary prevention would be used after acute treatment and that the most cost-effective comparator in acute treatment would be used after the failure of primary prevention. This assumes independence between treatments (i.e. the efficacy of secondary prevention does not depend on the therapy used for acute treatment). It also assumes that evidence from the wider acute/secondary prevention population (e.g. including medical patients) provides valid evidence for those primary prevention (i.e. surgical) patients who require acute treatment and secondary prevention.

In our base-case secondary prevention model, we assumed that patients would stop treatment only after ICH. In reality, patients may discontinue or switch treatment for various reasons. A proportion of patients will not comply with treatment because of side-effects or difficulty achieving a stable INR (on warfarin). Patients may also switch treatment after a recurrent symptomatic VTE event, which may be interpreted as 'treatment failure'. The secondary prevention RCTs, which have relatively short follow periods, provide very

BOX 1 Main assumptions of the VTE models

Transition probabilities/model structure

Patients with asymptomatic VTE have no greater risk of symptomatic recurrent VTE than patients with no VTE event.

VTE and bleeding events are independent.

Patients cannot move out of the 'PTS' or 'CTPH' states, with the exception to the death state.

All anticoagulation will be stopped for patients who have an ICH.

Proportion of VTE that is DVT vs. non-fatal PE vs. fatal PE is treatment independent.

ICH relative safety from AF population.

Quality of life and costs

Minor bleeds do not impact on quality of life and costs.

Clinically relevant bleeds, DVT and non-fatal PE do not have a long-term impact on quality of life.

little evidence on long-term treatment compliance. Our finding that NOACs were not more cost-effective than aspirin or 'no pharmacotherapy' was robust to a sensitivity analysis showing that patients switched to warfarin after a recurrent VTE, but may be sensitive to other treatment switching and non-compliance.

There is evidence that dabigatran is associated with MI in the AF population. The VTE RCTs typically did not report MI as an outcome, and we did not include it in the VTE models. It is likely to be most influential in the secondary prevention of VTE, when patients may be on therapy for prolonged periods. However, including the risk of MI in the secondary prevention model would not change our conclusion that none of the NOACs (including dabigatran) was cost-effective.

Edoxaban for the acute treatment of VTE is under review by NICE, but has not yet been approved and does not have BNF list cost in the UK. We assumed that the cost would be similar to other NOACs, and we performed a threshold analysis on cost to see how price influenced cost-effectiveness in acute treatment. Because edoxaban had very similar efficacy to warfarin, with lower benefits to apixaban, we found that it was not cost-effective at willingness-to-pay-threshold values of £20,000 or £30,000 per QALY, even at zero cost. When willingness to pay per QALY was low then it became cost-effective as the price decreased below that of warfarin, but such low threshold values are not used in practice.

Our systematic literature review identified evidence to inform model parameters for two primary prevention models (post THR and post TKR). We did not identify enough data to parameterise a model to estimate the cost-effectiveness of NOACs for patients who were hospitalised for medical treatment. These findings may not generalise to these patients and other patient groups.

Comparisons with the literature

There have been relatively few previous CEAs of NOACs for the prevention or treatment of VTE in the peer-reviewed literature. Most of the published studies focus on primary prevention after surgery and few compare more than one NOAC to LMWH.^{59–61,232} The published comparisons of rivaroxaban, dabigatran and LMWH are based on direct trial evidence and conclude that, although rivaroxaban, in particular, may be cost-effective, there is great uncertainty about which strategy is the most cost-effective.^{60,61,232} One industry-sponsored cost-effectiveness model comparing rivaroxaban to LMWH and a VKA, based on the EINSTEIN trial,^{204,215,216} concluded that there was a high probability that rivaroxaban was cost-effective.²³³ We also found that rivaroxaban was likely to be cost-effective for primary prevention after TKR and THR. However, despite including a larger number of trials in a NMA than previous cost-effectiveness models, our interpretation is tentative because of imprecise estimates about effect and safety.

Chapter 12 Discussion and conclusions

Main findings

In the following sections, we summarise the main findings for each therapeutic area, first summarising efficacy and safety comparisons of NOACs with established treatments and then comparing individual NOACs with one another. We also summarise the results of the CEAs.

Atrial fibrillation: results of clinical effectiveness analyses

There was evidence that apixaban (5 mg bd), dabigatran (150 mg bd), edoxaban (60 mg od) and rivaroxaban (20 mg od) all reduce the *risk of stroke or SE* compared with warfarin (INR 2–3). Among the NOACs, there was evidence of a higher risk of stroke or SE with edoxaban (60 mg od) and rivaroxaban (20 mg od) than dabigatran (150 mg bd).

There was evidence that dabigatran (150 mg bd) reduces the *risk of ischaemic stroke* compared with warfarin, whereas edoxaban (30 mg od) increases that risk. There was little evidence that the risk of ischaemic stroke differed between licensed doses of NOACs.

There was weak evidence that the *risk of MI* is higher with dabigatran (110 mg bd), dabigatran (150 mg bd) and edoxaban (30 mg od) than warfarin (INR 2–3), and weak evidence that the risk of MI is lower with rivaroxaban (20 mg od) than warfarin (INR 2–3). Among the NOACs, there was weak evidence that MI risk is higher with dabigatran (150 mg bd) than apixaban (5 mg bd), and lower with rivaroxaban (20 mg od) than dabigatran (150 mg bd).

There was evidence that apixaban (5 mg bd), dabigatran (110 mg bd), edoxaban (30 mg od) and edoxaban (60 mg od) all reduced *risk of major bleeding* compared with warfarin (INR 2–3). Among the NOACs, there was evidence that risk of major bleeding is higher with dabigatran (150 mg bd) than apixaban (5 mg bd), and with rivaroxaban (20 mg od) than apixaban (5 mg bd) and edoxaban (60 mg od).

There was evidence that the *risk of CRB* during antiplatelet therapy (aspirin < 150 mg od) is lower than with warfarin (INR 2–3). There was evidence that the risk of CRB with apixaban (5 mg bd), edoxaban (30 mg od) and edoxaban (60 mg od) is also lower than with warfarin (INR 2–3). However, edoxaban (30 mg bd) and edoxaban (60 mg bd) increased CRB compared with warfarin (INR 2–3). In comparisons among NOACs, there was evidence that CRB with edoxaban (60 mg od) and rivaroxaban (20 mg od) is higher than with apixaban (5 mg bd), and that rivaroxaban (20 mg od) increases CRB compared with edoxaban (60 mg od).

There was strong evidence that *risk of intracranial bleeding* was lower with apixaban (5 mg bd), dabigatran (110 mg bd), dabigatran (150 mg bd), edoxaban (30 mg od), edoxaban (60 mg od) and rivaroxaban (20 mg od) than warfarin (INR 2–3). For each of these NOACs and doses, except for rivaroxaban (20 mg od), the estimated relative risk reduction for intracranial bleeding was > 50%. There was weak evidence that risk of intracranial bleeding is higher with rivaroxaban (20 mg od) than apixaban (5 mg bd), dabigatran (150 mg bd) and edoxaban (60 mg od).

Risk of all-cause mortality was lower with apixaban (5 mg bd), dabigatran (110 mg bd), dabigatran (150 mg bd), edoxaban (30 mg od), edoxaban (60 mg od) and rivaroxaban (20 mg od) than warfarin (INR 2–3), but there was little evidence of a difference between the licensed doses of NOACs for this outcome.

Apixaban (5 mg bd) was ranked as being among the best interventions for a wide range of the outcomes that were evaluated, including stroke or SE, MI, major bleeding and all-cause mortality. Edoxaban (60 mg od) was ranked second for major bleeding and all-cause mortality. Except for all-cause mortality, outcomes for rivaroxaban (20 mg od) were ranked less highly than several other NOACs. The non-NOAC interventions [warfarin (INR 2–3) and antiplatelet therapy (aspirin/clopidogrel \geq 150 mg od)] were ranked worst for stroke or SE and were not among the best three interventions for any of the outcomes. We did not include apixaban (2.5 mg bd) or betrixaban (40 mg od) because comparisons involving these interventions were imprecisely estimated.

In our sensitivity analyses, results were similar when using HRs instead of ORs. Moreover, we found no evidence of effect modification according to mean TTR for patients on warfarin. However, our meta-regression models assumed a common interaction effect across treatments: that assumption could not be empirically tested because of a lack of replication for most comparisons. An important limitation is that primary studies did not report the mean time above or below therapeutic range for warfarin arms. Therefore, we were unable to address some clinically relevant questions regarding the impact of treatment settings for warfarin on stroke prevention, as well as on bleeding and other AEs.

Atrial fibrillation: results of cost-effectiveness analyses

Dabigatran (150 mg bd) has the lowest expected total cost (£23,064), followed by apixaban (5 mg bd), edoxaban (60 mg od), warfarin (INR 2–3) and rivaroxaban (20 mg od), which had the highest expected total cost (£24,841). Expected costs are similar across all treatments, and there is a high degree of uncertainty around the costs for all treatments.

Apixaban (5 mg bd) has the highest expected QALYs (5.49), followed by rivaroxaban (20 mg od) (5.45), dabigatran (150 mg bd) (5.42), edoxaban (60 mg od) (5.41) and warfarin (INR 2–3) (5.17). The NOACs have similar expected QALYs, all of which are higher than for warfarin (INR 2–3). There is a high degree of uncertainty around the QALY estimates.

At a willingness-to-pay threshold of £20,000 per QALY, all NOACs have positive expected INB compared with warfarin (INR 2–3), suggesting that they may be a cost-effective use of NHS resources. Apixaban (5 mg bd) has the highest expected INB (£7533), followed by dabigatran (150 mg bd) (£6365), rivaroxaban (20 mg od) (£5279) and edoxaban (60 mg od) (£5212). Apixaban (5 mg bd) is the only NOAC for which the 95% CI around INB is positive, suggesting that apixaban is cost-effective compared with warfarin. These conclusions also hold at the higher threshold of £30,000. The key drivers of these results are the lower rates of MI, ICH and other CRB for apixaban (5 mg bd).

The CEAC indicates that apixaban (5 mg bd) has the highest probability of being the most cost-effective first-line therapy for AF, close to 60% in the £20,000–30,000 range of willingness-to-pay thresholds generally considered by NICE. Dabigatran (150 mg bd) has the highest probability of being cost-effective if the willingness-to-pay threshold is very low as a result of having the lowest expected total costs. Warfarin (INR 2–3) and edoxaban (60 mg od) are unlikely to be cost-effective. These results are further highlighted by the CEAF. Apixaban (5 mg bd) has the highest expected net benefit at a wide range of willingness-to-pay thresholds. Apixaban (5 mg bd) is likely to be the most cost-effective first-line therapy for AF, under the assumptions of our model.

Primary prevention of venous thromboembolism: results of clinical effectiveness analyses

In *hip surgery patients* most treatment comparisons were imprecisely estimated, but there was evidence that *risk of symptomatic VTE* is lower with rivaroxaban (10 mg od) than LMWH (pre-op, standard dose) but higher with LMWH (post-op, standard dose) and warfarin (INR 2–3) than LMWH (pre-op, standard dose). Comparisons between the licensed doses of NOACs were imprecisely estimated. For *knee surgery patients*, there was little evidence that risk of symptomatic VTE differed between apixaban (2.5 mg bd), dabigatran (220 mg od) or rivaroxaban (10 mg od) compared with LMWH (post-op, standard dose).

Comparisons between licensed doses of NOACs were also imprecisely estimated. For *medical patients* there was weak evidence that the risk of symptomatic VTE is lower with apixaban (2.5 mg bd) than LMWH (standard dose), and also compared with rivaroxaban (10 mg od), although these comparisons were imprecisely estimated.

For *symptomatic DVT*, all comparisons for *hip surgery patients* were imprecisely estimated, but there was evidence that risk of symptomatic DVT is higher for LMWH (post-op, standard dose) and warfarin (INR 2–3) than LMWH (pre-op, standard dose). All comparisons for *knee surgery patients* were imprecisely estimated but there was evidence that risk of symptomatic DVT was higher for LMWH pre-op (standard dose) than LMWH (post-op, standard dose). For *medical patients*, all comparisons were imprecisely estimated, but there was evidence that risk of symptomatic DVT is lower for apixaban (2.5 mg bd) than LMWH (standard dose).

For *symptomatic PE*, all comparisons for trials in *hip surgery, knee surgery and medical patients* were imprecisely estimated. For *knee surgery patients*, there was some evidence that the risk of symptomatic PE is lower with dabigatran (150 mg od) and higher with apixaban (2.5 mg bd) than LMWH (post-op, standard dose). Among licensed doses of NOACs the risk of symptomatic PE may be lower for rivaroxaban (10 mg od) than apixaban (2.5 mg bd).

For *MI*, all comparisons were imprecisely estimated, although there was some evidence that risk of MI is lower for rivaroxaban (10 mg od) than LMWH (post-op, standard dose).

There was little evidence that *risk of major bleeding* differs between pre-op and post-op LMWH (standard dose). There was evidence that risk of major bleeding is lower with warfarin (INR 2–3) and higher with rivaroxaban (10 mg od) than LMWH (post-op, standard dose). There was evidence that risk of major bleeding is higher with rivaroxaban (10 mg od) than apixaban (2.5 mg bd) and dabigatran (220 mg od).

There was evidence that *risk of CRB* is higher for pre-op LMWH (standard dose) than post-op LMWH (standard dose), and higher for dabigatran (150 mg or 220 mg od) and rivaroxaban (10 mg od) than LMWH (post-op, standard dose). There was evidence that risk of CRB is higher for dabigatran (220 mg od) and rivaroxaban (10 mg od) than apixaban (2.5 mg bd).

There was little evidence that *risk of all-cause mortality* differed for any intervention compared with LMWH (post-op, standard dose). Comparisons between licensed doses of NOACs were imprecisely estimated.

Warfarin was ranked with high probability as the best intervention for major bleeding events, and LMWH (post-op, standard dose) was ranked with high probability as best or second-best intervention for CRB. Rivaroxaban (10 mg od) was ranked among the worst interventions for bleeding outcomes.

Primary prevention of venous thromboembolism following hip and knee surgery: results of cost-effectiveness analyses

Total hip replacement

The lowest expected total costs are for apixaban (£702), followed by rivaroxaban (£718) then dabigatran (£893). LMWH has the highest expected cost (£1062). Expected benefits are highest for rivaroxaban and LMWH (9.10 QALYs), followed by dabigatran (9.04 QALYs) then apixaban (8.96 QALYs). At both £20,000 and £30,000 willingness-to-pay QALY thresholds per QALY, rivaroxaban has the highest expected INB, although CIs around net benefit are wide (particularly for dabigatran) and also skewed (apixaban). Rivaroxaban has the highest expected net benefit over the range of willingness-to-pay thresholds we explored, but with substantial uncertainty: its probability of being the most cost-effective was 0.35 for willingness-to-pay threshold of £30,000 per QALY.

Total knee replacement

Rivaroxaban has the lowest expected total costs (£834), followed by post-op LMWH (£855) and dabigatran (£871), whereas apixaban has the highest expected total costs of £932. Rivaroxaban and LMWH had similar INB at willingness-to-pay thresholds of £20,000 and £30,000 per QALY. Dabigatran and apixaban have negative INB compared with post-op LMWH. The cost-effectiveness plane and the CEACs show substantial uncertainty around the relative costs and benefits of these interventions. Rivaroxaban has the highest expected net benefit over the range of willingness-to-pay thresholds that we explored, and the highest probability of being the most cost-effective treatment for willingness-to-pay thresholds of up to approximately £20,000 per QALY.

Acute treatment of venous thromboembolic disease: results of clinical effectiveness analyses

The planned edoxaban dose in the HOKUSAI-VTE study^{206,207} was 60 mg od but 17.6% of the patients in that intervention arm received a lower dose of 30 mg od. This intervention is denoted 'Edoxaban [60 or 30 (17.6%) mg od]'.

Compared with warfarin (INR 2–3), none of the NOACs reduced the *risk of symptomatic VTE, symptomatic DVT or symptomatic PE* on follow-up, nor did the risk of any of these outcomes differ between licensed doses of NOACs.

For *risk of MI*, all comparisons were imprecisely estimated.

There was strong evidence that apixaban (5 mg bd) and rivaroxaban (15 mg bd then 20 mg od) reduce *risk of major bleeding* compared with warfarin (INR 2–3). There was evidence that risk of major bleeding was higher for edoxaban [60 or 30 (17.6%) mg od] and dabigatran (150 mg bd) compared with apixaban (5 mg bd).

There was evidence that apixaban (5 mg bd), dabigatran (150 mg bd) and edoxaban [60 or 30 (17.6%) mg od] reduce *risk of CRB* compared with warfarin (INR 2–3). There was some evidence that rivaroxaban (15 mg bd then 20 mg od) reduces risk of CRB compared with warfarin (INR 2–3). There was evidence that risk of CRB is higher with dabigatran (150 mg bd), edoxaban [60 or 30 (17.6%) mg od] and rivaroxaban (15 mg bd then 20 mg od) than apixaban (5 mg bd). There was evidence that risk of CRB is higher with edoxaban [60 or 30 (17.6%) mg od] and rivaroxaban (15 mg bd then 20 mg od) than dabigatran (150 mg bd).

There was little evidence that *risk of all-cause mortality* differed for any of the NOAC interventions compared with warfarin (INR 2–3). Neither was there evidence that risk of all-cause mortality differed between licensed doses of NOACs.

There was a high probability that warfarin (INR 2–3) is ranked worst for major bleeding and CRB. There was a high probability that apixaban (5 mg bd) is ranked best for major bleeding and CRB, and this intervention also had a high probability of being ranked best or second best for symptomatic DVT, symptomatic VTE and all-cause mortality.

Acute treatment of venous thromboembolic disease: results of cost-effectiveness analyses

We estimated expected costs, QALYs, incremental costs, incremental QALYs and incremental NMB at willingness-to-pay thresholds of £20,000 and £30,000. Expected costs and benefits are similar across all treatments because of the short (6-month) treatment duration, and the small and imprecisely estimated effects of NOACs on VTE recurrence and AEs compared with warfarin. Warfarin has the lowest expected cost (£19,651), followed by dabigatran, edoxaban and apixaban, with rivaroxaban the most expensive (£19,753). Apixaban had the highest expected QALYs (12.02) but this is only 0.04 QALYs greater than the interventions with the lowest expected QALYs (edoxaban, warfarin and dabigatran).

The expected net benefit is highest for apixaban at willingness-to-pay thresholds of £20,000 and £30,000 per QALY. This is due to the marginally lower risk of recurrent VTE, CRB and non-VTE-related mortality with apixaban relative to other NOACs. However, there is substantial uncertainty around this estimate. Rivaroxaban also has a positive INB compared with warfarin. CIs for INB are wide for all treatments, reflecting substantial uncertainty that is also seen in the incremental cost-effectiveness plane.

The CEACs show that for very low willingness to pay per QALY, warfarin is the most cost-effective treatment (because it has lowest expected costs). For willingness-to-pay thresholds of > £1000, apixaban (5 mg) has the highest expected net benefit, with a probability of being most cost-effective at £20,000–30,000 per QALY thresholds of approximately 0.54. However, it is possible that rivaroxaban or dabigatran are the most cost-effective interventions, even at high willingness-to-pay thresholds.

Secondary prevention of venous thromboembolism: results of clinical effectiveness analyses

There was evidence that aspirin (100 mg od), warfarin (INR 1.5–2) and warfarin (INR 2–3) substantially reduced *risk of symptomatic VTE* compared with placebo. All NOACs at the doses included in the network also substantially reduced risk of symptomatic VTE compared with placebo. Risk of symptomatic VTE was lower for all NOACs at doses included in the network than aspirin. However, there was no clear evidence that risk of symptomatic VTE differed between these NOAC interventions and warfarin, although most comparisons were imprecisely estimated. There was no clear evidence that risk of symptomatic VTE differed between licensed doses of NOACs, although these comparisons were imprecisely estimated.

There was no clear evidence that aspirin (100 mg od) reduced *risk of symptomatic DVT* considered as an individual end point compared with placebo. There was evidence that warfarin (INR 2–3) and all NOACs at doses included in the network substantially reduced risk of symptomatic DVT compared with placebo. These NOAC interventions substantially reduced risk of symptomatic DVT compared with aspirin. By contrast, there was no clear evidence that risk of symptomatic DVT differed between these NOACs and warfarin (INR 2–3), although comparisons were imprecisely estimated. There was no clear evidence that risk of symptomatic DVT differed between NOACs at licensed doses, although all comparisons were imprecisely estimated.

There was evidence that warfarin (INR 2–3), apixaban (5 mg bd), dabigatran (150 mg bd) and rivaroxaban (20 mg od) substantially reduce *risk of symptomatic PE* compared with placebo. There was evidence that dabigatran (150 mg bd) and rivaroxaban (20 mg od) reduce risk of symptomatic PE compared with aspirin. There was evidence that risk of symptomatic PE was higher for apixaban (2.5 mg bd) than warfarin (INR 2–3). There was weak evidence that risk of symptomatic PE was lower for dabigatran (150 mg bd) and rivaroxaban (20 mg od) than apixaban (2.5 mg bd).

All comparisons of *risk of MI* were imprecisely estimated.

There was evidence that *risk of major bleeding* is higher for warfarin (INR 2–3) and rivaroxaban (20 mg od) than placebo, although these comparisons were imprecisely estimated. Comparisons of the risk of major bleeding for NOACs compared with aspirin were imprecisely estimated. There was evidence that risk of major bleeding is lower for dabigatran (150 mg bd), apixaban (2.5 mg bd) and apixaban (5 mg bd) than warfarin (INR 2–3). There was evidence that risk of major bleeding is higher with dabigatran (150 mg bd) and rivaroxaban (20 mg od) than apixaban (2.5 mg bd and 5 mg bd).

There was evidence that *risk of CRB* is substantially higher with warfarin (INR 2–3), dabigatran (150 mg od) and rivaroxaban (20 mg od) than placebo, and that risk of CRB is higher with rivaroxaban (20 mg od) than aspirin. There was evidence that risk of CRB is lower with apixaban (2.5 mg or 5 mg bd) and dabigatran (150 mg bd) than warfarin (INR 2–3). All comparisons between NOACs at licensed doses were imprecisely estimated, but there was evidence that risk of CRB is higher with dabigatran (150 mg bd) and rivaroxaban (20 mg od) than apixaban (2.5 mg bd and 5 mg bd).

All comparisons of *risk of all-cause mortality* with placebo, except that for aspirin (100 mg od), were imprecisely estimated. However, there was evidence that risk of all-cause mortality was lower for apixaban (5 mg bd) than placebo. Comparisons of NOACs with aspirin were imprecisely estimated, although there was weak evidence that risk of all-cause mortality is lower with apixaban (5 mg bd) than aspirin. There was no evidence that risk of all-cause mortality differed for NOACs than warfarin (INR 2–3), although all comparisons except that with dabigatran (150 mg bd) were imprecisely estimated. Comparisons of risk of all-cause mortality between NOACs at licensed doses were imprecisely estimated.

Secondary prevention of venous thromboembolism: results of cost-effectiveness analyses

We estimated expected costs, QALYs, incremental costs, incremental QALYs and incremental NMB at willingness-to-pay thresholds of £20,000 and £30,000. The cheapest comparator is aspirin (total expected cost £20,671). No pharmacotherapy is the next cheapest treatment with benefits similar to aspirin. Warfarin and the NOACs all have substantially higher costs than aspirin and no pharmacotherapy, and the NOACs are more expensive than warfarin. Dabigatran and apixaban (5 mg) have marginally higher expected QALYs than no pharmacotherapy. Apixaban (2.5 mg) has the lowest expected QALYs, followed by warfarin. Apixaban (2.5 mg) has the highest HR for the risk of ICH, albeit estimated imprecisely. Although the NOACs and warfarin prevent more recurrent VTEs than no pharmacotherapy or aspirin, the rate of recurrent VTE is low, and the rate of AEs (ICH and clinically relevant bleeds), which can have a long-term impact on quality of life, are generally higher for the NOACs than aspirin or no pharmacotherapy.

Aspirin has the highest expected net benefit at willingness-to-pay thresholds of £20,000 and £30,000 per QALY. However, the CI for the INB of aspirin includes zero, indicating uncertainty about whether or not it is more cost-effective than no pharmacotherapy. All NOACs have negative expected INBs at the £20,000 and £30,000 thresholds, and all CIs are negative at the £20,000 threshold, indicating that they are not cost-effective compared with no pharmacotherapy. Dabigatran, which had the lowest estimated HR for recurrent VTE and ICH of all the NOACs, also has the highest expected net benefit of any NOAC. However, dabigatran is not cost-effective relative to no pharmacotherapy, even at the £30,000 threshold, as the incremental NMB is negative (–£3402; 95% CI –£12,388 to £5424). Although there is uncertainty in the estimated costs and QALYs, it is clear that aspirin has lower costs and similar benefits in the majority of the samples. Over a wide range of willingness-to-pay-per-QALY thresholds, aspirin has the highest expected net benefit, and also the highest probability of being the most cost-effective, although there is a non-negligible probability that no pharmacotherapy is the most cost-effective intervention for secondary prevention of VTE at a threshold of £20,000–30,000. These results suggest that it is not cost-effective to prescribe NOACs or warfarin for secondary prevention of VTE over the range of willingness-to-pay thresholds that we explored (up to £40,000 per QALY).

Analyses of the value of information from future research

Value of information analyses exploit the cost-effectiveness models to quantify and summarise the value (in cost terms) of evidence that could potentially be generated from future research studies.

For AF, the optimal decision regarding the most cost-effective NOAC is most sensitive to the HRs comparing the NOACs, suggesting that a head-to-head trial comparing NOACs may be of value. The decision is also sensitive to costs, the effect of past events on future HRs, and probabilities of treatment switching. A head-to-head trial could also provide information about baseline event rates, costs and switching probabilities. However, a study powered to measure all of these outcomes with sufficient precision would require a very large sample size, which may be prohibitively expensive.

For VTE primary prevention in the THR population, the optimal decision is most sensitive to uncertainty in the treatment-independent transition parameters, and also the cost parameters. This suggests that there may be value in running a longitudinal study examining the treatment-independent transition parameters: rates of mild/moderate PTS, severe PTS, CTPH and the proportion split of VTE events.

For VTE primary prevention in the TKR population, the optimal decision is most sensitive to uncertainty in the utilities, relative treatment effects and treatment-independent transition parameters, and is also sensitive to the cost parameters. This suggests that there may be value in running a large trial comparing NOACs and warfarin, which would reduce the uncertainty in the relative treatment effects. There may also be value in conducting a study to estimate the utility values associated with VTE events and treatment-related events, and a longitudinal study examining the treatment-independent transition parameters: rates of mild/moderate PTS, severe PTS, CTPH and the proportion split of VTE events.

For VTE acute treatment, the optimal decision is most sensitive to uncertainty in the cost and utility model inputs. This suggests there may be value in conducting a study to estimate the utilities and costs associated with VTE events and treatment-related events. As such, a study is likely to be relatively inexpensive to conduct (compared with a RCT), and given the magnitude of likely benefits, this should be considered a research priority.

For VTE secondary prevention, the optimal decision is most sensitive to the relative treatment effects, suggesting that there may be value in running a large trial comparing one or more NOACs with aspirin and no pharmacotherapy. However, a study powered to capture VTE events may be prohibitively expensive, because event rates are low.

Strengths and limitations

Strengths

The strengths of this technology appraisal include its comprehensive coverage of all the therapeutic areas in which NOACs have been evaluated to date, using the same methodology. Previous analyses of comparative effectiveness have focused on individual therapeutic areas, making it more difficult to judge if one of the four licensed NOACs might emerge as a frontrunner in more than one therapeutic area. Additional strengths include careful appraisal of study quality; focus on clinically relevant end points; an evaluation of safety that considers evidence spanning all therapeutic areas together, to maximise power; the development of a possible treatment hierarchy for the different anticoagulant indications, where the data allowed it; and a CEA that is relevant to the NHS.

Limitations

The limitations of this technology appraisal relate mainly to shortfalls in the primary data, on which the overview is based. In particular:

- There were no direct head-to-head comparisons between different NOAC drugs – all such comparisons were therefore based on indirect evidence derived from the networks.
- Economic analyses for conditions such as AF and VTE necessarily make long-term projections on the basis of short-term trial evidence, observational data and clinically informed assumptions about plausible treatment pathways and health-state transitions. These assumptions and evidence limitations are discussed in previous sections [see *Chapter 6 (Summary of cost-effectiveness findings)* and *Chapter 11 (Summary of cost-effectiveness findings)*].
- The profile of patients entering trials may not be the same as those treated in practice, who may be older and have more comorbidities. Treatment benefits in such patients may be smaller, and rates of harm higher, than estimated by trials.
- As for all new drugs, adverse effects that remained undetected during development may come to light with high-volume use post licensing.
- It is possible that patients treated with warfarin in practice are at higher risk of bleeding complications than those in trials because of a greater number of comorbidities and less stringent control of anticoagulation. However, concerns have also been raised previously that the time spent in the therapeutic range was suboptimal among patients in clinical trials who were assigned to warfarin. Thus, clinical trials could have underestimated both the benefits and the risks of warfarin treatment.

For these reasons, guideline developers, prescribers and patients may wish to exercise caution when considering the prescription of new therapies over older, more established ones.

Several factors led to imprecision in the estimation of certain treatment effects. These included low rates of occurrence of certain end points, particularly in trials evaluating the safety and efficacy of NOACs in the primary and secondary prevention of VTE; widespread use of composite end points, with low rates of occurrence of certain (more clinically relevant) components of the composite; as well as substantial inconsistency in the reporting of end points in different trials in the same therapeutic area, leading to a substantial number of missing end point data (see *Tables 22, 23, 72, 73, 111, 112, 138 and 139*). Owing to the low event rates and lack of substantial replication of specific comparisons across studies, we used fixed-effects models for the NMA. This does not account for heterogeneity in treatment effects. Under fixed-effects models, our Bayesian analyses with vague priors will produce results very similar to frequentist analyses.

The evidence base for established antiplatelet and anticoagulant treatments in primary prevention of VTE among hospitalised patients extends to groups of patients beyond those who were evaluated in this report, for which comparisons were focused on patients undergoing hip and knee surgery. No trials of NOACs were identified among patients who were undergoing neurosurgery, gastroenterological surgery or gynaecological surgery. For this reason, conclusions about the comparative effectiveness of NOACs compared with established antiplatelet and anticoagulant medications for primary prevention of VTE should be limited to hip and knee surgery patients.

The apparent efficacy of NOACs when compared with warfarin could be inflated if control of the INR was suboptimal among patients who were randomised to warfarin. For this reason, many of the studies reported time spent in the therapeutic range (TTR), as an index of anticoagulant control. This is a potentially important issue for the studies of stroke prevention in AF, for which 16 (73%) of the 22 studies that included a warfarin intervention arm reported mean TTR. There was substantial variation in TTR (from 45.1% to 83%) between these studies. For acute treatment of VTE, eight (89%) of the nine studies that included a warfarin intervention arm reported mean TTR, but variation between them was less marked than for the AF studies (from 56.9% to 63.5%). For secondary prevention of VTE, mean TTR was reported in three (60%) of the five studies that included a warfarin intervention arm. The prespecified protocol for this health technology appraisal specified TTR as a potential modifier of NOAC treatment effect in trials in which warfarin was the comparator. We plan future analyses that address this issue.

The clinical effectiveness analyses reported are based on relative rather than absolute risk differences. However, event rates for different safety and efficacy end points were estimated within and contributed to the CEAs.

Factors beyond those considered in this technology appraisal could influence the choice of the optimal anticoagulant in each of the therapeutic areas evaluated.

In some situations, the need for anticoagulation monitoring with warfarin treatment may be viewed as a useful means to confirm adherence to anticoagulant therapy rather than as an inconvenience.

Recent studies have suggested that the efficacy and safety of dabigatran could be improved by monitoring of achieved drug levels, because these exhibit wide inter-individual variation. This may reduce the convenience of this NOAC and increase its cost compared with warfarin or other NOACs but we did not model this in the current report. Only one of the studies included in our reviews considered whether or not monitoring improves the efficacy and safety of NOACs: in a subsample of 9183 patients in the RE-LY trial,¹³ ischaemic stroke and major bleeding both correlated with dabigatran plasma concentrations. Specific tests to measure the anticoagulation effects of NOACs are being developed but are not yet widely available²³⁴ and routine coagulation tests such as prothrombin time and activated partial thromboplastin time are of limited use.^{235,236} It is therefore currently unclear whether or not the efficacy

and safety profiles of NOACs can be improved by monitoring and dose adjustment. Monitoring may be particularly helpful in certain clinical situations (e.g. emergency surgery or patients presenting with bleeding²³⁶) and patient groups (advanced age, renal impairment).

Finally, therapeutic decision making may be influenced by recognition that effective treatments for reversal of anticoagulation with NOACs are still in the developmental phase. For example:

- Aripazine (PER-977; PER 977; ciraparantag) is a synthetic cationic molecule that binds unfractionated and LMWH, the factor Xa inhibitors edoxaban, rivaroxaban and apixaban, and the factor II inhibitor dabigatran, but not to warfarin.²³⁷ In a Phase I trial involving 80 healthy volunteers, intravenous PER977 reversed the prolongation of whole blood clotting time induced by a single oral dose of edoxaban 60 mg in a dose-dependent fashion, within 10–30 minutes of administration.²³⁸ Phase II clinical studies of this agent are in progress.
- Andexanet alpha (PRT4445; PRT064445) is a recombinant modified factor Xa molecule that acts as an antidote to factor Xa inhibitors through a decoy mechanism. A number of Phase III studies of this agent are under way.^{239,240}
- Idarucizumab (BI 655075) is a humanised monoclonal antibody fragment that binds dabigatran to reverse its anticoagulant activity.^{241,242} Phase III studies of this agent have been completed. A Phase III study investigating reversal of anticoagulation in patients receiving dabigatran who have uncontrolled bleeding or who require emergency surgery or invasive procedures is under way.

Research needs

Evidence on the comparative efficacy of NOACs in this review has come exclusively from indirect comparisons, because of the lack of head-to-head trials. Among patients with AF, a long-term condition, the trials have also been of relatively short duration. A different manufacturer has developed each of the agents evaluated in this review and it is therefore unlikely that any head-to-head trials will be initiated by industry.

Reliable estimation of the cost-effectiveness of NOACs in different clinical scenarios requires high-quality data on absolute event rates for the various efficacy and safety outcomes. NHS health record data could provide a rich source for information, but so far health record data have been insufficiently utilised for this purpose.

Although NOACs were developed in part to supersede warfarin by obviating the need for therapeutic monitoring of anticoagulation, to improve convenience, recent studies¹³ have suggested that monitoring of drug levels may improve safety and efficacy of dabigatran treatment. Whether or not this is also the case for other NOACs is not known.

The requirement for therapeutic drug monitoring with warfarin also serves as a means to assess adherence. Thus far, long-term adherence rates for NOACs (e.g. among patients with AF who may require anticoagulation for many years have not been evaluated).

For secondary prevention of VTE, use of NOACs in high-risk patients is a potential area for further study. Further research is needed to clarify whether aspirin or no treatment should be the standard of care in this setting.

The research needs identified by this review are therefore as follows:

- To complete calculations of the expected value of sample information, in order to clarify whether it is justifiable to conduct one or more trials making direct comparisons between the most promising NOACs and NOAC doses, in situations typical of NHS clinical practice.

- To consider the merits of conducting cohort studies that reduce uncertainties in costs, utilities and transition probabilities in order to improve estimates of relative cost-effectiveness, in particular in the context of primary prevention of VTE in THR and TKR, and acute treatment of VTE.
- Information on long-term rates of the main efficacy and safety outcomes among patients receiving anticoagulants for AF (e.g. from registries or health record data).
- Information on the role (if any) of therapeutic monitoring to enhance the safety and efficacy of NOACs.
- Information on long-term adherence rates in patients receiving NOACs for AF.
- Development of tools to stratify risk of recurrent VTE.
- Further research is also needed to establish whether the secondary prevention of VTE with aspirin or other agents is cost-effective, with an adequate safety margin, in patients identified as being at particularly high risk of recurrence by validated risk stratification tools.

Implications for practice

This health technology appraisal was conducted to help guideline developers, doctors and patients decide when a NOAC might be preferred to an established anticoagulant and, when a NOAC is preferred to warfarin, if there is sufficient evidence to support the use of one particular NOAC over another. The evidence provided by this health technology appraisal indicates:

- NOACs have advantages over warfarin in patients with AF and, of the available NOACs, apixaban 5 mg bd offers the best balance between efficacy and safety, and has the highest probability of being most cost-effective.
- NOACs offer no efficacy advantage over warfarin in the acute treatment of VTE, but have a lower rate of bleeding complications albeit at a higher cost. For a willingness-to-pay threshold of > £5000, apixaban 5 mg bd emerges as the most cost-effective alternative to warfarin.
- Neither the clinical nor CEA provided strong evidence that NOACs replace post-op LMWH in primary prevention of VTE in patients who are undergoing hip or knee surgery.
- If secondary prevention after 3–6 months of anticoagulation for a first episode of VTE is to be considered (this is not currently established practice), NOACs provide no advantage over aspirin 100 mg od.

Chapter 13 Patient perspective

Anticoagulation Europe is a charity that provides education, information and support to patients requiring anticoagulation therapy in the UK.

Patients requiring anticoagulants for the treatment and prevention of VTE are given VKAs warfarin, heparin and LMWH. These treatments are effective and are now joined by newer technologies that work differently to warfarin.

The NOACs have become available to be used in the prevention of stroke in non-valvular AF and the treatment and secondary prevention of DVT and PE, complementing existing treatments.

In the UK, NICE and the Scottish Medicines Consortium (SMC) have produced guidelines that recommend the new agents. The benefits to patients and clinicians are that there is now a broader range of treatment options available to treat and prevent blood clots.

AntiCoagulation Europe has welcomed the opportunity to participate in this project, and has contributed the patient perspective of current anticoagulation practice, as captured by the experiences and feedback derived from their patient databases.

In our role as a dedicated anticoagulation charity, we have highlighted the need for equality of access to all of the anticoagulation therapies as recommended by NICE and the SMC. We advocate that patients should be adequately informed of the benefits and risks of all anticoagulation treatments in order that they can make an informed choice around their therapy options with the appropriate health-care professionals.

AntiCoagulation Europe anticipates that this comprehensive study will provide a helpful and informative reference resource for clinicians when considering and presenting the most effective and safe anticoagulation treatment options to patients for their condition.

Acknowledgements

We are grateful to Alexandra McAleenan for help with data extraction, Juan-Pablo Casas and Penny Whiting for help in preparing the original grant submission, and Alison Richards and Margaret Burke for help with designing and running search strategies.

Contributions of authors

PNB, PAB, PAD, JAL, GNO and HHT worked for substantial periods of time on the project, and are listed alphabetically. Other authors (DMC, SD, DE, JPTH, WH, CS, JS, RS, AS and NJW) apart from the first author (JACS) and last author (ADH) are then listed alphabetically.

Professor Jonathan AC Sterne (Professor of Medical Statistics and Epidemiology) co-conceived the project, led the grant application, led the project, contributed to statistical analyses and finalised the report.

Dr Pritesh N Bodalia (Principal Pharmacist) contributed to the grant application, extracted data and assessed risk of bias for the AF review, checked these aspects for the VTE reviews and provided pharmaceutical expertise.

Peter A Bryden (Research Associate in Health Economics Modelling) developed and analysed the economic models for VTE reviews and drafted relevant parts of the report.

Dr Philippa A Davies (Research Associate in Evidence Synthesis/Systematic Reviewing) extracted and checked data, assessed risk of bias and contributed to writing the report.

Dr Jose A López-López (Research Associate in Medical Statistics) undertook the statistical analyses of clinical effectiveness and safety and drafted relevant parts of the report.

Dr George N Okoli (Research Associate in Systematic Reviews) extracted data and assessed risk of bias for the VTE reviews, checked these aspects for the AF review, and drafted relevant parts of the report.

Dr Howard HZ Thom (Research Associate in Health Economic Modelling) developed and analysed the economic models for the AF review, and drafted relevant parts of the report.

Dr Deborah M Caldwell (Lecturer in Public Health Research) contributed to the grant application, contributed to the systematic review and planning of NMAs.

Dr Sofia Dias (Research Fellow) contributed to the statistical analyses.

Diane Eaton (Project Manager, AntiCoagulation Europe) provided a patient perspective.

Professor Julian PT Higgins (Professor of Evidence Synthesis) contributed to the grant application, contributed to the NMAs of clinical effectiveness and safety, contributed to management of the project and contributed to writing the report.

Professor Will Hollingworth (Professor of Health Economics) contributed to the grant application, contributed to the CEAs and contributed to writing the report.

Professor Chris Salisbury (Professor in Primary Health Care) contributed to the grant application and provided clinical expertise.

Dr Jelena Savović (Research Fellow) contributed to the grant application and contributed to the systematic review.

Dr Reecha Sofat (Senior Lecturer) provided clinical expertise and contributed to writing the report.

Annya Stephens-Boal (Executive Officer, Thrombosis UK) provided a patient perspective.

Dr Nicky J Welton (Reader in Statistical and Health Economic Modelling) contributed to the grant application, contributed to the statistical analyses and CEAs and contributed to writing the report.

Professor Aaron D Hingorani (Professor of Genetic Epidemiology) co-conceived the project, provided clinical expertise and contributed to writing the report.

Data sharing statement

All study data will be available from the corresponding author on request, once papers reporting the study findings have been published. Corresponding author's contact details: School of Social and Community Medicine, Canynge Hall, University of Bristol, Bristol, UK.

References

1. National Collaborating Centre for Chronic Conditions. *Atrial Fibrillation: National Clinical Guideline for Management in Primary and Secondary Care*. London: Royal College of Physicians; 2006.
2. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. *Am J Cardiol* 1998;**82**:2–9N. [http://dx.doi.org/10.1016/S0002-9149\(98\)00583-9](http://dx.doi.org/10.1016/S0002-9149(98)00583-9)
3. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. *Ann Intern Med* 1999;**131**:492–501. <http://dx.doi.org/10.7326/0003-4819-131-7-199910050-00003>
4. Lee S, Shafe AC, Cowie MR. UK stroke incidence, mortality and cardiovascular risk management 1999–2008: time-trend analysis from the General Practice Research Database. *BMJ Open* 2011;**1**:e000269. <http://dx.doi.org/10.1136/bmjopen-2011-000269>
5. Soliman EZ, Safford MM, Muntner P, Khodneva Y, Dawood FZ, Zakai NA, et al. Atrial fibrillation and the risk of myocardial infarction. *JAMA Intern Med* 2014;**174**:107–14. <http://dx.doi.org/10.1001/jamainternmed.2013.11912>
6. Smolina K, Wright FL, Rayner M, Goldacre MJ. Incidence and 30-day case fatality for acute myocardial infarction in England in 2010: national-linked database study. *Eur J Public Health* 2012;**22**:848–53. <http://dx.doi.org/10.1093/eurpub/ckr196>
7. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. *Thromb Haemost* 2000;**83**:657–60.
8. National Clinical Guideline Centre – Acute and Chronic Conditions. *Venous Thromboembolism: Reducing the Risk of Venous Thromboembolism (Deep Vein Thrombosis and Pulmonary Embolism) in Patients Admitted to Hospital*. London: Royal College of Physicians; 2010.
9. Connock M, Stevens C, Fry-Smith A, Jowett S, Fitzmaurice D, Moore D, Song F. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. *Health Technol Assess* 2007;**11**(38). <http://dx.doi.org/10.3310/hta11380>
10. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients. *BMJ* 2004;**329**:15–19. <http://dx.doi.org/10.1136/bmj.329.7456.15>
11. National Institute for Health and Clinical Excellence (NICE). *Clinical Guideline 36. National Cost Impact Report to accompany 'Atrial Fibrillation: the Management of Atrial Fibrillation'*. London: NICE; 2006.
12. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. *Blood* 2010;**115**:15–20. <http://dx.doi.org/10.1182/blood-2009-09-241851>
13. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). *J Am Coll Cardiol* 2014;**63**:321–8. <http://dx.doi.org/10.1016/j.jacc.2013.07.104>

14. Centre for Reviews and Dissemination (CRD). *Systematic Reviews. CRD's Guidance for Undertaking Reviews in Health Care*. 3rd edn. York: CRD, University of York; 2009.
15. Higgins JPT, Green S. *Cochrane Handbook for Systematic Reviews of Interventions*. Chichester: Wiley; 2008. <http://dx.doi.org/10.1002/9780470712184>
16. Assiri A, Al-Majzoub O, Kanaan AO, Donovan JL, Silva M. Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation. *Clin Ther* 2013;**35**:967–84.e2. <http://dx.doi.org/10.1016/j.clinthera.2013.05.011>
17. Castellucci LA, Cameron C, Le Gal G, Rodger MA, Coyle D, Wells PS, et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. *BMJ* 2013;**347**:f5133. <http://dx.doi.org/10.1136/bmj.f5133>
18. Fox BD, Kahn SR, Langleben D, Eisenberg MJ, Shimony A. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. *BMJ* 2012;**345**:e7498. <http://dx.doi.org/10.1136/bmj.e7498>
19. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011;**343**:d5928. <http://dx.doi.org/10.1136/bmj.d5928>
20. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. *Stat Med* 2004;**23**:3105–24. <http://dx.doi.org/10.1002/sim.1875>
21. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. *BMJ* 2005;**331**:897–900. <http://dx.doi.org/10.1136/bmj.331.7521.897>
22. Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. *Med Decis Making* 2013;**33**:607–17. <http://dx.doi.org/10.1177/0272989X12458724>
23. Spiegelhalter DJ, Best NG, Carlin BP, van der Linde A. Bayesian measures of model complexity and fit. *J R Statist Soc B* 2002;**64**:583–616. <http://dx.doi.org/10.1111/1467-9868.00353>
24. Berkey CS, Hoaglin DC, Mosteller F, Colditz GA. A random-effects regression model for meta-analysis. *Stat Med* 1995;**14**:395–411. <http://dx.doi.org/10.1002/sim.4780140406>
25. Salanti G, Higgins JP, Ades AE, Ioannidis JP. Evaluation of networks of randomized trials. *Stat Methods Med Res* 2008;**17**:279–301. <http://dx.doi.org/10.1177/0962280207080643>
26. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. *BMJ* 2003;**326**:472–5. <http://dx.doi.org/10.1136/bmj.326.7387.472>
27. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. *Stat Med* 2010;**29**:932–44. <http://dx.doi.org/10.1002/sim.3767>
28. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 2. *A Generalised Linear Modelling Framework for Pairwise and Network Meta-analysis of Randomised Controlled Trials*. London: NICE; 2011.
29. The R Foundation. *The R Project for Statistical Computing*. URL: www.r-project.org/ (accessed 12 August 2016).

30. Lunn DJ, Thomas A, Best N, Spiegelhalter DJ. WinBUGS – a Bayesian modelling framework: concepts, structure, and extensibility. *Stat Comput* 2000;**10**:325–37. <http://dx.doi.org/10.1023/A:1008929526011>
31. Gage BF, Cardinali AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. *JAMA* 1995;**274**:1839–45. <http://dx.doi.org/10.1001/jama.1995.03530230025025>
32. Lightowler S, McGuire A. Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke. *Stroke* 1998;**29**:1827–32. <http://dx.doi.org/10.1161/01.STR.29.9.1827>
33. Bayer plc. *Single Technology Appraisal (STA) of Rivaroxaban (Xarelto)*. Newbury: Bayer plc; 2011.
34. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. *Circulation* 2011;**123**:2562–70. <http://dx.doi.org/10.1161/CIRCULATIONAHA.110.985655>
35. Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, *et al*. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. *Ann Intern Med* 2011;**154**:1–11. <http://dx.doi.org/10.7326/0003-4819-154-1-201101040-00289>
36. Lee S, Mullin R, Blazawski J, Coleman CI. Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation. *PLOS ONE* 2012;**7**:e47473. <http://dx.doi.org/10.1371/journal.pone.0047473>
37. Lee S, Anglade MW, Pham D, Pisacane R, Kluger J, Coleman CI. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. *Am J Cardiol* 2012;**110**:845–51. <http://dx.doi.org/10.1016/j.amjcard.2012.05.011>
38. Harrington AR, Armstrong EP, Nolan PE, Malone DC. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. *Stroke* 2013;**44**:1676–81. <http://dx.doi.org/10.1161/STROKEAHA.111.000402>
39. Kamel H, Easton JD, Johnston SC, Kim AS. Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation. *Neurology* 2012;**79**:1428–34. <http://dx.doi.org/10.1212/WNL.0b013e31826d5fe8>
40. Wells G, Coyle D, Cameron C, Steiner S, Coyle K, Kelly S, *et al*. *Safety, Effectiveness, and Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation*. Ottawa, ON: Canadian Collaborative for Drug Safety, Effectiveness and Network Meta-Analysis, 2012.
41. Wisloff T, Tove R, Gunhild H, Asmund R, Marianne K. *Efficacy and Cost-effectiveness of New Oral Anticoagulants Compared to Warfarin for the Prevention of Stroke in Patients with Atrial Fibrillation*. Report from Kunnskapssenteret (Norwegian Knowledge Centre for the Health Services), no. 5. Oslo: Kunnskapssenteret; 2013.
42. Kansal AR, Sorensen SV, Gani R, Robinson P, Pan F, Plumb JM, Cowie MR. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. *Heart* 2012;**98**:573–8. <http://dx.doi.org/10.1136/heartjnl-2011-300646>
43. Canestaro WJ, Patrick AR, Avorn J, Ito K, Matlin OS, Brennan TA, *et al*. Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation. *Circ Cardiovasc Qual Outcomes* 2013;**6**:724–31. <http://dx.doi.org/10.1161/CIRCOUTCOMES.113.000661>
44. Nshimyumukiza L, Duplantie J, Gagnon M, Douville X, Fournier D, Lindsay C, *et al*. Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model. *Thromb J* 2013;**11**:14. <http://dx.doi.org/10.1186/1477-9560-11-14>

45. Krejczy M, Harenberg J, Marx S, Obermann K, Frölich L, Wehling M. Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries. *J Thromb Thrombolysis* 2014;**37**:507–23. <http://dx.doi.org/10.1007/s11239-013-0989-6>
46. Pink J, Lane S, Pirmohamed M, Hughes DA. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. *BMJ* 2011;**343**:d6333. <http://dx.doi.org/10.1136/bmj.d6333>
47. Lip GY, Kongnakorn T, Phatak H, Kuznik A, Lanitis T, Liu LZ, et al. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation. *Clin Ther* 2014;**36**:192–210.e20. <http://dx.doi.org/10.1016/j.clinthera.2013.12.011>
48. Rognoni C, Marchetti M, Quaglini S, Liberato NL. Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. *Clin Drug Investig* 2014;**34**:9–17. <http://dx.doi.org/10.1007/s40261-013-0144-3>
49. Limone BL, Baker WL, Mearns ES, White CM, Kluger J, Coleman CI. Common flaws exist in published cost-effectiveness models of pharmacologic stroke prevention in atrial fibrillation. *J Clin Epidemiol* 2014;**67**:1093–102. <http://dx.doi.org/10.1016/j.jclinepi.2014.05.013>
50. Bayer. *Rivaroxaban for the Treatment of Deep Vein Thrombosis and Prevention of Recurrent Deep Vein Thrombosis and Pulmonary Embolism*. 2012.
51. Bayer. *Rivaroxaban for Treating Pulmonary Embolism and Preventing Recurrent Venous Thromboembolism*. 2013.
52. Boehringer Ingelheim. *Dabigatran Etexilate for the Prevention of Venous Thromboembolism After Hip or Knee Replacement Surgery in Adults*. 2008.
53. Botteman MF, Caprini J, Stephens JM, Nadipelli V, Bell CF, Pashos CL, et al. Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States. *Clin Ther* 2002;**24**:1960–86. [http://dx.doi.org/10.1016/S0149-2918\(02\)80091-1](http://dx.doi.org/10.1016/S0149-2918(02)80091-1)
54. Bayer. *Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults*. 2009.
55. Bristol-Myers Squibb. *Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults*. 2012.
56. Dranitsaris G, Stumpo C, Smith R, Bartle W. Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery. *Am J Cardiovasc Drugs* 2009;**9**:45–58. <http://dx.doi.org/10.1007/BF03256594>
57. Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M. Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective. *Pharmacoeconomics* 2012;**30**:87–101. <http://dx.doi.org/10.2165/11599370-000000000-00000>
58. Monreal M, Folkerts K, Diamantopoulos A, Imberti D, Brosa M. Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain. *Thromb Haemost* 2013;**110**:987–94. <http://dx.doi.org/10.1160/TH12-12-0919>
59. Mahmoudi M, Sobieraj DM. The cost-effectiveness of oral direct factor Xa inhibitors compared with low-molecular-weight heparin for the prevention of venous thromboembolism prophylaxis in total hip or knee replacement surgery. *Pharmacotherapy* 2013;**33**:1333–40. <http://dx.doi.org/10.1002/phar.1269>

60. McCullagh L, Tilson L, Walsh C, Barry M. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting. *PharmacoEconomics* 2009;**27**:829–46. <http://dx.doi.org/10.2165/11313800-000000000-00000>
61. McCullagh L, Walsh C, Barry M. Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting. *PharmacoEconomics* 2012;**30**:941–59. <http://dx.doi.org/10.2165/11591510-000000000-00000>
62. Lundkvist J, Bergqvist D, Jönsson B. Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery. *Eur J Health Econ* 2007;**8**:313–23. <http://dx.doi.org/10.1007/s10198-006-0017-2>
63. Gordois A, Posnett J, Borris L, Bossuyt P, Jönsson B, Levy E, de Pouvourville G. The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. *J Thromb Haemost* 2003;**1**:2167–74. <http://dx.doi.org/10.1046/j.1538-7836.2003.00396.x>
64. Pishko AM, Smith KJ, Ragni MV. Anticoagulation in ambulatory cancer patients with no indication for prophylactic or therapeutic anticoagulation: a cost-effectiveness analysis from a U.S. perspective. *Thromb Haemost* 2012;**108**:303–10. <http://dx.doi.org/10.1160/TH12-03-0185>
65. Sullivan SD, Kwong L, Nutescu E. Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery. *Value Health* 2006;**9**:68–76.
66. Zindel S, Stock S, Müller D, Stollenwerk B. A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting. *BMC Health Serv Res* 2012;**12**:192. <http://dx.doi.org/10.1186/1472-6963-12-192>
67. Gómez-Outes A, Terleira-Fernández AI, Suárez-Gea ML, Vargas-Castrillón E. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. *BMJ* 2012;**344**:e3675. <http://dx.doi.org/10.1136/bmj.e3675>
68. National Institute for Health and Clinical Excellence (NICE). NICE Clinical Guideline 36. *Atrial Fibrillation: The Management of Atrial Fibrillation*. London: NICE; 2006.
69. National Joint Registry Editorial Board. *10th Annual Report*. Hemel Hempstead: National Joint Registry for England, Wales and Northern Ireland; 2013. URL: www.njrcentre.org.uk/njrcentre/Portals/0/Documents/England/Reports/10th_annual_report/NJR%2010th%20Annual%20Report%202013%20B.pdf (accessed 4 April 2015).
70. National Institute for Health and Care Excellence (NICE). *National Clinical Guideline Centre – Acute and Chronic Conditions. Venous Thromboembolism: Reducing the Risk of Venous Thromboembolism (Deep Vein Thrombosis and Pulmonary Embolism) in Patients Admitted to Hospital. Methods, Evidence and Guidance*. London: National Clinical Guideline Centre – Acute and Chronic Conditions; 2010. URL: www.nice.org.uk/guidance/cg92/evidence/full-guideline-243920125 (accessed 29 September 2016).
71. National Institute for Health and Care Excellence (NICE). *Venous Thromboembolism: Reducing the Risk of Venous Thromboembolism (Deep Vein Thrombosis and Pulmonary Embolism) in Patients Admitted to Hospital*. NICE Clinical Guideline 92. London: NICE; 2010. URL: www.nice.org.uk/guidance/cg92 (accessed 12 August 2016).

72. Briggs A, Sculpher M, Claxton K. *Decision Modelling for Health Economic Evaluation*. Oxford: Oxford University Press; 2006.
73. National Institute for Health and Care Excellence (NICE). *Guide to the Methods of Technology Appraisal 2013*. London: NICE; 2013.
74. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. *Health Econ* 2001;**10**:779–87. <http://dx.doi.org/10.1002/hec.635>
75. Strong M BP, Thomas C, Brennan A. *Sheffield Accelerated Value of Information*. Release version 2.0.8 (2015–06–19); 2015 (accessed July 2015).
76. Strong M, Oakley JE, Brennan A. Estimating multiparameter partial expected value of perfect information from a probabilistic sensitivity analysis sample: a nonparametric regression approach. *Med Decis Making* 2014;**34**:311–26. <http://dx.doi.org/10.1177/0272989X13505910>
77. Hori M, Connolly SJ, Zhu J, Liu LS, Lau CP, Pais P, *et al*. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. *Stroke* 2013;**44**:1891–6. <http://dx.doi.org/10.1161/STROKEAHA.113.000990>
78. Naimark DM, Bott M, Krahn M. The half-cycle correction explained: two alternative pedagogical approaches. *Med Decis Making* 2008;**28**:706–12. <http://dx.doi.org/10.1177/0272989X08315241>
79. Ali A, Bailey C, Abdelhafiz AH. Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis. *Age Ageing* 2012;**41**:681–4. <http://dx.doi.org/10.1093/ageing/afs017>
80. Office for National Statistics (ONS). *ONS Consumer Price Inflation Index for Medical Services (DKC3) for 2013/14*. London: ONS; 2013. URL: www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-323625,%202015%20#29 (accessed 1 November 2015).
81. Department of Health (DH). *NHS Reference Costs 2012–13*. London: DH; 2014.
82. Ioannides-Demos LL, Makarounas-Kirchmann K, Ashton E, Stoelwinder J, McNeil JJ. Cost of myocardial infarction to the Australian community: a prospective, multicentre survey. *Clin Drug Investig* 2010;**30**:533–43. <http://dx.doi.org/10.2165/11536350-000000000-00000>
83. Luengo-Fernandez R, Yiin GS, Gray AM, Rothwell PM. Population-based study of acute- and long-term care costs after stroke in patients with AF. *Int J Stroke* 2013;**8**:308–14. <http://dx.doi.org/10.1111/j.1747-4949.2012.00812.x>
84. National Institute for Health and Clinical Excellence (NICE). *Dabigatran Etexilate for the Prevention of Venous Thromboembolism After Hip or Knee Replacement Surgery in Adults*. TA157. London: NICE; 2008.
85. Caprini JA, Botteman MF, Stephens JM, Nadipelli V, Ewing MM, Brandt S, *et al*. Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States. *Value Health* 2003;**6**:59–64. <http://dx.doi.org/10.1046/j.1524-4733.2003.00204.x>
86. Locadia M, Bossuyt PM, Stalmeier PF, Sprangers MA, van Dongen CJ, Middeldorp S, *et al*. Treatment of venous thromboembolism with vitamin K antagonists: patients' health state valuations and treatment preferences. *Thromb Haemost* 2004;**92**:1336–41. <http://dx.doi.org/10.1160/th04-02-0075>
87. Berg J, Lindgren P, Nieuwlaat R, Bouin O, Crijns H. Factors determining utility measured with the EQ-5D in patients with atrial fibrillation. *Qual Life Res* 2010;**19**:381–90. <http://dx.doi.org/10.1007/s11136-010-9591-y>
88. Robinson A, Thomson R, Parkin D, Sudlow M, Eccles M. How patients with atrial fibrillation value different health outcomes: a standard gamble study. *J Health Serv Res Policy* 2001;**6**:92–8. <http://dx.doi.org/10.1258/1355819011927288>

89. Lenert L, Soetikno RM. Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis. *JAMA* 1997;**4**:49–56. <http://dx.doi.org/10.1136/jamia.1997.0040049>
90. Lacey EA, Walters SJ. Continuing inequality: gender and social class influences on self perceived health after a heart attack. *J Epidemiol Community Health* 2003;**57**:622–7. <http://dx.doi.org/10.1136/jech.57.8.622>
91. Haacke C, Althaus A, Spottke A, Siebert U, Back T, Dodel R. Long-term outcome after stroke: evaluating health-related quality of life using utility measurements. *Stroke* 2006;**37**:193–8. <http://dx.doi.org/10.1161/01.STR.0000196990.69412.fb>
92. Kind P, Hardman G, Macran S. *UK Population Norms for EQ-5D*. York: Centre for Health Economics, University of York; 1999.
93. Meads DM, McKenna SP, Doughty N, Das C, Gin-Sing W, Langley J, Pepke-Zaba J. The responsiveness and validity of the CAMPHOR Utility Index. *Eur Respir J* 2008;**32**:1513–19. <http://dx.doi.org/10.1183/09031936.00069708>
94. McKenna SP, Ratcliffe J, Meads DM, Brazier JE. Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses. *Health Qual Life Outcomes* 2008;**6**:65. <http://dx.doi.org/10.1186/1477-7525-6-65>
95. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. *Lancet* 1989;**1**:175–9. [http://dx.doi.org/10.1016/S0140-6736\(89\)91200-2](http://dx.doi.org/10.1016/S0140-6736(89)91200-2)
96. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. *Lancet* 1994;**343**:687–91.
97. Gulløv AL, Koefoed BG, Petersen P, Pedersen TS, Andersen ED, Godtfredsen J, Boysen G. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. *Arch Intern Med* 1998;**158**:1513–21. <http://dx.doi.org/10.1001/archinte.158.14.1513>
98. Hellemons BS, Langenberg M, Lodder J, Vermeer F, Schouten HJ, Lemmens T, *et al*. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. *BMJ* 1999;**319**:958–64. <http://dx.doi.org/10.1136/bmj.319.7215.958>
99. Hu DY, Zhang HP, Sun YH, Jiang LQ, Antithrombotic Therapy in Atrial Fibrillation Study Group. [The randomized study of efficiency and safety of antithrombotic therapy in nonvalvular atrial fibrillation: warfarin compared with aspirin.] *Zhonghua Xin Xue Guan Bing Za Zhi* 2006;**34**:295–8.
100. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, *et al*. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. *Lancet* 2006;**367**:1903–12. [http://dx.doi.org/10.1016/S0140-6736\(06\)68845-4](http://dx.doi.org/10.1016/S0140-6736(06)68845-4)
101. Rash A, Downes T, Portner R, Yeo WW, Morgan N, Channer KS. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). *Age Ageing* 2007;**36**:151–6. <http://dx.doi.org/10.1093/ageing/afl129>

102. Ezekowitz MD, Reilly PA, Nehmiz G, Simmers TA, Nagarakanti R, Parcham-Azad K, *et al.* Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). *Am J Cardiol* 2007;**100**:1419–26. <http://dx.doi.org/10.1016/j.amjcard.2007.06.034>
103. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, *et al.* Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. *Lancet* 2007;**370**:493–503. [http://dx.doi.org/10.1016/S0140-6736\(07\)61233-1](http://dx.doi.org/10.1016/S0140-6736(07)61233-1)
104. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, *et al.* Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2009;**361**:1139–51. <http://dx.doi.org/10.1056/NEJMoa0905561>
105. Eikelboom JW, O'Donnell M, Yusuf S, Diaz R, Flaker G, Hart R, *et al.* Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. *Am Heart J* 2010;**159**:348–53.e1. <http://dx.doi.org/10.1016/j.ahj.2009.08.026>
106. ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study. *Am Heart J* 2010;**159**:340–7.e1. <http://dx.doi.org/10.1016/j.ahj.2009.11.025>
107. Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, *et al.* Apixaban for reduction in stroke and other Thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. *Am Heart J* 2010;**159**:331–9. <http://dx.doi.org/10.1016/j.ahj.2009.07.035>
108. Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, *et al.* Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. *Thromb Haemost* 2010;**104**:633–41. <http://dx.doi.org/10.1160/TH10-01-0066>
109. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L, Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. *N Engl J Med* 2010;**363**:1875–6. <http://dx.doi.org/10.1056/NEJMc1007378>
110. Yamaguchi T. *A Dose Response Study of Dabigatran Etxilate (BIBR 1048) in Pharmacodynamics and Safety in Patients with Non-valvular Atrial Fibrillation in Comparison to Warfarin.* NCT01136408. ClinicalTrials.gov; 2010.
111. Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, *et al.* Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoagulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). *Am Heart J* 2010;**160**:635–41. <http://dx.doi.org/10.1016/j.ahj.2010.06.042>
112. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, *et al.* Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med* 2011;**365**:883–91. <http://dx.doi.org/10.1056/NEJMoa1009638>
113. Ogawa S, Shinohara Y, Kanmuri K. Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation – The ARISTOTLE-J study. *Circ J* 2011;**75**:1852–9. <http://dx.doi.org/10.1253/circj.CJ-10-1183>
114. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, *et al.* Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2011;**365**:981–92. <http://dx.doi.org/10.1056/NEJMoa1107039>

115. Chung N, Jeon HK, Lien LM, Lai WT, Tse HF, Chung WS, *et al.* Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation. *Thromb Haemost* 2011;**105**:535–44. <http://dx.doi.org/10.1160/TH10-07-0451>
116. Hohnloser S, Yusuf S, Eikelboom J, Steg G, Atar D, Budaj A, *et al.* Apixaban in patients with atrial fibrillation and their risk for cardiovascular hospitalization: insights from the AVERROES trial. *Eur Heart J* 2011;**32**:671.
117. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, *et al.* Apixaban in patients with atrial fibrillation. *N Engl J Med* 2011;**364**:806–17. <http://dx.doi.org/10.1056/NEJMoa1007432>
118. Yamashita T, Koretsune Y, Yasaka M, Inoue H, Kawai Y, Yamaguchi T, *et al.* Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation. *Circ J* 2012;**76**:1840–7. <http://dx.doi.org/10.1253/circj.CJ-11-1140>
119. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, *et al.* Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. *Eur Heart J* 2012;**33**:2821–30. <http://dx.doi.org/10.1093/eurheartj/ehs274>
120. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, *et al.* Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study –. *Circ J* 2012;**76**:2104–11. <http://dx.doi.org/10.1253/circj.CJ-12-0454>
121. Diener HC, Eikelboom J, Connolly SJ, Joyner CD, Hart RG, Lip GY, *et al.* Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. *Lancet Neurol* 2012;**11**:225–31. [http://dx.doi.org/10.1016/S1474-4422\(12\)70017-0](http://dx.doi.org/10.1016/S1474-4422(12)70017-0)
122. Chen KP, Huang CX, Huang DJ, Cao KJ, Ma CS, Wang FZ, Zhang S. Anticoagulation therapy in Chinese patients with non-valvular atrial fibrillation: a prospective, multi-center, randomized, controlled study. *Chin Med J* 2012;**125**:4355–60.
123. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, *et al.* Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. *Lancet Neurol* 2012;**11**:315–22. [http://dx.doi.org/10.1016/S1474-4422\(12\)70042-X](http://dx.doi.org/10.1016/S1474-4422(12)70042-X)
124. Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L, *et al.* Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. *Lancet Neurol* 2012;**11**:503–11. [http://dx.doi.org/10.1016/S1474-4422\(12\)70092-3](http://dx.doi.org/10.1016/S1474-4422(12)70092-3)
125. Flaker GC, Hohnloser S, Wojdyla D, Hylek E, Garcia D, Sullivan R, *et al.* Apixaban is efficacious and safe in patients with atrial fibrillation using concomitant amiodarone: an analysis from the ARISTOTLE trial. *J Am Coll Cardio* 2013;**1**:E317. [http://dx.doi.org/10.1016/S0735-1097\(13\)60317-4](http://dx.doi.org/10.1016/S0735-1097(13)60317-4)
126. Al-Khatib SM, Thomas L, Wallentin L, Lopes RD, Gersh B, Garcia D, *et al.* Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. *Eur Heart J* 2013;**34**:2464–71. <http://dx.doi.org/10.1093/eurheartj/ehs135>
127. Bahit MC, Lopes RD, Wojdyla DM, Hohnloser SH, Alexander JH, Lewis BS, *et al.* Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. *Int J Cardiol* 2013;**170**:215–20. <http://dx.doi.org/10.1016/j.ijcard.2013.10.062>

128. Connolly SJ, Eikelboom J, Dorian P, Hohnloser SH, Gretler DD, Sinha U, Ezekowitz MD. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). *Eur Heart J* 2013;**34**:1498–505. <http://dx.doi.org/10.1093/eurheartj/eh039>
129. Mahaffey KW, Wojdyla D, Hankey GJ, White HD, Nessel CC, Piccini JP, *et al*. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. *Ann Intern Med* 2013;**158**(12):861–8. [Summary for patients in *Ann Intern Med* 2013;**158**:1–28.] <http://dx.doi.org/10.7326/0003-4819-158-12-201306180-00003>
130. Garcia DA, Wallentin L, Lopes RD, Thomas L, Alexander JH, Hylek EM, *et al*. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. *Am Heart J* 2013;**166**:549–58. <http://dx.doi.org/10.1016/j.ahj.2013.05.016>
131. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, *et al*. Edoxaban versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2013;**369**:2093–104. <http://dx.doi.org/10.1056/NEJMoa1310907>
132. McMurray JJ, Ezekowitz JA, Lewis BS, Gersh BJ, van Diepen S, Amerena J, *et al*. Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. *Circ Heart Fail* 2013;**6**:451–60. <http://dx.doi.org/10.1161/CIRCHEARTFAILURE.112.000143>
133. Alexander JH, Lopes RD, Thomas L, Alings M, Atar D, Aylward P, *et al*. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. *Eur Heart J* 2014;**35**:224–32. <http://dx.doi.org/10.1093/eurheartj/eh0445>
134. Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Wojdyla DM, *et al*. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. *J Am Coll Cardiol* 2014;**63**:2141–7. <http://dx.doi.org/10.1016/j.jacc.2014.02.549>
135. Liu X, Huang H, Yu J, Cao G, Feng L, Xu Q, *et al*. Warfarin compared with aspirin for older Chinese patients with stable coronary heart diseases and atrial fibrillation complications. *Int J Clin Pharmacol Ther* 2014;**52**:454–9. <http://dx.doi.org/10.5414/CP201996>
136. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Ann Intern Med* 2007;**146**:857–67. <http://dx.doi.org/10.7326/0003-4819-146-12-200706190-00007>
137. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, *et al*. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. *N Engl J Med* 1992;**327**:1406–12. <http://dx.doi.org/10.1056/NEJM199211123272002>
138. Cairns JA. Stroke prevention in atrial fibrillation study. Final results. *Circulation* 1991;**84**:527–39. <http://dx.doi.org/10.1111/j.1524-4733.2006.00085.x>
139. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. *N Engl J Med* 1990;**323**:1505–11. <http://dx.doi.org/10.1056/NEJM199011293232201>
140. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. *J Am Coll Cardiol* 1991;**18**:349–55. [http://dx.doi.org/10.1016/0735-1097\(91\)90585-W](http://dx.doi.org/10.1016/0735-1097(91)90585-W)

141. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. *Lancet* 1993;**342**:1255–62.
142. Chimowitz MI, Furlan AJ. Prevention of stroke in atrial fibrillation. *N Engl J Med* 1990;**323**:481–4. <http://dx.doi.org/10.1056/NEJM199008163230712>
143. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. *Eur Heart J* 2012;**33**:1500–10. <http://dx.doi.org/10.1093/eurheartj/ehr488>
144. Andersen KK, Olsen TS. Reduced poststroke mortality in patients with stroke and atrial fibrillation treated with anticoagulants: results from a Danish quality-control registry of 22,179 patients with ischemic stroke. *Stroke* 2007;**38**:259–63. <http://dx.doi.org/10.1161/01.STR.0000254622.52483.03>
145. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, Brindle P. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. *BMJ* 2008;**336**:1475–82. <http://dx.doi.org/10.1136/bmj.39609.449676.25>
146. Office for National Statistics (ONS). National Life Tables, United Kingdom: 2011–13. *Stat Bull* 2014.
147. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, *et al*. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. *Eur Heart J* 2006;**27**:949–53. <http://dx.doi.org/10.1093/eurheartj/ehi825>
148. Office for National Statistics (ONS). *2011 Census, Population and Household Estimates for England and Wales*. Table P04 2011. London: ONS; 2012.
149. Kamel H, Johnston SC, Easton JD, Kim AS. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. *Stroke* 2012;**43**:881–3. <http://dx.doi.org/10.1161/STROKEAHA.111.641027>
150. Vanassche T, Lauw MN, Eikelboom JW, Healey JS, Hart RG, Alings M, *et al*. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. *Eur Heart J* 2015;**36**:281–7a. <http://dx.doi.org/10.1093/eurheartj/ehu307>
151. Hohnloser SH, Pajitnev D, Pogue J, Healey JS, Pfeffer MA, Yusuf S, Connolly SJ, ACTIVE W Investigators. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. *J Am Coll Cardiol* 2007;**50**:2156–61. <http://dx.doi.org/10.1016/j.jacc.2007.07.076>
152. Leclerc JR, Geerts WH, Desjardins L, Laflamme GH, L'Espérance B, Demers C, *et al*. Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. *Ann Intern Med* 1996;**124**:619–26. <http://dx.doi.org/10.7326/0003-4819-124-7-199604010-00001>
153. Francis CW, Pellegrini VD, Totterman S, Boyd AD, Marder VJ, Liebert KM, *et al*. Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. *J Bone Joint Surg Am* 1997;**79**:1365–72.
154. Colwell CW, Collis DK, Paulson R, McCutchen JW, Bigler GT, Lutz S, Hardwick ME. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. *J Bone Joint Surg Am* 1999;**81**:932–40.
155. Hull RD, Pineo GF, Francis C, Bergqvist D, Fellenius C, Soderberg K, *et al*. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators. *Arch Intern Med* 2000;**160**:2199–207. <http://dx.doi.org/10.1001/archinte.160.14.2199>

156. Fitzgerald RH Jr, Spiro TE, Trowbridge AA, Gardner JA Jr, Whitsett TL, O'Connell MB, *et al.* Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. *J Bone Joint Surg Am* 2001;**83A**:900–6.
157. Turpie AG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kälebo P, *et al.* BAY 59–7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. *J Thromb Haemost* 2005;**3**:2479–86. <http://dx.doi.org/10.1111/j.1538-7836.2005.01602.x>
158. Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, *et al.* A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59–7939), for thromboprophylaxis after total hip replacement. *Circulation* 2006;**114**:2374–81. <http://dx.doi.org/10.1161/CIRCULATIONAHA.106.642074>
159. Eriksson BI, Borris L, Dahl OE, Haas S, Huisman MV, Kakkar AK, *et al.* Oral, direct Factor Xa inhibition with BAY 59–7939 for the prevention of venous thromboembolism after total hip replacement. *J Thromb Haemost* 2006;**4**:121–8. <http://dx.doi.org/10.1111/j.1538-7836.2005.01657.x>
160. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, *et al.* Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. *Lancet* 2007;**370**:949–56. [http://dx.doi.org/10.1016/S0140-6736\(07\)61445-7](http://dx.doi.org/10.1016/S0140-6736(07)61445-7)
161. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, *et al.* Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. *J Thromb Haemost* 2007;**5**:2178–85. <http://dx.doi.org/10.1111/j.1538-7836.2007.02748.x>
162. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. *J Thromb Haemost* 2007;**5**:2368–75. <http://dx.doi.org/10.1111/j.1538-7836.2007.02764.x>
163. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, *et al.* Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. *N Engl J Med* 2008;**358**:2776–86. <http://dx.doi.org/10.1056/NEJMoa076016>
164. Kanan PS, Schwartzmann CR, Boschin LC, Conrad S, Silva MF. Comparative study between rivaroxaban and enoxaparin in deep venous thromboembolism prophylaxis in patients submitted to total hip arthroplasty. *Rev Bras Ortop* 2008;**43**:319–28. <http://dx.doi.org/10.1590/S0102-36162008000800002>
165. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, *et al.* Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. *N Engl J Med* 2008;**358**:2765–75. <http://dx.doi.org/10.1056/NEJMoa0800374>
166. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, *et al.* Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. *Lancet* 2008;**372**:31–9. [http://dx.doi.org/10.1016/S0140-6736\(08\)60880-6](http://dx.doi.org/10.1016/S0140-6736(08)60880-6)
167. Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, *et al.* Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. *J Arthroplasty* 2009;**24**:1–9. <http://dx.doi.org/10.1016/j.arth.2008.01.132>

168. Turpie AG, Bauer KA, Davidson BL, Fisher WD, Gent M, Huo MH, *et al.* A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). *Thromb Haemost* 2009;**101**:68–76.
169. Goel DP, Buckley R, deVries G, Abelseth G, Ni A, Gray R. Prophylaxis of deep-vein thrombosis in fractures below the knee: a prospective randomised controlled trial. *J Bone Joint Surg Br* 2009;**91**:388–94. <http://dx.doi.org/10.1302/0301-620X.91B3.20820>
170. Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, *et al.* Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. *Lancet Oncol* 2009;**10**:943–9. [http://dx.doi.org/10.1016/S1470-2045\(09\)70232-3](http://dx.doi.org/10.1016/S1470-2045(09)70232-3)
171. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. *N Engl J Med* 2009;**361**:594–604. <http://dx.doi.org/10.1056/NEJMoa0810773>
172. Fuji T, Fujita S, Tachibana S, Kawai Y. Randomized, double-blind, multi-dose efficacy, safety and biomarker study of the oral factor Xa inhibitor DU-176b compared with placebo for prevention of venous thromboembolism in patients after total knee arthroplasty [abstract no. 35]. *Blood* 2009;**112**(11):19.
173. Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, *et al.* Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. *Lancet* 2009;**373**:1673–80. [http://dx.doi.org/10.1016/S0140-6736\(09\)60734-0](http://dx.doi.org/10.1016/S0140-6736(09)60734-0)
174. Fuji T, Wang CJ, Fujita S, Tachibana S, Kawai Y. Edoxaban in patients undergoing total hip arthroplasty: A phase IIb dose-finding study. *Blood* 2009;**114**(22).
175. Fuji T, Fujita S, Ujihira T, Sato T. Dabigatran etexilate prevents venous thromboembolism after total knee arthroplasty in Japanese patients with a safety profile comparable to placebo. *J Arthroplasty* 2010;**25**:1267–74. <http://dx.doi.org/10.1016/j.arth.2009.08.010>
176. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM, ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. *N Engl J Med* 2010;**363**:2487–98. <http://dx.doi.org/10.1056/NEJMoa1006885>
177. Raskob G, Cohen AT, Eriksson BI, Puskas D, Shi M, Bocanegra T, Weitz JI. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. *Thromb Haemost* 2010;**104**:642–9. <http://dx.doi.org/10.1160/TH10-02-0142>
178. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P, ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. *Lancet* 2010;**375**:807–15. [http://dx.doi.org/10.1016/S0140-6736\(09\)62125-5](http://dx.doi.org/10.1016/S0140-6736(09)62125-5)
179. Fuji T, Fujita S, Tachibana S, Kawai Y, Koretsune Y, Yamashita T. Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: Stars J-V trial [abstract no. 3320]. *Blood* 2010;**116**(21).
180. Fuji T, Fujita S, Tachibana S, Kawai Y. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. *J Thromb Haemost* 2010;**8**:2458–68. <http://dx.doi.org/10.1111/j.1538-7836.2010.04021.x>
181. Fujita S, Fuji T, Tachibana S, Nakamura M, Kawai Y. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery. *Pathophysiol Haemost Thromb* 2010;**37**:A95.

182. Fuji T, Wang CJ, Fujita S, Tachibana S, Kawai Y, Koretsune Y, *et al.* Edoxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial. *Pathophysiol Haemost Thromb* 2010;**37**:A20.
183. Eriksson B, Dahl OE, Kurth AA, Hantel S, Huo MH, Hermansson K, *et al.* Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE-NOVATE II randomised trial. *Pathophysiol Haemost Thromb* 2010;**37**:A20.
184. Cohen AT, Spiro TE, Büller HR, *et al.* Rivaroxaban compared with enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients: MAGELLAN study methodology. *Blood* 2010;**116**(21).
185. Kakkar AK, Cimminiello C, Goldhaber SZ, Parakh R, Wang C, Bergmann JF, LIFENOX Investigators. Low-molecular-weight heparin and mortality in acutely ill medical patients. *N Engl J Med* 2011;**365**:2463–72. <http://dx.doi.org/10.1056/NEJMoa1111288>
186. Yokote R, Matsubara M, Hirasawa N, Hagio S, Ishii K, Takata C. Is routine chemical thromboprophylaxis after total hip replacement really necessary in a Japanese population? *J Bone Joint Surg Br* 2011;**93**:251–6. <http://dx.doi.org/10.1302/0301-620X.93B2.25795>
187. Iliopoulos E, Fotiadis E, Kravas A, Vittis F, Nenopoulos A, Ntovas T, *et al.* Thromboprophylaxis management in total knee arthroplasty. *Osteoporos Int* 2011;**22**:S120–1.
188. Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, Weitz JI, ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. *N Engl J Med* 2011;**365**:2167–77. <http://dx.doi.org/10.1056/NEJMoa1110899>
189. Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, *et al.* Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. *Thromb Haemost* 2011;**105**:721–9. <http://dx.doi.org/10.1160/TH10-10-0679>
190. Levine MN, Gu C, Liebman HA, Escalante CP, Solymoss S, Deitchman D, *et al.* A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. *J Thromb Haemost* 2012;**10**:807–14. <http://dx.doi.org/10.1111/j.1538-7836.2012.04693.x>
191. Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, *et al.* Rivaroxaban for thromboprophylaxis in acutely ill medical patients. *N Engl J Med* 2013;**368**:513–23. <http://dx.doi.org/10.1056/NEJMoa1111096>
192. Zhang H, Wang D, Sun HY, Li SW, Liu L. Efficacy and safety of rivaroxaban in the prevention of deep vein thrombosis after hip arthroplasty. *Chin J Tissue Eng Res* 2013;**17**:5440–5.
193. Fuji T, Fujita S, Kawai Y, Nakamura M, Kimura T, Kiuchi Y, *et al.* Safety and efficacy of edoxaban in patients undergoing hip fracture surgery. *Thromb Res* 2014;**133**:1016–22. <http://dx.doi.org/10.1016/j.thromres.2014.03.009>
194. Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, *et al.* Dose-escalation study of rivaroxaban (BAY 59–7939) – an oral, direct Factor Xa inhibitor – for the prevention of venous thromboembolism in patients undergoing total hip replacement. *Thromb Res* 2007;**120**:685–93. <http://dx.doi.org/10.1016/j.thromres.2006.12.025>
195. Eriksson BI, Dahl OE, Büller HR, Hettiarachchi R, Rosencher N, Bravo ML, *et al.* A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. *J Thromb Haemost* 2005;**3**:103–11. <http://dx.doi.org/10.1111/j.1538-7836.2004.01100.x>

196. Heit JA, Berkowitz SD, Bona R, Cabanas V, Corson JD, Elliott CG, Lyons R. Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Ardeparin Arthroplasty Study Group. *Thromb Haemost* 1997;**77**:32–8.
197. Haas SK, Freund M, Heigener D, Heilmann L, Kemkes-Matthes B, von Tempelhoff GF, *et al.* Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. *Clin Appl Thromb Hemost* 2012;**18**:159–65. <http://dx.doi.org/10.1177/1076029611433769>
198. Moise AI, Dragulin E, Casabalian D, Guran C, Mincu N, Stelea G. Dabigatran etexilate is effective and safe in patients undergoing total hip arthroplasty. *Eur J Anaesthesiol* 2011;**28**:87. <http://dx.doi.org/10.1097/00003643-201106001-00277>
199. Camporese G, Bernardi E, Noventa F. Efficacy of rivaroxaban for prevention of venous thromboembolism after knee arthroscopy: a randomized double-blind trial (Erika study). *J Thromb Haemost* 2011;**9**:156–7.
200. van der Veen L, van Raay JJ, Gerritsma-Bleeker CL, Veeger NJ, van Hulst M. Direct treatment comparison of DAbigatran and Rlvaroxaban versus NAdroparin in the prevention of venous thromboembolism after total knee arthroplasty surgery: design of a randomised pilot study (DARINA). *BMJ Open* 2013;**3**:e002218. <http://dx.doi.org/10.1136/bmjopen-2012-002218>
201. Cohen AT, Harrington R, Goldhaber SZ, Hull R, Gibson CM, Hernandez AF, *et al.* The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study. *Am Heart J* 2014;**167**:335–41. <http://dx.doi.org/10.1016/j.ahj.2013.11.006>
202. Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, *et al.* Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59–7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59–7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. *Circulation* 2007;**116**:180–7. <http://dx.doi.org/10.1161/CIRCULATIONAHA.106.668020>
203. Büller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, *et al.* A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. *Blood* 2008;**112**:2242–7. <http://dx.doi.org/10.1182/blood-2008-05-160143>
204. Büller H, Deitchman D, Prins M, Segers A, Botticelli Investigators, Writing Committee. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. *J Thromb Haemost* 2008;**6**:1313–18. <http://dx.doi.org/10.1111/j.1538-7836.2008.03054.x>
205. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, *et al.* Dabigatran versus warfarin in the treatment of acute venous thromboembolism. *N Engl J Med* 2009;**361**:2342–52. <http://dx.doi.org/10.1056/NEJMoa0906598>
206. Bauersachs R, Berkowitz SD, Brenner B, Büller HR, Decousus H, Gallus AS, *et al.* Oral rivaroxaban for symptomatic venous thromboembolism. *N Engl J Med* 2010;**363**:2499–510. <http://dx.doi.org/10.1056/NEJMoa1007903>
207. Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, *et al.* Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. *N Engl J Med* 2012;**366**:1287–97. <http://dx.doi.org/10.1056/NEJMoa1113572>
208. Raskob GE, Büller H, Angchaisuksiri P, Oh Boda Z, Lyons RM, *et al.* Edoxaban for long-term treatment of venous thromboembolism in cancer patients. *Blood* 2013;**122**(21).

209. Hokusai-VTE Investigators: Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, *et al.* Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. *N Engl J Med* 2013;**369**:1406–15. <http://dx.doi.org/10.1056/NEJMoa1306638>
210. Agnelli G, Büller HR, Cohen A, Curto M, Gallus AS, Johnson M, *et al.* Oral apixaban for the treatment of acute venous thromboembolism. *N Engl J Med* 2013;**369**:799–808. <http://dx.doi.org/10.1056/NEJMoa1302507>
211. Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, *et al.* Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. *Circulation* 2014;**129**:764–72. <http://dx.doi.org/10.1161/CIRCULATIONAHA.113.004450>
212. Young A, Dunn J, Chapman O, Grumett J, Marshall A, Phillips A, *et al.* SELECT-D: Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. *J Clin Oncol* 2014;**32**:5S.
213. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, *et al.* A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. *N Engl J Med* 1999;**340**:901–7. <http://dx.doi.org/10.1056/NEJM199903253401201>
214. Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, *et al.* Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. *N Engl J Med* 2001;**345**:165–9. <http://dx.doi.org/10.1056/NEJM200107193450302>
215. Agnelli G, Prandoni P, Becattini C, Silingardi M, Taliani MR, Miccio M, *et al.* Extended oral anticoagulant therapy after a first episode of pulmonary embolism. *Ann Intern Med* 2003;**139**:19–25. <http://dx.doi.org/10.7326/0003-4819-139-1-200307010-00008>
216. Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, *et al.* Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. *N Engl J Med* 2003;**348**:1425–34. <http://dx.doi.org/10.1056/NEJMoa035029>
217. Büller HR. Once-daily oral rivaroxaban versus placebo in the long-term prevention of recurrent symptomatic venous thromboembolism. The EINSTEIN-extension study. *Blood* 2009;**114**:22.
218. Romualdi E, Donadini MP, Ageno W. Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study). *Expert Rev Cardiovasc Ther* 2011;**9**:841–4. <http://dx.doi.org/10.1586/erc.11.62>
219. Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M, *et al.* Aspirin for preventing the recurrence of venous thromboembolism. *N Engl J Med* 2012;**366**:1959–67. <http://dx.doi.org/10.1056/NEJMoa1114238>
220. Brighton TA, Eikelboom JW, Mann K, Mister R, Gallus A, Ockelford P, *et al.* Low-dose aspirin for preventing recurrent venous thromboembolism. *N Engl J Med* 2012;**367**:1979–87. <http://dx.doi.org/10.1056/NEJMoa1210384>
221. Agnelli G, Büller HR, Cohen A, Curto M, Gallus AS, Johnson M, *et al.* Apixaban for extended treatment of venous thromboembolism. *N Engl J Med* 2013;**368**:699–708. <http://dx.doi.org/10.1056/NEJMoa1207541>
222. Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, *et al.* Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. *N Engl J Med* 2013;**368**:709–18. <http://dx.doi.org/10.1056/NEJMoa1113697>

223. Tullett J, Murray E, Nichols L, Holder R, Lester W, Rose P, *et al.* Trial Protocol: a randomised controlled trial of extended anticoagulation treatment versus routine anticoagulation treatment for the prevention of recurrent VTE and post thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (The ExACT Study). *BMC Cardiovasc Disord* 2013;**13**:16. <http://dx.doi.org/10.1186/1471-2261-13-16>
224. Mazilu L, Parepa IR, Suceveanu AI, Suceveanu A, Baz R, Catrinoiu D. Venous thromboembolism: secondary prevention with dabigatran vs. acenocumarolin patients with paraneoplastic deep vein thrombosis. Results from a small prospective study in Romania. *Cardiovasc Res* 2014;**103**:S39. <http://dx.doi.org/10.1093/cvr/cvu082.154>
225. White HD. Editorial: do we need another bleeding definition? What does the Bleeding Academic Research Consortium definition have to offer? *Curr Opin Cardiol* 2011;**26**:275–8. <http://dx.doi.org/10.1097/HCO.0b013e32834706a9>
226. Hart RG, Diener HC, Yang S, Connolly SJ, Wallentin L, Reilly PA, *et al.* Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. *Stroke* 2012;**43**:1511–17. <http://dx.doi.org/10.1161/STROKEAHA.112.650614>
227. Prandoni P, Villalta S, Bagatella P, Rossi L, Marchiori A, Piccioli A, *et al.* The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. *Haematologica* 1997;**82**:423–8.
228. Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R, *et al.* The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. *Haematologica* 2007;**92**:199–205. <http://dx.doi.org/10.3324/haematol.10516>
229. Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, *et al.* Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. *N Engl J Med* 2004;**350**:2257–64. <http://dx.doi.org/10.1056/NEJMoa032274>
230. Akaike H. A new look at the statistical model identification. *IEEE Trans Automat Contr* 1974;**19**:716–23. <http://dx.doi.org/10.1109/TAC.1974.1100705>
231. Fenwick E, Byford S. A guide to cost-effectiveness acceptability curves. *Br J Psychiatry* 2005;**187**:106–8. <http://dx.doi.org/10.1192/bjp.187.2.106>
232. Hamidi V, Ringerike T, Hagen G, Reikvam A, Klemp M. New anticoagulants as thromboprophylaxis after total hip or knee replacement. *Int J Technol Assess Health Care* 2013;**29**:234–43. <http://dx.doi.org/10.1017/S0266462313000251>
233. Lefebvre P, Coleman CI, Bookhart BK, Wang ST, Mody SH, Tran KN, *et al.* Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism. *J Med Econ* 2014;**17**:52–64. <http://dx.doi.org/10.3111/13696998.2013.858634>
234. Liew A, Eikelboom JW, O'Donnell M, Hart RG. Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants. *Can J Cardiol* 2013;**29**(Suppl. 7):34–44. <http://dx.doi.org/10.1016/j.cjca.2013.04.013>
235. Yang E. A clinician's perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation – full speed ahead or proceed with caution? *Vasc Health Risk Manag* 2014;**10**:507–22. <http://dx.doi.org/10.2147/VHRM.S68117>
236. Fenger-Eriksen C, Münster AM, Grove EL. New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications. *Acta Anaesthesiol Scand* 2014;**58**:651–9. <http://dx.doi.org/10.1111/aas.12319>

237. UKMi New Drugs Online Database. *New Drugs Online Report for Ciraparantag*. URL: www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=6443 (accessed 18 May 2015).
238. Ansell JE, Bakhru SH, Laulich BE, Steiner SS, Grosso M, Brown K, *et al*. Use of PER977 to reverse the anticoagulant effect of edoxaban. *N Engl J Med* 2014;**371**:2141–2. <http://dx.doi.org/10.1056/NEJMc1411800>
239. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, *et al*. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. *Nat Med* 2013;**19**:446–51. <http://dx.doi.org/10.1038/nm.3102>
240. UKMi New Drugs Online Database. *New Drugs Online Report for Andexanet Alfa*. URL: www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=6169 (accessed 18 May 2015).
241. Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, *et al*. A specific antidote for dabigatran: functional and structural characterization. *Blood* 2013;**121**:3554–62. <http://dx.doi.org/10.1182/blood-2012-11-468207>
242. UKMi New Drugs Online Database. *New Drugs Online Report for Idarucizumab*. URL: www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=6275 (accessed 18 May 2015).
243. Framingham Heart Study. Boston, MA. URL: www.framinghamstudy.org (accessed 22 August 2016).
244. Sorensen SV, Dewilde S, Singer DE, Goldhaber SZ, Monz BU, Plumb JM. Cost-effectiveness of warfarin: trial versus “real-world” stroke prevention in atrial fibrillation. *Am Heart J* 2009;**157**:1064–73. <http://dx.doi.org/10.1016/j.ahj.2009.03.022>
245. Roskell NS, Lip GY, Noack H, Clemens A, Plumb JM. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. *Thromb Haemost* 2010;**104**:1106–15. <http://dx.doi.org/10.1160/TH10-10-0642>

Appendix 1 MEDLINE search strategy

Venous thromboembolism

Database: MEDLINE 1950 to present (search date: 20 March 2014).

Search strategy

1. exp Venous Thrombosis/ (43,921)
2. exp Pulmonary Embolism/ (30,904)
3. thromboembolism/ or venous thromboembolism/ (24,405)
4. ((venous or vein\$) adj3 (thrombus\$ or thrombo\$)).ti,ab. (45,827)
5. (DVT or VTE).ti,ab. (9537)
6. (thrombophlebitis or thromboprophylaxis or thrombo-prophylaxis or thrombophlebitides).ti,ab. (7132)
7. ((pulmonary or lung or lungs) adj3 embol\$).ti,ab. (27,169)
8. ((leg or legs) adj3 (embol\$ or thrombo\$ or thrombus\$)).ti,ab. (1141)
9. or/1-8 (111,695)
10. exp *Anticoagulants/ (94,334)
11. exp *Coumarins/ (24,282)
12. Warfarin/ (14,323)
13. exp Vitamin K/ai [Antagonists & Inhibitors] (1537)
14. Thrombin/ai [Antagonists & Inhibitors] (3372)
15. Factor Xa/ai [Antagonists & Inhibitors] (2203)
16. Aspirin/ (37,741)
17. (anticoagula\$ or anti-coagula\$).ti. (20,512)
18. (oral anticoagula\$ or oral anti-coagula\$).ti,ab. (7048)
19. (coumarin\$ or coumadin\$ or warfarin or marevan or dicoumarol or dicoumarin or dicumarin or dicumarol or acenocoumarol or phenindione or aldocumar).ti,ab. (24,194)
20. (factor Xa adj2 (antagonist\$ or inhibitor\$)).ti,ab. (1356)
21. (factor 10a adj2 (antagonist\$ or inhibitor\$)).ti,ab. (2)
22. (factor 11a adj2 (antagonist\$ or inhibitor\$)).ti,ab. (25)
23. ((vitamin K or vitamin-k) adj2 (antagonist\$ or inhibitor\$)).ti,ab. (1830)
24. (dabigatram or pradaxa or BIBR1048 or Apixaban or Eliquis or BMS-562247-01 or Edoxaban or Lixiana or savaysa or DU-176b or betrixaban or PRT-054021 or PRT0504021 or rivaroxaban or xarelto or BAY-59739 or Erixaban or D0913).ti,ab. (1015)
25. (NOAC or NOACS).ti,ab. (86)
26. (aspirin or acetyl-salicylic acid or acetylsalicylic acid).ti,ab. (40,463)
27. or/10-26 (170,042)
28. *heparin/ or exp heparin, low-molecular-weight/ or heparinoids/ (33,841)
29. (Dalteparin or fragmin\$ or enoxaparin or clexane or lovenox or tinzaparin or innohep or bemiparin or badyket or hepadren or hibor or ivor or ivorat or zibor or certoparin or mono-embolx or sandoparin\$ or nadroparin\$ or fraxiparin\$ or parnaparin or fluxum or reviparin or clivarine or lowmorin).ti,ab. (4597)
30. (LMWH\$ or heparinoid\$ or danaparoid or organan).ti,ab. (4469)
31. (low\$ molecular adj2 heparin\$).ti,ab. (9114)
32. or/28-31 (37,314)
33. 27 or 32 (173,069)
34. 9 and 33 (22,835)
35. letter/ (803,375)
36. editorial/ (333,336)
37. news/ (151,695)

38. exp historical article/ (318,208)
39. Anecdotes as topic/ (4506)
40. comment/ (528,857)
41. case report/ (1,665,228)
42. (letter or comment\$.ti. (84,259)
43. or/35-42 (3,214,189)
44. randomized controlled trial/ or Randomized Controlled Trials as Topic/ or random\$.ti,ab. (774,175)
45. 43 not 44 (3,185,399)
46. animals/ not humans/ (3,810,079)
47. exp Animals, Laboratory/ (714,848)
48. exp Animal Experimentation/ (6196)
49. exp Models, Animal/ (407,481)
50. exp rodentia/ (2,630,754)
51. (rat or rats or mouse or mice).ti. (1,065,119)
52. or/45-51 (7,547,456)
53. 34 not 52 (16,525)
54. meta-analysis/ (45,670)
55. meta-analysis as topic/ (13,522)
56. (meta analy\$ or metaanaly\$ or metanaly\$ or meta regression).ti,ab. (54,350)
57. ((systematic\$ or evidence\$) adj2 (review\$ or overview\$)).ti,ab. (61,810)
58. (reference list\$ or bibliograph\$ or hand search\$ or manual search\$ or relevant journals).ab. (22,477)
59. (search strategy or search criteria or systematic search or study selection or data extraction).ab. (24,122)
60. (search\$ adj4 literature).ab. (23,275)
61. (medline or pubmed or cochrane or embase or psychlit or psychlit or psychinfo or cinahl or science citation index or bids or cancerlit).ab. (71,805)
62. cochrane.jw. (9850)
63. ((multiple treatment\$ or indirect or mixed) adj2 comparison).ti,ab. (813)
64. or/54-63 (169,922)
65. randomized controlled trial.pt. or randomized controlled trial/ or Randomized Controlled Trials as Topic/ (452,316)
66. controlled clinical trial.pt. (87,802)
67. randomi#ed.ab. (318,385)
68. placebo.ab. (143,748)
69. drug therapy.fs. (1,675,613)
70. randomly.ab. (189,528)
71. trial.ab. (275,251)
72. groups.ab. (1,220,973)
73. or/65-72 (3,169,503)
74. clinical trials as topic.sh. (168,638)
75. trial.ti. (114,737)
76. or/65-68,70,74-75 (899,851)
77. 64 or 76 (1,015,181)
78. 53 and 77 (4596)
79. limit 78 to yr="2008-Current" (1408)
80. atrial fibrillation.ti. (19,641)
81. *atrial fibrillation/ (25,973)
82. 80 or 81 (26,290)
83. 79 not 82 (1281)

Atrial fibrillation

Database: MEDLINE In-Process & Other Non-Indexed Citations – Current week, MEDLINE 1950 to present.

Search date: 20 March 2014.

Search strategy

1. tachycardia, supraventricular/ or tachycardia, ectopic atrial/ (5440)
2. atrial fibrillation/ (33,510)
3. ((atrial or atrium or auricular) adj3 fibrillat\$.ti,ab. (38,980)
4. heart fibrillat\$.ti,ab. (42)
5. (supraventricul\$ adj3 (arrhythmi\$ or tachycardia\$)).ti,ab. (7547)
6. ((atrial or atrium) adj3 (tachycardia\$ or arrhythmi\$)).ti,ab. (6888)
7. (atrial adj3 tachyarrhythmi\$.ti,ab. (1210)
8. Atrial Flutter/ (4944)
9. ((atrial or auricular) adj3 flutter\$.ti,ab. (5382)
10. or/1-9 (59,756)
11. exp *Anticoagulants/ (94,278)
12. exp *Coumarins/ (24,265)
13. Warfarin/ (14,307)
14. exp Vitamin K/ai [Antagonists & Inhibitors] (1534)
15. Thrombin/ai [Antagonists & Inhibitors] (3370)
16. Factor Xa/ai [Antagonists & Inhibitors] (2197)
17. Aspirin/ (37,712)
18. (anticoagula\$ or anti-coagula\$.ti. (21,584)
19. (oral anticoagula\$ or oral anti-coagula\$.ti,ab. (7768)
20. (coumarin\$ or coumadin\$ or warfarin or marevan or dicoumarol or dicoumarin or dicumarin or dicumarol or enocoumarol or phenindione or aldocumar).ti,ab. (26,479)
21. (factor Xa adj2 (antagonist\$ or inhibitor\$)).ti,ab. (1502)
22. (factor 10a adj2 (antagonist\$ or inhibitor\$)).ti,ab. (2)
23. (factor 11a adj2 (antagonist\$ or inhibitor\$)).ti,ab. (29)
24. ((vitamin K or vitamin-k) adj2 (antagonist\$ or inhibitor\$)).ti,ab. (2080)
25. (dabigatram or pradaxa or BIBR1048 or Apixaban or Eliquis or BMS-562247-01 or Edoxaban or Lixiana or savaysa or DU-176b or betrixaban or PRT-054021 or PRT0504021 or rivaroxaban or xarelto or BAY-59739 or Erixaban or D0913).ti,ab. (1330)
26. (NOAC or NOACS).ti,ab. (152)
27. (aspirin or acetyl-salicylic acid or acetylsalicylic acid).ti,ab. (42,763)
28. or/11-27 (175,520)
29. 10 and 28 (6721)
30. letter/ (829,317)
31. editorial/ (348,841)
32. news/ (159,814)
33. exp historical article/ (318,220)
34. Anecdotes as topic/ (4506)
35. comment/ (572,414)
36. case report/ (1,665,104)
37. (letter or comment\$.ti. (94,907)
38. or/30-37 (3,300,100)
39. randomized controlled trial/ or Randomized Controlled Trials as Topic/ or random\$.ti,ab. (835,720)
40. 38 not 39 (3,270,043)
41. animals/ not humans/ (3,807,926)
42. exp Animals, Laboratory/ (714,413)

43. exp Animal Experimentation/ (6188)
44. exp Models, Animal/ (407,073)
45. exp rodentia/ (2,629,200)
46. (rat or rats or mouse or mice).ti. (1,097,935)
47. or/40-46 (7,662,407)
48. 29 not 47 (5201)
49. systematic review/ (0)
50. meta analysis/ (45,623)
51. (meta analy\$ or metaanaly\$ or metanaly\$ or meta regression).ti,ab. (61,909)
52. ((systematic\$ or evidence\$) adj2 (review\$ or overview\$)).ti,ab. (71,965)
53. (reference list\$ or bibliograph\$ or hand search\$ or manual search\$ or relevant journals).ab. (24,936)
54. (search strategy or search criteria or systematic search or study selection or data extraction).ab. (26,492)
55. (search\$ adj4 literature).ab. (26,789)
56. (medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or cinahl or science citation dex or bids or cancerlit).ab. (82,698)
57. cochrane.jw. (10,337)
58. ((multiple treatment\$ or indirect or mixed) adj2 comparison).ti,ab. (901)
59. or/49-58 (186,127)
60. randomized controlled trial.pt. or randomized controlled trial/ or Randomized Controlled Trials as Topic/ (452,445)
61. controlled clinical trial.pt. (87,837)
62. randomi#ed.ab. (343,274)
63. placebo.ab. (151,447)
64. drug therapy.fs. (1,674,296)
65. randomly.ab. (208,182)
66. trial.ab. (297,177)
67. groups.ab. (1,328,911)
68. or/60-67 (3,312,451)
69. clinical trials as topic.sh. (168,554)
70. trial.ti. (123,158)
71. or/60-63,65,69-70 (946,554)
72. 59 or 71 (1,075,719)
73. 48 and 72 (1764)
74. 74 limit 73 to yr="2010-Current" (728)

Appendix 2 Forest plots: stroke prevention in atrial fibrillation




FIGURE 92 Stroke or SE [1/4] (stroke prevention in AF).




FIGURE 93 Stroke or SE [2/4] (stroke prevention in AF).




FIGURE 94 Stroke or SE [3/4] (stroke prevention in AF).




FIGURE 95 Stroke or SE [4/4] (stroke prevention in AF).




FIGURE 96 Ischaemic stroke (stroke prevention in AF).




FIGURE 97 Myocardial infarction (stroke prevention in AF).




FIGURE 98 Major bleeding [1/4] (stroke prevention in AF).




FIGURE 99 Major bleeding [2/4] (stroke prevention in AF).




FIGURE 100 Major bleeding [3/4] (stroke prevention in AF).




FIGURE 101 Major bleeding [4/4] (stroke prevention in AF).




FIGURE 102 Clinically relevant bleeding [1/3] (stroke prevention in AF).




FIGURE 103 Clinically relevant bleeding [2/3] (stroke prevention in AF).




FIGURE 104 Clinically relevant bleeding [3/3] (stroke prevention in AF).




FIGURE 105 Intracranial bleeding (stroke prevention in AF).




FIGURE 106 All-cause mortality (stroke prevention in AF).

Appendix 3 Forest plots: primary prevention of venous thromboembolism




FIGURE 107 Symptomatic DVT [1/3] (primary prevention of VTE).




FIGURE 108 Symptomatic DVT [2/3] (primary prevention of VTE).




FIGURE 109 Symptomatic DVT [3/3] (primary prevention of VTE).




FIGURE 110 Symptomatic PE [1/4] (primary prevention of VTE).




FIGURE 111 Symptomatic PE [2/4] (primary prevention of VTE). (continued)




FIGURE 111 Symptomatic PE [2/4] (primary prevention of VTE).




FIGURE 112 Symptomatic PE [3/4] (primary prevention of VTE). (continued)




FIGURE 112 Symptomatic PE [3/4] (primary prevention of VTE).




FIGURE 113 Symptomatic PE [4/4] (primary prevention of VTE). (continued)




FIGURE 113 Symptomatic PE [4/4] (primary prevention of VTE).




FIGURE 114 Symptomatic VTE [1/3] (primary prevention of VTE).




FIGURE 115 Symptomatic VTE [2/3] (primary prevention of VTE).




FIGURE 116 Symptomatic VTE [3/3] (primary prevention of VTE).




FIGURE 117 Myocardial infarction (primary prevention of VTE).




FIGURE 118 Major bleeding [1/4] (primary prevention of VTE).




FIGURE 119 Major bleeding [2/4] (primary prevention of VTE).




FIGURE 120 Major bleeding [3/4] (primary prevention of VTE).




FIGURE 121 Major bleeding [4/4] (primary prevention of VTE).




FIGURE 122 Clinically relevant bleeding [1/2] (primary prevention of VTE).




FIGURE 123 Clinically relevant bleeding [2/2] (primary prevention of VTE).




FIGURE 124 All-cause mortality [1/3] (primary prevention of VTE).




FIGURE 125 All-cause mortality [2/3] (primary prevention of VTE).




FIGURE 126 All-cause mortality [3/3] (primary prevention of VTE).

Appendix 4 Forest plots: acute treatment of venous thromboembolism




FIGURE 127 Symptomatic DVT (acute treatment of VTE).




FIGURE 128 Symptomatic PE (acute treatment of VTE).




FIGURE 129 Symptomatic VTE (acute treatment of VTE).




FIGURE 130 Myocardial infarction (acute treatment of VTE).




FIGURE 131 Major bleeding (acute treatment of VTE).




FIGURE 132 Clinically relevant bleeding (acute treatment of VTE).




FIGURE 133 All-cause mortality (acute treatment of VTE).

Appendix 5 Forest plots: secondary prevention of venous thromboembolism




FIGURE 134 Symptomatic DVT (secondary prevention of VTE).




FIGURE 135 Symptomatic PE (secondary prevention of VTE).




FIGURE 136 Symptomatic VTE (secondary prevention of VTE).




FIGURE 137 Myocardial infarction (secondary prevention of VTE).




FIGURE 138 Major bleeding (secondary prevention of VTE).




FIGURE 139 Clinically relevant bleeding (secondary prevention of VTE).




FIGURE 140 For all-cause mortality (secondary prevention of VTE).

Appendix 6 Discussion of previous economic models

The earliest model we identified was developed by Gage *et al.*³¹ in 1995. This used a Markov model comparing warfarin, aspirin and no therapy. States, such as 'second stroke', were used to record the event history of patients, and this history had an effect on risks of future events, costs and utilities. Strokes, ICH and TIA were included, whereas MI and extracranial bleeds were not. The time horizon was 10 years and the cycle length was 1 month. The RIND state [reversible ischaemic neurological deficit (RIND)] was used to represent recovery from a temporary stroke or TIA. Patients were assumed to switch treatments from warfarin to aspirin if they experienced a bleed, and from aspirin to warfarin if they experienced a stroke. In common with this model, we will adopt a Markov modelling framework with states that record event histories to account for their effect on risks, costs and utilities. In our model, we include all of the events in this model, although we rename haemorrhage as a bleed and model it in more detail, categorised by severity. We also account for the possibility of treatment switching. We also model the general RIND state in more detail, recording specific event histories, such as history of both MI and stroke.

One of the first published models in the UK setting was that by Lightowlers and McGuire³² in 1998. They used a very simple decision tree, with a 10-year time horizon, to assess the cost-effectiveness of different monitoring strategies for warfarin, compared with each other and 'no treatment' for over 75-year-olds. They included bleeding as an AE but made the simplifying assumption that it was roughly twice as likely in the warfarin group as in the no-treatment group. Our model will be more sophisticated than this decision tree approach. Our Markov model structure will allow us to evaluate lifetime cost-effectiveness as we can account for recurring events and long-term treatment effects, costs and utilities.

Recently, some more complicated model structures have been explored. The Bayer submission to NICE on rivaroxaban in 2011 used a 22-state Markov model to compare treatments for non-valvular AF in the 73-year-old population in the UK,³³ similar to our target population. The cycle length for the Markov model was 3 months and, as in our model, they used a life-time time horizon. The model accounted for treatment switching and for discontinuation of treatment, both of which be accounted for in our model. In a similar fashion to our model and that of Gage *et al.* 1995³¹ patient history was accounted for by memory states, such as the 'post minor stroke' states. Unlike in Gage *et al.* 1995³¹ ICH and minor/major bleed were distinguished and, under clinical advisement, this is a distinction we will also make. The model also separated SE and stroke, a distinction that we will adopt. The evidence used to inform the model was a mixture of trial data (ROCKET AF^{106,112,123,129}) and the results of a Bayesian NMA comparing rivaroxaban 20 mg od, dabigatran 110 mg, dabigatran 150 mg, warfarin, aspirin and placebo. We do not have access to individual patient trial data but will use a Bayesian NMA of aggregate data from RCTs to inform a majority of our model's transition probabilities.

Several recent publications have been largely based on the template set down by Gage *et al.*³¹ The models by Shah and Gage in 2011,³⁴ Freeman *et al.* 2011,³⁵ two by Lee *et al.* 2012^{36,37} separately looking at rivaroxaban and apixaban, and by Harrington *et al.* 2013³⁸ all used a similar structure to Gage *et al.*³¹ but with updated input evidence, extra states and different treatments. As in our model, these models used longer time horizons (up to 35 years). Owing to the availability of superior data, some of these models used shorter cycle lengths (2 weeks). They additionally used TIA itself rather than RIND to represent a non-disabling minor stroke, a choice that we will adopt in accordance with clinician advice, and some of the models included a MI event, using evidence of adverse treatment effect on MI rate of dabigatran 110 mg and 150 mg compared with warfarin from the RE-LY trial^{104,109} and the Framingham study.²⁴³ As in the study by Gage *et al.*,³¹ memory states were used to record event histories but these models also included a history of both stroke and ICH, a choice we will extend by including states with a history of up to four events (stroke, bleed, ICH and MI). Kamel *et al.*³⁹ used a similar structure to the Lee *et al.* models,^{36,37} with evidence from the ARISTOTLE trial,^{107,114,119,124–127,130,132–134} but investigated apixaban and

warfarin for the prevention of only secondary stroke. Our model will be interested in primary, secondary, and any subsequent stroke, so this is not a model of particular interest. The Harrington *et al.* study,³⁸ in the USA setting, is the latest of this series of models, and its parameters are based on the results of the ARISTOTLE,^{107,114,119,124–127,130,132–134} RE-LY^{104,109} and ROCKET AF^{106,112,123,129} studies of the NOACs.

A highly complex model was published by the Canadian Agency for Drugs and Technologies in Health (CADTH) comparing rivaroxaban, dabigatran and apixaban with each other and with warfarin in the Canadian setting. As in our model and previous AF models, this was a Markov model.⁴⁰ The model used a cycle length of 3 months and base-case time horizon of 40 years. CADTH analysed populations that were stratified by risk of stroke, assessed by CHADS₂ and by age (< 75 and ≥ 75 years), and allowed event rates to vary with the age of the cohort: an important feature that we will adopt for our model. A difference from our model is that CADTH included fatal and non-fatal PE, an event that we will not include as clinical advice was that PE was not an AF treatment. The CADTH model was informed by a broad evidence base, combining results from RE-LY,^{104,109} ARISTOTLE^{107,114,119,124–127,130,132–134} and ROCKET AF^{106,112,123,129} via a NMA conducted in both the Bayesian and frequentist setting.

Wisloff *et al.*⁴¹ used a decision tree followed by an eight-state Markov model to compare dabigatran, apixaban and rivaroxaban with warfarin for populations with a range of ages in the Norwegian setting. The model used eight health states, notably including gastrointestinal bleeding as the only possible bleed type. We grouped all CRB events as clinical advice was that they would have similar sequelae and effects on risks of future bleeds and other events. The cycle length of the Wisloff model⁴¹ was 12 months, as shorter cycle lengths of only 1 month led to spurious results, most likely due to limited data, although the model was based on the results of ROCKET AF, RE-LY and ARISTOTLE. A lifetime time horizon was used but a cut-off at 105 years was imposed. Our model will adopt a similar cut-off at 100 years. The Wisloff study⁴¹ is significant, as it was one of the few to conduct a VOI analysis.

Discrete event simulation was used by Pink *et al.*⁴⁶ in 2011 as an alternative to Markov modelling. This modelled similar events to our model, including stroke, MI, ICH, TIA and major bleeding, and simulated 50,000 individuals over a lifetime time horizon in the UK to compare dabigatran and warfarin. The model primarily used the RE-LY trial^{104,109} to inform its parameters. Although discrete event simulation has the advantage over Markov models of modelling events in continuous time and modelling individual patients, we decided that this extra level of detail was unnecessary and that the available data were, in any case, insufficient.

A recent model of dabigatran for stroke prevention in AF in the UK setting was published by Kansal *et al.*⁴² in 2012. This was a Markov model, which built on a previous model by Sorensen *et al.*²⁴⁴ This model used a 3-month cycle length and lifetime time horizon, with a cut-off at 100 years, as in our model. The model used a NMA of Roskell *et al.*²⁴⁵ to inform its clinical parameters. Although we will use a separate NMA and other long-term sources for clinical parameters, the costs and utilities in our model will largely follow those used in this Kansal *et al.* model,⁴² although we will update or inflate to today's prices where possible. Kansal *et al.*⁴² found that dabigatran was both more effective and less costly than warfarin for the prevention of stroke in AF, although they assumed that dabigatran did not require monitoring and the results may be very sensitivity to this assumption.

Appendix 7 Competing risks network meta-analysis for hazard ratios of events

All event types reported in the systematic literature review must be included to account for correlation and competing risks, giving a total of 17 types of events, although all trials report only a subset of these events:

1. ischaemic stroke
2. bleeding
3. minor bleeding
4. fatal bleeding
5. MI
6. death (all causes)
7. TIA
8. fatal stroke
9. composite CRB
10. hospital admission
11. death (cardiovascular)
12. arterial event
13. PE
14. extracranial minor bleeding
15. SE (obtained by subtracting 'All stroke' from 'Stroke or SE' in trials that report both)
16. intracranial bleeding (ICH) (to which we added haemorrhagic stroke, under clinical advice)
17. CRB (a combination of major bleeding and CRNM bleeding).

Events of interest to our model are death ('All causes'), MI, TIA, CRB, ischaemic stroke, SE and ICH.

In all of the following models, λ_i is the rate of events of type i , which is modelled on the log-scale. The data are reported in three different ways, which we describe, in turn, below. The interpretation of the λ_i 's is the same across different data types and can be estimated in a shared parameter model.

For each study j , arm k , and outcome i , the log of the hazard λ_{jki} is related to the study-specific baseline hazard μ_{ji} and log-HR of the treatment in arm k (t_{jk}) relative to the treatment in arm 1 (t_{j1}):

$$\log(\lambda_{jki}) = \mu_{ji} + d_{t_{jk}i} - d_{t_{j1}i}.$$

The baseline hazards μ_{ji} are treated as nuisance parameters and vague priors are placed on them: $\mu_{ji} \sim N(0, 0.0001)$.

Vague priors are also placed on the log-HRs for all outcomes i and treatments t : $d_{ti} \sim N(0, 0.0001)$

Number of first events

Here, only the first event is recorded for each individual, and they are assumed censored at the point at which the first event occurs. The outcomes are therefore competing risks, and need to be modelled jointly.

Let r_1, r_2, \dots, r_m be the number of individuals with first event being of type i , for $i = 1, \dots, m$, and $R = \sum_{i=1}^m r_i$.

Let E be the observed person-years at risk. Then the likelihood is:

$$R \sim Po\left(E \sum_{i=1}^m \lambda_i\right),$$

and conditional on R :

$$(r_1, r_2, \dots, r_m) \sim Multinomial\left(\left(\frac{\lambda_1}{\sum_{i=1}^m \lambda_i}, \dots, \frac{\lambda_m}{\sum_{i=1}^m \lambda_i}\right); R\right).$$

There are five studies^{97,98,100,103,105,116,117,121} that report in this format, of which four report the mean follow-up time. The observed person-years at risk can be obtained from the mean follow-up time by multiplying by the number of individuals randomised. In one study,¹⁰⁰ median follow-up and also study duration are reported, but not mean follow-up. Median follow-up is just over half that of study duration, owing to censoring. If we assume that mean follow-up is approximately equal to median follow-up then we can obtain the person-years at risk as if mean follow-up were reported.

Number of individuals experiencing at least one event of a given type

Here, the number of individuals experiencing at least one event of a given type are recorded. Each individual may count towards more than one event type, but only once for each event type. We need to consider mortality slightly differently from other event types because this event can happen only once.

Now let r_i be the number of individuals with at least one event of type i and r_m the number of mortalities.

The likelihood for the number of mortalities is: $r_m \sim Po(E\lambda_m)$.

The likelihood for other events is approximately (assuming an average follow-up time, $r_i \sim Bin(p_i, n)$, for each individual, and number randomised n): $r_i \sim Bin(p_i, n)$, where p_i is the probability that an individual has one or more event of type i over the follow-up period \bar{t} , giving $\text{cloglog}(p_i) = \log(\bar{t}) + \log(\lambda_i)$, where $\text{cloglog}(p_i) = \log(-\log(1 - p_i))$.

There are 14 studies^{12,95,99,101,102,106,108,110-113,115,120,122,123,128,129,131} reporting outcomes in this format. Of these, only three studies^{111,122,128,131} report mean follow-up time, \bar{t} , which can be used in the likelihood as described above. Two studies^{96,106,112,123,129} report median follow-up time, which we can use if we assume that the mean follow-up time is approximately equal to the median follow-up. One study¹²⁰ does not report any information on follow-up, and so has to be excluded from the analysis.

The remaining eight studies^{12,95,101,102,108,110,113,115} report only the study duration, which, we know from those studies reporting both study duration and mean or median follow-up, greatly overestimates mean follow-up time. In studies that report both, the mean follow-up time, as a proportion of the study duration, ranges from 36% to 69%. We used a prior for this proportion, π , then set $\bar{t} = \pi t$ (where $t =$ study duration). This allowed us to include these studies but reflected our uncertainty in the mean follow-up time.

Total number of events

Here we have total number of events of type i for given person-years at risk E .

Now let r_i be the number events of type i , including repeat events within individuals.

The likelihood is $r_i \sim Po(E\lambda_i)$.

There are three studies^{96,104,107,109,114,119,124–127,130,132–134} reporting results in this format. Of these, one study⁹⁶ reports mean follow-up time, from which we can derive E . The other two studies^{104,107,109,114,119,124–127,130,132–134} report median follow-up time, which we can use if we assume mean follow-up time is approximately equal to median follow-up time.

Estimating mean follow-up time from median follow-up time

If censoring follows an exponential distribution then mean = median/log(2) giving mean > median. However, in the only study¹¹ that reports both, they are very similar. This is probably because of the various different censoring mechanisms (mortality, lost to follow-up). We will therefore make the assumption that our analyses can use the median follow-up when the mean follow-up is not available.

Appendix 8 Competing risks model for hazard in warfarin arms of trials

The natural history model on standard care (warfarin, INR 2–3) requires estimates of the baseline log-hazard, rather than HRs, of events of interest. As in the treatment effects NMA, there are three types of outcomes data to be incorporated into the model. The main difference is that a common, random effect, baseline log-hazard for the warfarin arm (labelled 1) is assumed across studies with m_i and precision ω_i .

For each study j with a warfarin arm and outcome i , the log of the hazard λ_{ji} is $\log(\lambda_{ji}) = \mu_{ji}$.

The trial-specific baseline hazards are related to the across trial baseline hazard: $\mu_{ji} \sim N(m_i, \omega_i)$.

A vague prior is placed on the mean of baseline hazard: $m_i \sim N(0, 0.0001)$.

A vague prior is placed on the precision of the baseline hazard, on the SD scale: $\frac{1}{\omega_i} \sim Uniform(0, 5)$.

The rest of the model is identical to that presented in *Appendix 7*.

Appendix 9 All-cause mortality minus venous thromboembolism-related mortality data (acute treatment of venous thromboembolism)

TABLE 203 All-cause mortality minus VTE-related mortality data (acute treatment of VTE)

Study	Comparator	<i>n</i>	All-cause mortality minus VTE-related mortality
AMPLIFY ²¹⁰	Apixaban 2 × 5 mg	2691	0
	Warfarin	2704	37
BOTTICELLI DVT ²⁰⁴	Apixaban 2 × 5 mg	130	3
	Apixaban 2 × 10 mg	134	1
	Apixaban 1 × 20 mg	128	1
	Warfarin	128	0
EINSTEIN DVT ²⁰⁶	Rivaroxaban 2×15 mg (first 21 days), then 1 × 20 mg	1731	36
	Warfarin	1718	43
EINSTEIN DVT dose-ranging study ²⁰³	Rivaroxaban 1 × 20 mg	115	4
	Rivaroxaban 1 × 30 mg	112	6
	Rivaroxaban 1 × 40 mg	121	1
	Warfarin	101	0
EINSTEIN PE ²⁰⁷	Rivaroxaban 2 × 15 mg (first 21 days) then 1 × 20 mg	2419	48
	Warfarin	2413	44
HOKUSAI-VTE ^{208,209}	Edoxaban 60 or 30 (17.6%) mg	4118	108
	Warfarin	4122	102
RE-COVER ²⁰⁵	Dabigatran 2 × 150 mg	1274	20
	Warfarin	1265	18
RE-COVER II ²¹¹	Dabigatran 2 × 50 mg	1279	22
	Warfarin	1289	25

Appendix 10 Office for National Statistics life tables stratified by age and gender

TABLE 204 Office for National Statistics life tables stratified by age and gender

Age (years)	Males	Females
55	0.0052	0.0034
56	0.0059	0.0038
57	0.0062	0.0042
58	0.0069	0.0045
59	0.0074	0.0050
60	0.0082	0.0054
61	0.0090	0.0059
62	0.0098	0.0064
63	0.0105	0.0068
64	0.0115	0.0075
65	0.0124	0.0081
66	0.0142	0.0092
67	0.0155	0.0101
68	0.0167	0.0109
69	0.0190	0.0123
70	0.0213	0.0139
71	0.0235	0.0150
72	0.0257	0.0169
73	0.0279	0.0183
74	0.0311	0.0206
75	0.0340	0.0228
76	0.0380	0.0257
77	0.0420	0.0290
78	0.0470	0.0327
79	0.0516	0.0368
80	0.0581	0.0416
81	0.0657	0.0471
82	0.0735	0.0531
83	0.0817	0.0608
84	0.0915	0.0685
85	0.1019	0.0766
86	0.1130	0.0866

continued

TABLE 204 Office for National Statistics life tables stratified by age and gender (*continued*)

Age (years)	Males	Females
87	0.1263	0.0959
88	0.1386	0.1082
89	0.1570	0.1217
90	0.1694	0.1392
91	0.1840	0.1507
92	0.1974	0.1672
93	0.2147	0.1792
94	0.2382	0.2028
95	0.2594	0.2240
96	0.2830	0.2455
97	0.3041	0.2631
98	0.3240	0.2828
99	0.3424	0.3056
100	0.3654	0.3252

Appendix 11 Log-odds ratios relative to low-molecular-weight heparin

TABLE 205 Estimated (posterior mean) log-ORs relative to LMWH post-op (standard dose): pooled surgical primary population

Treatment	Log-OR	95% CI	Distribution
Apixaban (2.5 mg bd)	-0.05	-0.63 to 0.52	MCMC posterior simulations
Dabigatran (220 mg od)	-0.02	-0.60 to 0.56	
Rivaroxaban (10 mg od)	-0.67	-1.18 to -0.18	

Appendix 12 Venous thromboembolism sensitivity analyses

Primary prevention of venous thromboembolism: total knee replacement




FIGURE 141 Cost-effectiveness acceptability frontier for TKR primary prevention sensitivity analysis: pooling post THR and post TKR populations for relative treatment effect of VTE. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 142 Cost-effectiveness acceptability frontier for TKR primary prevention sensitivity analysis: setting the cost of dabigatran to 150 mg od. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 143 Cost-effectiveness acceptability frontier for TKR primary prevention sensitivity analysis: pooling over surgical population for VTE relative treatment effects. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 144 Cost-effectiveness acceptability frontier for TKR primary prevention sensitivity analysis: decreasing AE costs by 50%. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 145 Cost-effectiveness acceptability frontier for TKR primary prevention sensitivity analysis: decreasing AE utilities by 50%. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 146 Cost-effectiveness acceptability frontier for TKR primary prevention sensitivity analysis: increasing VTE costs by 50%. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 147 Cost-effectiveness acceptability frontier for TKR primary prevention sensitivity analysis: increasing VTE utilities by 50%. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.

Primary prevention of venous thromboembolism: post hip replacement surgery




FIGURE 148 Cost-effectiveness acceptability frontier for THR primary prevention sensitivity analysis: pooling post THR and post TKR populations for relative treatment effect of VTE. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 149 Cost-effectiveness acceptability frontier for THR primary prevention sensitivity analysis: setting the cost of dabigatran to 150 mg od. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 150 Cost-effectiveness acceptability frontier for THR primary prevention sensitivity analysis: decreasing AE costs by 50%. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 151 Cost-effectiveness acceptability frontier for THR primary prevention sensitivity analysis: increasing AE costs by 50%. See Chapter 4 (*Outcomes of atrial fibrillation and venous thromboembolism models*) for further details.




FIGURE 152 Cost-effectiveness acceptability frontier for THR primary prevention sensitivity analysis: decreasing AE utilities by 50%. See Chapter 4 (*Outcomes of atrial fibrillation and venous thromboembolism models*) for further details.




FIGURE 153 Cost-effectiveness acceptability frontier for THR primary prevention sensitivity analysis: increasing AE utilities by 50%. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 154 Cost-effectiveness acceptability frontier for THR primary prevention sensitivity analysis: decreasing VTE costs by 50%. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 155 Cost-effectiveness acceptability frontier for THR primary prevention sensitivity analysis: increasing VTE costs by 50%. See Chapter 4 (*Outcomes of atrial fibrillation and venous thromboembolism models*) for further details.




FIGURE 156 Cost-effectiveness acceptability frontier for THR primary prevention sensitivity analysis: decreasing VTE utilities by 50%. See Chapter 4 (*Outcomes of atrial fibrillation and venous thromboembolism models*) for further details.




FIGURE 157 Cost-effectiveness acceptability frontier for THR primary prevention sensitivity analysis: increasing VTE utilities by 50%. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.

Acute treatment of venous thromboembolism




FIGURE 158 Cost-effectiveness acceptability frontier for acute treatment sensitivity analysis: decreasing AE cost by 50%. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 159 Cost-effectiveness acceptability frontier acute treatment model: increasing AE costs by 50%. See Chapter 4 (*Outcomes of atrial fibrillation and venous thromboembolism models*) for further details.




FIGURE 160 Cost-effectiveness acceptability frontier for acute treatment sensitivity analysis: decreasing AE utility by 50%. See Chapter 4 (*Outcomes of atrial fibrillation and venous thromboembolism models*) for further details.




FIGURE 161 Cost-effectiveness acceptability frontier for acute treatment sensitivity analysis: increasing AE utility by 50%. See Chapter 4 (*Outcomes of atrial fibrillation and venous thromboembolism models*) for further details.




FIGURE 162 Cost-effectiveness acceptability frontier for acute treatment sensitivity analysis: decreasing VTE cost by 50%.




FIGURE 163 Cost-effectiveness acceptability frontier for acute treatment sensitivity analysis: increasing VTE cost by 50%. See Chapter 4 (*Outcomes of atrial fibrillation and venous thromboembolism models*) for further details.




FIGURE 164 Cost-effectiveness acceptability frontier for acute treatment sensitivity analysis: decreasing VTE utility by 50%. See Chapter 4 (*Outcomes of atrial fibrillation and venous thromboembolism models*) for further details.




FIGURE 165 Cost-effectiveness acceptability frontier for acute treatment sensitivity analysis: increasing VTE utility by 50%. See Chapter 4 (*Outcomes of atrial fibrillation and venous thromboembolism models*) for further details.




FIGURE 166 Cost-effectiveness acceptability frontier for acute treatment sensitivity analysis: NOACs rate of non-fatal ICH rate equal to warfarin. See Chapter 4 (*Outcomes of atrial fibrillation and venous thromboembolism models*) for further details.




FIGURE 167 Cost-effectiveness acceptability frontier for acute treatment sensitivity analysis: changing time on treatment from 6 months to 3 months. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.

Secondary prevention of venous thromboembolism




FIGURE 168 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analysis: patients on no pharmacotherapy and aspirin receive warfarin after a second VTE event. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 169 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analysis: change bleed base rate. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 170 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analysis: setting the cost of warfarin to £0. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 171 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analysis: decreasing the AE cost by 50%. See Chapter 4 (*Outcomes of atrial fibrillation and venous thromboembolism models*) for further details.




FIGURE 172 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analysis: increasing the AE cost by 50%. See Chapter 4 (*Outcomes of atrial fibrillation and venous thromboembolism models*) for further details.




FIGURE 173 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analysis: decreasing the AE utility by 50%. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 174 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analysis: increasing the AE utility by 50%. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.




FIGURE 175 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analysis: increasing the cost of VTE events by 50%. See Chapter 4 (*Outcomes of atrial fibrillation and venous thromboembolism models*) for further details.




FIGURE 176 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analysis: decreasing VTE utility by 50%. See Chapter 4 (*Outcomes of atrial fibrillation and venous thromboembolism models*) for further details.




FIGURE 177 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analysis: increasing VTE utility by 50%. See *Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)* for further details.

A decorative graphic consisting of numerous thin, parallel green lines that curve from the left side of the page towards the right, creating a sense of movement and depth.

**EME
HS&DR
HTA
PGfAR
PHR**

Part of the NIHR Journals Library
www.journalslibrary.nihr.ac.uk

This report presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health

Published by the NIHR Journals Library